| date |
work |
virus |
doi |
pubmed |
| 2025-03-01 |
Severity of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Diminished During Successive Waves of the COVID-19 Pandemic: Data from a Nationwide German Survey (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPEDS.2024.114419 |
|
| 2025-02-01 |
Neuroimaging markers of cognitive fatigue in individuals with post-acute sequelae of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BANDC.2024.106254 |
|
| 2025-02-01 |
Insight into potential long COVID effects: Antidepressant use in post SARS-CoV-2 Infection scenarios. A multiregional nested case-control study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PSYCHRES.2024.116290 |
|
| 2025-01-01 |
A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106364 |
|
| 2025-01-01 |
Association of SARS-CoV-2 Infection during pregnancy with placental weight and histopathologic lesions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PLACENTA.2024.12.017 |
|
| 2025-01-01 |
The burden, clinical features and outcomes of SARS-CoV-2, Influenza and co-infections during concurrently out-of-season outbreaks in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PUHE.2024.10.016 |
|
| 2024-12-30 |
Placentas From SARS‐CoV‐2 Infection During Pregnancy Exhibit Foci of Oxidative Stress and DNA Damage (edit) |
SARSコロナウイルス2 (edit) |
10.1111/AJI.70034 |
|
| 2024-12-28 |
New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-82983-7 |
|
| 2024-12-27 |
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40035-024-00458-1 |
|
| 2024-12-23 |
SARS-CoV-2 Spike S1 subunit triggers pericyte and microvascular dysfunction in human pancreatic islets (edit) |
SARSコロナウイルス2 (edit) |
10.2337/DB24-0816 |
|
| 2024-12-21 |
Post-coronavirus disease 2019–associated symptoms among children and adolescents in the SARS-CoV-2 Omicron era (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00431-024-05919-3 |
|
| 2024-12-20 |
Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16121955 |
|
| 2024-12-19 |
Impact of SARS-CoV-2 on the male reproductive tract: insights from semen analysis and cryopreservation (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10815-024-03321-4 |
|
| 2024-12-18 |
Pediatric SARS-CoV-2 long term outcomes study (PECOS): cross sectional analysis at baseline (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41390-024-03777-1 |
|
| 2024-12-18 |
Cardiac Damage in Patients Infected with Different SARS-CoV-2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12122617 |
|
| 2024-12-10 |
SARS-CoV-2 Spike Protein Amplifies the Immunogenicity of Healthy Renal Epithelium in the Presence of Renal Cell Carcinoma (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS13242038 |
|
| 2024-12-10 |
Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS14242774 |
|
| 2024-12-05 |
Impact of SARS-CoV-2 Infection on Physical Fitness in Air Force Basic Trainees (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MILMED/USAE542 |
|
| 2024-12-01 |
Multi‐Organ Spread and Intra‐Host Diversity of SARS‐CoV‐2 Support Viral Persistence, Adaptation, and a Mechanism That Increases Evolvability (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.70107 |
|
| 2024-12-01 |
Clinical features and predictive nomogram for fatigue sequelae in non-severe patients infected with SARS-CoV-2 Omicron variant in Shanghai, China (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBIH.2024.100889 |
|
| 2024-12-01 |
Placenta a potential gateway of prenatal SARS-CoV-2 infection: A review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJOGRB.2024.10.027 |
|
| 2024-12-01 |
The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106297 |
|
| 2024-12-01 |
Trends of common laboratory biomarkers after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106318 |
|
| 2024-12-01 |
Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.126356 |
|
| 2024-12-01 |
Defining long COVID using a population-based SARS-CoV-2 survey in California (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.126358 |
|
| 2024-12-01 |
"Outlaw" mutations in quasispecies of SARS-CoV-2 inhibit replication (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2024.2368211 |
38916498 |
| 2024-12-01 |
Acute hepatitis of unknown aetiology in children: evidence for and against causal relationships with SARS-CoV-2, HAdv and AAV2 (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJPO-2023-002410 |
|
| 2024-12-01 |
Higher Post-Acute Health Care Costs Following SARS-CoV-2 Infection Among Adults in Ontario, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.2147/JMDH.S465154 |
|
| 2024-11-26 |
PD-L1 expression and characterization of its carrier macrophages in placentas with acute and specifically post-SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00418-024-02340-7 |
|
| 2024-11-21 |
Maternal infection of SARS-CoV-2 during the first and second trimesters leads to newborn telomere shortening (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12967-024-05879-0 |
|
| 2024-11-21 |
SARS-CoV-2 Nsp7 plays a role in cognitive dysfunction by impairing synaptic plasticity (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNINS.2024.1490099 |
|
| 2024-11-21 |
Predictors of Long COVID Among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/HEALTHCARE12232321 |
|
| 2024-11-21 |
Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16121811 |
|
| 2024-11-20 |
Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BRAINSCI14111161 |
|
| 2024-11-18 |
Post-COVID recovery is faster after an infection with the SARS-CoV-2 Omicron variant: a population-based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S15010-024-02438-Z |
|
| 2024-11-16 |
Latent class analysis of post-acute sequelae of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1080/10543406.2024.2424844 |
|
| 2024-11-14 |
Long COVID Following Mild SARS-CoV-2 Infection: A Retrospective Study in a Portuguese Primary Health Care Unit (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.73655 |
|
| 2024-11-13 |
SARS-CoV-2 ORF3a induces COVID-19-associated kidney injury through HMGB1-mediated cytokine production (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02308-24 |
|
| 2024-11-12 |
Effect of SARS-CoV-2 Infection on Selected Parameters of the Apelinergic System in Repeat Blood Donors (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES12112583 |
|
| 2024-11-07 |
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-024-08315-X |
|
| 2024-11-07 |
Cardiovascular sequelae in symptomatic SARS-CoV-2 infection survivors (edit) |
SARSコロナウイルス2 (edit) |
10.5603/CJ.99538 |
|
| 2024-11-01 |
Executive deficits after SARS-CoV-2 infection: A cross-sectional population study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBIH.2024.100857 |
|
| 2024-11-01 |
SARS-CoV-2 infection elucidates features of pregnancy-specific immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2024.114933 |
|
| 2024-11-01 |
Immune response in vaccinated healthcare workers with frequent COVID-19 infections is characterised by blunted IFNγ and IL-2 responses to SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2024.110371 |
|
| 2024-11-01 |
Reactive oxygen species induced by SARS-CoV-2 infection can induce EMT in solid tumors: Potential role of COVID-19 in chemo-resistance and metastasis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E40297 |
|
| 2024-11-01 |
Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2024.107285 |
|
| 2024-11-01 |
Clinical and functional assessment of SARS-CoV-2 sequelae among young marines – a panel study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2024.100909 |
|
| 2024-11-01 |
Association between situs inversus and maternal SARS-CoV-2 infection at gestational age 4–6 weeks (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2024.07.009 |
|
| 2024-10-31 |
Longitudinal Fecal Microbiota Profiles in A Cohort of Non-Hospitalized Adolescents and Young Adults with COVID-19: Associations with SARS-CoV-2 Status and Long-Term Fatigue (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS13110953 |
|
| 2024-10-30 |
Investigating the impact of severe maternal SARS-CoV-2 infection on infant DNA methylation and neurodevelopment (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41380-024-02808-X |
|
| 2024-10-30 |
Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-024-01838-Z |
|
| 2024-10-30 |
SARS-CoV-2 propagation to the TPH2-positive neurons in the ventral tegmental area induces cell death via GSK3β-dependent accumulation of phosphorylated tau (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0312834 |
|
| 2024-10-25 |
Arterial floating mural thrombi are a characteristic imaging pattern in SARS-CoV-2-related ischemic stroke (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0311622 |
|
| 2024-10-22 |
Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S41687-024-00797-7 |
|
| 2024-10-21 |
SARS-CoV-2 Infection and the Neuroendocrine System (edit) |
SARSコロナウイルス2 (edit) |
10.1159/000542164 |
|
| 2024-10-19 |
In vitro analysis suggests that SARS-CoV-2 infection differentially modulates cancer-like phenotypes and cytokine expression in colorectal and prostate cancer cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-75718-1 |
|
| 2024-10-15 |
Placental pathology in SARS-CoV-2 infected pregnancies: A single-institution retrospective cohort analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3233/NPM-230177 |
|
| 2024-10-14 |
SARS-CoV-2 Infection and New-Onset Type 2 Diabetes Among Pediatric Patients, 2020 to 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2024.39444 |
|
| 2024-10-12 |
Baseline level of interleukin-6 is associated with the risk of acute coronary syndrome development in SARS-CoV‐2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12872-024-04234-X |
|
| 2024-10-11 |
Cardiac Function and Structure before and after Mild SARS-CoV-2 Infection in Elite Athletes Using Biventricular and Left Atrial Strain (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES12102310 |
|
| 2024-10-10 |
Transplacental SARS-CoV-2 protein ORF8 binds to complement C1q to trigger fetal inflammation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S44318-024-00260-9 |
|
| 2024-10-10 |
Macro- and Microstructural White Matter Differences in Neurologic Postacute Sequelae of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3174/AJNR.A8481 |
|
| 2024-10-09 |
Longitudinal assessment of health-related quality of life after SARS-CoV-2 infection and the associations with clinical and social characteristics in a general practice population (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12955-024-02301-7 |
|
| 2024-10-09 |
Acute onset psychiatric diseases after SARS-CoV-2 virus infection among pediatric patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNEUR.2024.1445903 |
|
| 2024-10-08 |
Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2024.1470953 |
|
| 2024-10-07 |
Elevated serum mtDNA in COVID-19 patients is linked to SARS-CoV-2 envelope protein targeting mitochondrial VDAC1, inducing apoptosis and mtDNA release (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10495-024-02025-5 |
|
| 2024-10-07 |
SARS-CoV-2 RNAemia as a reliable predictor of long-term mortality among older adults hospitalized in pulmonary intermediate care units: a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-024-02526-4 |
|
| 2024-10-05 |
Occupational and industry prevalence of new long‐term symptoms within American Red Cross blood donors with and without history of SARS‐CoV‐2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/AJIM.23670 |
|
| 2024-10-05 |
The Trajectory of Antibody Responses One Year Following SARS-CoV-2 Infection among Indigenous Individuals in the Southwest United States (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16101573 |
39459907 |
| 2024-10-02 |
Long-term COVID-19 sequelae by Theta and SARS-CoV-2 variants in a Philippine cohort (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2024.1455729 |
|
| 2024-10-01 |
Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2024.105976 |
39117283 |
| 2024-10-01 |
Changes in memory and cognition during the SARS-CoV-2 human challenge study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2024.102842 |
|
| 2024-10-01 |
SARS-CoV-2 infection decreases cardiorespiratory fitness and time-trial performance even two months after returning to regular training — Insights from a longitudinal case series of well-trained kayak athletes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JESF.2024.05.003 |
|
| 2024-10-01 |
Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: A cross-sectional survey in the SIREN cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106259 |
|
| 2024-10-01 |
Comparison of Maternal and Infant Outcomes in SARS-CoV-2 Infected Pregnancies and Contemporaneous General Population Pregnancies From British Columbia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JOGC.2024.102631 |
|
| 2024-10-01 |
Cytokine Profile in Children Following SARS-CoV-2 Infection: Preliminary Findings (edit) |
SARSコロナウイルス2 (edit) |
10.1097/INF.0000000000004558 |
|
| 2024-10-01 |
Impact of SARS-CoV-2 viral load on restrictive spirometry patterns in mild COVID-19 recovered middle-aged individuals: a six-month prospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-09959-W |
|
| 2024-09-30 |
Systemic cytokines related to memory function 6–9 months and 12–15 months after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-72421-Z |
|
| 2024-09-30 |
SARS-CoV-2 Omicron XBB infections boost cross-variant neutralizing antibodies, potentially explaining the observed delay of the JN.1 wave in some Brazilian regions (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2024.09.28.24314453 |
|
| 2024-09-28 |
Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00432-024-05963-4 |
|
| 2024-09-27 |
RNA-Seq analysis of human heart tissue reveals SARS-CoV-2 infection and inappropriate activation of the TNF-NF-κB pathway in cardiomyocytes (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-69635-6 |
|
| 2024-09-27 |
Risk of Reinfection and Incidence of Chronic Symptoms After SARS-CoV-2 Infections (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAE608 |
|
| 2024-09-27 |
Communication Skills in Toddlers Exposed to Maternal SARS-CoV-2 during Pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE14101237 |
|
| 2024-09-27 |
Common for COVID-19 cytokine storm in patients with SARS-CoV-2 infection and CLL (chronic lymphocytic leukemia) (edit) |
SARSコロナウイルス2 (edit) |
10.3897/PHARMACIA.71.E135468 |
|
| 2024-09-26 |
Oncogenic potential of SARS-CoV-2—targeting hallmarks of cancer pathways (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12964-024-01818-0 |
|
| 2024-09-26 |
Impact of Vaccination on Intra-Host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16101524 |
|
| 2024-09-19 |
Long COVID is not the same for everyone: a hierarchical cluster analysis of Long COVID symptoms 9 and 12 months after SARS-CoV-2 test (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-09896-8 |
|
| 2024-09-19 |
SARS-CoV-2 seroprevalence and preeclampsia markers in Mozambican pregnant women with perinatal loss (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12884-024-06800-9 |
|
| 2024-09-18 |
Transplacental Transmission of SARS-CoV-2: A Narrative Review (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MEDICINA60091517 |
|
| 2024-09-17 |
Infiltrating monocytes drive cardiac dysfunction in a cardiomyocyte-restricted mouse model of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01179-24 |
|
| 2024-09-13 |
Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAE469 |
|
| 2024-09-13 |
Multimodal neuroimaging in Long-COVID and its correlates with cognition 1.8 years after SARS-CoV-2 infection: a cross-sectional study of the Aliança ProHEpiC-19 Cognitiu (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNEUR.2024.1426881 |
|
| 2024-09-11 |
Symptom burden, coagulopathy and heart disease after acute SARS-CoV-2 infection in primary practice (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-71535-8 |
|
| 2024-09-11 |
Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1448780 |
|
| 2024-09-09 |
SARS-CoV-2 impairs male fertility by targeting semen quality and testosterone level: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0307396 |
|
| 2024-09-04 |
Two-year epidemiology of post-COVID-19 conditions in Bangladesh: a cohort study of post-COVID-19 from 12,925 SARS-CoV-2 cases between July and December 2021–2023 in Bangladesh (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13690-024-01358-6 |
|
| 2024-09-04 |
SARS-CoV-2 replicates in the placenta after maternal infection during pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2024.1439181 |
|
| 2024-09-03 |
The delivery device of SARS-CoV-2 mucosal vaccine matters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-024-01950-6 |
|
| 2024-09-02 |
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ADJ9285 |
|
| 2024-09-01 |
Cardiovascular disease risk after a SARS-CoV-2 infection: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106215 |
|
| 2024-09-01 |
A prospective cohort study of pregnancy outcomes following antepartum infection with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PREGHY.2024.101152 |
|
| 2024-09-01 |
Cognitive function in Mexican older adults 6-months after recovering from SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REGG.2024.101479 |
|
| 2024-09-01 |
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus (edit) |
SARSコロナウイルス2 (edit) |
10.1136/LUPUS-2023-001104 |
|
| 2024-08-30 |
Analysis of Cultured Gut Microbiota Using MALDI-TOF MS in COVID-19 Patients from Serbia during the Predominance of the SARS-CoV-2 Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12091800 |
|
| 2024-08-28 |
Recent evolutionary origin and localized diversity hotspots of mammalian coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.91745.3 |
|
| 2024-08-27 |
Fecal shedding of SARS-CoV-2 in infants born to SARS-CoV-2 positive mothers: a pilot study (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.17956 |
|
| 2024-08-23 |
Evolution of SARS-CoV-2 in the murine central nervous system drives viral diversification (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-024-01786-8 |
|
| 2024-08-22 |
Mathematical Model of SARS-CoV-2 infection with Andrographolide Therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3670085.3670102 |
|
| 2024-08-20 |
The Impact of SARS-CoV-2 Infection on Sleep, Daytime Sleepiness, and Depression—Longitudinal Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MEDICINA60081352 |
|
| 2024-08-16 |
Clinical characteristics, treatment and prognosis of children with SARS-CoV-2 infection complicated with severe neurological dysfunctions in Foshan, China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPED.2024.1414023 |
|
| 2024-08-13 |
Impact of Vaccination on Intra-host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202408.0940.V1 |
|
| 2024-08-13 |
In Situ Analyses of Placental Inflammatory Response to SARS-CoV-2 Infection in Cases of Mother–Fetus Vertical Transmission (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25168825 |
|
| 2024-08-10 |
Hospitalized children with COVID-19 infection during large outbreak of SARS-CoV-2 Omicron strain: a retrospective study in Chaozhou, Guangdong, China (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07853890.2024.2389301 |
|
| 2024-08-10 |
Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infection (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2024.08.08.607190 |
39211190 |
| 2024-08-08 |
Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMOA2403211 |
|
| 2024-08-03 |
Challenges in the Diagnosis of SARS-CoV-2 Infection in the Nervous System (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16081247 |
39205221 |
| 2024-08-02 |
SARS-CoV-2 variants divergently infect and damage cardiomyocytes in vitro and in vivo (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-024-01280-Y |
|
| 2024-08-01 |
Exploring the underlying molecular mechanisms of acute myocardial infarction after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AHJO.2024.100417 |
|
| 2024-08-01 |
The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(24)00171-3 |
|
| 2024-08-01 |
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2213-8587(24)00159-1 |
|
| 2024-08-01 |
Effects of Maternal SARS‐CoV‐2 Infection During Pregnancy on Fetal Development (edit) |
SARSコロナウイルス2 (edit) |
10.1111/AJI.13911 |
|
| 2024-08-01 |
The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01240-24 |
39087765 |
| 2024-08-01 |
Mild Primary or Breakthrough SARS-CoV-2 Infection Promotes Autoantibody Production in Individuals with and without Neuro-PASC (edit) |
SARSコロナウイルス2 (edit) |
10.4049/IMMUNOHORIZONS.2400033 |
|
| 2024-07-30 |
Clusters of emerging multidrug-resistant organisms in United States healthcare facilities during the initial months of the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2024.07.013 |
|
| 2024-07-29 |
SARS‐CoV‐2 spike protein acts as a β‐adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JOIM.20000 |
|
| 2024-07-27 |
A Comparative Study on the Pain Threshold Experienced by Fibromyalgia Patients Following Acute SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE14080942 |
|
| 2024-07-26 |
Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S44319-024-00216-4 |
|
| 2024-07-26 |
Impacto de las variantes genéticas del SARS-CoV-2 en la hospitalización de pacientes con COVID-19 procedentes de la vigilancia nacional del Ministerio de Salud de Nicaragua, marzo 2020 – septiembre 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.5377/ESTELI.V13I50.18474 |
|
| 2024-07-23 |
Mitochondrial antioxidants abate SARS-COV-2 pathology in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2321972121 |
39008677 |
| 2024-07-23 |
SARS-CoV-2 spike does not interact with the T cell receptor or directly activate T cells (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2406615121 |
|
| 2024-07-23 |
A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2408109121 |
39028694 |
| 2024-07-16 |
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2310421121 |
38976733 |
| 2024-07-16 |
Point mutations at specific sites of the nsp12-nsp8 interface dramatically affect the RNA polymerization activity of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2317977121 |
38990941 |
| 2024-07-14 |
Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.16210 |
|
| 2024-07-11 |
Comparative Proteomics and Interactome Analysis of the SARS-CoV-2 Nucleocapsid Protein in Human and Bat Cell Lines (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16071117 |
|
| 2024-07-10 |
Pre-or co-SARS-CoV-2 Infections Significantly Increase Severe Dengue Virus Disease Criteria: Implications for Clinicians (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS13070573 |
|
| 2024-07-03 |
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ADK3295 |
|
| 2024-07-02 |
SARS-CoV-2 Infection during Delivery Causes Histopathological Changes in the Placenta (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DISEASES12070142 |
|
| 2024-07-01 |
Prevalence and co-occurrence of cognitive impairment in children and young people up to 12-months post infection with SARS-CoV-2 (Omicron variant) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBI.2024.05.001 |
|
| 2024-07-01 |
Neurological manifestations of SARS-CoV-2 infection in children in Taiwan: A cross-section, multicenter study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JFMA.2023.12.020 |
|
| 2024-07-01 |
Unveiling long COVID symptomatology, co-occurrence trends, and symptom distress post SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIPH.2024.05.052 |
|
| 2024-07-01 |
Immune encephalitis/meningitis, cerebral vasculitis, or HANDL syndrome following SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NEUROP.2024.100157 |
|
| 2024-07-01 |
A mini-review of the anti-SARS-CoV-2 potency of Amaryllidaceae alkaloids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYMED.2024.155576 |
|
| 2024-07-01 |
Short-term and long-term stroke risk following SARS-CoV-2 infection in relation to disease severity: a Danish national cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2023-083171 |
|
| 2024-06-28 |
Respiratory SARS-CoV-2 Infection Causes Skeletal Muscle Atrophy and Long-Lasting Energy Metabolism Suppression (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES12071443 |
|
| 2024-06-22 |
Multicenter and multimodal imaging study reveals rare fundus lesions in patients after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-65216-9 |
|
| 2024-06-21 |
In silico analysis of the protein-protein interaction of the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.33448/RSD-V13I6.46139 |
|
| 2024-06-20 |
EEG signatures of cognitive decline after mild SARS-CoV-2 infection: an age-dependent study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-024-03481-1 |
|
| 2024-06-19 |
Human SARS-CoV-2 challenge uncovers local and systemic response dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-024-07575-X |
|
| 2024-06-17 |
Epidemiologic Features of Recovery From SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2024.17440 |
|
| 2024-06-17 |
Neurological Manifestations of Acute SARS-CoV-2 Infection in Pediatric Patients: A 3-Year Study on Differences between Pandemic Waves (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16060967 |
|
| 2024-06-14 |
Prediction of Potential Repurposed Drugs against SARS-CoV-2 based on Text Mining and Molecular Docking Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3641584.3641805 |
|
| 2024-06-14 |
Complexity and Diversity of the Neurological Spectrum of SARS-CoV-2 over Three Waves of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM13123477 |
|
| 2024-06-14 |
Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications (edit) |
SARSコロナウイルス2 (edit) |
10.3748/WJG.V30.I22.2866 |
|
| 2024-06-12 |
Meta-analysis of Cognitive Function Following Non-severe SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11065-024-09642-6 |
|
| 2024-06-08 |
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-49235-8 |
38851796 |
| 2024-06-06 |
Screening of Mpro Protease (SARS-CoV-2) Covalent Inhibitors from an Anthocyanin-Rich Blueberry Extract Using an HRMS-Based Analytical Platform (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES29112702 |
|
| 2024-06-01 |
Association of obstructive sleep apnea with post-acute sequelae of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJMED.2024.02.023 |
|
| 2024-06-01 |
Acquired Immune Deficiency Syndrome correlation with SARS-CoV-2 N genotypes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BJ.2023.100650 |
|
| 2024-06-01 |
Effect of SARS-CoV-2 IgG Seroconversion After Convalescent Plasma Transfusion on Hospital Outcomes in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHSTCC.2024.100048 |
|
| 2024-06-01 |
Association of antenatal or neonatal SARS-COV-2 exposure with developmental and respiratory outcomes, and healthcare usage in early childhood: a national prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2024.102628 |
|
| 2024-06-01 |
Estimating measures to reduce the transmission of SARS-CoV-2 in Australia to guide a ‘National Plan’ to reopening (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EPIDEM.2024.100763 |
|
| 2024-06-01 |
Inferring community transmission of SARS-CoV-2 in the United Kingdom using the ONS COVID-19 Infection Survey (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDM.2024.01.011 |
|
| 2024-06-01 |
Risk of herpes zoster in adults with SARS-CoV-2 infection in Spain: A population-based, retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2024.107037 |
|
| 2024-06-01 |
An efficient ELISA protocol for measurement of SARS-CoV-2 spike-specific IgG in human plasma and serum samples (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEX.2024.102596 |
|
| 2024-06-01 |
Use of hybrid molecular simulation techniques for systematic analysis of polyphenols as promising therapeutic agent against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2024.137744 |
|
| 2024-05-30 |
Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.90316 |
|
| 2024-05-29 |
Initial COVID-19 severity influenced by SARS-CoV-2-specific T cells imprints T-cell memory and inversely affects reinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-024-01867-4 |
|
| 2024-05-27 |
Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-48825-W |
38802352 |
| 2024-05-24 |
Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-61918-2 |
38789553 |
| 2024-05-22 |
Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12014-024-09482-9 |
|
| 2024-05-19 |
Increased risk of fetal left–right asymmetry disorders associated with maternal SARS-CoV-2 infection during the first trimester (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-61778-W |
|
| 2024-05-16 |
Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-48556-Y |
|
| 2024-05-07 |
Upregulation of mRNA Expression of ADGRD1/GPR133 and ADGRG7/GPR128 in SARS-CoV-2-Infected Lung Adenocarcinoma Calu-3 Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS13100791 |
|
| 2024-05-03 |
Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure (edit) |
SARSコロナウイルス2 (edit) |
10.18632/ONCOTARGET.28582 |
|
| 2024-05-01 |
Reverse Zoonotic Transmission of SARS-CoV-2 and Monkeypox Virus: A Comprehensive Review (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12275-024-00138-9 |
|
| 2024-05-01 |
Artificial Intelligence Electrocardiography Detecting Thyrotoxic Periodic Paralysis Following a SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJMED.2024.01.018 |
|
| 2024-05-01 |
The silent reservoir? SARS-CoV-2 detection in the middle ear effusion of patients with Otitis media with effusion after omicron infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJOTO.2024.104229 |
|
| 2024-05-01 |
A CRISPR/Cas12 trans-cleavage reporter enabling label-free colorimetric detection of SARS-CoV-2 and its variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOS.2024.116102 |
|
| 2024-05-01 |
Fucoidan from Ascophyllum nodosum and Undaria pinnatifida attenuate SARS-CoV-2 infection in vitro and in vivo by suppressing ACE2 and alleviating inflammation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CARBPOL.2024.121884 |
|
| 2024-05-01 |
Solid organ transplantation in SARS-CoV-2 positive recipients: a web-survey among ESGICH members (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMI.2024.01.012 |
|
| 2024-05-01 |
Exposure to urban particulate matter alters responses of olfactory mucosal cells to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2024.118451 |
|
| 2024-05-01 |
Quality assurance of SARS-CoV-2 testing laboratories during the pandemic period in India – An experience from a designated provider laboratory (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJMMB.2024.100577 |
|
| 2024-05-01 |
Duration of antibody response to the receptor binding domain of SARS-CoV-2 in infected or vaccinated individuals – A one year retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2024.112084 |
|
| 2024-05-01 |
Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2024.106150 |
|
| 2024-05-01 |
Interaction analysis of SARS-CoV-2 omicron BA1 and BA2 of RBD with fifty monoclonal antibodies: Molecular dynamics approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2024.108719 |
|
| 2024-05-01 |
Synthesis of 5-heptadecyl-4H-1,2,4-triazole incorporated indole moiety: Antiviral (SARS-CoV-2), antimicrobial, and molecular docking studies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2024.137517 |
|
| 2024-05-01 |
Molecular interaction of heparin and proteins–A relationship with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2024.137559 |
|
| 2024-05-01 |
In-hospital breastfeeding and predictive factors during the SARS-CoV-2 pandemic: A retrospective cohort study — Aleitamento materno hospitalar e fatores preditores durante a pandemia pelo SARS-CoV-2: Coorte retrospectiva (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PEDN.2024.01.030 |
|
| 2024-05-01 |
Nanoscale porphyrinic metal-organic frameworks as a photodynamic probe for highly sensitive detection of SARS-CoV-2 related RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SNB.2024.135413 |
|
| 2024-05-01 |
SARS-CoV-2 infection exacerbates the cellular pathology of Parkinson’s disease in human dopaminergic neurons and a mouse model (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2024.101570 |
|
| 2024-05-01 |
Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAE183 |
38800610 |
| 2024-04-30 |
Correction to: Relative role of community transmission and campus contagion in driving the spread of SARS-CoV-2: Lessons from Princeton University (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAE180 |
38706728 |
| 2024-04-30 |
A Tiny Viral Protein, SARS-CoV-2-ORF7b: Functional Molecular Mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM14050541 |
|
| 2024-04-27 |
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12050467 |
|
| 2024-04-26 |
A SARS-CoV-2 outbreak investigation at a storage and distribution centre in England: an assessment of worker- and workplace-related risk factors (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-60194-4 |
|
| 2024-04-20 |
Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25084522 |
|
| 2024-04-19 |
Correction: Factors associated with SARS-COV-2 positive test in Lifelines (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0302619 |
|
| 2024-04-19 |
Investigating SARS-CoV-2 Incidence and Morbidity in Ponce, Puerto Rico: Protocol and Baseline Results From a Community Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.2196/53837 |
|
| 2024-04-18 |
CCN1-Mediated Signaling in Placental Villous Tissues after SARS-CoV-2 Infection in Term Pregnant Women: Implications for Dysregulated Angiogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB46040221 |
|
| 2024-04-18 |
Cytokine profiles of mild-to-moderate SARS-CoV-2 infected and recovered pre-vaccinated individuals residing in Indonesia (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.17257 |
|
| 2024-04-17 |
The plasma proteome differentiates the multisystem inflammatory syndrome in children (MIS-C) from children with SARS-CoV-2 negative sepsis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S10020-024-00806-X |
|
| 2024-04-17 |
Binding of Natural Antibodies Generated after COVID-19 and Vaccination with Individual Peptides Corresponding to the SARS-CoV-2 S-Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12040426 |
|
| 2024-04-16 |
Are Kidneys Affected by SARS-CoV-2 Infection? An Updated Review on COVID-19-Associated AKI (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS13040325 |
|
| 2024-04-15 |
Prediction of Prospective Mutational Landscape of SARS-CoV-2 Spike ssRNA and Evolutionary Basis of Its Host Interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12033-024-01146-1 |
|
| 2024-04-15 |
Age-specific nasal epithelial responses to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-024-01658-1 |
|
| 2024-04-15 |
Critically ill children with SARS-COV-2 Omicron infection at a national children medical center, Guangdong, China (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12887-024-04735-W |
|
| 2024-04-15 |
Anti-synthase syndrome associated with SARS-Cov-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12890-024-02966-2 |
|
| 2024-04-15 |
Study anti-viral drugs for their efficiency against multiple SARS CoV-2 drug targets within molecular docking, molecular quantum similarity, and chemical reactivity indices frameworks (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.146350.1 |
|
| 2024-04-14 |
Molecular modelling studies and in vitro enzymatic assays identified A 4-(nitrobenzyl)guanidine derivative as inhibitor of SARS-CoV-2 Mpro (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-59292-0 |
|
| 2024-04-13 |
Positive selection underlies repeated knockout of ORF8 in SARS-CoV-2 evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-47599-5 |
|
| 2024-04-10 |
SARS-CoV-2 infects cells lining the blood-retinal barrier and induces a hyperinflammatory immune response in the retina via systemic exposure (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1012156 |
|
| 2024-04-08 |
Long-Term Symptoms Associated With SARS-CoV-2 Infection Among Blood Donors (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2024.5611 |
|
| 2024-04-08 |
SARS-CoV-2 causes dysfunction in human iPSC-derived brain microvascular endothelial cells potentially by modulating the Wnt signaling pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12987-024-00533-9 |
|
| 2024-04-05 |
ER-export and ARFRP1/AP-1–dependent delivery of SARS-CoV-2 Envelope to lysosomes controls late stages of viral replication (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ADL5012 |
|
| 2024-04-05 |
The Kinetic parameters, Thermodynamic parameters, and Mechanism of PLpro from SARS-CoV and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3644116.3644322 |
|
| 2024-04-05 |
Analysis of the mechanism of alliin and allicin against SARS-CoV-2S/ACE2 and SARS-CoV-2 Mpro based on molecular docking and molecular dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3644116.3644341 |
|
| 2024-04-04 |
Alterations of Whole-Body Glucose Metabolism in a Feline SARS-CoV-2 Infection Model (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPREGU.00228.2023 |
|
| 2024-04-04 |
Clinical presentation of post-COVID pain and its impact on quality of life in long COVID patients: a cross-sectional household survey of SARS-CoV-2 cases in Bangladesh (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-09267-3 |
|
| 2024-04-04 |
Unveiling hidden structural patterns in the SARS-CoV-2 genome: Computational insights and comparative analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0298164 |
|
| 2024-04-04 |
Assessing the emergence time of SARS-CoV-2 zoonotic spillover (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0301195 |
|
| 2024-04-02 |
A Comparative Analysis of Innate Immune Responses and the Structural Characterization of Spike from SARS-CoV-2 Gamma Variants and Subvariants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12040720 |
|
| 2024-04-01 |
Risk of Major Adverse Cardiovascular Events After SARS-CoV-2 Infection in British Columbia: A Population-Based Study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJMED.2024.04.010 |
|
| 2024-04-01 |
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2024.105837 |
|
| 2024-04-01 |
Low SARS-CoV-2 prevalence in asymptomatic children during the first year of the pandemic: A French retrospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARCPED.2023.09.019 |
|
| 2024-04-01 |
Inhibition potential of steroidal compounds from Nerium oleander against SARS-CoV-2 using molecular docking approach. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BCAB.2024.103051 |
|
| 2024-04-01 |
High enhancement of sensitivity and reproducibility in label-free SARS-CoV-2 detection with graphene field-effect transistor sensors through precise surface biofunctionalization control (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOS.2024.116040 |
|
| 2024-04-01 |
Unleashing inkjet-printed nanostructured electrodes and battery-free potentiostat for the DNA-based multiplexed detection of SARS-CoV-2 genes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOS.2024.116079 |
|
| 2024-04-01 |
Function and mechanism of bispecific antibodies targeting SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELLIN.2024.100150 |
|
| 2024-04-01 |
Alpha 1-acid glycoprotein is upregulated in severe COVID-19 patients and decreases neutrophil NETs in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CYTO.2024.156503 |
|
| 2024-04-01 |
Incidence of Common Glomerular Diseases Other Than Collapsing Glomerulopathy is Not Increased After SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EKIR.2024.01.028 |
|
| 2024-04-01 |
SARS-CoV-2 virus variant detection and mortality prediction through symptom analysis using machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENGAPPAI.2023.107743 |
|
| 2024-04-01 |
Differences in Report of Post-COVID Conditions Among Adults Tested for SARS-CoV-2 by Race and Ethnicity: 2022 Porter Novelli SummerStyles Survey, U.S. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FOCUS.2023.100181 |
|
| 2024-04-01 |
Representative Public Health Surveys Pose Several Challenges: Lessons Learned Across 9 Communities During the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FOCUS.2024.100198 |
38379957 |
| 2024-04-01 |
A retrospective study suggests 55 days of persistence of SARS-CoV-2 during the first wave of the pandemic in Santiago de Chile (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E24419 |
|
| 2024-04-01 |
Corrigendum to "Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey" [International Journal of Infectious Diseases 139 (2024) 159-167] (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2024.02.007 |
38452689 |
| 2024-04-01 |
A prognostic model for SARS-CoV-2 breakthrough infection: Analyzing a prospective cellular immunity cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2024.111829 |
|
| 2024-04-01 |
Examining the Association between Frailty and Antibody Neutralization of SARS-CoV-2: A Multisite Retrospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAMDA.2023.12.013 |
|
| 2024-04-01 |
SARS-CoV-2 among liver transplant recipients: clinical course and mutational analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCVP.2024.100181 |
|
| 2024-04-01 |
Predicting potential SARS-CoV-2 spillover and spillback in animals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMII.2024.01.002 |
|
| 2024-04-01 |
The wind of change: Gibbs energy of binding and infectivity evolution of Omicron BA.2.86 Pirola, EG.5.1, XBB.1.16 Arcturus, CH.1.1 and BN.1 variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MRAN.2024.100290 |
|
| 2024-04-01 |
Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MUCIMM.2024.01.004 |
|
| 2024-04-01 |
Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RXENG.2023.10.002 |
|
| 2024-04-01 |
Activity and inhibition of the SARS-CoV-2 Omicron nsp13 R392C variant using RNA duplex unwinding assays (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SLASD.2024.01.006 |
|
| 2024-04-01 |
A cell-adapted SARS-CoV-2 mutant, showing a deletion in the spike protein spanning the furin cleavage site, has reduced virulence at the lung level in K18-hACE2 mice. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2024.109997 |
|
| 2024-04-01 |
Quantitative and qualitative subgenomic RNA profiles of SARS-CoV-2 in respiratory samples: A comparison between Omicron BA.2 and non-VOC-D614G (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2024.01.010 |
|
| 2024-04-01 |
Network Activity Evaluation Reveals Significant Gene Regulatory Architectures During SARS-CoV-2 Viral Infection From Dynamic scRNA-seq Data (edit) |
SARSコロナウイルス2 (edit) |
10.1109/JBHI.2024.3360529 |
|
| 2024-04-01 |
Community health worker outreach to farmworkers in rural North Carolina: Learning from adaptations to the SARS‐CoV‐2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1111/HEX.14047 |
|
| 2024-04-01 |
SARS-CoV-2 infection by trimester of pregnancy and adverse perinatal outcomes: a Mexican retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2023-075928 |
|
| 2024-04-01 |
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset (edit) |
SARSコロナウイルス2 (edit) |
10.1164/RCCM.202308-1438OC |
|
| 2024-04-01 |
SARS-CoV-2 Lurking and Lingering in the Depths of Lungs (edit) |
SARSコロナウイルス2 (edit) |
10.1164/RCCM.202401-0067ED |
|
| 2024-04-01 |
Persistence of SARS-CoV-2 colonization and high expression of inflammatory factors in cardiac tissue 6 months after COVID-19 recovery: a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.21037/CDT-23-381 |
|
| 2024-04-01 |
High-throughput screening for a SARS-CoV-2 frameshifting inhibitor using a cell-free protein synthesis system (edit) |
SARSコロナウイルス2 (edit) |
10.2144/BTN-2023-0102 |
|
| 2024-04-01 |
Before SARS-CoV-2-related Encephalitis Can Be Attributed to Anti-GFAP Antibodies, Alternative Etiologies Must Be Ruled out (edit) |
SARSコロナウイルス2 (edit) |
10.2169/INTERNALMEDICINE.3237-23 |
|
| 2024-04-01 |
Response to: Before SARS-CoV-2-related Encephalitis Can Be Attributed to Anti-GFAP Antibodies, Alternative Etiologies Must Be Ruled out (edit) |
SARSコロナウイルス2 (edit) |
10.2169/INTERNALMEDICINE.3323-23 |
|
| 2024-03-28 |
Diving into the proteomic atlas of SARS-CoV-2 infected cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-56328-3 |
|
| 2024-03-28 |
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADM9724 |
|
| 2024-03-25 |
Use of Sentinel Surveillance Platforms for Monitoring SARS-CoV-2 Activity: Evidence From Analysis of Kenya Influenza Sentinel Surveillance Data (edit) |
SARSコロナウイルス2 (edit) |
10.2196/50799 |
|
| 2024-03-23 |
Who Is the Intermediate Host of RNA Viruses? A Study Focusing on SARS-CoV-2 and Poliovirus (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12040643 |
|
| 2024-03-21 |
Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41562-024-01853-4 |
|
| 2024-03-20 |
Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-55762-7 |
|
| 2024-03-19 |
Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01157-23 |
|
| 2024-03-18 |
Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-57093-Z |
|
| 2024-03-18 |
Mechanistic Insight into Binding of Graphene Towards Multiple Therapeutic Target of SARS-CoV-2 by Molecular Docking and Dynamics Studies (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0126667975297302240306111904 |
|
| 2024-03-15 |
Screening of Some Ayurvedic Phytochemicals to Identify Potential Inhibitors against SARS-CoV-2 Mpro by In Silico Computational Approach (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0122113525255835240107162255 |
|
| 2024-03-14 |
Developing inhibitory peptides against SARS-CoV-2 envelope protein (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3002522 |
|
| 2024-03-13 |
Rapid, high-throughput, cost-effective whole-genome sequencing of SARS-CoV-2 using a condensed library preparation of the Illumina DNA Prep kit (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00103-22 |
|
| 2024-03-13 |
NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03358-23 |
|
| 2024-03-12 |
Transmission electron microscopy reveals the presence of SARS‐CoV‐2 in human spermatozoa associated with an ETosis‐like response (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ANDR.13612 |
|
| 2024-03-11 |
Impact of mutations on the stability of SARS-CoV-2 nucleocapsid protein structure (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-55157-8 |
|
| 2024-03-09 |
Risks of incident major osteoporotic fractures following SARS-CoV-2 infection among older individuals: a population-based cohort study in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JBMR/ZJAE041 |
|
| 2024-03-07 |
Extracellular vesicles derived from SARS-CoV-2 M-protein-induced triple negative breast cancer cells promoted the ability of tissue stem cells supporting cancer progression (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FONC.2024.1346312 |
|
| 2024-03-06 |
Aspergillus fumigatus secretes a protease(s) that displays in silico binding affinity towards the SARS-CoV-2 spike protein and mediates SARS-CoV-2 pseudovirion entry into HEK-293T cells (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-024-02331-Z |
|
| 2024-03-05 |
Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45400-1 |
|
| 2024-03-05 |
A photocontrolled one-pot isothermal amplification and CRISPR-Cas12a assay for rapid detection of SARS-CoV-2 Omicron variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03645-23 |
|
| 2024-03-05 |
Development and evaluation of three automated media pooling and molecular diagnostic systems for the detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03684-23 |
|
| 2024-03-05 |
Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03831-23 |
|
| 2024-03-04 |
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-55320-1 |
|
| 2024-03-01 |
Current clinical findings of acute neurological syndromes after SARS‐CoV‐2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/MCO2.508 |
|
| 2024-03-01 |
Myocardial Infarction During SARS-CoV-2 Infection: Another Piece in the Long-COVID Puzzle (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJCARD.2024.01.013 |
|
| 2024-03-01 |
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2024.105813 |
|
| 2024-03-01 |
Exploring 2-methyl–substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BMCL.2024.129642 |
|
| 2024-03-01 |
Smart and emerging point of care electrochemical sensors based on nanomaterials for SARS-CoV-2 virus detection: Towards designing a future rapid diagnostic tool (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMOSPHERE.2024.141269 |
|
| 2024-03-01 |
A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2024.109902 |
|
| 2024-03-01 |
Development of a potent recombinant scFv antibody against the SARS-CoV-2 by in-depth bioinformatics study: Paving the way for vaccine/diagnostics development (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2024.108091 |
|
| 2024-03-01 |
Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2024.102500 |
|
| 2024-03-01 |
Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJMECH.2024.116132 |
|
| 2024-03-01 |
Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENDMTS.2024.100163 |
|
| 2024-03-01 |
A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HLIFE.2024.02.001 |
|
| 2024-03-01 |
Oxygen debt as a predictor of high-flow nasal cannula therapy failure in SARS-CoV-2 patients with acute respiratory failure: A retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HRTLNG.2023.10.013 |
|
| 2024-03-01 |
Assessment of the predictive value of plasma calprotectin in the evolution of SARS-Cov-2 primo-infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDNOW.2024.104860 |
|
| 2024-03-01 |
Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJANTIMICAG.2024.107094 |
|
| 2024-03-01 |
Overview of the SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2024.129523 |
|
| 2024-03-01 |
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2024.129926 |
|
| 2024-03-01 |
Accelerating SARS-CoV-2 genomic surveillance in a routine clinical setting with nanopore sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJMM.2024.151599 |
|
| 2024-03-01 |
Post-COVID syndrome and work ability 9-12 months after a SARS-CoV-2 infection among over 9000 employees from the general population (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJREGI.2023.11.015 |
|
| 2024-03-01 |
Whole genome sequencing and phylogenetic analysis of SARS-CoV-2 strains isolated during the COVID-19 pandemic in Nigeria (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJREGI.2024.01.005 |
|
| 2024-03-01 |
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJREGI.2024.01.007 |
|
| 2024-03-01 |
Methods for SARS-CoV-2 hospital disinfection, in vitro observations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INFPIP.2024.100339 |
|
| 2024-03-01 |
Predictors of in-hospital mortality in elderly unvaccinated patients during SARS-CoV-2 Alpha variants epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INFPIP.2024.100341 |
|
| 2024-03-01 |
Fourth dose of microneedle array patch of SARS-CoV-2 S1 protein subunit vaccine elicits robust long-lasting humoral responses in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2024.111569 |
|
| 2024-03-01 |
Autoantibody profiles assessment in individuals with persistent olfactory impairment following SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2024.111599 |
|
| 2024-03-01 |
Ferritin-binding and ubiquitination-modified mRNA vaccines induce potent immune responses and protective efficacy against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2024.111630 |
|
| 2024-03-01 |
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.109049 |
|
| 2024-03-01 |
Wide-range and selective detection of SARS-CoV-2 DNA via surface modification of electrolyte-gated IGZO thin-film transistors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.109061 |
|
| 2024-03-01 |
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.109123 |
|
| 2024-03-01 |
Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.109177 |
|
| 2024-03-01 |
SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JGEB.2023.100347 |
|
| 2024-03-01 |
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIPH.2023.12.026 |
|
| 2024-03-01 |
Caveolin-1 mediates blood-brain barrier permeability, neuroinflammation, and cognitive impairment in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JNEUROIM.2024.578309 |
|
| 2024-03-01 |
SARS-CoV-2 infection is associated with physical but not mental fatigue – Findings from a longitudinal controlled population-based study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPSYCHORES.2024.111598 |
|
| 2024-03-01 |
In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANEPE.2024.100855 |
|
| 2024-03-01 |
Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANEPE.2024.100872 |
|
| 2024-03-01 |
Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023): a multicentre prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANSEA.2023.100348 |
|
| 2024-03-01 |
Virus-mediated cell fusion of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MBS.2024.109144 |
|
| 2024-03-01 |
Understanding SARS-CoV-2 spike glycoprotein clusters and their impact on immunity of the population from Rio Grande do Norte, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2024.105556 |
|
| 2024-03-01 |
Description of nasopharyngeal bacterial pathogens associated with different SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2024.106561 |
|
| 2024-03-01 |
Comparison of molecular and microbiological detection rates of Mycobacterium tuberculosis and prevalence of SARS-CoV-2 variants in Monterrey, Mexico (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICROB.2024.100038 |
|
| 2024-03-01 |
Targeting the main SARS-Cov-2 pathways with peptide inhibitors by molecular docking and molecular simulation approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLLIQ.2024.124193 |
|
| 2024-03-01 |
High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTM.2024.101189 |
|
| 2024-03-01 |
On the impact of surveillance test strategies: a cost–benefit modelling analysis based upon real-world data from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PUHE.2023.12.027 |
|
| 2024-03-01 |
Nursing and healthcare-associated pneumonia due to SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RESINV.2023.12.014 |
|
| 2024-03-01 |
Correspondence of SARS-CoV-2 genomic sequences obtained from wastewater samples and COVID-19 patient at long-term care facilities (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2024.170103 |
|
| 2024-03-01 |
Influences of 23 different equations used to calculate gene copies of SARS-CoV-2 during wastewater-based epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2024.170345 |
|
| 2024-03-01 |
Mucosal-Associated Invariant T Cells are not susceptible in vitro to SARS-CoV-2 infection but accumulate into the lungs of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2024.199315 |
|
| 2024-03-01 |
Results from the SARS-CoV-2 wastewater-based surveillance system in Denmark, July 2021 to June 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.WATRES.2024.121223 |
|
| 2024-03-01 |
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2024.01.025 |
|
| 2024-03-01 |
The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00258-6 |
|
| 2024-03-01 |
Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00324-5 |
|
| 2024-03-01 |
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00336-1 |
|
| 2024-03-01 |
Air change rate and SARS-CoV-2 exposure in hospitals and residences: a meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02786826.2024.2312178 |
38764553 |
| 2024-03-01 |
Role of the SARS-CoV-2 Virus in Brain Cells (edit) |
SARSコロナウイルス2 (edit) |
10.1089/VIM.2023.0116 |
|
| 2024-03-01 |
COVID-19 in pregnant women: a systematic review and meta-analysis on the risk and prevalence of pregnancy loss (edit) |
SARSコロナウイルス2 (edit) |
10.1093/HUMUPD/DMAD030 |
38016805 |
| 2024-03-01 |
Correction to: Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAE098 |
38463038 |
| 2024-03-01 |
SARS‐CoV‐2 infection negatively impacts on the quality of embryos by delaying early embryonic development (edit) |
SARSコロナウイルス2 (edit) |
10.1111/AJI.13831 |
|
| 2024-03-01 |
The S1 subunits of SARS-CoV-2 variants differentially trigger the IL-6 signaling pathway in human brain endothelial cells and downstream impact on microglia activation (edit) |
SARSコロナウイルス2 (edit) |
10.1515/NIPT-2023-0024 |
38532784 |
| 2024-03-01 |
Determination of Anti-Spike S1 RBD IgG Values in Healthcare Workers with Inactivated SARS-CoV-2 Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.19127/BSHEALTHSCIENCE.1387834 |
|
| 2024-03-01 |
New Insights into the Effects of SARS-CoV-2 on Metabolic Organs: A Narrative Review of COVID-19 Induced Diabetes (edit) |
SARSコロナウイルス2 (edit) |
10.2147/DMSO.S454408 |
|
| 2024-03-01 |
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID3003.230893 |
|
| 2024-03-01 |
Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID3003.231194 |
|
| 2024-02-29 |
Risk factors for SARS-CoV-2 transmission during a movie theater outbreak in Incheon in the Republic of Korea, November 2021: a retrospective study (edit) |
SARSコロナウイルス2 (edit) |
10.24171/J.PHRP.2023.0269 |
|
| 2024-02-28 |
Unveiling the Antiviral Capabilities of Targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.3C07845 |
|
| 2024-02-27 |
An ultra-sensitive SARS-CoV-2 antigen optical biosensor based on angiotensin converting enzyme 2 (ACE-2) functionalized magnetic-fluorescent silica nanoparticles (edit) |
SARSコロナウイルス2 (edit) |
10.1088/1361-6528/AD27AA |
|
| 2024-02-27 |
Computational Screening of Potential Drug Candidates Against the Exonuclease Activity of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3632047.3632059 |
|
| 2024-02-27 |
Rapid Development of Achalasia After SARS-CoV-2 Infection: Polymerase Chain Reaction Analysis of Esophageal Muscle Tissue (edit) |
SARSコロナウイルス2 (edit) |
10.14309/AJG.0000000000002669 |
|
| 2024-02-23 |
Clinical characteristics of 4,520 paediatric patients infected with the SARS-CoV-2 omicron variant, in Xi'an, China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPED.2024.1325562 |
|
| 2024-02-21 |
Conversion of Host Cell Receptor into Virus Destructor by Immunodisc to Neutralize Diverse SARS‐CoV‐2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADHM.202302803 |
|
| 2024-02-21 |
Interpretable Prediction of SARS-CoV-2 Epitope-Specific TCR Recognition Using a Pre-Trained Protein Language Model (edit) |
SARSコロナウイルス2 (edit) |
10.1109/TCBB.2024.3368046 |
|
| 2024-02-21 |
The role of ion dissolution in metal and metal oxide surface inactivation of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AEM.01553-23 |
|
| 2024-02-20 |
SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01546-23 |
|
| 2024-02-20 |
Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01571-23 |
|
| 2024-02-20 |
SARS-CoV-2 and oncolytic EV-D68-encoded proteases differentially regulate pyroptosis (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01909-23 |
|
| 2024-02-15 |
Factors associated with older adults’ cognitive decline 6 months after gamma-variant SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNEUR.2024.1334161 |
|
| 2024-02-14 |
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-024-01748-W |
|
| 2024-02-14 |
The E3 ligase TRIM22 restricts SARS-CoV-2 replication by promoting proteasomal degradation of NSP8 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02320-23 |
|
| 2024-02-14 |
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02722-23 |
|
| 2024-02-14 |
CRL4B E3 ligase recruited by PRPF19 inhibits SARS-CoV-2 infection by targeting ORF6 for ubiquitin-dependent degradation (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03071-23 |
|
| 2024-02-13 |
Receptor-binding domain-associated serotypes of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2024.2309968 |
|
| 2024-02-12 |
Post-discharge outcomes of hospitalized children diagnosed with acute SARS-CoV-2 or MIS-C (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPED.2024.1340385 |
|
| 2024-02-11 |
Genomic and Phylogenetic Characterisation of SARS-CoV-2 Genomes Isolated in Patients from Lambayeque Region, Peru (edit) |
SARSコロナウイルス2 (edit) |
10.3390/TROPICALMED9020046 |
38393135 |
| 2024-02-09 |
Updated Risk Evaluation of JN.1, 09 January 2023 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2024-02-09 |
Application of a Biomimetic Nanoparticle-Based Mock Virus to Determine SARS-CoV-2 Neutralizing Antibody Levels in Blood Samples Using a Lateral Flow Assay (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.3C04372 |
|
| 2024-02-09 |
Sub-Second Electrochemiluminescence Imaging Assay of SARS-CoV-2 Nucleocapsid Protein Based on Reticulation of Endo-Coreactants (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.3C05388 |
|
| 2024-02-09 |
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.3C01938 |
|
| 2024-02-09 |
Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-024-01743-X |
|
| 2024-02-09 |
Time dependent dihedral angle oscillations of the spike protein of SARS-CoV-2 reveal favored frequencies of dihedral angle rotations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-53954-9 |
|
| 2024-02-09 |
SARS-CoV-2 Nsp1 cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1011535 |
|
| 2024-02-09 |
Approaching Personalized Medicine: The Use of Machine Learning to Determine Predictors of Mortality in a Population with SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES12020409 |
|
| 2024-02-09 |
Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020273 |
|
| 2024-02-09 |
Wastewater Surveillance of SARS-CoV-2 in Minnesota (edit) |
SARSコロナウイルス2 (edit) |
10.3390/W16040541 |
|
| 2024-02-08 |
BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.3C00685 |
|
| 2024-02-08 |
Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges (edit) |
SARSコロナウイルス2 (edit) |
10.1097/CRD.0000000000000640 |
|
| 2024-02-08 |
Booster vaccination against the SARS-CoV-2: mechanisms and efficiency (edit) |
SARSコロナウイルス2 (edit) |
10.15829/1728-8800-2023-3820 |
|
| 2024-02-08 |
SARS-CoV-2 Infection Alters the Phenotype and Gene Expression of Adipocytes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25042086 |
|
| 2024-02-08 |
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020175 |
|
| 2024-02-08 |
PCR TESTING FOR SARS-CoV-2 AMONG STUDENTS OF MEDICAL UNIVERSITY-PLEVEN DURING THE FOURTH WAVE OF COVID PANDEMIC (edit) |
SARSコロナウイルス2 (edit) |
10.5272/JIMAB.2024301.5350 |
|
| 2024-02-07 |
Evaluation of the inhibitory potential of bioactive compounds against SARS-CoV-2 by in silico approach (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00894-024-05858-8 |
|
| 2024-02-07 |
Neonatal SARS-CoV-2 immunoglobulin G antibodies at delivery and their impact on COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10096-024-04773-3 |
|
| 2024-02-07 |
Endothelial dysfunction and cardiovascular risk in post-COVID-19 patients after 6- and 12-months SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S15010-024-02173-5 |
|
| 2024-02-07 |
Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-53656-2 |
|
| 2024-02-07 |
Mortality associated with SARS-CoV-2 in nondomestic felids (edit) |
SARSコロナウイルス2 (edit) |
10.1177/03009858231225500 |
|
| 2024-02-07 |
Risk of transmission of SARS-CoV-2 on international flights, a retrospective cohort study using national surveillance data in England (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-09052-2 |
|
| 2024-02-07 |
Maternal SARS-CoV-2 infection in pregnancy disrupts gene expression in Hofbauer cells with limited impact on cytotrophoblasts (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1011990 |
|
| 2024-02-07 |
Postacute Sequelae of SARS-CoV-2 in Children (edit) |
SARSコロナウイルス2 (edit) |
10.1542/PEDS.2023-062570 |
|
| 2024-02-07 |
Acute macular neuroretinopathy and COVID-19 or SARS-CoV-2 infection: case report and literature review (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2024.1267392 |
|
| 2024-02-07 |
A highly susceptible hACE2-transgenic mouse model for SARS-CoV-2 research (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2024.1348405 |
|
| 2024-02-07 |
Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNUT.2024.1346510 |
|
| 2024-02-07 |
T Cell Responses in Pregnant Women Who Received mRNA-Based Vaccination to Prevent COVID-19 Revealed Unknown Exposure to the Natural Infection and Numerous SARS-CoV-2-Specific CD4- CD8- Double Negative T Cells and Regulatory T Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25042031 |
|
| 2024-02-07 |
Chemical Compositions of Scutellaria baicalensis Georgi. (Huangqin) Extracts and Their Effects on ACE2 Binding of SARS-CoV-2 Spike Protein, ACE2 Activity, and Free Radicals (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25042045 |
|
| 2024-02-07 |
Perspectives on SARS-CoV-2 Cases in Zoological Institutions (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VETSCI11020078 |
|
| 2024-02-06 |
Research Progress of Nanomaterials for Prevention, Diagnosis, and Treatment of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12668-024-01310-6 |
|
| 2024-02-06 |
Layer-by-Layer Assembly of Polymeric Nanoparticles with Heparin-RBD Complexes as an Adjuvant for SARS-CoV-2 Protein-Based Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSANM.3C05644 |
|
| 2024-02-06 |
SARS-CoV-2 Variants Genotyping and Diagnostic Performance of a 2-Genes Detection Assay (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JALM/JFAD127 |
|
| 2024-02-06 |
Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01492-23 |
|
| 2024-02-06 |
Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Beijing Omicron wave (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03005-23 |
|
| 2024-02-06 |
Optimization of the STARlet workflow for semi-automatic SARS-CoV-2 screening of swabs and deep respiratory materials using the RealAccurate Quadruplex SARS-CoV-2 PCR kit and Allplex SARS-CoV-2 PCR kit (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03296-23 |
|
| 2024-02-06 |
Comparison of analytical performance and economic value of two biosurveillance methods for tracking SARS-COV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03484-23 |
|
| 2024-02-06 |
Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-024-02304-2 |
|
| 2024-02-06 |
SARS-CoV-2 Infection is Associated with Age- and Gender-Specific Changes in the Nasopharyngeal Microbiome (edit) |
SARSコロナウイルス2 (edit) |
10.31083/J.FBL2902059 |
|
| 2024-02-06 |
Corrigendum: Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1375028 |
|
| 2024-02-06 |
Genomic Surveillance of SARS-CoV-2: Data Analysis and Assessment of Tunisian Strategy from January 2021 to February 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/EPIDEMIOLOGIA5010005 |
|
| 2024-02-06 |
Acquired hemophilia A after SARS-CoV-2 infection: A causal or casual association? (edit) |
SARSコロナウイルス2 (edit) |
10.55633/S3ME/010.2024 |
|
| 2024-02-05 |
Risk of subsequent SARS‐CoV‐2 infection among vaccinated employees with or without hybrid immunity acquired early in the Omicron‐predominant era of the COVID‐19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1002/AJIM.23570 |
|
| 2024-02-05 |
Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00284-023-03597-2 |
|
| 2024-02-05 |
SARS-CoV-2-related myelitis: two cases from a major neurological clinic in Central Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10072-024-07370-6 |
|
| 2024-02-05 |
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45171-9 |
|
| 2024-02-05 |
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-024-00815-1 |
|
| 2024-02-05 |
Design of human ACE2 mimic miniprotein binders that interact with RBD of SARS-CoV-2 variants of concerns (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2024.2310789 |
|
| 2024-02-05 |
XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2024.02.03.578771 |
38370837 |
| 2024-02-05 |
SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-024-17869-4 |
|
| 2024-02-05 |
Profiles of Cough and Associated Risk Factors in Nonhospitalized Individuals With SARS-CoV-2 Omicron Variant Infection: Cross-Sectional Online Survey in China (edit) |
SARSコロナウイルス2 (edit) |
10.2196/47453 |
|
| 2024-02-05 |
Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1330864 |
|
| 2024-02-05 |
Multifaceted role of SARS-CoV-2 structural proteins in lung injury (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1332440 |
|
| 2024-02-05 |
Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1344184 |
|
| 2024-02-05 |
Virus sequencing performance during the SARS-CoV-2 pandemic: a retrospective analysis of data from multiple rounds of external quality assessment in Austria (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2024.1327699 |
|
| 2024-02-05 |
The context of COVID-19 affected the long-term sleep quality of older adults more than SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPSYT.2024.1305945 |
|
| 2024-02-05 |
How Much Does SARS-CoV-2 Infection during Pregnancy Affect the Neonatal Brain, Heart, and Kidney? A Parallel between COVID-19, Vaccination, and Normal Pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE14020224 |
|
| 2024-02-05 |
The Impact of Clinical Factors and SARS-CoV-2 Variants on Antibody Production in Vaccinated German Healthcare Professionals Infected Either with the Delta or the Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020163 |
|
| 2024-02-05 |
Temporal Dynamics and Genomic Landscape of SARS-CoV-2 After Four Years of Evolution (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.53654 |
|
| 2024-02-03 |
CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00011-024-01852-1 |
|
| 2024-02-03 |
CORONAVIRUS SARS-COV-2 MODIFIES ANTITUMOR REDOX STATUS OF BLOOD AND INTERCELLULAR MATRIX IN METASTATIC COLORECTAL CANCER PATIENTS (A PILOT STUDY) (edit) |
SARSコロナウイルス2 (edit) |
10.15407/EXP-ONCOLOGY.2023.04.483 |
|
| 2024-02-03 |
Review of: "Interventional Radiology And CT Scan in SARS-COV-2: A Review" (edit) |
SARSコロナウイルス2 (edit) |
10.32388/GKR03E |
|
| 2024-02-03 |
Prior Influenza Infection Mitigates SARS-CoV-2 Disease in Syrian Hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020246 |
|
| 2024-02-02 |
Comparative analysis of aptamers binding to SARS-CoV-2 N protein using capillary electrophoresis and bio-layer interferometry (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-024-05174-3 |
|
| 2024-02-02 |
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-44973-1 |
|
| 2024-02-02 |
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45180-8 |
|
| 2024-02-02 |
An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45348-2 |
|
| 2024-02-02 |
Binding behavior of receptor binding domain of the SARS-CoV-2 virus and ivermectin (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-53086-0 |
|
| 2024-02-02 |
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2300644120 |
|
| 2024-02-02 |
Healthcare Provider N95 Respirator Contamination Worn Behind Face Shields With SARS-CoV-2 During Routine Clinical Care of Patients With COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAE040 |
|
| 2024-02-02 |
SARS-CoV-2 may play a direct role in the pathogenesis of posterior reversible encephalopathy syndrome (PRES) associated with COVID-19: A CARE-compliant case report and literature review (edit) |
SARSコロナウイルス2 (edit) |
10.1097/MD.0000000000037192 |
|
| 2024-02-02 |
Enhancing detection of SARS-CoV-2 re-infections using longitudinal sero-monitoring: demonstration of a methodology in a cohort of people experiencing homelessness in Toronto, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-09013-9 |
|
| 2024-02-02 |
Origin and Evolution of SARS-CoV-2: An Enigma (edit) |
SARSコロナウイルス2 (edit) |
10.23880/VIJ-16000338 |
|
| 2024-02-02 |
Identification of potential therapeutic targets for COVID-19 through a structural-based similarity approach between SARS-CoV-2 and its human host proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2024.1292280 |
|
| 2024-02-01 |
Synthesis and Cell‐Based Evaluation of Umifenovir Analogues as Anti‐SARS‐CoV‐2 Agents (edit) |
SARSコロナウイルス2 (edit) |
10.1002/HLCA.202300208 |
|
| 2024-02-01 |
Elucidating systemic immune responses to acute and convalescent SARS‐CoV‐2 infection in children and elderly individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1002/IID3.1167 |
|
| 2024-02-01 |
Innate immune response to SARS‐CoV‐2 infection contributes to neuronal damage in human iPSC‐derived peripheral neurons (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29455 |
|
| 2024-02-01 |
Genomic surveillance of omicron B.1.1.529 SARS‐CoV‐2 and its variants between December 2021 and March 2023 in Tamil Nadu, India—A state‐wide prospective longitudinal study (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29456 |
|
| 2024-02-01 |
Resistance‐associated mutations to the anti‐SARS‐CoV‐2 agent nirmatrelvir: Selection not induction (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29462 |
|
| 2024-02-01 |
Natural products from Streptomyces spp. as potential inhibitors of the major factors (holoRdRp and nsp13) for SARS-CoV-2 replication: an in silico approach (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00203-023-03820-5 |
|
| 2024-02-01 |
Efficient assembly of a synthetic attenuated SARS-CoV-2 genome in Saccharomyces cerevisiae using multi-copy yeast vectors (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12041-023-01455-5 |
|
| 2024-02-01 |
The interplay between Sars-Cov-2 infection related cardiovascular diseases and depression. Common mechanisms, shared symptoms (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AHJO.2024.100364 |
|
| 2024-02-01 |
SARS-CoV-2 Infection During Pregnancy and Gene Co-expression Network Analyses of the Placental Transcriptome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.09.042 |
|
| 2024-02-01 |
Comparison of Maternal and Infant Outcomes in SARS-COV-2 Affected Pregnancies and Contemporaneous Pregnancies from British Columbia, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.09.055 |
|
| 2024-02-01 |
Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance – Surveillance for Emerging Threats to Pregnant People and Infants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOGMF.2023.101265 |
|
| 2024-02-01 |
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2024.105814 |
|
| 2024-02-01 |
An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2024.105815 |
|
| 2024-02-01 |
Multimerization of the heptad repeat regions of the SARS-CoV 2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAMEM.2023.184259 |
|
| 2024-02-01 |
Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOPHA.2024.116180 |
|
| 2024-02-01 |
Flipped over u: Structural basis for dsRNA cleavage by the SARS-CoV-2 endoribonuclease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1069 |
|
| 2024-02-01 |
Structural insights into cross-reactive antibodies recognizing the N-terminal and receptor binding domains of the SARS-CoV-2 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1074 |
|
| 2024-02-01 |
Real-time visualization of intermolecular interactions between SARS-CoV-2 spike protein and NTD-binding antibody using high-speed atomic force microscopy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1256 |
|
| 2024-02-01 |
The evolving biophysics and antigenicity of the SARS-CoV-2 Omicron spike receptor binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1294 |
|
| 2024-02-01 |
Computational investigations of SARS-CoV-2 proofreading exoribonuclease (ExoN) suggest strategies for antiviral design (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1317 |
|
| 2024-02-01 |
Interactions of SARS-CoV-2 nsp7 or nsp8 with nsp12 causes severe constriction of RNA entry channel: Implications for novel RdRp inhibitor drug discovery (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1441 |
|
| 2024-02-01 |
Molecular dynamics simulations of the SARS-CoV-2 membrane protein and its implications for viral assembly (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1497 |
|
| 2024-02-01 |
Reversal of the fusion catalytic role of SARS-CoV-2 fusion peptide by restricting the N terminus: Implications to tackle viral infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1513 |
|
| 2024-02-01 |
Investigating how the anionic lipid, BMP, plays a crucial role in the initation of SARS-CoV-2 fusion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1515 |
|
| 2024-02-01 |
Cooperativity and induced oligomerization control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.1931 |
|
| 2024-02-01 |
SARS-CoV-2 nsp3 C-terminal region: Conserved beyond coronavirus with potential role in DMV pore formation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2065 |
|
| 2024-02-01 |
The role of ATP hydrolysis and product release in the translocation mechanism of SARS-CoV-2 nsp13 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2069 |
|
| 2024-02-01 |
Synthesis and characterization of SARS-CoV-2 membrane protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2118 |
|
| 2024-02-01 |
Structures and stability of SARS-CoV-2 spike S2 subunit mutants targeting inter-subunit interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2136 |
|
| 2024-02-01 |
Understanding the assembly and budding mechanisms of SARS CoV-2 M and N proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2284 |
|
| 2024-02-01 |
The SARS-CoV-2 envelope protein channel displays weak selectivity and heterogeneous oligomerization (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2298 |
|
| 2024-02-01 |
Impact of crowding on conformations and interactions of the SARS-CoV-2 nucleocapsid protein and RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.261 |
|
| 2024-02-01 |
Role of the proton-activated chloride channel in SARS-CoV-2 viral entry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2699 |
|
| 2024-02-01 |
CIS-mediated interactions of the SARS-CoV-2 frameshift RNA alter its conformations and affect function (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2759 |
|
| 2024-02-01 |
Adsorption of pulmonary surfactants on the spike proteins of SARS-CoV-2 and its variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2867 |
|
| 2024-02-01 |
Investigating spike S2 subunit hairpin proteins of the SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2917 |
|
| 2024-02-01 |
Structural restraints in the SARS-CoV-2 spike tail control its intra-cellular trafficking to virion assembly and immune presentation sites (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.2918 |
|
| 2024-02-01 |
Optimization and applications of a compact stem-loop DNA aptamer targeting SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.3027 |
|
| 2024-02-01 |
SARS-CoV-2 binding to terminal sialic acid of gangliosides embedded in lipid membranes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.3065 |
|
| 2024-02-01 |
EPR spectroscopic characterization of the topology of SARS-CoV-2 envelope protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.3078 |
|
| 2024-02-01 |
Mitochondrial network physiology disruption during SARS-CoV-2 infection in human lung organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.3154 |
|
| 2024-02-01 |
Phosphorylation regulates the function of the SARS-COV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.324 |
|
| 2024-02-01 |
Single-molecule spectroscopy of the SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.507 |
|
| 2024-02-01 |
The effect of lipid and protein flexibility on membrane deformations caused by the SARS-CoV-2 E protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.701 |
|
| 2024-02-01 |
Biophysical principles predict fitness of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2023.11.908 |
|
| 2024-02-01 |
PDA-mediated colorimetric-fluorescence co-enhanced immunochromatography assay for the simultaneous and rapid detection of SARS-CoV-2 and HAdV (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CEJ.2024.148756 |
|
| 2024-02-01 |
Development of SARS-CoV-2 entry antivirals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELLIN.2023.100144 |
|
| 2024-02-01 |
Virological characteristics of the SARS-CoV-2 BA.2.86 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2024.01.001 |
|
| 2024-02-01 |
Immune correlates with disease severity in older patients after SARS-CoV-2 BA.2 infection in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2024.109900 |
|
| 2024-02-01 |
Evolving SARS-CoV-2 severity among hospital and university affiliates in Spain and Greater Boston (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EIMC.2023.12.011 |
|
| 2024-02-01 |
Prevalence of post-COVID symptoms one-year after SARS-CoV-2 infection in patients with interstitial lung disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJIM.2024.01.039 |
|
| 2024-02-01 |
Mental health of pregnant sars-cov-2 positive women during global pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJOGRB.2023.08.325 |
|
| 2024-02-01 |
Viral and host small RNA transcriptome analysis of SARS-CoV-1 and SARS-CoV-2-infected human cells reveals novel viral short RNAs (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E24570 |
|
| 2024-02-01 |
Silica-coated magnetic particles for efficient RNA extraction for SARS-CoV-2 detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25377 |
|
| 2024-02-01 |
IgG responses against SARS-CoV-2 vaccines AZD1222 and BBV-152 and breakthrough infections among health care workers in southern India (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25528 |
|
| 2024-02-01 |
A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25539 |
|
| 2024-02-01 |
Acute hemorrhagic leukoencephalitis following the first dose of BNT162b2 vaccine against SARS-CoV-2: A case report (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25545 |
|
| 2024-02-01 |
Genetic characteristics of SARS-CoV-2 virus variants observed upon three waves of the COVID-19 pandemic in Ukraine between February 2021–January 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25618 |
|
| 2024-02-01 |
Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E25734 |
|
| 2024-02-01 |
A comparative study of SARS-CoV-2 and common human coronavirus infections among children presenting to tertiary care in Oman (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2023.08.006 |
|
| 2024-02-01 |
Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2023.11.039 |
38070701 |
| 2024-02-01 |
UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.108887 |
|
| 2024-02-01 |
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.108964 |
|
| 2024-02-01 |
Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2024.108976 |
|
| 2024-02-01 |
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IT.2024.01.003 |
|
| 2024-02-01 |
Wildfire Smoke Exposure during SARS-CoV-2 Vaccination Impairs Immunity via Natural Killer Cell derived IL-13 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.11.480 |
|
| 2024-02-01 |
A comparison of Fc receptors via single-cell RNA sequencing between Kawasaki disease and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.11.607 |
|
| 2024-02-01 |
Lack of association between SARS-CoV-2 PCR positivity and subsequent asthma diagnosis in a pediatric cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.11.612 |
|
| 2024-02-01 |
Immunophenotypic Risk Factors for Low SARS-CoV-2 Immunization Response in Adults with Predominantly Antibody Deficiency over Five Total Vaccine Doses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.11.784 |
|
| 2024-02-01 |
Age dependent discrepancy between SARS-CoV-2 anti-nucleoprotein antibody and anti-RBD spike protein antibody in children reflects vaccine coverage (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIAC.2024.01.020 |
|
| 2024-02-01 |
Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2023.12.004 |
|
| 2024-02-01 |
Sars-Cov-2 As a Potential Trigger for Renal Graft-Versus-Host Disease Following Allogenic Bone Marrow Transplant: A Case Series Report. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCT.2023.12.392 |
|
| 2024-02-01 |
Navigating the Intersection of Multiple Myeloma and Severe Sars-Cov-2: Therapeutic Insights from Exosomal Vesicles (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCT.2023.12.518 |
|
| 2024-02-01 |
Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of SARS-CoV-2 infection: comment from Kell et al. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTHA.2023.09.035 |
|
| 2024-02-01 |
Prevalence and determinants of post-acute sequelae after SARS-CoV-2 infection (Long COVID) among adults in Mexico during 2022: a retrospective analysis of nationally representative data (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2024.100688 |
|
| 2024-02-01 |
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2024.01.013 |
|
| 2024-02-01 |
SARS-CoV-2 infection causes dopaminergic neuron senescence (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEM.2023.12.012 |
|
| 2024-02-01 |
Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2023.12.084 |
|
| 2024-02-01 |
SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.01.006 |
|
| 2024-02-01 |
Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.01.052 |
|
| 2024-02-01 |
Short term safety of BNT162b2 (Pfizer–BioNTech) SARS-CoV-2 vaccine among children aged 5–11 years, a nationwide parental survey (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.01.055 |
|
| 2024-02-01 |
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.01.073 |
|
| 2024-02-01 |
Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2024.01.080 |
|
| 2024-02-01 |
RNA barcode segments for SARS-CoV-2 identification from HCoVs and SARSr-CoV-2 lineages (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2024.01.006 |
|
| 2024-02-01 |
Patient-reported experiences during the SARS-CoV-2 (COVID-19): Results from a cross-sectional survey (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMGME.2023.107993 |
|
| 2024-02-01 |
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2024.01.007 |
|
| 2024-02-01 |
Prevalence of SARS-CoV-2, RSV, and Rhinovirus/ Enterovirus in pediatric patients in the ER and ICU (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0002-9629(24)00600-1 |
|
| 2024-02-01 |
Effects of SARS-CoV-2 variants on CD8+ T cell epitope diversity: estimating clinical severity in the United States population (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0002-9629(24)00636-0 |
|
| 2024-02-01 |
Risk factors for SARS-COV-2 infection in expecting mothers and newborn infants in jefferson parish in the early COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0002-9629(24)00744-4 |
|
| 2024-02-01 |
Persistent SARS-CoV-2 infection: significance and implications (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(23)00815-0 |
|
| 2024-02-01 |
The omicron BA.2.86 subvariant as a new serotype of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00411-1 |
|
| 2024-02-01 |
Neutralization of SARS-CoV-2 and Intranasal Protection of Mice with a nanoCLAMP Antibody Mimetic (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSPTSCI.3C00306 |
|
| 2024-02-01 |
Successful ablation of Purkinje ectopy–triggered ventricular fibrillation storm in a patient with orthotopic heart transplantation and severe SARS-CoV-2 pneumonia: a case report (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EHJCR/YTAE057 |
|
| 2024-02-01 |
Identification of druggable host dependency factors shared by multiple SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAE004 |
|
| 2024-02-01 |
Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAE065 |
38463611 |
| 2024-02-01 |
Predicting potential SARS-CoV-2 mutations of concern via full quantum mechanical modelling (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSIF.2023.0614 |
|
| 2024-02-01 |
Functional decline at 1 year in hospitalized elderly pneumonia with SARS‐CoV‐2 Omicron variant: Comparison with the ancestral strain and Alpha variant (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IRV.13251 |
|
| 2024-02-01 |
Molecular Investigation of SARS-CoV-2 Circulating in Iranian Bats Using Real-Time RT-PCR for Detection of Envelop (E) Gene of the Virus (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2024/5313346 |
|
| 2024-02-01 |
Pulmonary function in children post -SARS-CoV-2 infection: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12887-024-04560-1 |
|
| 2024-02-01 |
Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID) (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-023-03221-X |
|
| 2024-02-01 |
Integrated approach for detection of SARS-CoV-2 and its variant by utilizing LAMP and ARMS-PCR (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12941-023-00665-0 |
|
| 2024-02-01 |
Antimicrobial peptides and other potential biomarkers of critical illness in SARS‐CoV‐2 patients with acute kidney injury. AMPAKI‐CoV study (edit) |
SARSコロナウイルス2 (edit) |
10.14814/PHY2.15945 |
|
| 2024-02-01 |
Exacerbation of Pre-Existing Chronic Pain in Older Adults After SARS-CoV-2 Infection: A Single-Center, Cross-Sectional, Observational Study (edit) |
SARSコロナウイルス2 (edit) |
10.2147/JPR.S395042 |
|
| 2024-02-01 |
Development of Magnetic-Silica Particles and In-house Buffers Kit for SARS-CoV-2 and CDV RNA Extraction (edit) |
SARSコロナウイルス2 (edit) |
10.22146/IJC.83804 |
|
| 2024-02-01 |
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 20211 (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID3002.230863 |
|
| 2024-02-01 |
Experimental SARS-CoV-2 Infection of Elk and Mule Deer (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID3002.231093 |
|
| 2024-02-01 |
Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ORGANOIDS3010002 |
|
| 2024-02-01 |
Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch (edit) |
SARSコロナウイルス2 (edit) |
10.3899/JRHEUM.2024-0006 |
|
| 2024-02-01 |
Study of Oxadiazole derivatives as precursor for multi-functional inhibitor to SARS-CoV-2: A detailed virtual screening analysis (edit) |
SARSコロナウイルス2 (edit) |
10.5564/MJC.V25I51.2909 |
|
| 2024-02-01 |
Predictive factors of mortality in patients admitted to the emergency department for SARS-Cov2 pneumonia (edit) |
SARSコロナウイルス2 (edit) |
10.62438/TUNISMED.V102I2.4659 |
38567472 |
| 2024-01-31 |
SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29415 |
|
| 2024-01-31 |
Screening Commercial Tea for Rapid Inactivation of Infectious SARS-CoV-2 in Saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12560-023-09581-0 |
|
| 2024-01-31 |
An in-silico investigation of volatile compounds in Tulsi and Ginger as a potent inhalant for SARS-CoV-2 treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13738-023-02939-Y |
|
| 2024-01-31 |
Age-specific transmission dynamics of SARS-CoV-2 during the first 2 years of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAE024 |
38312225 |
| 2024-01-31 |
Simulation of energy absorption and dose of ionizing radiation on spike of SARS-CoV-2 and comparing it with human mortality statistics, using Geant4-DNA toolkit (edit) |
SARSコロナウイルス2 (edit) |
10.1140/EPJP/S13360-024-04928-3 |
|
| 2024-01-31 |
Hierarchical Virtual Screening of SARS-CoV-2 Main Protease Potential Inhibitors: Similarity Search, Pharmacophore Modeling, and Molecular Docking Study (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0122113525280410240106122715 |
|
| 2024-01-31 |
Exacerbation of Autoimmune Hepatitis following Inactivated SARS-CoV-2 Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.31584/JHSMR.20241030 |
|
| 2024-01-31 |
Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE14020210 |
|
| 2024-01-31 |
The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020215 |
|
| 2024-01-31 |
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020217 |
|
| 2024-01-31 |
Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020223 |
|
| 2024-01-31 |
Serological and Molecular Investigation of SARS-CoV-2 in Horses and Cattle in Switzerland from 2020 to 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020224 |
|
| 2024-01-30 |
A snapshot of SARS‐CoV‐2 viral RNA throughout wastewater treatment plants in Arkansas (edit) |
SARSコロナウイルス2 (edit) |
10.1002/WER.10992 |
|
| 2024-01-30 |
Longitudinal Wastewater-Based Surveillance for SARS-CoV-2 in High-Density Student Dormitories in Singapore (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSESTWATER.3C00304 |
|
| 2024-01-30 |
Necroptosis does not drive disease pathogenesis in a mouse infective model of SARS-CoV-2 in vivo (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41419-024-06471-6 |
|
| 2024-01-30 |
Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45075-8 |
|
| 2024-01-30 |
Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45181-7 |
|
| 2024-01-30 |
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-024-00805-3 |
|
| 2024-01-30 |
Campesterol and dithymoquinone as a potent inhibitors of SARS cov-2 main proteases—promising drug candidates for targeting its novel variants (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2023.2301684 |
|
| 2024-01-30 |
Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket (edit) |
SARSコロナウイルス2 (edit) |
10.1107/S2059798324000329 |
|
| 2024-01-30 |
Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3002463 |
|
| 2024-01-30 |
Ethnic and racial differences in self-reported symptoms, health status, activity level, and missed work at 3 and 6 months following SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1324636 |
|
| 2024-01-30 |
SARS-CoV-2 Spike Protein Stimulates Macropinocytosis in Murine and Human Macrophages via PKC-NADPH Oxidase Signaling (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX13020175 |
|
| 2024-01-30 |
Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020144 |
|
| 2024-01-30 |
A 22-Year-Old Woman with NMDA Receptor Antibody Encephalitis Possibly Triggered by SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.58624/SVOANE.2024.05.0128 |
|
| 2024-01-29 |
DON/DRP‐104 as potent serine protease inhibitors implicated in SARS‐CoV‐2 infection: Comparative binding modes with human TMPRSS2 and novel therapeutic approach (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JCB.30528 |
|
| 2024-01-29 |
Reconstitution of RNA cap methylation reveals different features of SARS‐CoV‐2 and SARS‐CoV methyltransferases (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29411 |
|
| 2024-01-29 |
A human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S44307-024-00011-1 |
|
| 2024-01-29 |
Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45050-3 |
|
| 2024-01-29 |
Impact of the SARS-CoV-2 Pandemic on Prevalence and Incidence of Bacterial Gastroenteritis in Spain, 2019–2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1089/FPD.2023.0124 |
|
| 2024-01-29 |
Emergence and spread of SARS-CoV-2 variants of concern in Canada: a retrospective analysis from clinical and wastewater data (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-08997-8 |
|
| 2024-01-29 |
Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1011832 |
|
| 2024-01-29 |
Bioinformatic analysis of defective viral genomes in SARS-CoV-2 and its impact on population infection characteristics (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1341906 |
|
| 2024-01-29 |
Antiviral Action against SARS-CoV-2 of a Synthetic Peptide Based on a Novel Defensin Present in the Transcriptome of the Fire Salamander (Salamandra salamandra) (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACEUTICS16020190 |
|
| 2024-01-29 |
The Importance of Natural and Acquired Immunity to SARS-CoV-2 Infection in Patients on Peritoneal Dialysis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020135 |
|
| 2024-01-29 |
SARS-CoV-2-related polyradiculitis during pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.4103/IJA.IJA_455_23 |
|
| 2024-01-29 |
Calibration of Prediction Models of In-hospital Mortality in SARS-CoV-2 Patients Depends also on Data Quality (edit) |
SARSコロナウイルス2 (edit) |
10.5005/JP-JOURNALS-10071-24564 |
|
| 2024-01-29 |
In Silico Study of Organic Compounds from Dipteryx odorata with SARS-COV-2 Targets by Molecular Docking and ADME-TOX Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.9734/JAMMR/2024/V36I15351 |
|
| 2024-01-28 |
Comparative Analysis of Direct Cold Atmospheric Plasma Treatment vs. Plasma Activated Water for the Deactivation of Omicron Variant of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11090-024-10449-9 |
|
| 2024-01-28 |
Assessing the current epidemiological status of SARS-CoV-2 and its potential evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S15010-024-02190-4 |
|
| 2024-01-28 |
Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.3C00483 |
|
| 2024-01-28 |
Global Transcriptomic Analysis of Placentas from Women with Gestational SARS-CoV-2 Infection during the Third Trimester of Pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25031608 |
|
| 2024-01-27 |
High vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1002/UEG2.12528 |
|
| 2024-01-27 |
Rapid Profiling of the Glycosylation Effects on the Binding of SARS-CoV-2 Spike Protein to Angiotensin-Converting Enzyme 2 Using MALDI-MS with High Mass Detection (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.3C03930 |
|
| 2024-01-27 |
An ensemble docking-based virtual screening and molecular dynamics simulation of phytochemical compounds from Malaysian Kelulut Honey (KH) against SARS-CoV-2 target enzyme, human angiotensin-converting enzyme 2 (ACE-2) (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2024.2308762 |
|
| 2024-01-27 |
A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020132 |
|
| 2024-01-27 |
Relationship Between Rhabdomyolysis and SARS-CoV-2 Disease Severity (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.53029 |
|
| 2024-01-26 |
SARS-CoV-2 Neutralization by Cell Membrane-Coated Antifouling Nanoparticles (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSABM.3C00936 |
|
| 2024-01-26 |
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.3C08326 |
|
| 2024-01-26 |
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice (edit) |
ベータコロナウイルス１ (edit) |
10.1038/S41467-024-45043-2 |
|
| 2024-01-26 |
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-45043-2 |
|
| 2024-01-26 |
SARS-CoV-2 sneezing explained (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADO2398 |
|
| 2024-01-26 |
Epigenetic repression of antiviral genes by SARS-CoV-2 NSP1 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0297262 |
|
| 2024-01-26 |
EPIDEMIC SITUATION OF TUBERCULOSIS IN UKRAINE (PRE-PANDEMIC AND PANDEMIC PERIOD CORONAVIRUS INFECTION SARS-CoV-2) (edit) |
SARSコロナウイルス2 (edit) |
10.32782/2786-9067-2023-25-9 |
|
| 2024-01-26 |
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1221587 |
|
| 2024-01-26 |
Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1291048 |
|
| 2024-01-26 |
Comprehensive Dataset on Pre-SARS-CoV-2 Infection Sports-Related Physical Activity Levels, Disease Severity, and Treatment Outcomes: Insights and Implications for COVID-19 Management (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DATA9020023 |
|
| 2024-01-26 |
The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer–BioNTech Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020187 |
|
| 2024-01-26 |
Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020129 |
|
| 2024-01-25 |
Characteristics of patients who died in the hospital emergency service during the SARS-CoV-2 pandemic: a retrospective cohort study in a tertiary hospital in Spain (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11739-023-03519-X |
|
| 2024-01-25 |
Effect of SARS‐CoV‐2 preventive measures on early lung transplant fungal acquisition: An observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TID.14246 |
|
| 2024-01-25 |
Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-024-02299-W |
|
| 2024-01-25 |
Mutational signature dynamics indicate SARS-CoV-2’s evolutionary capacity is driven by host antiviral molecules (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1011795 |
|
| 2024-01-25 |
Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PLpro) Inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACEUTICS16020169 |
|
| 2024-01-25 |
Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020184 |
|
| 2024-01-25 |
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020185 |
|
| 2024-01-25 |
Factors Associated with SARS-CoV-2 Infection in Fully Vaccinated Nursing Home Residents and Workers (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020186 |
|
| 2024-01-24 |
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL (edit) |
SARSコロナウイルス2 (edit) |
10.1002/AJH.27218 |
|
| 2024-01-24 |
Respiratory distress in SARS-CoV-2 exposed uninfected neonates followed in the COVID Outcomes in Mother-Infant Pairs (COMP) Study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-44549-5 |
|
| 2024-01-24 |
Use of air curtains for creating safe areas in bodybuilding salons for controlling the spread of SARS-CoV-2-carrying respiratory droplets (edit) |
SARSコロナウイルス2 (edit) |
10.1140/EPJP/S13360-024-04899-5 |
|
| 2024-01-24 |
SARS-CoV-2 neurovascular invasion supported by Mendelian randomization (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12967-024-04907-3 |
|
| 2024-01-24 |
Association of common variant rs9934336 of SLC5A2 (SGLT2) gene with SARS-CoV-2 infection and mortality (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S43042-024-00481-X |
|
| 2024-01-24 |
Systematic Review On Major Antiviral Phytocompounds from Common Medicinal Plants Against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0115734064262843231120051452 |
|
| 2024-01-24 |
SARS-CoV-2 and chronic myeloid leukemia: a systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2023.1280271 |
|
| 2024-01-24 |
Unveiling the Antiviral Properties of Panduratin A through SARS-CoV-2 Infection Modeling in Cardiomyocytes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25031427 |
38338708 |
| 2024-01-24 |
Heterologous Booster Immunization Based on Inactivated SARS-CoV-2 Vaccine Enhances Humoral Immunity and Promotes BCR Repertoire Development (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020120 |
|
| 2024-01-23 |
Compartmentalized SARS-CoV-2 Replication in the Upper vs Lower Respiratory Tract After Intranasal Inoculation or Aerosol Exposure (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAE018 |
|
| 2024-01-23 |
Long-term symptoms after SARS-CoV-2 infection in a cohort of hospital employees: duration and predictive factors (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-023-08710-1 |
|
| 2024-01-23 |
Gene expression profiling of host lipid metabolism in SARS-CoV-2 infected patients: a systematic review and integrated bioinformatics analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-024-08983-0 |
|
| 2024-01-23 |
A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-023-02282-X |
|
| 2024-01-23 |
A high throughput immuno-affinity mass spectrometry method for detection and quantitation of SARS-CoV-2 nucleoprotein in human saliva and its comparison with RT-PCR, RT-LAMP, and lateral flow rapid antigen test (edit) |
SARSコロナウイルス2 (edit) |
10.1515/CCLM-2023-0243 |
|
| 2024-01-23 |
The Effect of SARS-CoV-2 on the Gut and Its Microbiome: What We Know and What We Would Like to Know (edit) |
SARSコロナウイルス2 (edit) |
10.23934/2223-9022-2023-12-4-658-666 |
|
| 2024-01-23 |
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16020168 |
|
| 2024-01-23 |
Association between COVID-19 Vaccination and SARS-CoV-2 Infection among Household Contacts of Infected Individuals: A Prospective Household Study in England (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12020113 |
|
| 2024-01-23 |
Brain infection by SARS-CoV-2: Lifelong consequences (edit) |
SARSコロナウイルス2 (edit) |
10.56367/OAG-041-10397 |
|
| 2024-01-22 |
Application of genomic signal processing as a tool for high-performance classification of SARS-CoV-2 variants: a machine learning-based approach (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00500-023-09577-9 |
|
| 2024-01-22 |
Miscarriage after SARS‐CoV‐2 vaccination: A request to report more details of the regression models and analyses (edit) |
SARSコロナウイルス2 (edit) |
10.1111/1471-0528.17767 |
|
| 2024-01-22 |
Increase in venous thromboembolism in SARS‐CoV‐2 infected lung tissue: proteome analysis of lung parenchyma, isolated endothelium, and thrombi (edit) |
SARSコロナウイルス2 (edit) |
10.1111/HIS.15143 |
|
| 2024-01-22 |
Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1297195 |
|
| 2024-01-22 |
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1328905 |
|
| 2024-01-22 |
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2024.1348041 |
|
| 2024-01-22 |
An interpretative review of the wastewater-based surveillance of the SARS-CoV-2: where do we stand on its presence and concern? (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2024.1338100 |
|
| 2024-01-22 |
Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25021353 |
|
| 2024-01-22 |
SARS-CoV-2 ORF8 as a Modulator of Cytokine Induction: Evidence and Search for Molecular Mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16010161 |
|
| 2024-01-21 |
In Silico and In Vitro Analyses of Multiple Terpenes Predict Cryptotanshinone as a Potent Inhibitor of the Omicron Variant of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PR12010230 |
|
| 2024-01-20 |
Ultrasensitive and fast detection of SARS-CoV-2 using RT-LAMP without pH-dependent dye (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10142-024-01297-Z |
|
| 2024-01-20 |
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10238-023-01263-2 |
|
| 2024-01-20 |
Sequence analysis of the Spike, RNA-dependent RNA polymerase, and protease genes reveals a distinct evolutionary pattern of SARS-CoV-2 variants circulating in Yogyakarta and Central Java provinces, Indonesia (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11262-023-02048-1 |
|
| 2024-01-20 |
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-024-00806-2 |
|
| 2024-01-20 |
SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JLEUKO/QIAE017 |
|
| 2024-01-20 |
Computer Aided Structure-Based Drug Design of Novel SARS-CoV-2 Main Protease Inhibitors: Molecular Docking and Molecular Dynamics Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/COMPUTATION12010018 |
|
| 2024-01-20 |
Evaluation of a New Standardized Nasal Sampling Method for Detection of SARS-CoV-2 RNA via RT-PCR (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12010210 |
|
| 2024-01-20 |
The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACY12010016 |
|
| 2024-01-20 |
Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12010103 |
|
| 2024-01-20 |
Reviewed the Research Strategy and Progress of SARS-CoV-2 Live Attenuated Vaccine Under the Global Omicron Epidemic Trend (edit) |
SARSコロナウイルス2 (edit) |
10.57237/J.MRF.2024.01.001 |
|
| 2024-01-20 |
Nafamostat Mesylate for the Hypercoagulable State of SARS-CoV-2 With Renal Replacement Therapy: A Case Report (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.52641 |
|
| 2024-01-19 |
Peptide Nucleic Acid Clamp‐Assisted Photothermal Multiplexed Digital PCR for Identifying SARS‐CoV‐2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADVS.202306088 |
|
| 2024-01-19 |
Multiplexed electrochemical liposomes applied to the detection of nucleic acids for Influenza A, Influenza B and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-024-05145-8 |
|
| 2024-01-19 |
Structural Insights into SARS-CoV-2 Nonstructural Protein 1 Interaction with Human Cyclophilin and FKBP1 to Regulate Interferon Production (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCLETT.3C02959 |
|
| 2024-01-19 |
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSPTSCI.3C00313 |
|
| 2024-01-19 |
Rapid, Multispecies Detection of SARS-CoV-2 Antibodies via a Meta-Surface Plasmon Resonance Biosensor (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2024/9350822 |
|
| 2024-01-19 |
PandoGen: Generating complete instances of future SARS-CoV-2 sequences using Deep Learning (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1011790 |
|
| 2024-01-19 |
The Impact of SARS-CoV-2 on the Coagulation Profile of Pregnant Women (edit) |
SARSコロナウイルス2 (edit) |
10.31926/BUT.MS.2023.65.16.2.8 |
|
| 2024-01-19 |
Triterpenoidal Saponins from the Leaves of Aster koraiensis Offer Inhibitory Activities against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PLANTS13020303 |
|
| 2024-01-19 |
Associations between Teacher Wellbeing and Social Support for Physical Activity in Two Urban School Districts during the early stages of the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.51250/JHEAL.V3I3.61 |
|
| 2024-01-18 |
A comprehensive profile of SARS-CoV-2 variants spreading during the COVID-19 pandemic: a genomic characterization study from Chhattisgarh State, India (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00203-023-03807-2 |
|
| 2024-01-18 |
A nanogap-enhanced SERS nanotag–based lateral flow assay for ultrasensitive and simultaneous monitoring of SARS-CoV-2 S and NP antigens (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00604-023-06126-X |
|
| 2024-01-18 |
SARS-CoV-2 and its Multifaceted Impact on Bone Health: Mechanisms and Clinical Evidence (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11914-023-00843-1 |
|
| 2024-01-18 |
Cycle threshold dynamics of non–severe acute respiratory coronavirus virus 2 (SARS-CoV-2) respiratory viruses (edit) |
SARSコロナウイルス2 (edit) |
10.1017/ICE.2023.286 |
|
| 2024-01-18 |
Allosteric Signal within the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Mediated by a Class 3 Monoclonal Antibody Revealed through Molecular Dynamics Simulations and Protein Residue Networks (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.3C07947 |
|
| 2024-01-18 |
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-024-44830-1 |
|
| 2024-01-18 |
Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42004-024-01104-7 |
|
| 2024-01-18 |
Examining potential Long COVID effects through utilization of healthcare resources: a retrospective, population-based, matched cohort study comparing individuals with and without prior SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EURPUB/CKAE001 |
|
| 2024-01-18 |
Risk of SARS-CoV-2 Reinfection in Children Within the 12 Months Following Mild COVID-19: Insights From a Survey Study (edit) |
SARSコロナウイルス2 (edit) |
10.1097/INF.0000000000004233 |
|
| 2024-01-18 |
A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/09612033241227811 |
|
| 2024-01-18 |
Anti-SARS-CoV-2-specific antibodies in human breast milk following SARS-CoV-2 infection during pregnancy: a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13006-023-00605-W |
|
| 2024-01-18 |
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors (edit) |
SARSコロナウイルス2 (edit) |
10.1515/CCLM-2023-1283 |
|
| 2024-01-18 |
Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2023.1325588 |
|
| 2024-01-18 |
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DISEASES12010029 |
|
| 2024-01-18 |
SARS-CoV-2 Accessory Protein Orf7b Induces Lung Injury via c-Myc Mediated Apoptosis and Ferroptosis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25021157 |
|
| 2024-01-18 |
What SARS-CoV-2 Variants Have Taught Us: Evolutionary Challenges of RNA Viruses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V16010139 |
|
| 2024-01-18 |
Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12010094 |
|
| 2024-01-18 |
SARS-CoV-2 vs Streptococcus pneumoniae: a comparison of clinical features, laboratory findings, and clinical outcomes in patients hospitalized at Alessandria’s General Hospital (edit) |
SARSコロナウイルス2 (edit) |
10.4081/WPPH.2023.9809 |
|
| 2024-01-18 |
SARS-CoV-2 and COVID-19: From Crisis to Solution (edit) |
SARSコロナウイルス2 (edit) |
10.59454/WHN-2401-334 |
|
| 2024-01-18 |
Characteristics and Outcomes of Children With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Admitted to a Quaternary Hospital: A Single-Center Experience (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.52532 |
|
| 2024-01-17 |
Developing of SARS-CoV-2 fusion protein expressed in E. coli Shuffle T7 for enhanced ELISA detection sensitivity – an integrated experimental and bioinformatic approach (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2024.2302941 |
|
| 2024-01-17 |
Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-024-01639-4 |
|
| 2024-01-17 |
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS HOSPITALIZED DUE TO SARS-COV-2, INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA (edit) |
SARSコロナウイルス2 (edit) |
10.18229/KOCATEPETIP.1192685 |
|
| 2024-01-16 |
Inclusion of deuterated glycopeptides provides increased sequence coverage in hydrogen/deuterium exchange mass spectrometry analysis of SARS‐CoV‐2 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1002/RCM.9690 |
|
| 2024-01-16 |
High quality of SARS-CoV-2 molecular diagnostics in a diverse laboratory landscape through supported benchmark testing and External Quality Assessment (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-023-50912-9 |
|
| 2024-01-16 |
Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralization titers in seropositive subjects (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-51968-X |
|
| 2024-01-16 |
Mining genomic repositories to further our knowledge of the extent of SARS-CoV-2 co-infections (edit) |
SARSコロナウイルス2 (edit) |
10.1099/MGEN.0.001158 |
|
| 2024-01-16 |
A surveillance study of SARS-CoV-2 infection in immunosuppressed patients (edit) |
SARSコロナウイルス2 (edit) |
10.1177/17571774241226584 |
|
| 2024-01-16 |
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13643-023-02411-1 |
|
| 2024-01-16 |
Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0286848 |
|
| 2024-01-16 |
Global Stability of a Delayed Model for the Interaction of SARS-CoV-2/ACE2 and Adaptive Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.28924/2291-8639-22-2024-14 |
|
| 2024-01-16 |
Elucidating the binding mechanism of SARS-CoV-2 NSP6-TBK1 and structure-based designing of phytocompounds inhibitors for instigating the host immune response (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2023.1346796 |
|
| 2024-01-16 |
Safety and efficacy of COVID-19 vaccine immunization during pregnancy in 1024 pregnant women infected with the SARS-CoV-2 Omicron virus in Shanghai, China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1303058 |
|
| 2024-01-15 |
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-024-01127-Z |
|
| 2024-01-15 |
Reduced clinical severity during 2022 Shanghai Spring epidemic of SARS-CoV-2 omicron BA.2 variant infection - An integrated account of virus pathogenicity and vaccination effectiveness (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NSR/NWAE011 |
|
| 2024-01-15 |
Development and clinical application of loop-mediated isothermal amplification combined with lateral flow assay for rapid diagnosis of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-023-08924-3 |
|
| 2024-01-15 |
Factors associated with SARS-CoV-2 infection in unvaccinated children and young adults (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-023-08950-1 |
|
| 2024-01-15 |
SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12964-023-01397-6 |
|
| 2024-01-15 |
Frequency and risk factors of psychological distress among individuals with epilepsy before and during the outbreak of the SARS-CoV-2 Omicron variant in China: an online questionnaire survey (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S42494-023-00146-Z |
|
| 2024-01-15 |
Mechanism of infection of SARS-CoV-2 and gender based differential impacts (edit) |
SARSコロナウイルス2 (edit) |
10.18231/J.IJCAP.2023.061 |
|
| 2024-01-15 |
Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1273604 |
|
| 2024-01-15 |
A case series exploring the human milk polyclonal IgA1 response to repeated SARS-CoV-2 vaccinations by LC–MS based fab profiling (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNUT.2023.1305086 |
|
| 2024-01-15 |
Persisting Gastrointestinal Symptoms in Children with SARS-CoV-2: Temporal Evolution over 18 Months and Possible Role of Lactoferrin (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CHILDREN11010105 |
|
| 2024-01-14 |
A Bayesian framework for modeling COVID‐19 case numbers through longitudinal monitoring of SARS‐CoV‐2 RNA in wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SIM.10009 |
|
| 2024-01-14 |
SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS13010075 |
|
| 2024-01-13 |
Comparison of Six Aptamer-Aptamer Pairs on Rapid Detection of SARS-CoV-2 by Lateral Flow Assay (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JAOACINT/QSAE004 |
|
| 2024-01-13 |
Chronic shedding of a SARS-CoV-2 Alpha variant in wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12864-024-09977-7 |
|
| 2024-01-13 |
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12865-024-00596-1 |
|
| 2024-01-12 |
As COVID-19 Cases Surge, Here’s What to Know About JN.1, the Latest SARS-CoV-2 “Variant of Interest” (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2023.27841 |
|
| 2024-01-12 |
Differences in Oligomerization of the SARS-CoV-2 Envelope Protein, Poliovirus VP4, and HIV Vpu (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.3C00437 |
|
| 2024-01-12 |
Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0294271 |
|
| 2024-01-12 |
AH971 and AV865 antibodies label the SARS-CoV-2 nucleocapsid protein in focus-forming assay (edit) |
SARSコロナウイルス2 (edit) |
10.24450/JOURNALS/ABREP.2023.E1316 |
|
| 2024-01-12 |
Optimasi Kodon dan Konstruksi Plasmid Rekombinan Protein RBD SARS-CoV-2 pada E. coli BL21(DE3) (edit) |
SARSコロナウイルス2 (edit) |
10.30590/JOH.V11N1.715 |
|
| 2024-01-12 |
Potential Alternative Receptors for SARS-CoV-2-Induced Kidney Damage: TLR-4, KIM-1/TIM-1, and CD147 (edit) |
SARSコロナウイルス2 (edit) |
10.31083/J.FBL2901008 |
|
| 2024-01-12 |
Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study (edit) |
SARSコロナウイルス2 (edit) |
10.3310/NIHROPENRES.13517.1 |
|
| 2024-01-12 |
Mutational analysis of SARS-CoV-2 ORF6-KPNA2 binding interface and identification of potent small molecule inhibitors to recuse the host immune system (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1266776 |
|
| 2024-01-12 |
Ready for new waves: optimizing SARS-CoV-2 variants monitoring in pooled samples with droplet digital PCR (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1340420 |
|
| 2024-01-12 |
An Open View on SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS12010156 |
|
| 2024-01-12 |
Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12010076 |
|
| 2024-01-12 |
Methicillin-Sensitive Staphylococcus aureus Co-infection in Adolescent Patients With Delta-Variant SARS-CoV-2 Acute Respiratory Failure (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.52164 |
|
| 2024-01-12 |
Dermal Granuloma Annulare After SARS-CoV-2 Vaccination: A Rare Complication (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.52174 |
|
| 2024-01-11 |
Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-023-01724-6 |
|
| 2024-01-11 |
In silico and in vitro prediction of new synthesized N-heterocyclic compounds as anti-SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-024-51443-7 |
|
| 2024-01-11 |
Expression of the SARS-CoV-2 Receptor ACE2 and Protease TMPRSS2 in Ocular Hypertension Eyes of Nonhuman Primate and Human (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02713683.2023.2291749 |
|
| 2024-01-11 |
The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JS9.0000000000001070 |
|
| 2024-01-11 |
Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2024.29.2.2300740 |
|
| 2024-01-11 |
Nomogram to predict the incidence of delirium in elderly patients with non-severe SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPSYT.2023.1288948 |
|
| 2024-01-10 |
Outcomes of SARS‐CoV‐2 infection in early pregnancy—A systematic review and meta‐analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1111/AOGS.14764 |
|
| 2024-01-10 |
Molecular, Immunological, and Clinical Characterization of SARS-CoV-2 Infection in Breakthrough-Infected Healthcare Workers During the Last Wave of The Pandemic in Shiraz, Iran (edit) |
SARSコロナウイルス2 (edit) |
10.5812/JJM-142644 |
|
| 2024-01-09 |
Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-44621-0 |
|
| 2024-01-09 |
Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NSR/NWAE030 |
|
| 2024-01-08 |
Prevalence of depressive symptoms and correlates among individuals who self-reported SARS-CoV-2 infection after optimizing the COVID-19 response in China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1268799 |
|
| 2024-01-07 |
The spike-specific TCRβ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12967-024-04852-1 |
|
| 2024-01-06 |
Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES12010055 |
|
| 2024-01-04 |
SARS-CoV-2’s brain impact: revealing cortical and cerebellar differences via cluster analysis in COVID-19 recovered patients (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10072-023-07266-X |
|
| 2024-01-04 |
TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-44502-6 |
|
| 2024-01-04 |
Enhanced SARS-CoV-2 case prediction using public health data and machine learning models (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JAMIAOPEN/OOAE014 |
|
| 2024-01-04 |
In-silico design of a new multi-epitope vaccine candidate against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/AV.2023.12481 |
|
| 2024-01-03 |
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-44090-5 |
38172101 |
| 2024-01-02 |
The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S44319-023-00043-Z |
|
| 2024-01-01 |
SARS‐CoV‐2‐associated T‐cell infiltration in the central nervous system (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTI2.1487 |
|
| 2024-01-01 |
Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signatures (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTI2.1488 |
|
| 2024-01-01 |
The swab site of the upper airways influences the diagnostic sensitivity for the omicron variant of SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29390 |
|
| 2024-01-01 |
One dose versus two doses of COVID‐19 vaccine for the prevention of breakthrough infections among people previously infected with SARS‐Cov‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29391 |
|
| 2024-01-01 |
SARS‐CoV‐2 NSP12 utilizes various host splicing factors for replication and splicing regulation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29396 |
|
| 2024-01-01 |
Mucosal antibody response and SARS‐CoV‐2 shedding in patients with COVID‐19 related olfactory dysfunction (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29398 |
|
| 2024-01-01 |
Th2 and Th17‐associated immunopathology following SARS‐CoV‐2 breakthrough infection in Spike‐vaccinated ACE2‐humanized mice (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29408 |
|
| 2024-01-01 |
Generation of SARS‐CoV‐2 spike receptor binding domain mutants and functional screening for immune evaders using a novel lentivirus‐based system (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29425 |
|
| 2024-01-01 |
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40121-023-00908-9 |
|
| 2024-01-01 |
Natural SARS-CoV-2 infection in dogs: Determination of viral loads, distributions, localizations, and pathology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACTATROPICA.2023.107070 |
|
| 2024-01-01 |
51 Association of SARS CoV-2 infection in pregnancy and placental gene expression at delivery (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.071 |
|
| 2024-01-01 |
1086 Risk Factors for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Symptoms Among Postpartum Birthing People (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.1113 |
|
| 2024-01-01 |
1146 Single-cell transcriptomic profiling of Hofbauer cells reveals varied baseline functions and cluster-specific responses to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.1170 |
|
| 2024-01-01 |
LB01 Development of post-acute sequelae of SARS-CoV-2 (PASC) after infection in pregnancy: NIH RECOVER-Pregnancy Cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.1258 |
|
| 2024-01-01 |
591 Association of SARS-CoV-2 variant type and placental pathology changes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.616 |
|
| 2024-01-01 |
628 Association of disease severity and placental pathology changes in pregnant patients with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.653 |
|
| 2024-01-01 |
686 Histopathologic placental findings in SARS-CoV-2 exposed gravida compared to unexposed controls (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.712 |
|
| 2024-01-01 |
757 Maternal, Neonatal and Delivery Outcomes Following a SARS-CoV-2 Moratorium on Elective Deliveries (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.11.782 |
|
| 2024-01-01 |
Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOPHA.2023.115959 |
|
| 2024-01-01 |
Long-term, unilateral third cranial nerve palsy, ocular myositis, and high CSF interleukine-2 persisting for 14 months after mild SARS-CoV-2 infection-case report (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLINSP.2024.100331 |
|
| 2024-01-01 |
Comparison of RT-ddPCR and RT-qPCR platforms for SARS-CoV-2 detection: Implications for future outbreaks of infectious diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVINT.2024.108438 |
|
| 2024-01-01 |
High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with in vitro viral neutralizing activity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2024.E24513 |
|
| 2024-01-01 |
Patterns of Myocardial Scar After Non-hospitalized sars-cov-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JOCMR.2024.100911 |
|
| 2024-01-01 |
Natural 7,8-secolignans from Schisandra sphenanthera fruit potently inhibit SARS-CoV-2 3CLpro and inflammation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCME.2024.01.005 |
|
| 2024-01-01 |
Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2024.100443 |
|
| 2024-01-01 |
Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2024.100445 |
|
| 2024-01-01 |
Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2024.100446 |
|
| 2024-01-01 |
SARS-CoV-2 vaccines in China could reduce COVID-19-related respiratory syndromes and deaths: A retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2024.100448 |
|
| 2024-01-01 |
Placental pathology in a large (Swedish) cohort of SARS-CoV-2 infected mothers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PLACENTA.2023.12.010 |
|
| 2024-01-01 |
Invasive mucinous adenocarcinoma of the lung with bronchorrhea — A marked reduction volume of sputum after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RMCR.2024.101982 |
|
| 2024-01-01 |
3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2213-2600(23)00387-9 |
|
| 2024-01-01 |
As air relative humidity increases, infectivity of SARS-CoV-2 decreases within water droplets (edit) |
SARSコロナウイルス2 (edit) |
10.1017/QRD.2024.7 |
|
| 2024-01-01 |
Case–control study of behavioural and societal risk factors for sporadic SARS-CoV-2 infections, Germany, 2020–2021 (CoViRiS study) (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S0950268824000050 |
|
| 2024-01-01 |
A heparan sulfate proteoglycan-mimicking AIE fluorescent probe for SARS-CoV-2 detection (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D3NJ04949C |
|
| 2024-01-01 |
SARS-CoV-2 recombinase polymerase amplification assay with lateral flow readout and duplexed full process internal control (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D3SD00246B |
|
| 2024-01-01 |
A semi-quantitative visual lateral flow immunoassay for SARS-CoV-2 antibody detection for the follow-up of immune response to vaccination or recovery (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D3TB02895J |
|
| 2024-01-01 |
Allosteric regulation in SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D4CP00106K |
|
| 2024-01-01 |
Si–rhodamine derivative with a large stokes shift for ELISA-based detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D4SD00038B |
|
| 2024-01-01 |
SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register–based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BRAINCOMMS/FCAE406 |
|
| 2024-01-01 |
When the Background Looms Large over the Foreground: Medical Professionals, Diplomats, and Co-Managing SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ISAGSQ/KSAE001 |
|
| 2024-01-01 |
SARS-CoV-2 inactivation on hard non-porous airplane cabin material surfaces was limited after exposure to far UV-C (222 nm) radiation (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JAMBIO/LXAE007 |
|
| 2024-01-01 |
Magnitude and durability of the antibody response to mRNA-based vaccination among SARS-CoV-2 seronegative and seropositive health care personnel (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAE009 |
38293246 |
| 2024-01-01 |
Optimal entropic properties of SARS-CoV-2 RNA sequences (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.231369 |
|
| 2024-01-01 |
Lack of detection of SARS-CoV-2 in wildlife from Kerala, India in 2020–21 (edit) |
SARSコロナウイルス2 (edit) |
10.1099/ACMI.0.000686.V3 |
|
| 2024-01-01 |
Cost-sensitive ordinal classification methods to predict SARS-CoV-2 pneumonia severity (edit) |
SARSコロナウイルス2 (edit) |
10.1109/JBHI.2024.3363765 |
|
| 2024-01-01 |
Internationally standardized respiratory viral load testing with limited resources: A derivative‐of‐care calibration strategy for SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IRV.13207 |
|
| 2024-01-01 |
Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IRV.13237 |
|
| 2024-01-01 |
Adverse perinatal outcomes in gestational diabetes mellitus with and without SARS-CoV-2 infection during pregnancy: results from two nationwide registries in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJDRC-2023-003724 |
|
| 2024-01-01 |
Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study) (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJDRC-2023-003777 |
|
| 2024-01-01 |
Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1148/RADIOL.231928 |
|
| 2024-01-01 |
Retrospective Analysis of the Impact of SARS‐CoV‐2 (COVID‐19) on Pregnancy and Neonatal Outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2024/1177119 |
|
| 2024-01-01 |
Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1159/000536064 |
|
| 2024-01-01 |
Long-Term Growth and Neurodevelopmental Outcomes of Neonates Infected with SARS-CoV-2 during the COVID-19 Pandemic at 18–24 Months Corrected Age: A Prospective Observational Study (edit) |
SARSコロナウイルス2 (edit) |
10.1159/000537803 |
|
| 2024-01-01 |
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry (edit) |
SARSコロナウイルス2 (edit) |
10.1177/17588359231225028 |
|
| 2024-01-01 |
Chronic Symptomatology Among Infants, Children, and Adolescents Within 12 Months After SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1177/2333794X241287096 |
|
| 2024-01-01 |
SARS-CoV-2 S Protein Reduces Cytoprotective Defenses and Promotes Human Endothelial Cell Senescence (edit) |
SARSコロナウイルス2 (edit) |
10.14336/AD.2024.0405 |
|
| 2024-01-01 |
Analysis of the SARS-CoV-2 nsp12 P323L/A529V mutations: coeffect in the transiently peaking lineage C.36.3 on protein structure and response to treatment in Egyptian records (edit) |
SARSコロナウイルス2 (edit) |
10.1515/ZNC-2023-0132 |
|
| 2024-01-01 |
The Intra-Host Evolution of SARS-CoV-2 After Neutralizing Antibody Therapy, Revealed by Nanopore Sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.15212/ZOONOSES-2023-0032 |
|
| 2024-01-01 |
Outcomes of SARS-CoV-2 and Seasonal Viruses Among Children Hospitalized in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1542/PEDS.2023-064326 |
|
| 2024-01-01 |
Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1590/0102-311XEN152023 |
39194089 |
| 2024-01-01 |
Telomere length in subjects with and without SARS-CoV-2 infection: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1590/1806-9282.20240387 |
|
| 2024-01-01 |
Cognitive impairment and neuropsychiatric symptoms among individuals with history of symptomatic SARS-CoV-2 infection: a retrospective longitudinal study (edit) |
SARSコロナウイルス2 (edit) |
10.1590/1980-5764-DN-2023-0053 |
|
| 2024-01-01 |
SARS-CoV-2 vaccination and semen quality: a study based on sperm donor candidate data in southwest China (edit) |
SARSコロナウイルス2 (edit) |
10.21037/TAU-23-395 |
|
| 2024-01-01 |
Highly Specific Sars-Cov-2 Main Protease (Mpro) Mutations Against the Clinical Antiviral Ensitrelvir Selected in a Safe, Vsv-Based System (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4686131 |
|
| 2024-01-01 |
Rejection of corneal transplant after administration of SARS-CoV-2 messenger RNA vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.26502/FJOR.2644-00240089 |
|
| 2024-01-01 |
OmiCrisp: A CRISPR SARS-CoV-2 Test with Omicron Detection (edit) |
SARSコロナウイルス2 (edit) |
10.26502/JBB.2642-91280128 |
|
| 2024-01-01 |
Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) (edit) |
SARSコロナウイルス2 (edit) |
10.3346/JKMS.2024.39.E237 |
|
| 2024-01-01 |
Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.3346/JKMS.2024.39.E43 |
|
| 2024-01-01 |
Evidence of Placental Villous Inflammation and Apoptosis in Third-Trimester Symptomatic SARS-CoV-2 Maternal Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3349/YMJ.2023.0309 |
|
| 2024-01-01 |
ASSOCIATION BETWEEN BIRTH DURING THE COVID- 19 PANDEMIC AND NEURODEVELOPMENTAL STATUS OF INFANTS BETWEEN THE AGE OF 5-7 MONTHS WITH AND WITHOUT IN UTERO EXPOSURE TO MATERNAL SARS-COV-2 INFECTION (edit) |
SARSコロナウイルス2 (edit) |
10.36106/IJSR/1601417 |
|
| 2024-01-01 |
Characteristics of ST-Elevation Myocardial Infarction during the SARS-CoV-2 Outbreak (edit) |
SARSコロナウイルス2 (edit) |
10.36660/IJCS.20220203 |
|
| 2024-01-01 |
In-silico study MM/GBSA binding free energy and molecular dynamics simulation of some designed remdesivir derivatives as the inhibitory potential of SARS-CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
10.4103/1735-5362.394818 |
|
| 2024-01-01 |
SARS-CoV-2 Pooled Testing Methodology for PCR Testing Applied in Private Laboratory in Armenia (edit) |
SARSコロナウイルス2 (edit) |
10.4236/AID.2024.141006 |
|
| 2024-01-01 |
Alpinia galanga bioactive constituents as multi-target inhibitors of SARS-CoV-2 proteins: A molecular docking, molecular simulation and ADMET analysis (edit) |
SARSコロナウイルス2 (edit) |
10.53388/TMR20230902001 |
|
| 2024-01-01 |
Relative effectiveness and durability of booster doses of SARS-CoV-2 vaccines: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.59717/J.XINN-MED.2024.100051 |
|
| 2024-01-01 |
A Case of Nosocomial Coinfection of SARS-CoV-2 and Influenza A Virus in a Hospitalized Patient with Acute Myocardial Infarction (edit) |
SARSコロナウイルス2 (edit) |
10.7754/CLIN.LAB.2023.230735 |
|
| 2023-12-30 |
Retrospective study on the prevalence of oral symptoms in the specific manifestations of pathology caused by SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.22551/MSJ.2023.04.15 |
|
| 2023-12-30 |
Computational Approaches for Lead Discovery against SARS-CoV-2 3C-Like Protease: Virtual Screening and Molecular Dynamics Studies (edit) |
SARSコロナウイルス2 (edit) |
10.37881/JMAHS.225 |
|
| 2023-12-30 |
An Investigation of a SARS-CoV-2 Omicron Variant Cluster Linked to Nightclubs, Kalasin Province, Thailand, December 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.59096/OSIR.V16I4.263662 |
|
| 2023-12-30 |
SARS-CoV-2 Infections, Vaccination, and Vaccine Effectiveness in Thailand, January 2021–January 2022: Results of a Cohort Study in Four Provinces (edit) |
SARSコロナウイルス2 (edit) |
10.59096/OSIR.V16I4.264238 |
|
| 2023-12-28 |
STUDI MOLECULAR DOCKING SENYAWA TURUNAN AURON SEBAGAI INHIBITOR GLIKOPROTEIN SPIKE SARS-COV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.12962/J25493736.V8I2.16827 |
|
| 2023-12-26 |
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS25010354 |
|
| 2023-12-26 |
Coronavirus (SARS-CoV-2) Infection and Pathogenicity: The Roles of Cell Death and Autophagy (edit) |
SARSコロナウイルス2 (edit) |
10.55248/GENGPI.4.1223.0111 |
|
| 2023-12-22 |
SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCHEMNEURO.3C00468 |
|
| 2023-12-22 |
Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.12.21.572824 |
|
| 2023-12-22 |
Examining the Relationship between SARS-CoV-2 Infection and Type 1 Diabetes: A Reanalysis of Recent Findings (edit) |
SARSコロナウイルス2 (edit) |
10.33696/IMMUNOLOGY.5.179 |
|
| 2023-12-20 |
SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAD336 |
37571849 |
| 2023-12-20 |
Unravelling the Complexity of SARS-CoV-2 and COVID-19: A Comprehensive Review (edit) |
SARSコロナウイルス2 (edit) |
10.48165/BPAS.2023.42A.2.11 |
|
| 2023-12-18 |
Evolving spike-protein -glycosylation in SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.05.08.539897 |
37214937 |
| 2023-12-18 |
Management of Non-hospitalized patients with Acute SARS-CoV-2 (COVID-19) viral infection in among human adult population (edit) |
SARSコロナウイルス2 (edit) |
10.52711/2321-5763.2023.00038 |
|
| 2023-12-15 |
Characteristics of innate immunity cells after diseases caused by the SARS-COV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.17816/CI2023231-6 |
|
| 2023-12-12 |
The impact of government pandemic policies on the vulnerability of healthcare workers to SARS-CoV-2 infection and mortality in Jakarta Province, Indonesia (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07853890.2023.2293306 |
|
| 2023-12-08 |
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ADH0687 |
|
| 2023-12-07 |
Infection precaution adherence varies by potential exposure risks to SARS-CoV-2 and job role: findings from a US medical center (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2023.10.010 |
|
| 2023-12-07 |
Rare studies expose bats to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADN3526 |
|
| 2023-12-06 |
Environmental monitoring of SARS-CoV-2 in the metropolitan area of Porto Alegre, Rio Grande do Sul (RS), Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-023-31081-8 |
|
| 2023-12-06 |
<em>Science</em>Adviser: Why scientists are trying to infect bats with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADN3715 |
|
| 2023-12-06 |
Antibody-mediated SARS-CoV-2 entry in cultured cells (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBR.202357724 |
38277394 |
| 2023-12-04 |
Prevalence of SARS-CoV-2 infection among US blood donors by industry, May-December 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/AJIM.23552 |
38047323 |
| 2023-12-02 |
The cardiovascular response to exercise in athletes recovering from SARS-CoV-2 infection: A prospective cohort study with repeated measures over 16 weeks – AWARE IX (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02640414.2024.2312054 |
|
| 2023-12-01 |
Corrigendum to “Does SARS-CoV-2 re-infection depend on virus variant?” [Clin Microbiol Infect 27 (9) (2021 Sep) 1374–1375] (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMI.2023.08.012 |
37597618 |
| 2023-12-01 |
A bioinformatic analysis: Previous allergen exposure may support anti- SARS-CoV-2 immune response (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2023.107961 |
|
| 2023-12-01 |
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COPH.2023.102404 |
37734241 |
| 2023-12-01 |
Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2023.10.022 |
|
| 2023-12-01 |
Predicted risk of heart failure pandemic due to persistent SARS-CoV-2 infection using a three-dimensional cardiac model (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2023.108641 |
|
| 2023-12-01 |
High Cardiac Troponin Levels in Infants with Acute SARS-CoV-2 Infection: A Prospective Comparative study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPEDS.2023.113876 |
|
| 2023-12-01 |
A new alkaloid from Pancratium maritimum - Structure elucidation using computer-assisted structure elucidation (CASE) and evaluation of cytotoxicity and anti-SARS-CoV-2 activity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYTOL.2023.09.006 |
|
| 2023-12-01 |
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD403 |
38077689 |
| 2023-12-01 |
Impact of the SARS-COV-2 Pandemic on Changes in the Financing and Delivery of Forestry Education in Poland – A Case Study (edit) |
SARSコロナウイルス2 (edit) |
10.2478/ERS-2023-0038 |
|
| 2023-12-01 |
USE OF MOLECULAR DOCKING TO VALIDATE EFFICACY OF BEE POLLEN PHYTOCHEMICALS ON SARS-COV-2 AND PREDICTION OF ADMET/TOXICITY PROPERTIES (edit) |
SARSコロナウイルス2 (edit) |
10.31032/IJBPAS/2023/12.12.7634 |
|
| 2023-12-01 |
Discovering the epigenetic pathways underlying SARS-CoV-2 infections and exploring recent epigenetic-associated clinical trials (edit) |
SARSコロナウイルス2 (edit) |
10.54085/AP.2023.12.2.3 |
|
| 2023-12-01 |
New Alcohol Sensitivity in Patients With Post-acute Sequelae of SARS-CoV-2 (PASC): A Case Series (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.51286 |
38288178 |
| 2023-11-30 |
Gray Matter Thickness and Subcortical Nuclear Volume in Men After SARS-CoV-2 Omicron Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2023.45626 |
|
| 2023-11-30 |
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS12121408 |
38133292 |
| 2023-11-30 |
Diagnostic Values of SARS-COV-2 Antibodies using Lifotronic ECL-8000 (edit) |
SARSコロナウイルス2 (edit) |
10.52711/0974-360X.2023.00815 |
|
| 2023-11-29 |
Vagus nerve SARS‐CoV‐2 infection and inflammatory reflex dysfunction: Is there a causal relationship? (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JOIM.13746 |
|
| 2023-11-27 |
2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAD500.2076 |
|
| 2023-11-22 |
Long COVID in Icelandic Children: A Matched Cohort Study of Nonspecific Symptoms Following SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1097/INF.0000000000004187 |
|
| 2023-11-22 |
Using Chaos-Game-Representation for Analysing the SARS-CoV-2 Lineages, Newly Emerging Strains and Recombinants (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0113892029264990231013112156 |
38178984 |
| 2023-11-20 |
Is SARS‐CoV‐2‐induced disease a decisive factor influencing testosterone in males? Findings from a case‐control ex post facto study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ANDR.13558 |
|
| 2023-11-17 |
Impact on Hearing Among SARS COV-2 Infected Adults and Children Born to Gestational COVID-19 Infected Mothers: A Prospective Case Control Study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12070-023-04304-0 |
|
| 2023-11-15 |
Immune escape of SARS-CoV-2 variants to therapeutic monoclonal antibodies: a system review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-023-01977-5 |
|
| 2023-11-15 |
Rapid Decline in the Uptake Interests for Different SARS CoV-2 Vaccination Doses Over the Post Vaccination Period in Different European Community Countries (edit) |
SARSコロナウイルス2 (edit) |
10.33533/JPM.V17I2.6597 |
|
| 2023-11-15 |
Impact of COVID-19 vaccination to SARS-Cov-2 infection and outcomes among end-stage renal disease patients in South Korea (edit) |
SARSコロナウイルス2 (edit) |
10.4285/ATW2023.F-7631 |
|
| 2023-11-15 |
Excess mortality of end-stage renal disease patients during early SARS-Cov-2 pandemic in South Korea (edit) |
SARSコロナウイルス2 (edit) |
10.4285/ATW2023.F-8897 |
|
| 2023-11-14 |
The Role of Mesenchymal Stem Cells in Modulating the Immune System and Repairing Lung Damage in ARDS Patients with SARS-COV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.30654/MJCH.10024 |
|
| 2023-11-10 |
SARS-CoV-2 and the DNA damage response (edit) |
SARSコロナウイルス2 (edit) |
10.1099/JGV.0.001918 |
|
| 2023-11-10 |
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABO7201 |
|
| 2023-11-08 |
Analysis of the Tropism of SARS-CoV-2 Based on the Host Interactome of the Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.3C00387 |
|
| 2023-11-08 |
Research on Variation of Sars-Cov-2 and Rapid Detection (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3608164.3608197 |
|
| 2023-11-08 |
SARS-CoV-2 Orf1ab Genome Mutations, the Driving Force for Virus Pathogenicity (edit) |
SARSコロナウイルス2 (edit) |
10.23880/VIJ-16000336 |
|
| 2023-11-07 |
Virtual Screening of Traditional Chinese Medicine for Discovery of Potential Anti-SARS-CoV-2 Lead Molecules (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3608164.3608199 |
|
| 2023-11-02 |
A method for obtaining aqueous and dry ethanol extracts of grass (a mixture of flowers with leaves) and a stalk of St. John's wort (Hypericum perforatum L.) with inhibitory activity on the replication of the SARS‐CoV‐2 coronavirus in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.18470/1992-1098-2023-3-103-117 |
|
| 2023-11-01 |
Superior neutralizing response after first versus second SARS‐CoV‐2 infection in fully vaccinated individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29225 |
|
| 2023-11-01 |
Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2023.105731 |
|
| 2023-11-01 |
Single-cell RNA-Seq reveals intracellular microbial diversity within immune cells during SARS-CoV-2 infection and recovery (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2023.108357 |
|
| 2023-11-01 |
SARS-CoV-2 vaccination strategies: Should the extended dosing interval strategy be implemented in future pandemics? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TMAID.2023.102650 |
|
| 2023-11-01 |
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-023-02674-0 |
|
| 2023-11-01 |
Correction to: Development of a rapid and ultra-sensitive RNA:DNA hybrid immunocapture based biosensor for visual detection of SARS-CoV-2 RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD370 |
38024419 |
| 2023-11-01 |
Neurologic Effects of SARS-CoV-2 Transmitted among Dogs (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2911.230804 |
|
| 2023-10-30 |
Neuroproteomic Analysis after SARS-CoV-2 Infection Reveals Overrepresented Neurodegeneration Pathways and Disrupted Metabolic Pathways (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM13111597 |
38002279 |
| 2023-10-26 |
Billions boost next-generation weapons against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADL5523 |
|
| 2023-10-26 |
SARS-CoV-2 Affects Thyroid and Adrenal Glands: An 18F-FDG PET/CT Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES11112899 |
|
| 2023-10-23 |
The role of location in the spread of SARS-CoV-2: examination of cases and exposed contacts in South Texas, using social network analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2023.189 |
|
| 2023-10-18 |
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-42346-8 |
|
| 2023-10-18 |
SARS‐CoV‐2 infection correlates with male benign prostatic hyperplasia deterioration (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JOIM.13719 |
|
| 2023-10-12 |
Erratum for the Research Article “The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2” by J. E. Pekar et al. (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADL0585 |
|
| 2023-10-11 |
Mapping SARS-CoV-2 antigenic relationships and serological responses (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADJ0070 |
|
| 2023-10-05 |
Viral kinetics of sequential SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-41941-Z |
37798265 |
| 2023-10-05 |
Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES11101564 |
|
| 2023-10-01 |
Emergence of a second SARS‐CoV‐2 variant with a tremendous genetic leap from its ancestors (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.29124 |
|
| 2023-10-01 |
SARS-CoV-2 S and N protein peptides drive invasion abilities of colon cancer cells through TGF-β1 regulation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAMCR.2023.119541 |
|
| 2023-10-01 |
Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOCHI.2023.05.014 |
|
| 2023-10-01 |
RNA structure and multiple weak interactions balance the interplay between RNA binding and phase separation of SARS-CoV-2 nucleocapsid (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD333 |
37901441 |
| 2023-10-01 |
Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1152/JAPPLPHYSIOL.00158.2023 |
|
| 2023-09-29 |
Genetic variant powers up immune cells that remember SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/D41586-023-03009-2 |
|
| 2023-09-29 |
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7239A3 |
|
| 2023-09-28 |
SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S44161-023-00336-5 |
|
| 2023-09-28 |
An extended catalytic model to assess changes in risk for multiple reinfections with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.09.27.23296231 |
|
| 2023-09-27 |
Oral manifestations of COVID-19 in unvaccinated patients: a cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12903-023-03325-Z |
37759210 |
| 2023-09-25 |
Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination (edit) |
SARSコロナウイルス2 (edit) |
10.1055/A-2180-9872 |
|
| 2023-09-18 |
Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-41381-9 |
37723181 |
| 2023-09-17 |
The Environmental Surveillance in Medical Center During the SARS-CoV-2 Omicron Variant Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1289/ISEE.2023.FP-006 |
|
| 2023-09-17 |
Citywide wastewater SARS-CoV-2 concentration predicts the epidemic curve in Taipei City, Taiwan (edit) |
SARSコロナウイルス2 (edit) |
10.1289/ISEE.2023.FP-017 |
|
| 2023-09-17 |
Investigating links between long-term air pollution exposure and SARS-CoV-2 infection, hospitalisation and mortality:a meta-analysis of cohort studies (edit) |
SARSコロナウイルス2 (edit) |
10.1289/ISEE.2023.OP-309 |
|
| 2023-09-17 |
Association between long-term exposure to air pollution, risk of infection by SARS-CoV-2 virus and COVID-19 in the French CONSTANCES cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1289/ISEE.2023.VO-053 |
|
| 2023-09-11 |
SARS-CoV-2 infection as a potential risk factor for the development of cancer (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2023.1260776 |
|
| 2023-09-08 |
Real-time surveillance of international SARS-CoV-2 prevalence using systematic traveller arrival screening: An observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PMED.1004283 |
|
| 2023-09-04 |
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC) (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-023-01601-2 |
|
| 2023-09-01 |
SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ATHPLU.2023.06.002 |
|
| 2023-09-01 |
Establishing causality between SARS-CoV-2 and stroke/bleeding requires a temporal relationship and plausible pathophysiology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HEST.2022.10.004 |
|
| 2023-09-01 |
Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2023.06.017 |
|
| 2023-09-01 |
Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYMED.2023.154942 |
|
| 2023-09-01 |
Analysis of RBD-ACE2 interactions in livestock species as a factor in the spread of SARS-CoV-2 among animals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VAS.2023.100303 |
|
| 2023-09-01 |
Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00115-5 |
|
| 2023-09-01 |
Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD282 |
37731949 |
| 2023-09-01 |
Substances of abuse and their effect on SAR-CoV-2 pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1515/NIPT-2023-0004 |
38013836 |
| 2023-08-22 |
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM13091273 |
|
| 2023-08-19 |
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-40750-8 |
37598213 |
| 2023-08-19 |
Emerging Role of Kinin B1 Receptor in Persistent Neuroinflammation and Neuropsychiatric Symptoms in Mice Following Recovery from SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS12162107 |
|
| 2023-08-19 |
SARS-CoV-2 Reinfections and Long COVID in the Post-Omicron Phase of the Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS241612962 |
|
| 2023-08-18 |
MDM2 Influences ACE2 Stability and SARS-CoV-2 Uptake (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15081763 |
|
| 2023-08-11 |
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CEI/UXAD096 |
|
| 2023-08-09 |
Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABQ1533 |
|
| 2023-08-06 |
SARS-CoV-2 Infection in Unvaccinated High-Risk Pregnant Women in the Bronx, NY, USA Is Associated with Decreased Apgar Scores and Placental Villous Infarcts (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM13081224 |
|
| 2023-08-03 |
Differential effects of SARS-CoV-2 variants on central nervous system cells and blood–brain barrier functions (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12974-023-02861-3 |
|
| 2023-08-01 |
Systematic review and synthesis of stillbirths and late miscarriages following SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2023.01.019 |
|
| 2023-08-01 |
Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2023.105666 |
|
| 2023-08-01 |
Fetal brain vulnerability to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBI.2023.06.015 |
|
| 2023-08-01 |
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2023.112991 |
|
| 2023-08-01 |
Does pollen exposure influence innate immunity to SARS-CoV-2 in allergy or asthma? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.05.008 |
|
| 2023-08-01 |
An overview of SARS-CoV-2 transmission and engineering strategies to mitigate risk (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JOBE.2023.106737 |
|
| 2023-08-01 |
Single particle tracking reveals SARS-CoV-2 regulating and utilizing dynamic filopodia for viral invasion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCIB.2023.08.031 |
|
| 2023-07-31 |
SARS-CoV-2 uses CD4 to infect T helper lymphocytes (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.84790 |
|
| 2023-07-28 |
Host susceptibility and structural and immunological insight of S proteins of two SARS-CoV-2 closely related bat coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-023-00581-9 |
|
| 2023-07-27 |
Descriptive analysis of a SARS-CoV-2 outbreak among health-care workers in a regional hospital in the Philippines (edit) |
SARSコロナウイルス2 (edit) |
10.5365/WPSAR.2023.14.3.1050 |
|
| 2023-07-26 |
Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-40228-7 |
|
| 2023-07-24 |
Diterpenoid and C20 diterpenoid alkaloid as a potent inhibitor of SARS-CoV-2 main protease (Mpro): from Piper barberi Gamble, an endemic and endangered species of Southern Western Ghats (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2023.2238075 |
|
| 2023-07-24 |
Incubation-period estimates of Omicron (BA.1) variant from Taiwan, December 2021–January 2022, and its comparison to other SARS-CoV-2 variants: a statistical modeling, systematic search and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.07.20.23292983 |
|
| 2023-07-21 |
A Systematic Review of Persistent Clinical Features After SARS-CoV-2 in the Pediatric Population (edit) |
SARSコロナウイルス2 (edit) |
10.1542/PEDS.2022-060351 |
|
| 2023-07-21 |
Neurotropic Manifestations as a Potential Risk Factor for Schizophrenia Following in utero Exposure to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.55504/2473-2869.1268 |
|
| 2023-07-20 |
Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADG6605 |
|
| 2023-07-19 |
Perceptions of the availability of personal protective equipment and its association with burnout among US healthcare personnel during the SARS-CoV-2 pandemic, 2020-2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JOM.0000000000002926 |
|
| 2023-07-18 |
Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses' Entry (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS12070951 |
37513798 |
| 2023-07-15 |
Structure-based Drug Design, ADME and Molecular Docking analyses of anti-viral agents against SARS-CoV-2 virus, Zika virus and Hepatitis C virus (edit) |
SARSコロナウイルス2 (edit) |
10.22270/JDDT.V13I7.5909 |
|
| 2023-07-14 |
Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1220600 |
|
| 2023-07-14 |
Genome-Wide Mining of Selaginella moellendorffii for Hevein-like Lectins and Their Potential Molecular Mimicry with SARS-CoV-2 Spike Glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB45070372 |
|
| 2023-07-13 |
Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41559-023-02123-8 |
|
| 2023-07-11 |
The Potential of Probiotics as Ingestible Adjuvants and Immune Modulators for Antiviral Immunity and Management of SARS-CoV-2 Infection and COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS12070928 |
|
| 2023-07-01 |
New‐onset neurodegenerative diseases as long‐term sequelae of SARS‐CoV‐2 infection: A systematic review and meta‐analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28909 |
|
| 2023-07-01 |
Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJIM.2023.04.008 |
|
| 2023-07-01 |
SARS-CoV-2 niches in human placenta revealed by spatial transcriptomics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2023.06.003 |
|
| 2023-07-01 |
Exposure of adult zebrafish (Danio rerio) to SARS-CoV-2 at predicted environmentally relevant concentrations: Outspreading warns about ecotoxicological risks to freshwater fish (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2023.163269 |
|
| 2023-07-01 |
Relative role of community transmission and campus contagion in driving the spread of SARS-CoV-2: Lessons from Princeton University (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD201 |
37457892 |
| 2023-07-01 |
Fitness effects of mutations to SARS-CoV-2 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAD055 |
|
| 2023-07-01 |
Comparing COVID-19 pandemic health responses in two high-income island nations: Iceland and New Zealand (edit) |
SARSコロナウイルス2 (edit) |
10.1177/14034948221149143 |
36717984 |
| 2023-07-01 |
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1212/NXI.0000000000200097 |
|
| 2023-06-23 |
Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years — 18 U.S. Jurisdictions, September 2021–December 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7225A3 |
|
| 2023-06-21 |
Author Correction: Coordinated surveillance is essential to monitor and mitigate the evolutionary impacts of SARS-CoV-2 spillover and circulation in animal hosts (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41559-023-02118-5 |
|
| 2023-06-20 |
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2023.101079 |
37327781 |
| 2023-06-16 |
The Role of Children in Household Transmission of SARS-CoV-2 Across Four Waves of the Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JPIDS/PIAD044 |
37327193 |
| 2023-06-15 |
Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-39267-X |
|
| 2023-06-15 |
Assessing SARS-CoV-2 vaccine hesitancy among the people living with and without HIV from May to September 2022 in Blantyre, Malawi (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21645515.2023.2222052 |
|
| 2023-06-14 |
Comparative characteristics of the cellular immune response to SARS-CoV-2 during infection and post-vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.15789/1563-0625-CCO-2690 |
|
| 2023-06-13 |
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2023.8823 |
|
| 2023-06-13 |
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOODADVANCES.2022009475 |
36622349 |
| 2023-06-09 |
SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ADG2248 |
|
| 2023-06-09 |
Mild SARS-CoV-2 infection results in long-lasting microbiota instability (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.00889-23 |
|
| 2023-06-09 |
Mini Review; Role of Changes in SARS-CoV-2 Spike Protein and Its Human Interaction (edit) |
SARSコロナウイルス2 (edit) |
10.21608/EAJBSC.2023.303781 |
|
| 2023-06-07 |
Construction of Gene Expression Patterns to Identify Critical Genes Under SARS-CoV-2 Infection Conditions (edit) |
SARSコロナウイルス2 (edit) |
10.1109/TCBB.2023.3283534 |
|
| 2023-06-07 |
Comparison of different techniques for evaluation of cellular immunity to SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.15789/1563-0625-COD-2640 |
|
| 2023-06-05 |
The Impact of the SARS-CoV-2 Pandemic on Stress and Anxiety of Dental Students (edit) |
SARSコロナウイルス2 (edit) |
10.1055/S-0042-1760299 |
|
| 2023-06-05 |
A SARS-CoV-2 outbreak in a plastics manufacturing plant (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-023-16025-8 |
|
| 2023-06-05 |
Post-COVID-19 Syndrome in Non-Hospitalized Individuals: Healthcare Situation 2 Years after SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15061326 |
|
| 2023-06-04 |
The Reduction of SARS-CoV-2 RNA Concentration in the Presence of Sewer Biofilms (edit) |
SARSコロナウイルス2 (edit) |
10.3390/W15112132 |
|
| 2023-06-01 |
Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2023.03.049 |
|
| 2023-06-01 |
Brain disorders: Impact of mild SARS-CoV-2 may shrink several parts of the brain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NEUBIOREV.2023.105150 |
|
| 2023-06-01 |
Association of SARS-CoV-2 infection and persistence with long COVID (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2213-2600(23)00142-X |
|
| 2023-06-01 |
First shared SARS-CoV-2 genome: GISAID vs virological.org (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(23)00133-7 |
37116518 |
| 2023-06-01 |
Allosteric communication between ACE2 active site and binding interface with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1063/5.0137654 |
|
| 2023-06-01 |
Head and neck reconstruction in the SARS-CoV-2 pandemic era: outcomes and lessons learned (edit) |
SARSコロナウイルス2 (edit) |
10.21037/FOMM-21-4 |
|
| 2023-06-01 |
Uptake and effectiveness of a mobile application for real-time reporting and quality assurance of decentralized SARS-CoV-2 testing in Uganda (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1053544 |
|
| 2023-05-31 |
Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJ-2022-074425 |
|
| 2023-05-31 |
Single-cell analysis of adult human heart across healthy and cardiovascular disease patients reveals the cellular landscape underlying SARS-CoV-2 invasion of myocardial tissue through ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12967-023-04224-1 |
|
| 2023-05-30 |
Inferring the differences in incubation-period and generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2221887120 |
37216529 |
| 2023-05-29 |
Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1158905 |
|
| 2023-05-26 |
Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro) (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2023.2217513 |
|
| 2023-05-25 |
Coordinated surveillance is essential to monitor and mitigate the evolutionary impacts of SARS-CoV-2 spillover and circulation in animal hosts (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41559-023-02082-0 |
|
| 2023-05-23 |
Brain imaging and neuropsychological assessment of individuals recovered from a mild to moderate SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2217232120 |
|
| 2023-05-23 |
Luteolin Isolated from Juncus acutus L., a Potential Remedy for Human Coronavirus 229E (edit) |
ヒトコロナウイルス229E (edit) |
10.3390/MOLECULES28114263 |
|
| 2023-05-22 |
Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2023.1192832 |
|
| 2023-05-18 |
Mechanisms of impairment of interferon production by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BST20221037 |
|
| 2023-05-18 |
Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8+T cells (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1151659 |
|
| 2023-05-17 |
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES11050991 |
|
| 2023-05-16 |
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-38435-3 |
37193706 |
| 2023-05-16 |
Comparative study of quality of life 9 months post-COVID-19 infection with SARS-CoV-2 of varying degrees of severity: impact of hospitalization vs. outpatient treatment (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FSOC.2023.1143561 |
|
| 2023-05-15 |
Gaucher Hastalığı olan Olgularda SARS-CoV-2 enfeksiyonu (edit) |
SARSコロナウイルス2 (edit) |
10.37990/MEDR.1139421 |
|
| 2023-05-12 |
A Review of the Role of Pollen in COVID-19 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH20105805 |
37239533 |
| 2023-05-11 |
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-38188-Z |
37169744 |
| 2023-05-11 |
Panorama da infecção pelo SARS-COV-2 no Centro de Progressão Penitenciária do Butantan (edit) |
SARSコロナウイルス2 (edit) |
10.11606/S1518-8787.2023057004717 |
|
| 2023-05-11 |
Infectious SARS-CoV-2 Particles from Rectal Swab Samples from COVID-19 Patients in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15051152 |
37243238 |
| 2023-05-10 |
Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1160283 |
|
| 2023-05-09 |
SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S42826-023-00157-4 |
|
| 2023-05-09 |
New Developments in Climate Change, Air Pollution, Pollen Allergy, and Interaction with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ATMOS14050848 |
|
| 2023-05-08 |
Excess risk of SARS-CoV-2 infection among in-person nonhealthcare workers in six states, September 2020-June 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/AJIM.23487 |
|
| 2023-05-05 |
SARS-CoV-2 intra-host diversity, antibody response, and disease severity after reinfection by the variant of concern Gamma in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-023-33443-1 |
37147348 |
| 2023-05-05 |
Accuracy of saliva for SARS-CoV-2 detection in outpatients and their household contacts during the circulation of the Omicron variant of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-023-08271-3 |
37147601 |
| 2023-05-02 |
Determining half-life of SARS-CoV-2 antigen in respiratory secretion (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-023-27326-1 |
|
| 2023-05-01 |
Updated analysis to reject the laboratory-engineering hypothesis of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2023.115481 |
|
| 2023-05-01 |
SARS-CoV-2 Infection and Increased Risk for Pediatric Stroke (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PEDIATRNEUROL.2022.10.003 |
|
| 2023-05-01 |
P071 - L'avantage du Pooling dans le dépistage de masse du SARS-CoV-2: une évaluation économique de la stratégie au Rwanda (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RESPE.2023.101714 |
|
| 2023-05-01 |
Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2023.2204166 |
|
| 2023-05-01 |
The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AAC.00020-21 |
33649117 |
| 2023-04-28 |
Modeling SARS-CoV-2 nucleotide mutations as a stochastic process (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0284874 |
|
| 2023-04-26 |
Surveillance of sars-cov-2 load and types in open sewage streams within slum districts of medellin-columbia, caracas-venezuela, kampala-uganda, and suva-fiji: a multidisciplinary approach to inform public health on pathogen spread in low resource se (edit) |
SARSコロナウイルス2 (edit) |
10.18332/POPMED/164620 |
|
| 2023-04-25 |
Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41429-023-00623-0 |
|
| 2023-04-24 |
SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CEI/UXAD046 |
|
| 2023-04-24 |
The Trajectories of Hepato-Biliary Indices Following Exposure to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.11648/J.WJMCR.20230401.13 |
|
| 2023-04-24 |
Un año de contagio municipal por el SARS-CoV-2 en México: análisis jerárquico-espacial bayesiano (edit) |
SARSコロナウイルス2 (edit) |
10.24201/ES.2023V41N123.2300 |
|
| 2023-04-21 |
Application of Phylodynamic Tools to Inform the Public Health Response to COVID-19: Qualitative Analysis of Expert Opinions (edit) |
SARSコロナウイルス2 (edit) |
10.2196/39409 |
36848460 |
| 2023-04-20 |
A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00119-23 |
|
| 2023-04-20 |
Monitoring of indoor bioaerosol for the detection of SARS-CoV-2 in different hospital settings (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1169073 |
|
| 2023-04-19 |
Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0269104 |
|
| 2023-04-14 |
SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15040967 |
|
| 2023-04-06 |
Share all SARS-CoV-2 data immediately (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADI0490 |
|
| 2023-04-06 |
Dispute simmers over who first shared SARS-CoV-2’s genome (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADI1218 |
|
| 2023-04-06 |
A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0284046 |
|
| 2023-04-06 |
Maternal SARS-CoV-2, Placental Changes and Brain Injury in 2 Neonates (edit) |
SARSコロナウイルス2 (edit) |
10.1542/PEDS.2022-058271 |
|
| 2023-04-05 |
Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1093/GBE/EVAD052 |
36974986 |
| 2023-04-03 |
Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.MOLPHARMACEUT.3C00114 |
36946991 |
| 2023-04-03 |
Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-023-32441-7 |
|
| 2023-04-03 |
Oral Supplementation with AHCC, a Standardized Extract of Cultured Mycelia, Enhances Host Resistance against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS12040554 |
37111440 |
| 2023-04-01 |
Risk factors of COVID-19 severity among Tunisian patients in the Emergency Department of Sousse, Tunisia. (edit) |
SARSコロナウイルス2 (edit) |
|
38372540 |
| 2023-04-01 |
Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PUL2.12220 |
|
| 2023-04-01 |
Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2023.105576 |
|
| 2023-04-01 |
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel S (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2023.E15032 |
37035348 |
| 2023-04-01 |
Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2023.03.005 |
|
| 2023-04-01 |
SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2023.01.022 |
|
| 2023-04-01 |
Risk of within-hotel transmission of SARS-CoV-2 during on-arrival quarantine in Hong Kong: an epidemiological and phylogenomic investigation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANWPC.2022.100678 |
36643735 |
| 2023-04-01 |
Activity of nsp14 Exonuclease from SARS-CoV-2 towards RNAs with Modified 3'-Termini (edit) |
SARSコロナウイルス2 (edit) |
10.1134/S1607672923700102 |
|
| 2023-04-01 |
Implementing SARS-CoV-2 antigen testing scale-up in Rwanda: retrospective analysis of national programme data and qualitative findings (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-066776 |
|
| 2023-04-01 |
Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-067611 |
|
| 2023-04-01 |
COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-068334 |
|
| 2023-04-01 |
Photobiomodulation Therapy in Mitigating the Risk of SARS CoV-2 Infection by Enhancing Biodiversity of Oral Microbiome-A Conceptual Hypothesis Based on Scoping Review (edit) |
SARSコロナウイルス2 (edit) |
10.1166/SAM.2023.4493 |
|
| 2023-04-01 |
Lessons learned during COVID-19 pandemic, a worldwide survey: impact of SARS-CoV-2 vaccination on neurosurgeons and neurosurgical practice (edit) |
SARSコロナウイルス2 (edit) |
10.23736/S0390-5616.22.05885-4 |
|
| 2023-04-01 |
Comparative ELISA Detection of SARS-COV-2 Monoclonal Antibodies in Patients` Serum, Saliva, and Nasal Fluid in Iraq (edit) |
SARSコロナウイルス2 (edit) |
10.52865/NWGT5493 |
|
| 2023-03-31 |
Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS11040912 |
37110335 |
| 2023-03-29 |
Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00253-023-12490-8 |
|
| 2023-03-29 |
Dispute simmers over who first shared SARS-CoV-2’s genome (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADI0300 |
|
| 2023-03-28 |
Copper(II) and Cobalt(II) Complexes Based on Abietate Ligands from Pinus Resin: Synthesis, Characterization and Their Antibacterial and Antiviral Activity against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NANO13071202 |
|
| 2023-03-27 |
Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-36494-0 |
|
| 2023-03-23 |
SARS-CoV-2 restructures host chromatin architecture (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-023-01344-8 |
|
| 2023-03-23 |
New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010903 |
|
| 2023-03-22 |
Unwarranted Exclusion of Intermediate Lineage A-B SARS-CoV-2 Genomes Is Inconsistent with the Two-Spillover Hypothesis of the Origin of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROBIOLRES14010033 |
|
| 2023-03-21 |
Molecular detection of SARS-CoV-2 from throat swabs performed with or without specimen collection from the palatine tonsils: Proposal for a multicenter randomized controlled trial (Preprint) (edit) |
SARSコロナウイルス2 (edit) |
10.2196/47446 |
|
| 2023-03-21 |
Evaluation of SARS-CoV-2 ORF7a Deletions from COVID-19-Positive Individuals and Its Impact on Virus Spread in Cell Culture (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15030801 |
36992509 |
| 2023-03-20 |
An in-solution snapshot of SARS-COV-2 main protease maturation process and inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-37035-5 |
36941262 |
| 2023-03-17 |
A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCHEMBIO.2C00695 |
36629751 |
| 2023-03-17 |
Developmental screening of full-term infants at 16 to 18 months of age after in-utero exposure to maternal SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41372-023-01642-3 |
|
| 2023-03-17 |
Lessons learned from the SARS-CoV-2 pandemic; from nucleic acid nanomedicines, to clinical trials, herd immunity, and the vaccination divide (edit) |
SARSコロナウイルス2 (edit) |
10.1080/17425247.2023.2189697 |
|
| 2023-03-17 |
Assessing suicidality during the SARS-CoV-2 pandemic: Lessons learned from adaptation and implementation of a telephone-based suicide risk assessment and response protocol in Malawi (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0281711 |
|
| 2023-03-17 |
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES11030682 |
|
| 2023-03-16 |
Links between Vitamin K, Ferroptosis and SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX12030733 |
|
| 2023-03-16 |
Immunohistochemical Analysis of Spermatogenesis in Patients with SARS-CoV-2 Invasion in Different Age Groups (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB45030159 |
|
| 2023-03-15 |
Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-023-00264-2 |
36922542 |
| 2023-03-15 |
The viral hypothesis in Alzheimer’s disease: SARS-CoV-2 on the cusp (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNAGI.2023.1129640 |
|
| 2023-03-14 |
SARS-CoV-2 receptor-binding domain deep mutational AlphaFold2 structures (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41597-023-02035-Z |
|
| 2023-03-13 |
A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-023-05735-4 |
|
| 2023-03-12 |
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia (edit) |
SARSコロナウイルス2 (edit) |
10.1080/10428194.2023.2183730 |
|
| 2023-03-11 |
Lack of SARS-CoV-2 RNA evidence in the lungs from wild European polecats (Mustela putorius) from Spain (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10344-023-01662-6 |
|
| 2023-03-10 |
Between Plague and Corona. Epidemics in the past and present (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2023-03-09 |
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-023-36686-8 |
36894554 |
| 2023-03-09 |
SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41556-023-01096-X |
|
| 2023-03-09 |
Occupational risk factors for SARS-CoV-2 seropositivity in healthcare workers: results of a longitudinal cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JOM.0000000000002831 |
36893070 |
| 2023-03-08 |
SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0282151 |
|
| 2023-03-08 |
The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1011167 |
|
| 2023-03-07 |
HLA typing of patients who developed subacute thyroiditis and Graves’ disease after SARS-CoV-2 vaccination: a case report (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12902-023-01287-5 |
|
| 2023-03-07 |
The SARS-CoV-2 Virus could Downregulate Dual Specificity Phosphatase-1 Expression in Oral Cancer: A Plausible Hypothesis that could Explain Oral Cancer Progression in the COVID-19 Pandemic and Post-pandemic Situation (edit) |
SARSコロナウイルス2 (edit) |
10.5005/JP-JOURNALS-10024-3334 |
|
| 2023-03-05 |
Acute bone loss following SARS‐CoV‐2 infection in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JOR.25537 |
|
| 2023-03-04 |
Transmission of SARS-CoV-2 in the workplace: key findings from a rapid review of the literature (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02786826.2023.2166394 |
37213938 |
| 2023-03-03 |
Could the lake ecosystems influence the pathogenicity of the SARS-COV-2 in the air? (edit) |
SARSコロナウイルス2 (edit) |
10.18388/ABP.2020_6514 |
|
| 2023-03-02 |
Heme, Heme Oxygenase-1, Statins, and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX12030614 |
|
| 2023-03-02 |
Managing the Next Wave of Influenza and/or SARS-CoV-2 in the ICU—Practical Recommendations from an Expert Group for CAPA/IAPA Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JOF9030312 |
|
| 2023-03-01 |
The potential role of SARS‐CoV‐2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread (edit) |
SARSコロナウイルス2 (edit) |
10.1002/IID3.798 |
|
| 2023-03-01 |
A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2023.02.001 |
|
| 2023-03-01 |
Evolution of increased positive charge on the SARS-CoV-2 spike protein may be adaptation to human transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2023.106230 |
|
| 2023-03-01 |
Sensitivity of wastewater surveillance: What is the minimum COVID-19 cases required in population for SARS-CoV-2 RNA to be detected in wastewater? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JES.2022.08.020 |
|
| 2023-03-01 |
Evaluation of Safety Measures at a Medical Summer Camp During the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.WEM.2022.10.006 |
|
| 2023-03-01 |
Development of a rapid and ultra-sensitive RNA:DNA hybrid immunocapture based biosensor for visual detection of SARS-CoV-2 RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD031 |
36909823 |
| 2023-03-01 |
Extreme differences in SARS-CoV-2 viral loads among respiratory specimen types during presumed pre-infectious and infectious periods (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAD033 |
36926220 |
| 2023-03-01 |
Extreme value modelling of SARS-CoV-2 community transmission using discrete generalized Pareto distributions (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.220977 |
|
| 2023-03-01 |
Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES11030564 |
|
| 2023-02-28 |
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13104-023-06281-7 |
|
| 2023-02-27 |
Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-CoV-2 variants of concern in Laikipia, Kenya: institutional and community-based genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.12688/WELLCOMEOPENRES.18306.2 |
|
| 2023-02-24 |
SARS-CoV-2 Omicron variant of concern in the Seychelles: Introduction and spread (edit) |
SARSコロナウイルス2 (edit) |
10.12688/WELLCOMEOPENRES.18908.1 |
|
| 2023-02-23 |
SARS‐CoV‐2 Effects on Psychophysical Olfactory Scores: Prospective Study With Evaluation Before and 60‐Days After Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/OHN.166 |
|
| 2023-02-23 |
Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41592-023-01769-3 |
|
| 2023-02-23 |
Evidence of Leaky Protection Following COVID-19 Vaccination and SARS-CoV-2 Infection in an Incarcerated Population (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.02.17.23286049 |
|
| 2023-02-23 |
Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-023-08033-1 |
|
| 2023-02-23 |
SARS-CoV-2 Main Protease Targets Host Selenoproteins and Glutathione Biosynthesis for Knockdown via Proteolysis, Potentially Disrupting the Thioredoxin and Glutaredoxin Redox Cycles (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX12030559 |
36978807 |
| 2023-02-22 |
Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England (edit) |
SARSコロナウイルス2 (edit) |
10.12688/WELLCOMEOPENRES.17995.1 |
|
| 2023-02-22 |
Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0281429 |
|
| 2023-02-22 |
Ectopic expression of SARS-CoV-2 S and ORF-9B proteins alters metabolic profiles and impairs contractile function in cardiomyocytes (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2023.1110271 |
|
| 2023-02-21 |
SARS-CoV-2 antibody prevalence among industrial livestock operation workers and nearby community residents, North Carolina, 2021 to 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00522-22 |
36656002 |
| 2023-02-18 |
Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS‐C) associated with SARS‐CoV‐2 infection: Systematic review and meta‐analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1002/RMV.2432 |
|
| 2023-02-16 |
Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-023-29087-W |
|
| 2023-02-15 |
Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2022.55978 |
|
| 2023-02-15 |
Performance of a SARS-CoV-2 RT-PCR Assay with Non-Traditional Specimen Types (edit) |
SARSコロナウイルス2 (edit) |
10.55504/2473-2869.1260 |
|
| 2023-02-13 |
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41531-023-00467-3 |
|
| 2023-02-13 |
Performance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03259-22 |
|
| 2023-02-09 |
Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: An exploratory study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0281444 |
|
| 2023-02-09 |
Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load Specimens (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS24043478 |
|
| 2023-02-08 |
Clinical Validation of GenBody COVID-19 Ag, Nasal and Nasopharyngeal Rapid Antigen Tests for Detection of SARS-CoV-2 in European Adult Population (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES11020493 |
36831028 |
| 2023-02-08 |
Endogenous miRNA-Based Innate-Immunity against SARS-CoV-2 Invasion of the Brain (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS24043363 |
|
| 2023-02-06 |
AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-023-28785-9 |
|
| 2023-02-04 |
SARS-COV-2 spike protein promotes RPE cell senescence via the ROS/P53/P21 pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10522-023-10019-0 |
|
| 2023-02-02 |
Proteomic Analysis of Mucosal and Systemic Responses to SARS-CoV-2 Antigen (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES11020334 |
|
| 2023-02-01 |
Effectiveness of natural immune protection against COVID-19 reinfection: systematic review with meta-analysis. (edit) |
SARSコロナウイルス2 (edit) |
|
37682268 |
| 2023-02-01 |
Viral load of SARS‐CoV‐2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/IID3.783 |
|
| 2023-02-01 |
Extra-experimental scarcity impacts hypothetical operant demand: A natural SARS-CoV-2 eperiment (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BEPROC.2022.104817 |
|
| 2023-02-01 |
Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2022.101800 |
|
| 2023-02-01 |
Inactivation of two SARS-CoV-2 virus surrogates by electron beam irradiation on large yellow croaker slices and their packaging surfaces (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FOODCONT.2022.109340 |
|
| 2023-02-01 |
Global asymptotic stability, extinction and ergodic stationary distribution in a stochastic model for dual variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MATCOM.2022.08.012 |
|
| 2023-02-01 |
Adipocytes in obesity: A perfect reservoir for SARS-CoV-2? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2023.111020 |
|
| 2023-02-01 |
Detection of SARS-CoV-2 RNA in wastewater and comparison to COVID-19 cases in two sewersheds, North Carolina, USA (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.159996 |
36356771 |
| 2023-02-01 |
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00644-2 |
|
| 2023-02-01 |
Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-6367(23)00500-6 |
|
| 2023-02-01 |
Pseudo-Complementary G:C Base Pair for Mixed Sequence dsDNA Invasion and Its Applications in Diagnostics (SARS-CoV-2 Detection) (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACSAU.2C00588 |
|
| 2023-02-01 |
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAC411 |
36214810 |
| 2023-02-01 |
Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJMED-2022-000373 |
|
| 2023-02-01 |
Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1136/OPENHRT-2022-002241 |
|
| 2023-02-01 |
Host heterogeneity and epistasis explain punctuated evolution of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010896 |
36791146 |
| 2023-02-01 |
Impact of the SARS-CoV-2 pandemic on the diagnostic delay of oral carcinoma: a retrospective analysis (edit) |
SARSコロナウイルス2 (edit) |
10.23736/S2724-6329.22.04645-9 |
|
| 2023-02-01 |
Co-testing a single sputum specimen for TB and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.5588/IJTLD.22.0404 |
|
| 2023-02-01 |
Indicators of Cardiometabolic Function in Pregnancy and Long-Term Risk of COVID-19: Population-Based Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.35325 |
36968929 |
| 2023-01-31 |
Plant Extracts and SARS-CoV-2: Research and Applications (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE13020386 |
|
| 2023-01-31 |
Reconocimiento de la presencia de sars-cov-2 en pulmones a través de imágenes de radiodiagnóstico haciendo uso de Machine Learning con Python (edit) |
SARSコロナウイルス2 (edit) |
10.56712/LATAM.V4I1.296 |
|
| 2023-01-30 |
Performance Evaluation of Different RT-PCR Kits for the Direct Detection of SARS-CoV-2 in Preheated Specimens (edit) |
SARSコロナウイルス2 (edit) |
10.1055/S-0043-1760752 |
|
| 2023-01-26 |
Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1092910 |
|
| 2023-01-25 |
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS11020312 |
|
| 2023-01-24 |
PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACC.2022.10.030 |
36653090 |
| 2023-01-24 |
Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010822 |
|
| 2023-01-23 |
Estimation of reproduction number of SARS-CoV-2 Omicron variant outbreak in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2023.01.21.23284868 |
|
| 2023-01-18 |
Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2022.51360 |
|
| 2023-01-18 |
Coronavirus Inhibitors Targeting nsp16 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES28030988 |
|
| 2023-01-16 |
Haemorrhage of human foetal cortex associated with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BRAIN/AWAC372 |
|
| 2023-01-16 |
Long-Term Consequences of Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH20021613 |
|
| 2023-01-15 |
Electronic Sensors to Detect SARS-CoV-2 Viruses in Real Time (edit) |
SARSコロナウイルス2 (edit) |
10.1109/JSEN.2022.3185896 |
|
| 2023-01-13 |
Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November–December 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-023-02212-Y |
|
| 2023-01-13 |
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC796 |
36196614 |
| 2023-01-11 |
Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJ-2022-072529 |
|
| 2023-01-09 |
Weekly symptom profiles of nonhospitalized individuals infected with SARS‐CoV‐2 during the Omicron outbreak in Hong Kong: A retrospective observational study from a telemedicine center (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28447 |
|
| 2023-01-07 |
Anti-SARS-CoV-2 IgG ELISA: Replacing the Absorbance Plate Reader by a Regular Scanner with Open-Source Software (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PR11010194 |
|
| 2023-01-06 |
Patient Care Satisfaction and Emergency Room Utilization among Young Adult Colorectal Cancer Survivors during the SARS-CoV-2 Pandemic: Lessons Learned (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM12020469 |
|
| 2023-01-03 |
Assessment of a SARS-CoV-2 wastewater monitoring program in El Paso, Texas, from November 2020 to June 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/09603123.2022.2159017 |
|
| 2023-01-03 |
SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinoma (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0279578 |
|
| 2023-01-02 |
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-02138-X |
|
| 2023-01-01 |
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28157 |
36117402 |
| 2023-01-01 |
Audiological and vestibular symptoms following SARS-CoV-2 infection and COVID-19 vaccination in children aged 5–11 years (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJOTO.2022.103669 |
|
| 2023-01-01 |
An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.106433 |
|
| 2023-01-01 |
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.104402 |
|
| 2023-01-01 |
Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: A multi-model study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2022.100398 |
36437905 |
| 2023-01-01 |
Insulin may promote SARS-CoV-2 cell entry and replication in diabetes patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110997 |
|
| 2023-01-01 |
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41588-022-01267-W |
|
| 2023-01-01 |
Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ABT/TBAD001 |
36741194 |
| 2023-01-01 |
PS-C16-11: PREVALENCE AND HOSPITAL OUTCOME OF BACTERIAL CO-INFECTION IN RESPIRATORY TRACT SPECIMEN AMONG COVID 19 PATIENTS WITH SARS-COV-2 PNEUMONIA (edit) |
SARSコロナウイルス2 (edit) |
10.1097/01.HJH.0000915116.70234.A3 |
|
| 2023-01-01 |
Analysis of Regional Scenarios of New Epidemic Waves of SARS-CoV-2 Coronavirus Based on Equations with a Deviating Argument and Damping Functions (edit) |
SARSコロナウイルス2 (edit) |
10.1134/S1063785023010042 |
|
| 2023-01-01 |
Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJGH-2022-009495 |
36646475 |
| 2023-01-01 |
Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation (edit) |
SARSコロナウイルス2 (edit) |
10.1177/11779322231171777 |
|
| 2023-01-01 |
SARS-CoV-2 and Hypertension: Evidence Supporting Invasion into the Brain Via Baroreflex Circuitry and the Role of Imbalanced Renin-Angiotensin-Aldosterone-System (edit) |
SARSコロナウイルス2 (edit) |
10.1177/26331055231151926 |
|
| 2023-01-01 |
Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly (edit) |
SARSコロナウイルス2 (edit) |
10.12932/AP-120822-1434 |
|
| 2023-01-01 |
Trinucleotide Substitutions at Two Locations in the SARS-CoV-2 Nucleocapsid (<i>N</i>) Gene (edit) |
SARSコロナウイルス2 (edit) |
10.1620/TJEM.2023.J010 |
|
| 2023-01-01 |
Evaluation of the safety of dose escalation period of subcutaneous specific allergic immunotherapy in patients with rhino-conjunctivitis or allergic asthma previously vaccinated against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.18103/MRA.V11I4.3750 |
|
| 2023-01-01 |
Simultaneous Onset of Thrombocytopenia and Hypereosinophilia With Sars-Cov-2 Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.22259/2639-3581.0501001 |
|
| 2023-01-01 |
Postmortem detectability and viability of SARS-COV-2 virus in various biological specimens (edit) |
SARSコロナウイルス2 (edit) |
10.2298/SARH220118014P |
|
| 2023-01-01 |
LAMP amplification of nucleic acids. II. Detection of the SARS-CoV-2 coronavirus using various variants of reverse transcription loop amplification (edit) |
SARSコロナウイルス2 (edit) |
10.31301/2221-6197.BMCS.2023-24 |
|
| 2023-01-01 |
The Effects of SARS-CoV-2 Infection on the Cognitive Functioning of Patients with Pre-Existing Dementia (edit) |
SARSコロナウイルス2 (edit) |
10.3233/ADR-220090 |
|
| 2023-01-01 |
Features of cell immunity of healthcare workers in the first wave of the SARS-CoV-2 infection pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.33029/0206-4952-2023-44-6-776-787 |
|
| 2023-01-01 |
Dynamics and functional characteristics of antibodies and memory B cells to SARS-CoV-2 in peripheral blood from COVID-19 patients for up to 16 months (edit) |
SARSコロナウイルス2 (edit) |
10.33029/0206-4952-2023-44-6-788-801 |
|
| 2023-01-01 |
Long-term cytokine content in children with SARS-CoV-2-associated multisystem inflammatory syndrome in comparison with the initial period of the disease (edit) |
SARSコロナウイルス2 (edit) |
10.33029/2305-3496-2023-12-4-10-16 |
|
| 2023-01-01 |
Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2023.1123724 |
36845156 |
| 2023-01-01 |
Routine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2023.1003158 |
36817891 |
| 2023-01-01 |
One Health investigation of SARS-CoV-2 in people and animals on multiple mink farms in Utah (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15010096 |
36680136 |
| 2023-01-01 |
The impact of the SARS-CoV-2 pandemic on hospital admissions and diagnosis of emergency patients (edit) |
SARSコロナウイルス2 (edit) |
10.36740/EMEMS202302104 |
|
| 2023-01-01 |
SARS-COV-2 INFECTION AS A POSSIBLE TRIGGER FOR MICROSCOPIC POLYANGIITIS: CASE REPORT AND MINI-REVIEW (edit) |
SARSコロナウイルス2 (edit) |
10.36740/WLEK202312127 |
|
| 2023-01-01 |
SARS-CoV-2 getting into the brain; neurological phenotype of COVID-19, and management by nano-biotechnology (edit) |
SARSコロナウイルス2 (edit) |
10.4103/1673-5374.346486 |
|
| 2023-01-01 |
Subacute Thyroiditis Following Sars-CoV-2 Vaccination: An Autoimmune/ Inflammatory Syndrome Induced by Adjuvants (Asia Syndrome) (edit) |
SARSコロナウイルス2 (edit) |
10.4183/AEB.2023.390 |
|
| 2023-01-01 |
Differences in the clinical picture at the onset of diagnosis of severe autoimmune hypothyroidism in children depending on the time of diagnosis: before or during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.5114/PEDM.2023.133123 |
|
| 2023-01-01 |
Upgrade on Monoclonal Antibodies as Prophylaxis-Therapy in the Elderly and Immunocompromised Sars-Cov-2 Population. A Review (edit) |
SARSコロナウイルス2 (edit) |
10.51737/2766-5003.2023.043 |
|
| 2023-01-01 |
Investigation of the relationship between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase with SARS CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.5455/JABET.2023.D104 |
|
| 2023-01-01 |
ICU Physical Therapy Benefits for Patients Infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.61215/RJPT.2023.29.51.24 |
|
| 2023-01-01 |
CREUTZFELDT-JAKOB DISEASE IN MAN CO-INFECTED WITH SARS-COV-2-VIRUS, AND HUMAN HERPESVIRUS TYPE 7 (edit) |
SARSコロナウイルス2 (edit) |
10.61948/PREVMED-2023-4-41 |
|
| 2022-12-29 |
LARGE-SCALE SCREENING FOR SARS-COV-2 INFECTION IN ENT PATIENTS DURING THE COVID-19 PANDEMIC (edit) |
SARSコロナウイルス2 (edit) |
10.17430/JHS.2022.12.4.3 |
|
| 2022-12-27 |
Cost of wastewater-based environmental surveillance for SARS-CoV-2: Evidence from pilot sites in Blantyre, Malawi and Kathmandu, Nepal (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PGPH.0001377 |
|
| 2022-12-23 |
Rapid Detection of SARS-CoV-2 RNA in Human Nasopharyngeal Specimens Using Surface-Enhanced Raman Spectroscopy and Deep Learning Algorithms (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSSENSORS.2C02194 |
|
| 2022-12-23 |
Inactivation of Ebola Virus and SARS-CoV-2 in Cell Culture Supernatants and Cell Pellets by Gamma Irradiation (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V15010043 |
36680083 |
| 2022-12-22 |
The presence of SARS-CoV-2 in multiple clinical specimens of a fatal case of COVID-19: a case report (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13256-022-03706-Y |
|
| 2022-12-22 |
CORRELATION OF SARS-COV-2 EXPRESSION IN THE PLACENTA AND THE INCIDENCE OF PREECLAMPSIA (edit) |
SARSコロナウイルス2 (edit) |
10.21010/AJIDV17I1.4 |
|
| 2022-12-21 |
Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01355-22 |
36255326 |
| 2022-12-21 |
Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02196-22 |
36350127 |
| 2022-12-21 |
Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03949-22 |
|
| 2022-12-21 |
Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202212.0386.V1 |
|
| 2022-12-20 |
Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02308-22 |
|
| 2022-12-20 |
La ruta sanitaria de la seda y el poder suave de la República Popular China ante el SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.24201/FI.V63I1.2937 |
|
| 2022-12-19 |
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05644-7 |
|
| 2022-12-19 |
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-25558-8 |
|
| 2022-12-17 |
Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH192416996 |
|
| 2022-12-16 |
Negative Perception of Bats, Exacerbated by the SARS-CoV-2 Pandemic, May Hinder Bat Conservation in Northern Uganda (edit) |
SARSコロナウイルス2 (edit) |
10.3390/SU142416924 |
|
| 2022-12-14 |
SARS-CoV-2 infection and persistence in the human body and brain at autopsy (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05542-Y |
|
| 2022-12-12 |
Ocular tropism of SARS-CoV-2 in animal models with retinal inflammation via neuronal invasion following intranasal inoculation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-35225-1 |
|
| 2022-12-12 |
Impact of high prebiotic and probiotic dietary education in the SARS-CoV-2 era: improved cardio-metabolic profile in schizophrenia spectrum disorders (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12888-022-04426-9 |
|
| 2022-12-12 |
SARS-CoV-2 Omicron (B.1.1.529) Infection of Wild White-Tailed Deer in New York City (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14122770 |
|
| 2022-12-12 |
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10122125 |
36560536 |
| 2022-12-09 |
Estimation of the impact of hospital-onset SARS-CoV-2 infections on length of stay in English hospitals using causal inference (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07870-W |
|
| 2022-12-07 |
Prevalence and Severity of Symptoms 3 Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population Controls in the Netherlands (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAC474 |
|
| 2022-12-06 |
Long-term benefits of nonpharmaceutical interventions for endemic infections are shaped by respiratory pathogen dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2208895119 |
36445971 |
| 2022-12-03 |
Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS232315264 |
36499592 |
| 2022-12-02 |
RETRACTED: Gradual emergence followed by exponential spread of the SARS-CoV-2 Omicron variant in Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADD8737 |
|
| 2022-12-01 |
Zonal modeling of air distribution impact on the long-range airborne transmission risk of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.APM.2022.08.027 |
|
| 2022-12-01 |
Impedimetric and amperometric genosensors for the highly sensitive quantification of SARS-CoV-2 nucleic acid using an avidin-functionalized multi-walled carbon nanotubes biocapture platform (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOSX.2022.100222 |
|
| 2022-12-01 |
Evaluation of SARS-CoV-2 concentrations in wastewater and river water samples (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSCEE.2022.100214 |
|
| 2022-12-01 |
Is the virus-laden standing water change the transmission intensity of SARS-CoV-2 after precipitation? A framework for empirical studies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2022.114127 |
|
| 2022-12-01 |
A phylogenetic perspective of antiviral species of the genus Artemisia (Asteraceae-Anthemideae): A proposal of anti SARS-CoV-2 (COVID-19) candidate taxa (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HERMED.2022.100601 |
|
| 2022-12-01 |
Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.09.184 |
36174872 |
| 2022-12-01 |
Computational investigation of potent inhibitors against SARS-CoV-2 2′-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2022.108306 |
|
| 2022-12-01 |
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2022.100211 |
|
| 2022-12-01 |
Autophagy: A self-guard against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110984 |
|
| 2022-12-01 |
Beyond COVID-19: Do biothermodynamic properties allow predicting the future evolution of SARS-CoV-2 variants? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MRAN.2022.100232 |
|
| 2022-12-01 |
A standardized instrument quantifying risk factors associated with bi-directional transmission of SARS-CoV-2 and other zoonotic pathogens: The COVID-19 human-animal interactions survey (CHAIS) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ONEHLT.2022.100422 |
|
| 2022-12-01 |
Fractal–fractional age-structure study of omicron SARS-CoV-2 variant transmission dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PADIFF.2022.100455 |
|
| 2022-12-01 |
The impact of maternal SARS-CoV-2 infection and COVID-19 vaccination on maternal-fetal outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REPROTOX.2022.10.003 |
|
| 2022-12-01 |
Impact of SARS-CoV-2 variants on mobility and air pollution in the United Kingdom (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.158279 |
|
| 2022-12-01 |
Application of a high-throughput quantitative PCR system for simultaneous monitoring of SARS-CoV-2 variants and other pathogenic viruses in wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.158659 |
|
| 2022-12-01 |
SARS-CoV-2 infection dynamics revealed by wastewater sequencing analysis and deconvolution (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.158931 |
|
| 2022-12-01 |
Highly valued despite burdens: Qualitative implementation research on rapid tests for hospital-based SARS-CoV-2 screening (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SSMQR.2022.100140 |
|
| 2022-12-01 |
Protocol to quantify and phenotype SARS-CoV-2-specific T cell response using a rapid flow-cytometry-based whole blood assay (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2022.101771 |
|
| 2022-12-01 |
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-022-01351-7 |
|
| 2022-12-01 |
Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1080/13880209.2022.2063341 |
35594385 |
| 2022-12-01 |
ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21505594.2021.2019959 |
34967260 |
| 2022-12-01 |
Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.2008775 |
34818119 |
| 2022-12-01 |
A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain) (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.2011617 |
34842496 |
| 2022-12-01 |
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.2011623 |
34836485 |
| 2022-12-01 |
Two novel human coronavirus OC43 genotypes circulating in hospitalized children with pneumonia in China (edit) |
ベータコロナウイルス１ (edit) |
10.1080/22221751.2021.2019560 |
34907853 |
| 2022-12-01 |
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.2022440 |
34935594 |
| 2022-12-01 |
Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2031311 |
35060426 |
| 2022-12-01 |
Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2054369 |
35293847 |
| 2022-12-01 |
Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2081615 |
35603455 |
| 2022-12-01 |
Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2093135 |
35730665 |
| 2022-12-01 |
Comparison of Dose–Response Relationships for Two Isolates of SARS-CoV-2 in a Nonhuman Primate Model of Inhalational COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1089/JAMP.2022.0043 |
|
| 2022-12-01 |
The role of antigen availability during B cell induction and its effect on sustained memory and antibody production after infection and vaccination—lessons learned from the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CEI/UXAC113 |
|
| 2022-12-01 |
1880. Detection of Infectious SARS-CoV-2 in Specimens with High CT Values Is More Common for Omicron than for Delta Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAC492.1507 |
|
| 2022-12-01 |
Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-062747 |
|
| 2022-12-01 |
Next-Day Discharge after Kidney Transplant During the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.6002/ECT.2021.0309 |
|
| 2022-11-30 |
Inflammatory responses in SARS-CoV-2 associated Multisystem Inflammatory Syndrome and Kawasaki Disease in children: An observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266336 |
|
| 2022-11-30 |
Detection of Respiratory Viruses in SARS-CoV-2-Negative Specimens from January to March 2020 in Fukuoka, Japan (edit) |
SARSコロナウイルス2 (edit) |
10.7883/YOKEN.JJID.2022.079 |
|
| 2022-11-26 |
Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07878-2 |
|
| 2022-11-26 |
Optimal control strategies of SARS-CoV-2 Omicron supported by invasive and dynamic models (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40249-022-01039-Y |
|
| 2022-11-26 |
Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB44120400 |
|
| 2022-11-24 |
SARS-CoV-2 infection increases risk of intracranial hemorrhage (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNHUM.2022.991382 |
|
| 2022-11-23 |
WHO’s departing chief scientist regrets errors in debate over whether SARS-CoV-2 spreads through air (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADF9731 |
|
| 2022-11-23 |
Relação imunológica causal entre a reativação do Herpes Zoster e pacientes infectados ou vacinados contra o Sars-Cov 2: uma revisão de literatura (edit) |
SARSコロナウイルス2 (edit) |
10.34119/BJHRV5N6-090 |
|
| 2022-11-23 |
Variation in the ACE2 receptor has limited utility for SARS-CoV-2 host prediction (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.80329 |
|
| 2022-11-22 |
Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-24730-4 |
|
| 2022-11-22 |
Effects of general and corona-specific stressors on mental burden during the SARS-CoV-2 pandemic in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.991292 |
|
| 2022-11-21 |
SARS-CoV-2 accessory protein 7b forms homotetramers in detergent (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-022-01920-0 |
|
| 2022-11-20 |
Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-01241-2 |
|
| 2022-11-20 |
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.1200/JCO.21.02986 |
35759727 |
| 2022-11-19 |
Various advanced wastewater treatment methods to remove microplastics and prevent transmission of SARS-CoV-2 to airborne microplastics (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13762-022-04654-2 |
|
| 2022-11-18 |
Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.105427 |
36310645 |
| 2022-11-18 |
Perception of Local COVID-19 Transmission and Use of Preventive Behaviors Among Adults with Recent SARS-CoV-2 Infection - Illinois and Michigan, June 1-July 31, 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7146A2 |
36395064 |
| 2022-11-18 |
Diagnosis of SARS-CoV-2 during the Pandemic by Multiplex RT-rPCR hCoV Test: Future Perspectives (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11111378 |
|
| 2022-11-18 |
Long-term Follow-up Results of Tinnitus and Dizziness Disorders in Patients after SARS-CoV-2 Infection Based on a Questionnaire (edit) |
SARSコロナウイルス2 (edit) |
10.4274/BALKANMEDJ.GALENOS.2022.2022-7-8 |
|
| 2022-11-15 |
Post–COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2022.42106 |
|
| 2022-11-15 |
Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOOD-2022-158716 |
|
| 2022-11-12 |
Post-Viral Olfactory Loss: What We Learned from the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE12111868 |
|
| 2022-11-12 |
Simulating the Environmental Spread of SARS-CoV-2 via Cough and the Effect of Personal Mitigations (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS10112241 |
|
| 2022-11-11 |
Capturing SARS-CoV-2 from patient samples with low viral abundance: a comparative analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-23422-3 |
|
| 2022-11-11 |
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADC9127 |
|
| 2022-11-11 |
SARS-CoV-2-Induced Amyloidgenesis: Not One, but Three Hypotheses for Cerebral COVID-19 Outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/METABO12111099 |
|
| 2022-11-10 |
Spatial modeling of vaccine deserts as barriers to controlling SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-022-00183-8 |
|
| 2022-11-10 |
Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of Escherichia coli (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOENGINEERING9110670 |
|
| 2022-11-09 |
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2022.10.003 |
36272413 |
| 2022-11-09 |
Frequency of Positive Results for SARS-CoV-2 Infection in Symptomatic Pediatric Patients Treated in the Emergency Department of a Regional Hospital (edit) |
SARSコロナウイルス2 (edit) |
10.3390/COVID2110113 |
|
| 2022-11-08 |
Lineage abundance estimation for SARS-CoV-2 in wastewater using transcriptome quantification techniques (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13059-022-02805-9 |
|
| 2022-11-03 |
Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-23235-4 |
|
| 2022-11-03 |
Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021–22: a status-based multi-variant model (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07821-5 |
|
| 2022-11-03 |
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES27217522 |
|
| 2022-11-02 |
Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0275823 |
|
| 2022-11-02 |
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0276929 |
|
| 2022-11-01 |
Lingering SARS-CoV-2 in Gastric and Gallbladder Tissues of Patients with Previous COVID-19 Infection Undergoing Bariatric Surgery (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11695-022-06338-9 |
|
| 2022-11-01 |
Cardiac screening before returning to elite sport after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACVD.2022.06.005 |
|
| 2022-11-01 |
A prospective study of the association between SARS-CoV-2 infection and COVID-19 vaccination with changes in usual menstrual cycle characteristics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2022.07.003 |
35841938 |
| 2022-11-01 |
Virus replication and competition in a cell culture: Application to the SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AML.2022.108217 |
|
| 2022-11-01 |
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2022.09.010 |
|
| 2022-11-01 |
Asymptomatic SARS-COV-2 infection in children's tonsils (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BJORL.2022.10.016 |
|
| 2022-11-01 |
Microstructural evaluation and recommendations for face masks in community use to reduce the transmission of respiratory infectious diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMPB.2022.107154 |
36182670 |
| 2022-11-01 |
Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2022.115788 |
|
| 2022-11-01 |
“Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HRTLNG.2022.06.024 |
|
| 2022-11-01 |
Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.09.086 |
|
| 2022-11-01 |
Cardiovascular symptom phenotypes of post-acute sequelae of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJCARD.2022.07.018 |
|
| 2022-11-01 |
Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INDCROP.2022.115338 |
|
| 2022-11-01 |
Bioinformatics pipeline unveils genetic variability to synthetic vaccine design for Indian SARS-CoV-2 genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2022.109224 |
|
| 2022-11-01 |
Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCVP.2022.100110 |
|
| 2022-11-01 |
Nosocomial human parainfluenza virus type 3 outbreak in immunocompromised patients, and possible lessons from the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHIN.2022.07.002 |
|
| 2022-11-01 |
Is SARS-CoV-2 an oncogenic virus? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2022.08.005 |
|
| 2022-11-01 |
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2022.09.004 |
|
| 2022-11-01 |
Modal analysis of novel coronavirus (SARS COV-2) using finite element methodology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMBBM.2022.105406 |
|
| 2022-11-01 |
Macro-level drivers of SARS-CoV-2 transmission: A data-driven analysis of factors contributing to epidemic growth during the first wave of outbreaks in the United States (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SSTE.2022.100539 |
|
| 2022-11-01 |
Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198915 |
|
| 2022-11-01 |
Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2214-109X(22)00359-X |
|
| 2022-11-01 |
Acute and postacute sequelae associated with SARS-CoV-2 reinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-02051-3 |
|
| 2022-11-01 |
The Assessment of the Diagnostic Accuracy of Antigen-Detecting Rapid Diagnostic Test using Nasopharyngeal Swab Specimen in Detecting SARS-CoV-2 among Patients in a Private Hospital in Bulacan, Philippines (edit) |
SARSコロナウイルス2 (edit) |
10.1093/AJCP/AQAC126.302 |
|
| 2022-11-01 |
SARS-CoV-2 Outbreak Dynamics in an Isolated US Military Recruit Training Center With Rigorous Prevention Measures (edit) |
SARSコロナウイルス2 (edit) |
10.1097/EDE.0000000000001523 |
35944149 |
| 2022-11-01 |
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept (edit) |
SARSコロナウイルス2 (edit) |
10.1515/CCLM-2022-0873 |
|
| 2022-11-01 |
Reinfections with Different SARS-CoV-2 Omicron Subvariants, France (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2811.221109 |
|
| 2022-11-01 |
The Absence of Permanent Sensorineural Hearing Loss in a Cohort of Children with SARS-CoV-2 Infection and the Importance of Performing the Audiological “Work-Up” (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CHILDREN9111681 |
|
| 2022-10-31 |
The relation between SARS-CoV-2 cases in Bahrain and meteorological parameters: 27 months of data (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FBUIL.2022.997380 |
|
| 2022-10-31 |
Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14112416 |
36366515 |
| 2022-10-29 |
Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14112401 |
|
| 2022-10-28 |
Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES27217336 |
36364158 |
| 2022-10-27 |
Managing Complexity: The Experience of an Italian Internal Medicine Unit During the SARS-CoV-2 Pandemic, Looking to the Future (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42399-022-01320-Z |
|
| 2022-10-27 |
Air travel and SARS-CoV-2: many remaining knowledge gaps (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAC123 |
|
| 2022-10-27 |
A SEIRD+V Model for the Effect of Vaccination and Social Distancing on SARS-CoV-2 Infection and Mortality (edit) |
SARSコロナウイルス2 (edit) |
10.26717/BJSTR.2022.46.007413 |
|
| 2022-10-27 |
Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14112367 |
|
| 2022-10-27 |
HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.79924 |
|
| 2022-10-26 |
A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-22921-7 |
|
| 2022-10-26 |
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01315-22 |
36121252 |
| 2022-10-26 |
Erratum for Nikiforuk et al., "Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Detect a SARS-CoV-2 Antibody Response" (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.03376-22 |
36214688 |
| 2022-10-26 |
SARS-CoV-2: Searching for the Missing Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14112364 |
|
| 2022-10-25 |
A Timeframe for SARS-CoV-2 Genomes: A Proof of Concept for Postmortem Interval Estimations (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS232112899 |
|
| 2022-10-25 |
SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14112336 |
|
| 2022-10-24 |
SARS-CoV-2 Is Not Special, but the Pandemic Is: The Ecology, Evolution, Policy, and Future of the Deadliest Pandemic in Living Memory (edit) |
SARSコロナウイルス2 (edit) |
10.1146/ANNUREV-ANTHRO-041420-100047 |
|
| 2022-10-22 |
Targeting an evolutionarily conserved “E-L-L” motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC198 |
36712339 |
| 2022-10-21 |
Erratum for the Research Article “Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome,” by P. R. Bhatt et al (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADF3953 |
|
| 2022-10-20 |
Lack of evidence of viability and infectivity of SARS-CoV-2 in the fecal specimens of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.1030249 |
|
| 2022-10-17 |
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0276241 |
|
| 2022-10-15 |
Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-33899-1 |
36243713 |
| 2022-10-15 |
Lipidomics Revealed Plasma Phospholipid Profile Differences between Deceased and Recovered COVID-19 Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM12101488 |
36291697 |
| 2022-10-13 |
How SARS-CoV-2 battles our immune system (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADF3220 |
|
| 2022-10-12 |
SARS-CoV-2 placentitis, stillbirth, and maternal COVID-19 vaccination: clinical-pathologic correlations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2022.10.001 |
36243041 |
| 2022-10-12 |
Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-33801-Z |
|
| 2022-10-12 |
Prioritizing Pregnant Women for Coronavirus Disease 2019 Vaccination in African Countries (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC362 |
36130226 |
| 2022-10-11 |
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2022.17876 |
|
| 2022-10-10 |
Dysphagia in the Presence of Varicella-Zoster Virus and SARS-CoV-2: A Case Report on the Role of Speech-Language Pathology (edit) |
SARSコロナウイルス2 (edit) |
10.1044/2022_PERSP-22-00070 |
|
| 2022-10-10 |
Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2202871119 |
|
| 2022-10-10 |
Occupational characteristics associated with SARS-CoV-2 infection in the UK Biobank during August-November 2020: a cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-022-14311-5 |
36217157 |
| 2022-10-10 |
Lifestyle changes during the SARS-CoV-2 pandemic confinement in Europe: a systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.53519/ANALESRANF.2022.88.03.03 |
|
| 2022-10-07 |
The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-33632-Y |
|
| 2022-10-07 |
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABQ5358 |
36108049 |
| 2022-10-07 |
Perspectives to fight viruses. The example of Sars-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.4081/PEASA.16 |
|
| 2022-10-06 |
Risk assessment for long- and short-range airborne transmission of SARS-CoV-2, indoors and outdoors (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC223 |
36712338 |
| 2022-10-05 |
Diversified Effects of COVID-19 as a Consequence of the Differential Metabolism of Phospholipids and Lipid Peroxidation Evaluated in the Plasma of Survivors and Deceased Patients upon Admission to the Hospital (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS231911810 |
36233111 |
| 2022-10-04 |
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.09.15.507787 |
|
| 2022-10-04 |
Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.985938 |
|
| 2022-10-03 |
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADFM.202206055 |
|
| 2022-10-03 |
Estimating SARS-CoV-2 variant fitness and the impact of interventions in England using statistical and geo-spatial agent-based models (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSTA.2021.0304 |
35965459 |
| 2022-10-01 |
Mental health status of healthcare workers at a third line Tunisian hospital during COVID-19 pandemic. (edit) |
SARSコロナウイルス2 (edit) |
|
36571751 |
| 2022-10-01 |
A fast, ultrasensitive SERS immunoassay to detect SARS-CoV-2 in saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACA.2022.340290 |
|
| 2022-10-01 |
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2022.105403 |
36041646 |
| 2022-10-01 |
Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOPHA.2022.113534 |
|
| 2022-10-01 |
Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOTECHADV.2022.107986 |
|
| 2022-10-01 |
A geometric deep learning model for display and prediction of potential drug-virus interactions against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMOLAB.2022.104640 |
|
| 2022-10-01 |
Persistence of SARS-CoV-2 on surfaces and relevance to the food industry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COFS.2022.100875 |
|
| 2022-10-01 |
Single-particle detection of native SARS-CoV-2 virions by microfluidic resistive pulse sensing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COLSURFB.2022.112716 |
|
| 2022-10-01 |
Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105969 |
|
| 2022-10-01 |
Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.106035 |
|
| 2022-10-01 |
Design and finite element modeling of two–dimensional nanomechanical biosensors for SARS–CoV–2 detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAMOND.2022.109263 |
|
| 2022-10-01 |
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DRUDIS.2022.07.015 |
|
| 2022-10-01 |
Association between long-term exposure to particulate air pollution with SARS-CoV-2 infections and COVID-19 deaths in California, U.S.A (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVADV.2022.100270 |
35912397 |
| 2022-10-01 |
Wastewater-based epidemiological surveillance to monitor the prevalence of SARS-CoV-2 in developing countries with onsite sanitation facilities (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVPOL.2022.119679 |
|
| 2022-10-01 |
Genetic sequencing detected the SARS-CoV-2 delta variant in wastewater a month prior to the first COVID-19 case in Ahmedabad (India) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVPOL.2022.119757 |
|
| 2022-10-01 |
Comment to the article by Pedro Brotons: Validation and implementation of a direct RT-qPCR method for rapid screening of SARS-CoV-2 infection by using non-invasive saliva samples, IJID 110 (2021) 363–370 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.08.005 |
|
| 2022-10-01 |
Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJSU.2022.106903 |
|
| 2022-10-01 |
Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 SARS-CoV-2 vaccine via non-negative tensor factorization (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.105237 |
|
| 2022-10-01 |
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAUT.2022.102906 |
|
| 2022-10-01 |
Risk of vertical transmission of SARS CoV-2 infection to neonates born to covid positive mothers: A pilot study from a tertiary care hospital of North India (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIAC.2022.06.004 |
|
| 2022-10-01 |
Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2022.102277 |
|
| 2022-10-01 |
SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANEPE.2022.100491 |
|
| 2022-10-01 |
Tailored lipopeptide surfactants as potentially effective drugs to treat SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110948 |
|
| 2022-10-01 |
Wastewater-based epidemiology in countries with poor wastewater treatment — Epidemiological indicator function of SARS-CoV-2 RNA in surface waters (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.156964 |
|
| 2022-10-01 |
Good and bad get together: Inactivation of SARS-CoV-2 in particulate matter pollution from different fuels (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.157241 |
|
| 2022-10-01 |
Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: Study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCP.2022.100744 |
|
| 2022-10-01 |
Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.THROMRES.2022.08.005 |
|
| 2022-10-01 |
Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.THROMRES.2022.08.021 |
|
| 2022-10-01 |
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100781 |
|
| 2022-10-01 |
Ethics and governance challenges related to genomic data sharing in southern Africa: the case of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2214-109X(22)00417-X |
|
| 2022-10-01 |
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2215-0366(22)00260-7 |
|
| 2022-10-01 |
Reported exposures among in-person workers with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in 6 states, September 2020-June 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC486 |
35717638 |
| 2022-10-01 |
Cardiac impairment in Long Covid 1-year post SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EURHEARTJ/EHAC544.219 |
|
| 2022-10-01 |
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010882 |
36191037 |
| 2022-10-01 |
SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2810.220494 |
|
| 2022-10-01 |
GPS tracking of free-roaming cats (Felis catus) on SARS-CoV-2-infected mink farms in Utah (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14102131 |
36298686 |
| 2022-09-30 |
Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-33498-0 |
|
| 2022-09-30 |
Performance of saline and water gargling for SARS-CoV-2 reverse transcriptase PCR testing: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1183/16000617.0014-2022 |
36130785 |
| 2022-09-30 |
Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS231911589 |
36232891 |
| 2022-09-30 |
Natural humoral immunity to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.4024/11AB22L.JBPC.22.03 |
|
| 2022-09-29 |
An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11427-022-2166-Y |
|
| 2022-09-29 |
Changes in preterm birth and birthweight during the SARS-CoV-2 pandemic: a nationwide study in South Korea (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-20049-2 |
|
| 2022-09-28 |
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABO5070 |
|
| 2022-09-27 |
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00642-9 |
|
| 2022-09-26 |
High-yield production in Escherichia coli and convenient purification of a candidate vaccine against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10529-022-03298-Z |
|
| 2022-09-26 |
Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10101609 |
36298474 |
| 2022-09-24 |
Impact of mass rapid antigen testing for SARS-CoV-2 to mitigate Omicron outbreaks in China (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAC110 |
36263876 |
| 2022-09-24 |
Sustained Delivery of a Monoclonal Antibody against SARS-CoV-2 by Microencapsulated Cells: A Proof-of-Concept Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACEUTICS14102042 |
|
| 2022-09-23 |
Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2022.33014 |
|
| 2022-09-23 |
SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABO6783 |
36129989 |
| 2022-09-22 |
An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010828 |
|
| 2022-09-22 |
Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS231911131 |
|
| 2022-09-21 |
Unveiling HERV‐K113‐ENV as SARS‐CoV‐2 severity admissible biomarker by mining transcriptome data (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28149 |
|
| 2022-09-21 |
Considerations regarding Interpretation of Positive SARS-CoV-2 Molecular Results with Late Cycle Threshold Values (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00501-22 |
|
| 2022-09-20 |
The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CBDV.202200655 |
|
| 2022-09-20 |
Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00449-022-02788-8 |
|
| 2022-09-20 |
Alterations of the Antioxidant and Inflammatory Response of the Peripheral Blood Granulocytes to SARS-CoV-2 Infection in the Deceased COVID-19 Patients (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202209.0298.V1 |
|
| 2022-09-20 |
Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14102087 |
|
| 2022-09-19 |
'Like building a plane and flying it all in one go': an interview study of infection prevention and control in Australian general practice during the first 2 years of the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-061513 |
36123071 |
| 2022-09-19 |
SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010782 |
|
| 2022-09-19 |
Barriers to SARS-CoV-2 testing among U.S. employers in the COVID-19 pandemic: a qualitative analysis conducted January through April 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH191811805 |
36142077 |
| 2022-09-18 |
Vaccination Decreases the Infectious Viral Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14092071 |
36146877 |
| 2022-09-17 |
Shorter serial intervals and incubation periods in SARS-CoV-2 variants than the SARS-CoV-2 ancestral strain (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAC052 |
35442440 |
| 2022-09-17 |
International risk of SARS-CoV-2 Omicron variant importations originating in South Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAC073 |
35704033 |
| 2022-09-17 |
Predicting onset risk of COVID-19 symptom to support healthy travel route planning in the new normal of long-term coexistence with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/23998083221127703 |
|
| 2022-09-16 |
Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104925 |
35992305 |
| 2022-09-16 |
Outbreak of SARS-CoV-2 B.1.617.2 (Delta Variant) in a Youth Camp Associated With Community Spread, Nebraska, June–July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/00333549221123582 |
|
| 2022-09-15 |
When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.2C00604 |
|
| 2022-09-15 |
Phylodynamic analysis of SARS-CoV-2 spread in Rio de Janeiro, Brazil, highlights how metropolitan areas act as dispersal hubs for new variants (edit) |
SARSコロナウイルス2 (edit) |
10.1099/MGEN.0.000859 |
|
| 2022-09-15 |
IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.1013322 |
|
| 2022-09-15 |
The Waxing, Waning, and Predictors of Humoral Responses to Vector-Based SARS-CoV-2 Vaccine in Hemodialysis Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10091537 |
|
| 2022-09-14 |
Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12033-022-00563-4 |
|
| 2022-09-14 |
SARS-CoV-2 can infect human embryos (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-18906-1 |
|
| 2022-09-14 |
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2209651 |
|
| 2022-09-14 |
Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2109515 |
|
| 2022-09-14 |
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00582-22 |
35976000 |
| 2022-09-14 |
Synthesis of Novel N4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PH15091144 |
|
| 2022-09-13 |
Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2022.2120537 |
|
| 2022-09-13 |
SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.945317 |
|
| 2022-09-13 |
Single-cell sequencing of brain tissues reveal the central nervous system’s susceptibility to SARS-CoV-2 and the drug (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.971017 |
|
| 2022-09-13 |
Liver Fibrosis Indices Predict the Severity of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM11185369 |
|
| 2022-09-12 |
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.2C00383 |
|
| 2022-09-12 |
Development of a Deep Learning Generative Neural Network for Computer-Aided Design of Potential SARS-Cov-2 Inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.17537/2022.17.188 |
|
| 2022-09-11 |
Biosurfactants in the sustainable eradication of SARS COV-2 from the environmental surfaces (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13205-022-03320-1 |
|
| 2022-09-11 |
NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1503/CMAJ.220688 |
|
| 2022-09-10 |
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma (edit) |
SARSコロナウイルス2 (edit) |
10.1200/JCO.21.02257 |
|
| 2022-09-09 |
Efficient compression of SARS-CoV-2 genome data using Nucleotide Archival Format (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PATTER.2022.100562 |
35818472 |
| 2022-09-09 |
IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ABL9943 |
|
| 2022-09-09 |
Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ADD4906 |
|
| 2022-09-09 |
SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0274509 |
|
| 2022-09-09 |
Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens — San Francisco Bay Area, California, July 2021—March 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7136A3 |
|
| 2022-09-09 |
Tracing the trajectories of SARS-CoV-2 variants of concern between December 2020 and September 2021 in the Canary Islands (Spain) (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.919346 |
|
| 2022-09-09 |
Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS10091809 |
|
| 2022-09-09 |
A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS10091812 |
|
| 2022-09-08 |
mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.953949 |
|
| 2022-09-08 |
Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination? (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.954093 |
36159791 |
| 2022-09-07 |
Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-18912-3 |
|
| 2022-09-07 |
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2210546 |
|
| 2022-09-07 |
Time Series Analysis of SARS-CoV-2 Genomes and Correlations among Highly Prevalent Mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01219-22 |
|
| 2022-09-07 |
Murine Hepatitis Virus, a Biosafety Level 2 Model for SARS-CoV-2, Can Remain Viable on Meat and Meat Packaging Materials for at Least 48 Hours (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01862-22 |
|
| 2022-09-06 |
Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.2C04225 |
|
| 2022-09-06 |
Genomic surveillance of SARS-CoV-2 Omicron variants on a university campus (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-32786-Z |
|
| 2022-09-06 |
Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex (edit) |
SARSコロナウイルス2 (edit) |
10.1161/CIRCULATIONAHA.122.059970 |
|
| 2022-09-05 |
The Impact of SARS-CoV-2 Variants on the Clinical Phenotype and Severity of Multisystem Inflammatory Syndrome in Children in South Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1097/INF.0000000000003691 |
|
| 2022-09-05 |
Risks of SARS‐CoV‐2 transmission between free‐ranging animals and captive mink in the Netherlands (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14686 |
|
| 2022-09-05 |
Prediction of the effects of the top 10 synonymous mutations from 26645 SARS-CoV-2 genomes (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.72896.2 |
|
| 2022-09-05 |
Levantamento bibliográfico do mecanismo de desenvolvimento de Diabetes Mellitus tipo II após infeção pelo SARS-COV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.33448/RSD-V11I12.33999 |
|
| 2022-09-05 |
Benchmark datasets for SARS-CoV-2 surveillance bioinformatics (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13821 |
|
| 2022-09-04 |
Towards Efficient and Accurate SARS-CoV-2 Genome Sequence Typing Based on Supervised Learning Approaches (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS10091785 |
|
| 2022-09-03 |
Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28124 |
|
| 2022-09-02 |
Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12–18 years group (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42770-022-00820-3 |
|
| 2022-09-02 |
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03849-0 |
|
| 2022-09-02 |
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-022-02480-4 |
|
| 2022-09-02 |
Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.915001 |
|
| 2022-09-02 |
SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.919958 |
|
| 2022-09-02 |
Oral microbial taxa associated with risk for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FROH.2022.886341 |
|
| 2022-09-02 |
Predicting the Kinetic Coordination of Immune Response Dynamics in SARS-CoV-2 Infection: Implications for Disease Pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MATH10173154 |
|
| 2022-09-02 |
Łysienie telogenowe jako przejaw zakażenia SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.5603/FD.A2022.0025 |
|
| 2022-09-01 |
Association of masking policies with mask adherence and distancing during the SARS-COV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2022.04.010 |
|
| 2022-09-01 |
COVID-19 clusters in a teaching hospital during the second wave of the SARS-CoV-2 pandemic in France: A descriptive study and lessons learned for waves to come (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2022.06.018 |
|
| 2022-09-01 |
Can SARS-CoV-2 positive pregnant women affect the hearing of their newborns: A systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJOTO.2022.103523 |
|
| 2022-09-01 |
Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2022.105383 |
|
| 2022-09-01 |
SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARR.2022.101687 |
|
| 2022-09-01 |
Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBI.2022.09.004 |
|
| 2022-09-01 |
Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of anosognosia for cognitive deficits in the chronic phase (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBIH.2022.100511 |
|
| 2022-09-01 |
Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOMATERIALS.2022.121671 |
35953331 |
| 2022-09-01 |
FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOSX.2022.100158 |
|
| 2022-09-01 |
Role of the coronary and non-coronary cardiovascular findings on non-cardiac gated thoracic CT in predicting mortality in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLINIMAG.2022.06.002 |
|
| 2022-09-01 |
SARS-CoV-2 infection showing signs of cerebral sinus vein thrombosis in the infantile period (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DSCB.2022.100051 |
|
| 2022-09-01 |
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.104248 |
|
| 2022-09-01 |
Lockdowns exert selection pressure on overdispersion of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EPIDEM.2022.100613 |
35939969 |
| 2022-09-01 |
Predicting the dispersal of SARS-CoV-2 RNA from the wastewater treatment plant to the coast (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2022.E10547 |
|
| 2022-09-01 |
Before blaming SARS-CoV-2 for intra-cerebral aneurysm formation and rupture, alternative mechanisms need to be ruled out (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HEST.2022.09.001 |
|
| 2022-09-01 |
Considering the precautionary principle and its application to MRSA and SARS-CoV-2 as emerging novel pathogens of their time (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDH.2022.08.003 |
|
| 2022-09-01 |
TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.05.051 |
|
| 2022-09-01 |
SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104959 |
|
| 2022-09-01 |
Can systemic immune inflammation index at admission predict in-hospital mortality in chronic kidney disease patients with SARS-CoV-2 infection? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NEFRO.2021.09.001 |
|
| 2022-09-01 |
New insights on circular RNAs and their potential applications as biomarkers, therapeutic agents, and preventive vaccines in viral infections: with a glance at SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2022.08.012 |
|
| 2022-09-01 |
UV 254 nm is more efficient than UV 222 nm in inactivating SARS-CoV-2 present in human saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PDPDT.2022.103015 |
35843562 |
| 2022-09-01 |
Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: from histopathological features to clinical presentations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PULMOE.2021.03.003 |
|
| 2022-09-01 |
Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REC.2021.11.001 |
|
| 2022-09-01 |
Afección pericárdica y miocárdica tras infección por SARS-CoV-2: estudio descriptivo transversal en trabajadores sanitarios (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RECESP.2021.10.021 |
|
| 2022-09-01 |
Protocol to identify host-viral protein interactions between coagulation-related proteins and their genetic variants with SARS-CoV-2 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2022.101648 |
|
| 2022-09-01 |
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00307-3 |
|
| 2022-09-01 |
Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2213-2600(22)00182-5 |
|
| 2022-09-01 |
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2665-9913(22)00190-4 |
|
| 2022-09-01 |
Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41576-022-00483-8 |
35459859 |
| 2022-09-01 |
Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05049-6 |
35798029 |
| 2022-09-01 |
Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05189-9 |
35952714 |
| 2022-09-01 |
Probing the mutational landscape of the SARS-CoV-2 spike protein via quantum mechanical modeling of crystallographic structures (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC180 |
36712320 |
| 2022-09-01 |
Subtyping of major SARS-CoV-2 variants reveals different transmission dynamics based on 10 million genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC181 |
36714842 |
| 2022-09-01 |
Estimating R0 from early exponential growth: parallels between 1918 influenza and 2020 SARS-CoV-2 pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC194 |
36714850 |
| 2022-09-01 |
Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC197 |
36714870 |
| 2022-09-01 |
New insights into human immune memory from SARS‐CoV‐2 infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.15502 |
|
| 2022-09-01 |
Systematic review and meta-analyses of superspreading of SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14655 |
35799321 |
| 2022-09-01 |
Curating a knowledge base for individuals with coinfection of HIV and SARS-CoV-2: a study protocol of EHR-based data mining and clinical implementation (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-067204 |
|
| 2022-09-01 |
Effect of SARS-CoV-2 infection in neonates or in pregnancy on developmental outcomes at 21–24 months (SINEPOST): study protocol for a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJPO-2022-001571 |
|
| 2022-09-01 |
Cardiac postacute sequelae symptoms of SARS-CoV-2 in community-dwelling adults: cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/OPENHRT-2022-002084 |
|
| 2022-09-01 |
Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1136/RMDOPEN-2022-002622 |
|
| 2022-09-01 |
A Study on the Fractal-Fractional Epidemic Probability-Based Model of SARS-CoV-2 Virus along with the Taylor Operational Matrix Method for Its Caputo Version (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2022/2388557 |
|
| 2022-09-01 |
SARS-CoV-2 reinfections during the Delta and Omicron waves (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.162007 |
|
| 2022-09-01 |
Pre-Illness Training And Acute Symptom Clusters Predict Prolonged Return-To-Play In Athletes After Recent SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1249/01.MSS.0000882600.84039.EA |
|
| 2022-09-01 |
Mitigation of the biosafety risks of SARS-CoV-2 at BSL-3 laboratories (edit) |
SARSコロナウイルス2 (edit) |
10.15312/EURASIANJVETSCI.2021.344 |
|
| 2022-09-01 |
Psychopathological Symptoms Among Chronically Ill Patients During SARS-CoV-2 Pandemic in Poland (edit) |
SARSコロナウイルス2 (edit) |
10.2147/PRBM.S362918 |
|
| 2022-09-01 |
TARGETING THE MAIN PROTEASE AND THE SPIKE PROTEIN OF SARS-COV-2 WITH NATURALLY OCCURRING COMPOUNDS FROM SOME CAMEROONIAN MEDICINAL PLANTS: AN IN-SILICO STUDY FOR DRUG DESIGNING (edit) |
SARSコロナウイルス2 (edit) |
10.4067/S0717-97072022000305602 |
|
| 2022-08-31 |
Structural investigations of proteins encoded by SARS‐CoV ‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/2211-5463.13465 |
|
| 2022-08-31 |
Symptomatic and Asymptomatic Transmission of SARS-CoV-2 in K-12 Schools, British Columbia, Canada April to June 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00622-22 |
35862938 |
| 2022-08-31 |
Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02495-21 |
|
| 2022-08-31 |
Retraction: Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0273489 |
36044431 |
| 2022-08-31 |
The Effect of SARS-CoV-2 Vaccination on B-Cell Phenotype in Systemic Sclerosis Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JPM12091420 |
|
| 2022-08-30 |
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-32565-W |
|
| 2022-08-30 |
Author Correction: Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-19152-1 |
|
| 2022-08-30 |
A Retinol Derivative Inhibits SARS-CoV-2 Infection by Interrupting Spike-Mediated Cellular Entry (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01485-22 |
|
| 2022-08-29 |
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.2C02794 |
|
| 2022-08-29 |
SARS-CoV-2 Surface Swabs in Locations With Public Access—Potential for Improved Source Control (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAC431 |
|
| 2022-08-29 |
Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2022-062567 |
36038173 |
| 2022-08-29 |
In Silico Evaluation of Sesquiterpenes and Benzoxazinoids Phytotoxins against Mpro, RNA Replicase and Spike Protein of SARS-CoV-2 by Molecular Dynamics. Inspired by Nature (edit) |
SARSコロナウイルス2 (edit) |
10.3390/TOXINS14090599 |
|
| 2022-08-28 |
Comparative outcomes after early Sotrovimab administration in vaccinated and unvaccinated kidney transplant recipients with SARS‐CoV‐2 infection during the Delta and Omicron BA.1 surges (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TID.13930 |
|
| 2022-08-28 |
Ergonomic Factors That Impact Job Satisfaction and Occupational Health during the SARS-CoV-2 Pandemic Based on a Structural Equation Model: A Cross-Sectional Exploratory Analysis of University Workers (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH191710714 |
|
| 2022-08-26 |
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABP8337 |
35881005 |
| 2022-08-26 |
Wildlife trade is likely the source of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADD8384 |
|
| 2022-08-26 |
Seasonal variation in SARS-CoV-2 transmission in temperate climates: A Bayesian modelling study in 143 European regions (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010435 |
|
| 2022-08-26 |
SARS-CoV-2 PCR positivity in elementary school classes in Bavaria in the school year 2021/22—initial results from the evaluation of the Bavarian pool test project in elementary and special schools (edit) |
SARSコロナウイルス2 (edit) |
10.3238/ARZTEBL.M2022.0310 |
|
| 2022-08-26 |
A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.966847 |
|
| 2022-08-25 |
SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010349 |
|
| 2022-08-25 |
Computational Pipeline for Reference-Free Comparative Analysis of RNA 3D Structures Applied to SARS-CoV-2 UTR Models (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23179630 |
36077037 |
| 2022-08-24 |
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14760584.2022.2116008 |
|
| 2022-08-24 |
Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC032 |
35037030 |
| 2022-08-24 |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC142 |
35178548 |
| 2022-08-24 |
Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.952916 |
|
| 2022-08-24 |
Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES27175413 |
|
| 2022-08-23 |
The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S43440-022-00394-9 |
|
| 2022-08-23 |
Humoral response to heterologous prime‐booster vaccination in heart transplant recipients aged 18–70 years primed with a viral vector SARS‐CoV‐2 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TID.13935 |
|
| 2022-08-23 |
Impact of Vaccination and Testing in an Urban Campus Model for the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3524458.3547269 |
|
| 2022-08-23 |
Plant-derived compounds effectively inhibit the main protease of SARS-CoV-2: An in silico approach (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0273341 |
|
| 2022-08-22 |
Structure-Based Virtual Screening, Docking, ADMET, Molecular Dynamics, and MM-PBSA Calculations for the Discovery of Potential Natural SARS-CoV-2 Helicase Inhibitors from the Traditional Chinese Medicine (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2022/7270094 |
|
| 2022-08-21 |
The Impact of Severe COVID-19 on Plasma Antioxidants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES27165323 |
36014561 |
| 2022-08-19 |
SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41390-022-02266-7 |
|
| 2022-08-19 |
Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC159 |
36111270 |
| 2022-08-18 |
In silico identification of novel SARS-CoV-2 main protease and non-structural protein 13 (nsp13) inhibitors through consensus docking and free binding energy calculations. (edit) |
SARSコロナウイルス2 (edit) |
10.2174/1386207325666220818141112 |
|
| 2022-08-18 |
Awake Prone-Positioning in Patients on Non-Invasive Ventilation for Management of SARS-CoV-2 Pneumonia: A Systematic Review (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ARM90040046 |
|
| 2022-08-18 |
Seroprevalence of SARS-CoV-2 among Children Visiting a Tertiary Hospital during the Prevaccination Period, Southwest Region, Saudi Arabia (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10081344 |
|
| 2022-08-17 |
Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1 nCoV-19, Vaxzevria) (edit) |
SARSコロナウイルス2 (edit) |
10.1177/08850666221121589 |
|
| 2022-08-17 |
Folic acid restricts SARS-CoV-2 invasion by methylating ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.980903 |
|
| 2022-08-16 |
Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-17953-Y |
|
| 2022-08-12 |
Suppression of SARS‐CoV‐2 Replication with Stabilized and Click‐Chemistry Modified siRNAs (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ANIE.202204556 |
|
| 2022-08-12 |
Vaccines against SARS-CoV-2 variants and future pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14760584.2022.2110075 |
|
| 2022-08-12 |
Within‐host dynamics of SARS‐CoV‐2 infection: A systematic review and meta‐analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14673 |
35907777 |
| 2022-08-12 |
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABQ2679 |
35857703 |
| 2022-08-12 |
Leveraging artificial intelligence and data science techniques in harmonizing, sharing, accessing and analyzing SARS-COV-2/COVID-19 data in Rwanda (LAISDAR Project): study design and rationale (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12911-022-01965-9 |
|
| 2022-08-12 |
SARS-CoV-2 Viroporins: A Multi-Omics Insight from Nucleotides to Amino Acids (edit) |
SARSコロナウイルス2 (edit) |
10.3390/APPLMICROBIOL2030045 |
|
| 2022-08-11 |
Descriptive analysis of clinical and laboratory findings in relation to changes in SARS-CoV-2 viral dynamics and cyclic threshold: a retrospective, single center observational study in patients treated with Hydroxychloroquine/Azithromycin combinatio (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.28290.1 |
|
| 2022-08-11 |
Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.37349/EI.2022.00063 |
|
| 2022-08-10 |
Initial introduction and spread of the SARS‐CoV‐2 AY.4.2.1 Delta variant in Bulgaria, a genomic insight (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.28033 |
|
| 2022-08-10 |
SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-022-22333-0 |
|
| 2022-08-10 |
An exploration on the topologies of SARS-CoV-2/human protein-protein interaction network (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2022.2108496 |
|
| 2022-08-10 |
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.08.09.503384 |
|
| 2022-08-10 |
Impact on Education and Ecological Footprint as a Consequence of SARS-CoV-2 in the Perception of the Quality of Teaching Engineering Students in the Brazilian Amazon (edit) |
SARSコロナウイルス2 (edit) |
10.3390/SU14169891 |
|
| 2022-08-09 |
The mechanism of RNA capping by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05185-Z |
35944563 |
| 2022-08-09 |
Monitoring wastewater for SARS-CoV-2, and looking back at the biggest questions about the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADB1867 |
|
| 2022-08-09 |
Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.161045 |
|
| 2022-08-08 |
SARS-CoV-2 Transmission by Arthropod Vectors: A Scoping Review (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2022/4329423 |
|
| 2022-08-08 |
Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.160989 |
|
| 2022-08-08 |
Roles and functions of SARS-CoV-2 proteins in host immune evasion (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.940756 |
|
| 2022-08-07 |
Forecasting the spread of SARS-CoV-2 in the campania region using genetic programming (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00500-022-07385-1 |
|
| 2022-08-06 |
Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-32357-2 |
|
| 2022-08-06 |
COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10081266 |
|
| 2022-08-05 |
Molecular surveillance revealed no SARS-CoV-2 spillovers to raccoons (Procyon lotor) in four German federal states (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10344-022-01605-7 |
|
| 2022-08-05 |
Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03739-5 |
|
| 2022-08-04 |
SARS-CoV-2 Transmission Potential and Policy Changes in South Carolina, February 2020 – January 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.212 |
|
| 2022-08-04 |
Nasopharyngeal microbiota profiling of pregnant women with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-17542-Z |
|
| 2022-08-03 |
The Microalgal Diatoxanthin Inflects the Cytokine Storm in SARS-CoV-2 Stimulated ACE2 Overexpressing Lung Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX11081515 |
|
| 2022-08-02 |
Mixed-methods process evaluation of a residence-based SARS-CoV-2 testing participation pilot on a UK university campus during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-022-13792-8 |
|
| 2022-08-01 |
Lessons learned from the COVID-19 pandemic in a North African country (Tunisia). (edit) |
SARSコロナウイルス2 (edit) |
|
36571723 |
| 2022-08-01 |
Maternal fructose intake reinforces the effects of a Western-type diet in promoting SARS-CoV-2 cell entry factors in male offspring (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ATHEROSCLEROSIS.2022.06.840 |
|
| 2022-08-01 |
Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAMEM.2022.183945 |
|
| 2022-08-01 |
Persistently positive PCR SARS-CoV-2 at low cycle threshold in an immunosuppressed patient (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BJID.2022.102696 |
|
| 2022-08-01 |
Elucidation of correlation between SARS-CoV-2 RdRp and N gene cycle threshold (Ct) by RT-PCR with age and gender (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CCA.2022.06.008 |
|
| 2022-08-01 |
FRET-based hACE2 receptor mimic peptide conjugated nanoprobe for simple detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CEJ.2022.136143 |
|
| 2022-08-01 |
Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.08.024 |
|
| 2022-08-01 |
Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELLIN.2022.100046 |
|
| 2022-08-01 |
Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COPBIO.2022.102715 |
35447504 |
| 2022-08-01 |
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJCA.2022.04.036 |
|
| 2022-08-01 |
Maintaining safe office spaces to minimise risks of SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDH.2022.03.003 |
|
| 2022-08-01 |
Useful molecular tools for facing next pandemic events: Effective sample preparation and improved RT-PCR for highly sensitive detection of SARS-CoV-2 in wastewater environment (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJHEH.2022.114017 |
|
| 2022-08-01 |
Immunomodulatory LncRNA on antisense strand of ICAM-1 augments SARS-CoV-2 infection-associated airway mucoinflammatory phenotype (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104685 |
|
| 2022-08-01 |
A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JEMERMED.2021.10.005 |
|
| 2022-08-01 |
Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2022.05.033 |
|
| 2022-08-01 |
A study on the role of aedes mosquitoes in arboviruses and SARS-CoV-2 infection: A new challenge (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2022.102179 |
|
| 2022-08-01 |
Knowledge about COVID-19 and vaccine acceptability among priority groups defined for vaccination: A cross-sectional study in Araba/Alava, Spain, before the vaccination against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVACX.2022.100176 |
|
| 2022-08-01 |
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2022.05.003 |
|
| 2022-08-01 |
Simple approximation of sample size for precise estimates of SARS-CoV-2 infection from point-seroprevalence studies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PUHE.2022.08.008 |
|
| 2022-08-01 |
Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2022.06.010 |
|
| 2022-08-01 |
Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2022.05.006 |
|
| 2022-08-01 |
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00119-0 |
|
| 2022-08-01 |
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00420-0 |
|
| 2022-08-01 |
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2213-2600(22)00131-X |
|
| 2022-08-01 |
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05053-W |
35790190 |
| 2022-08-01 |
Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1080/19490976.2022.2105609 |
|
| 2022-08-01 |
Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAC349 |
35937649 |
| 2022-08-01 |
Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents (edit) |
SARSコロナウイルス2 (edit) |
10.1097/INF.0000000000003653 |
|
| 2022-08-01 |
Alternative COVID-19 mitigation measures in school classrooms: analysis using an agent-based model of SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.211985 |
35958084 |
| 2022-08-01 |
Severity of maternal SARS-CoV-2 infection and perinatal outcomes of women admitted to hospital during the omicron variant dominant period using UK Obstetric Surveillance System data: prospective, national cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJMED-2022-000190 |
|
| 2022-08-01 |
Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-060555 |
35981767 |
| 2022-08-01 |
Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0271074 |
|
| 2022-08-01 |
Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2808.220617 |
|
| 2022-08-01 |
Pandemic Preparedness: The Potential Advantage of Medicines That Prevent Acute Side Effects of Vaccination, SARS-CoV-2 as an Example (edit) |
SARSコロナウイルス2 (edit) |
10.3390/FUTUREPHARMACOL2030019 |
|
| 2022-08-01 |
The unmitigated profile of COVID-19 infectiousness (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.79134 |
35913120 |
| 2022-07-31 |
Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS12081852 |
|
| 2022-07-30 |
Regional disparities in SARS-CoV-2 infections by labour market indicators: a spatial panel analysis using nationwide German data on notified infections (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07643-5 |
|
| 2022-07-29 |
Immune Heterogeneity and Epistasis Explain Punctuated Evolution of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.07.27.22278129 |
35982659 |
| 2022-07-29 |
Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice (edit) |
SARSコロナウイルス2 (edit) |
10.2147/IJN.S367494 |
35937077 |
| 2022-07-28 |
Comparing the Psychological Problems Among the Health Care Workers Across Two Waves of SARS-CoV-2 (COVID-19) Pandemic: An Observational Study from India (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.192 |
|
| 2022-07-28 |
COVID-19 (SARS-CoV-2) in Patients Treated in The Unified Health System (SUS) with Flu and Respiratory Symptoms from Three Brazilian Municipalities in the Border Region (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.195 |
|
| 2022-07-28 |
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14081653 |
|
| 2022-07-27 |
Implementation of Multi-level Interventions to Mitigate Risk of SARS-CoV-2 Delta Variant at a PUBLIC UNIVERSITY in Southern United States (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.179 |
|
| 2022-07-27 |
Low SARS-CoV-2 Antibodies in Blood Donors After the First 6 Months of COVID-19 Epidemic in the Tobruk Region, Eastern Libya (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.180 |
|
| 2022-07-27 |
Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-01123-7 |
|
| 2022-07-27 |
Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2203437119 |
|
| 2022-07-27 |
Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00488-22 |
35758692 |
| 2022-07-27 |
Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0270276 |
|
| 2022-07-27 |
Influencing factors for the persistence of SARS-CoV-2 (COVID-19) exposed in environmental matrices and disinfection methods: systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.18203/2394-6040.IJCMPH20222040 |
|
| 2022-07-26 |
Vertical Transmission of SARS-CoV-2 Infection and Miscarriage in the Second Trimester: Report of an Immunohistochemically Proven Case (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CLINPRACT12040061 |
|
| 2022-07-25 |
An analysis of 45 large-scale wastewater sites in England to estimate SARS-CoV-2 community prevalence (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-31753-Y |
|
| 2022-07-25 |
Detection of SARS-CoV-2 Using a Miniaturized Spectrometer Chip: A Comparative Study Against Benchtop Spectrometer and Its Potential Application to Handheld Detection (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3543081.3543098 |
|
| 2022-07-25 |
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.882918 |
|
| 2022-07-23 |
SARS-ANI: a global open access dataset of reported SARS-CoV-2 events in animals (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41597-022-01543-8 |
|
| 2022-07-22 |
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00432-022-04185-W |
|
| 2022-07-22 |
Crisis management checklist: lessons learned from the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S44186-022-00033-0 |
|
| 2022-07-22 |
Evolution of ACE2-Independent SARS-CoV-2 Infection and Mouse Adaption After Passage in Cells Expressing Human and Mouse ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC063 |
|
| 2022-07-22 |
An overview of possible pivotal mechanisms of Genistein as a potential phytochemical against SARS‐CoV‐2 infection: A hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JFBC.14345 |
|
| 2022-07-22 |
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN8939 |
|
| 2022-07-22 |
Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABO7896 |
35762884 |
| 2022-07-22 |
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7129E1 |
|
| 2022-07-22 |
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.919408 |
|
| 2022-07-22 |
Resilience and Protection of Health Care and Research Laboratory Workers During the SARS-CoV-2 Pandemic: Analysis and Case Study From an Austrian High Security Laboratory (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPSYG.2022.901244 |
|
| 2022-07-22 |
An update on the impact of SARS-CoV-2 pandemic public awareness on cancer patients' COVID-19 vaccine compliance: Outcomes and recommendations (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.923815 |
|
| 2022-07-22 |
Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19158895 |
|
| 2022-07-22 |
Forecasting the Post-Pandemic Effects of the SARS-CoV-2 Virus Using the Bullwhip Phenomenon Alongside Use of Nanosensors for Disease Containment and Cure (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MA15145078 |
|
| 2022-07-22 |
Histopathological and Immunological Findings in the Common Marmoset Following Exposure to Aerosolized SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14071580 |
|
| 2022-07-22 |
Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice (edit) |
SARSコロナウイルス2 (edit) |
10.34133/2022/9864089 |
|
| 2022-07-21 |
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41587-022-01382-3 |
|
| 2022-07-21 |
The importance of effect sizes when comparing cycle threshold values of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0271808 |
|
| 2022-07-21 |
Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010686 |
|
| 2022-07-20 |
LB981 Pandemic associated chilblain-like lesions result from an inducible type 1 interferon response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JID.2022.05.1004 |
|
| 2022-07-20 |
Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANSEA.2022.100046 |
|
| 2022-07-20 |
COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.17650/1818-8346-2022-17-3-119-126 |
|
| 2022-07-20 |
Progress in Electrochemical Biosensing of SARS-CoV-2 Virus for COVID-19 Management (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CHEMOSENSORS10070287 |
|
| 2022-07-20 |
Development of Lateral Flow Immunochromatographic Test for Rapid Detection of SARS-CoV-2 Virus Antigens in Clinical Specimens (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NANO12142477 |
|
| 2022-07-20 |
The Biological Properties of the SARS-CoV-2 Cameroon Variant Spike: An Intermediate between the Alpha and Delta Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11070814 |
|
| 2022-07-19 |
Chronic biopsy proven post‐COVID myoendocarditis with SARS‐Cov‐2 persistence and high level of antiheart antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CLC.23886 |
|
| 2022-07-19 |
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100679 |
35798000 |
| 2022-07-19 |
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2200592119 |
|
| 2022-07-19 |
Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS‐CoV‐2 vaccines in solid organ transplant recipients: A case series (edit) |
SARSコロナウイルス2 (edit) |
10.1111/CTR.14772 |
|
| 2022-07-19 |
SARS-CoV-2 pandemics and RSV off-season outbreaks (edit) |
SARSコロナウイルス2 (edit) |
10.23822/EURANNACI.1764-1489.263 |
|
| 2022-07-18 |
Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2022.2098821 |
|
| 2022-07-18 |
A qualitative process analysis of daily contact testing as an alternative to self-isolation following close contact with a confirmed carrier of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-022-13800-X |
|
| 2022-07-18 |
Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010330 |
|
| 2022-07-18 |
In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010733 |
|
| 2022-07-18 |
Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.967493 |
|
| 2022-07-18 |
Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14071553 |
|
| 2022-07-16 |
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-15930-Z |
|
| 2022-07-15 |
Interaction of Bioactive Compounds of Moringa oleifera Leaves with SARS-CoV-2 Proteins to Combat COVID-19 Pathogenesis: a Phytochemical and In Silico Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12010-022-04040-1 |
|
| 2022-07-15 |
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.910136 |
|
| 2022-07-15 |
The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10071123 |
|
| 2022-07-14 |
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.2C00404 |
35731933 |
| 2022-07-14 |
Single vs replicate Real-Time PCR SARS-CoV-2 testing: Lessons learned for effective pandemic management (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0269883 |
|
| 2022-07-14 |
Immunopathology and pulmonary complications associated with SARS-CoV-2 virus infection. Can plants help us? (edit) |
SARSコロナウイルス2 (edit) |
10.53301/LW/147770 |
|
| 2022-07-13 |
Respiratory syncytial virus after the SARS-CoV-2 pandemic — what next? (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41577-022-00764-7 |
|
| 2022-07-13 |
T-cell responses to SARS-CoV-2 in unexposed South African women (edit) |
SARSコロナウイルス2 (edit) |
10.12688/GATESOPENRES.13373.2 |
|
| 2022-07-12 |
Tropism of SARS-CoV-2 for human cortical astrocytes (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2122236119 |
|
| 2022-07-12 |
The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00765-22 |
|
| 2022-07-11 |
Harnessing Natural Products by a Pharmacophore-Oriented Semisynthesis Approach for the Discovery of Potential Anti-SARS-CoV-2 Agents (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ANIE.202201684 |
35484726 |
| 2022-07-11 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198852 |
|
| 2022-07-11 |
Air dispersal of respiratory viruses other than severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and the implication on hospital infection control (edit) |
SARSコロナウイルス2 (edit) |
10.1017/ICE.2022.186 |
|
| 2022-07-11 |
Neuroinvasion of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2): future risk of epilepsy (edit) |
SARSコロナウイルス2 (edit) |
10.1080/00207454.2022.2100784 |
|
| 2022-07-11 |
Evaluating Transferability for Covid 3D Localization Using CT SARS-CoV-2 segmentation models (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3529190.3534736 |
|
| 2022-07-11 |
Saponin-based PAK-1 inhibitors as promising agents for struggle against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3535694.3535720 |
|
| 2022-07-11 |
Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009834 |
|
| 2022-07-09 |
Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198857 |
|
| 2022-07-09 |
NUCLEOSIDE ANALOG FAVIPIRAVIR IS A POOR INHIBITOR AGAINST THE SARS-COV-2 VIRUS IN CELL CULTURE, BUT FAVIPIRAVIR IS HIGHLY ACTIVE AGAINST VENEZUELAN EQUINE ENCEPHALITIS VIRUS (edit) |
SARSコロナウイルス2 (edit) |
10.11134/BTP.2.2022.7 |
|
| 2022-07-08 |
The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University Hospital (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PMEDR.2022.101899 |
|
| 2022-07-08 |
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-31721-6 |
|
| 2022-07-08 |
Inhibitor induced conformational changes in SARS-COV-2 papain-like protease (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-15181-Y |
|
| 2022-07-08 |
Consequences of Transplacental Transmission of the SARS-CoV-2 Virus: A Single-Center Experience (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CHILDREN9071020 |
|
| 2022-07-07 |
Lack of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission from a healthcare worker to a cohort of immunosuppressed patients during the SARS-CoV-2 omicron variant surge, California, 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.1017/ICE.2022.175 |
|
| 2022-07-07 |
How Reproducible Are QM/MM Simulations? Lessons from Computational Studies of the Covalent Inhibition of the SARS-CoV-2 Main Protease by Carmofur (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.2C00286 |
|
| 2022-07-07 |
Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13054-022-04062-5 |
35799268 |
| 2022-07-07 |
Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.941009 |
|
| 2022-07-06 |
Clinical and epidemiological characteristics of SARS-CoV-2 Infection in Los Angeles County youth during the first year of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.06.040 |
|
| 2022-07-06 |
Cloaking the ACE2 receptor with salivary cationic proteins inhibits SARS-CoV-2 entry (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JB/MVAC054 |
|
| 2022-07-06 |
SARS-CoV-2 seroprevalence among public school staff in Metro Vancouver after the first Omicron wave in British Columbia, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.07.04.22277230 |
|
| 2022-07-06 |
RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00781-22 |
|
| 2022-07-06 |
Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.943407 |
|
| 2022-07-05 |
Hygiene in der Dermatologie: SARS-CoV-2 und weitere Virus-Varianten (edit) |
SARSコロナウイルス2 (edit) |
10.1055/A-1703-1692 |
|
| 2022-07-05 |
Inferring the differences in incubation-period and generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.07.02.22277186 |
|
| 2022-07-05 |
Saponin and Immune Stimulant Based Gargles and Nasal Rinses: A Potential Virucidal for Preventive Management of SARS-CoV-2 Infection? (edit) |
SARSコロナウイルス2 (edit) |
10.14218/ERHM.2021.00007 |
|
| 2022-07-04 |
Investigating the influence of shift work rosters on stress measured as cortisol in hair during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PSYNEUEN.2022.105858 |
|
| 2022-07-04 |
Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.905197 |
|
| 2022-07-04 |
Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JPM12071103 |
|
| 2022-07-03 |
Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02813432.2022.2139480 |
|
| 2022-07-02 |
Quantification of SARS-CoV-2 RNA in wastewater treatment plants mirrors the pandemic trend in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.157121 |
|
| 2022-07-02 |
Importance score of SARS-CoV-2 genome predicts the death risk of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41420-022-01100-7 |
|
| 2022-07-01 |
A surge of pediatric hepatitis: Why SARS-CoV-2 should be considered guilty until proven innocent (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMSU.2022.103956 |
|
| 2022-07-01 |
A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANNEMERGMED.2022.03.009 |
35461719 |
| 2022-07-01 |
Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2022.105332 |
|
| 2022-07-01 |
Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBI.2022.04.013 |
|
| 2022-07-01 |
T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CCA.2022.05.025 |
|
| 2022-07-01 |
What SARS-CoV-2 does to our brains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2022.06.013 |
|
| 2022-07-01 |
Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INTIMP.2022.108697 |
|
| 2022-07-01 |
Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104500 |
|
| 2022-07-01 |
Vocal fold palsy after vaccination against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDCLE.2021.12.008 |
|
| 2022-07-01 |
Parálisis de cuerda vocal tras vacunación contra el SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDCLI.2021.12.013 |
|
| 2022-07-01 |
An alternative to airborne droplet transmission route of SARS-CoV-2, the feco-oral route, as a factor shaping COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110903 |
|
| 2022-07-01 |
Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2022.06.020 |
|
| 2022-07-01 |
CRISPR-based assays for rapid detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMETH.2020.10.003 |
33045362 |
| 2022-07-01 |
Monkeypox genomic surveillance will challenge lessons learned from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(22)01106-0 |
|
| 2022-07-01 |
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0168-8278(22)00515-3 |
|
| 2022-07-01 |
Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0168-8278(22)01860-8 |
|
| 2022-07-01 |
Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0168-8278(22)01927-4 |
|
| 2022-07-01 |
Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2352-4642(22)00100-6 |
|
| 2022-07-01 |
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04778-Y |
35447027 |
| 2022-07-01 |
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04865-0 |
35584773 |
| 2022-07-01 |
Author Correction: Bat coronaviruses related to SARS-CoV-2 and infectious for human cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-05048-7 |
35798954 |
| 2022-07-01 |
SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC071 |
35860600 |
| 2022-07-01 |
Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC096 |
35799833 |
| 2022-07-01 |
Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC100 |
35909795 |
| 2022-07-01 |
Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC105 |
35899067 |
| 2022-07-01 |
A 10 GHz Metamaterial Sensor to Detect SARS COV-2 and Dust Particles in Free Space (edit) |
SARSコロナウイルス2 (edit) |
10.1109/JSEN.2022.3178049 |
|
| 2022-07-01 |
Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.15206 |
34986501 |
| 2022-07-01 |
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry (edit) |
SARSコロナウイルス2 (edit) |
10.1136/RMDOPEN-2022-002322 |
|
| 2022-07-01 |
Regional clustering and waves patterns due to COVID-19 by the index virus and the lambda/gamma, and delta/omicron SARS-CoV-2 variants in Peru (edit) |
SARSコロナウイルス2 (edit) |
10.12688/GATESOPENRES.13644.1 |
|
| 2022-07-01 |
Hematological Findings and Alteration of Oxidative Stress Markers in Hospitalized Patients with SARS-COV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.2478/PRILOZI-2022-0029 |
|
| 2022-07-01 |
Romania’s Social Changes During the Sars Cov 2 Pandemic, as Effect of the Digitalisation Process (edit) |
SARSコロナウイルス2 (edit) |
10.2478/SBEEF-2022-0006 |
|
| 2022-07-01 |
Suspected Cat-to-Human Transmission of SARS-CoV-2, Thailand, July–September 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2807.212605 |
|
| 2022-07-01 |
The Seroprevalence of SARS-CoV-2 IgG Antibodies in Children Hospitalized for Reasons Other Than COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM11133819 |
35807103 |
| 2022-07-01 |
Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3) (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10071064 |
|
| 2022-06-30 |
A Topology-Matching Spike Protein-Capping Tetrahedral DNA Nanocrown for SARS-CoV-2 Neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.31635/CCSCHEM.022.202201945 |
|
| 2022-06-30 |
An Altered Metabolism in Leukocytes Showing in vitro igG Memory From SARS-CoV-2-Infected Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.894207 |
|
| 2022-06-30 |
Predicting the Spread of SARS-CoV-2 in Italian Regions: The Calabria Case Study, February 2020–March 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DISEASES10030038 |
|
| 2022-06-30 |
Is There a Correlation Between the Cycle Threshold of SARS-CoV-2 RT-PCR and the Clinical Course of COVID-19? (edit) |
SARSコロナウイルス2 (edit) |
10.4274/ATFM.GALENOS.2022.97658 |
|
| 2022-06-29 |
Transmission of SARS-CoV-2 on Cold-Chain Food: Precautions Can Effectively Reduce the Risk (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12560-022-09521-4 |
|
| 2022-06-29 |
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2202092 |
|
| 2022-06-29 |
Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00913-21 |
|
| 2022-06-29 |
Insertion-and-Deletion Mutations between the Genomes of SARS-CoV, SARS-CoV-2, and Bat Coronavirus RaTG13 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00716-22 |
|
| 2022-06-29 |
Entorhinal Cortex and Persistent Olfactory Loss in COVID-19 Patients: A Neuroanatomical Hypothesis. Comment on Fiorentino et al. Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection. Brain Sci. 2022, 12, (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BRAINSCI12070850 |
|
| 2022-06-29 |
Global m6A RNA Methylation in SARS-CoV-2 Positive Nasopharyngeal Samples in a Mexican Population: A First Approximation Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/EPIGENOMES6030016 |
|
| 2022-06-29 |
Contrasting Epidemiology and Population Genetics of COVID-19 Infections Defined by Multilocus Genotypes in SARS-CoV-2 Genomes Sampled Globally (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14071434 |
|
| 2022-06-28 |
A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107721 |
|
| 2022-06-28 |
Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198853 |
|
| 2022-06-28 |
Putative Host-Derived Insertions in the Genomes of Circulating SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSYSTEMS.00179-22 |
|
| 2022-06-28 |
Taking on SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.80552 |
|
| 2022-06-27 |
Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11224-022-01999-9 |
|
| 2022-06-27 |
Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2022.105222 |
|
| 2022-06-27 |
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC526 |
35758873 |
| 2022-06-27 |
Estimating decay curves of neutralizing antibodies to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/IMAMMB/DQAC008 |
|
| 2022-06-26 |
Evaluation of the DiaSorin LIAISON SARS-CoV-2 antigen assay on nasopharyngeal swabs in two different SARS-CoV-2 pandemic waves in Switzerland: The impact of the Omicron variant on its performance (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCVP.2022.100095 |
|
| 2022-06-25 |
Screening of honey bee pollen constituents against COVID-19: an emerging hot spot in targeting SARS-CoV-2-ACE-2 interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14786419.2022.2092865 |
|
| 2022-06-25 |
Associated-Onset Symptoms and Post-COVID-19 Symptoms in Hospitalized COVID-19 Survivors Infected with Wuhan, Alpha or Delta SARS-CoV-2 Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11070725 |
|
| 2022-06-24 |
Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNEUR.2022.914411 |
|
| 2022-06-23 |
Differences in pediatric SARS-CoV-2 symptomology and Co-infection rates among COVID-19 Pandemic waves (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2022.105220 |
|
| 2022-06-22 |
Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity (edit) |
SARSコロナウイルス2 (edit) |
10.1177/07487304221100951 |
|
| 2022-06-21 |
In-silico screening to delineate novel antagonists to SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-21 |
The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00455-22 |
|
| 2022-06-21 |
SARS-CoV-2 wildlife surveillance in Ontario and Québec (edit) |
SARSコロナウイルス2 (edit) |
10.14745/CCDR.V48I06A02 |
|
| 2022-06-21 |
Projected resurgence of COVID-19 in the United States in July-December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.73584 |
35726851 |
| 2022-06-20 |
SARS-CoV-2 Transmission Associated with an Indoor Music Event That Required Proof of Full Vaccination Against COVID-19 Prior to Entry—Seattle, July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC494 |
|
| 2022-06-20 |
SARS-CoV-2 infection and seizures: the perfect storm (edit) |
SARSコロナウイルス2 (edit) |
10.31083/J.JIN2104115 |
|
| 2022-06-19 |
Cerebral vasospasm after subarachnoid hemorrhage from intracranial aneurysm rupture in SARS-CoV-2 positive patients. A retrospective review from two Bulgarian hospitals (edit) |
SARSコロナウイルス2 (edit) |
10.1080/13102818.2022.2092421 |
|
| 2022-06-18 |
Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-17 |
QSAR, homology modeling, and docking simulation on SARS-CoV-2 and pseudomonas aeruginosa inhibitors, ADMET, and molecular dynamic simulations to find a possible oral lead candidate (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-17 |
Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVIROMET.2022.114569 |
|
| 2022-06-17 |
A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-31097-7 |
|
| 2022-06-17 |
Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC062 |
35865361 |
| 2022-06-17 |
An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC091 |
35873792 |
| 2022-06-17 |
Electrostatic features for the Receptor binding domain of SARS-COV-2 wildtype and its variants. Compass to the severity of the future variants with the charge-rule (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.06.16.496458 |
|
| 2022-06-17 |
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM1208 |
35608456 |
| 2022-06-17 |
SARS-CoV-2: phenotype, genotype, and characterization of different variants (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S11658-022-00352-6 |
|
| 2022-06-17 |
Early Emergence and Dispersal of Delta SARS-CoV-2 Lineage AY.99.2 in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2022.930380 |
|
| 2022-06-16 |
Narrow transmission bottlenecks and limited within-host viral diversity during a SARS-CoV-2 outbreak on a fishing boat (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC052 |
|
| 2022-06-15 |
De Novo design of potential inhibitors against SARS-CoV-2 Mpro (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-15 |
Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00075-22 |
|
| 2022-06-14 |
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2022.7493 |
|
| 2022-06-14 |
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABQ1841 |
|
| 2022-06-14 |
Spatial Sampling Design to Improve the Efficiency of the Estimation of the Critical Parameters of the SARS-CoV-2 Epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.2478/JOS-2022-0019 |
|
| 2022-06-14 |
SARS-CoV-2 Risk Quantification Model and Validation Based on Large-Scale Dutch Test Events (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19127238 |
|
| 2022-06-13 |
RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-13 |
Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11033-022-07545-4 |
35698014 |
| 2022-06-13 |
Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PH15060744 |
|
| 2022-06-13 |
SARS-CoV-2 IgG Antibody Levels After Inactivated Vaccine (CoronaVac) among Elderly (edit) |
SARSコロナウイルス2 (edit) |
10.36519/IDCM.2022.115 |
|
| 2022-06-12 |
Exploration of potential inhibitors for SARS‐CoV‐2 Mpro considering its mutants via structure‐based drug design, molecular docking, MD simulations, MM/PBSA, and DFT calculations (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BAB.2369 |
|
| 2022-06-12 |
Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11030-022-10468-8 |
35690957 |
| 2022-06-11 |
Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain a conserved rational immunogenic peptide (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-11 |
Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27907 |
|
| 2022-06-11 |
Thrombosis and hemorrhage experienced by hospitalized children with SARS‐CoV‐2 infection or MIS‐C: Results of the PICNIC registry (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PBC.29793 |
|
| 2022-06-11 |
Can machines learn the mutation signatures of SARS-CoV-2 and enable viral-genotype guided predictive prognosis? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2022.167684 |
35700770 |
| 2022-06-11 |
Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-14263-1 |
35690632 |
| 2022-06-10 |
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13073-022-01066-2 |
|
| 2022-06-10 |
High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14061265 |
|
| 2022-06-09 |
Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-09 |
Implementation of Immuno-chemoinformatics Approaches to Construct Multi-epitope for Vaccine Development against Omicron and Delta SARS-CoV-2 Variants Implementación de enfoques inmunoquimioinformáticos para construir múltiples epítopos para la vacun (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-09 |
A diminished immune response underlies age-related SARS-CoV-2 pathologies (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-09 |
Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2022.05.020 |
35716662 |
| 2022-06-09 |
An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VETMIC.2022.109491 |
|
| 2022-06-09 |
Mitigation of SARS-CoV-2 transmission at a large public university (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30833-3 |
|
| 2022-06-09 |
Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12929-022-00823-0 |
|
| 2022-06-08 |
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC082 |
35832867 |
| 2022-06-08 |
A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00685-22 |
|
| 2022-06-08 |
Do SNPs in Glutathione S-Transferase-Omega Allow Predictions of the Susceptibility of Vertebrates to SARS-CoV-2? (edit) |
SARSコロナウイルス2 (edit) |
10.20455/ROS.2022.C805 |
|
| 2022-06-08 |
SARS-CoV-2 Detection Limits in Swab and Gargle Samples by Comparing Antigen and RT-qPCR Testing (edit) |
SARSコロナウイルス2 (edit) |
10.3390/COVID2060056 |
|
| 2022-06-08 |
SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11060662 |
35745516 |
| 2022-06-07 |
Clinical Profiles at the Time of Diagnosis of SARS-CoV-2 Infection in Costa Rica During the Pre-vaccination Period Using a Machine Learning Approach (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-07 |
Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-07 |
Paradoxes of pandemic infection control: Proximity, pace and care within and beyond SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SSMQR.2022.100110 |
|
| 2022-06-07 |
A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TRSL.2022.06.004 |
35688318 |
| 2022-06-07 |
Insight towards the effect of the multi basic cleavage site of SARS-CoV-2 spike protein on cellular proteases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198845 |
|
| 2022-06-07 |
Metagenomic pipeline for identifying co-infections among distinct SARS-CoV-2 variants of concern: study cases from Alpha to Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-13113-4 |
35672431 |
| 2022-06-07 |
SARS-CoV-2 M Protein Facilitates Malignant Transformation of Breast Cancer Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FONC.2022.923467 |
|
| 2022-06-06 |
Insight towards the effect of the multi basic cleavage site of SARS-CoV-2 spike protein on cellular proteases (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-06-06 |
Classification of SARS-CoV-2 viral genome sequences using Neurochaos Learning (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11517-022-02591-3 |
|
| 2022-06-06 |
Wastewater surveillance of SARS-CoV-2 in dormitories as a part of comprehensive university campus COVID-19 monitoring (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2022.113580 |
35671797 |
| 2022-06-06 |
Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41398-022-01985-Z |
|
| 2022-06-06 |
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30878-4 |
35668119 |
| 2022-06-06 |
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSIF.2021.0900 |
35670221 |
| 2022-06-06 |
Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.74443 |
|
| 2022-06-05 |
Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13062-022-00325-X |
35658928 |
| 2022-06-05 |
Development of Nested PCR for SARS-CoV-2 Detection and Its Application for Diagnosis of Active Infection in Cats (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VETSCI9060272 |
|
| 2022-06-04 |
In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13258-022-01255-8 |
35665465 |
| 2022-06-04 |
Appearance and re-appearance of zoonotic disease during the pandemic period: long-term monitoring and analysis of zoonosis is crucial to confirm the animal origin of SARS-CoV-2 and monkeypox virus (edit) |
SARSコロナウイルス2 (edit) |
10.1080/01652176.2022.2086718 |
|
| 2022-06-03 |
Manufacturer Signal-to-Cutoff Threshold Underestimates Cumulative Incidence of SARS-CoV-2 Infection: Evidence from the Los Angeles Firefighters Study (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JALM/JFAC034 |
|
| 2022-06-03 |
Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0268919 |
|
| 2022-06-03 |
The impact of pre-existing thyroid diseases on susceptibility to respiratory infections or self-reported sickness during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.20945/2359-3997000000436 |
|
| 2022-06-02 |
Identification of conserved regions from 230,163 SARS-CoV-2 genomes and their use in diagnostic PCR primer design (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13258-022-01264-7 |
35653026 |
| 2022-06-02 |
Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TRF.16934 |
|
| 2022-06-02 |
Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures (edit) |
SARSコロナウイルス2 (edit) |
10.1183/13993003.01881-2021 |
34675048 |
| 2022-06-02 |
Emergency SARS-CoV-2 variants of concern: rapidly direct RT-qPCR detection without RNA extraction, clinical comparison, cost-effective, and high-throughput (edit) |
SARSコロナウイルス2 (edit) |
10.18632/AGING.204095 |
|
| 2022-06-02 |
Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins—A Possible Signature of Adaptive Selection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2022.875406 |
|
| 2022-06-02 |
A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.889643 |
|
| 2022-06-02 |
A Universal Fluorescent Immunochromatography Assay Based on Quantum Dot Nanoparticles for the Rapid Detection of Specific Antibodies against SARS-CoV-2 Nucleocapsid Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23116225 |
|
| 2022-06-01 |
Precision health diagnostic and surveillance network uses S gene target failure (SGTF) combined with sequencing technologies to track emerging SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1002/IID3.634 |
35634961 |
| 2022-06-01 |
The Ministry of Religious Congregations to People Affected by the SARS-CoV-2 Coronavirus in Poland: Geographies of Care During the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10943-022-01570-0 |
35484437 |
| 2022-06-01 |
Diabetes and COVID-19: a bitter nightmare (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40200-022-00994-5 |
35284345 |
| 2022-06-01 |
Experiences from the management of COVID-19 pandemic in a nursing home in Iran (March-April, 2020) (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40200-022-01005-3 |
35317104 |
| 2022-06-01 |
Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBIOSY.2022.100042 |
|
| 2022-06-01 |
Approaches to Deployment of Molecular Testing for SARS-CoV-2 in Resource-Limited Settings (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLL.2022.02.008 |
|
| 2022-06-01 |
SARS-CoV-2 triggering autoimmune diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CYTO.2022.155873 |
35461172 |
| 2022-06-01 |
Decontamination of SARS-CoV-2 from cold-chain food packaging provides no marginal benefit in risk reduction to food workers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FOODCONT.2022.108845 |
|
| 2022-06-01 |
Ongoing positive selection drives the evolution of SARS-CoV-2 genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GPB.2022.05.009 |
|
| 2022-06-01 |
SARS-CoV-2 cycle threshold (Ct) values predict future COVID-19 cases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2022.105153 |
|
| 2022-06-01 |
The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JLR.2022.100208 |
35436499 |
| 2022-06-01 |
WITHDRAWN: Elevated histamine etiology model for most major vaccine associated adverse events including SARS-CoV-2 spike vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110893 |
|
| 2022-06-01 |
Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NANTOD.2022.101499 |
|
| 2022-06-01 |
Perception of the SARS-CoV-2 pandemic by pregnant women during the first lockdown in France: worry, perceived vulnerability, adoption and maintenance of prevention measures according to the Covimater study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PMEDR.2022.101807 |
|
| 2022-06-01 |
Perceptions of the ethical permissibility of strict travel restrictions to mitigate transmission of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TRIP.2022.100577 |
|
| 2022-06-01 |
Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(22)00941-2 |
|
| 2022-06-01 |
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(22)00224-9 |
|
| 2022-06-01 |
IMPACT OF HYPERTENSION AS AN ADDITIONAL RISK FACTOR IN CARDIORESPIRATORY STATUS OF POST SARS-COV-2 INFECTED SUBJECTS (edit) |
SARSコロナウイルス2 (edit) |
10.1097/01.HJH.0000837180.39534.C1 |
|
| 2022-06-01 |
The importance of the generation interval in investigating dynamics and control of new SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSIF.2022.0173 |
35702867 |
| 2022-06-01 |
Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities (edit) |
SARSコロナウイルス2 (edit) |
10.1136/OEMED-2021-107487 |
34740981 |
| 2022-06-01 |
Relationship between SARS-CoV-2 and hearing loss: A mini-review (edit) |
SARSコロナウイルス2 (edit) |
10.1177/20101058221139957 |
|
| 2022-06-01 |
The level of depressive, anxiety and obsessive-compulsive psychopathological dimensions in symptomatic versus asymptomatic SARS-CoV-2 infected pregnant women (edit) |
SARSコロナウイルス2 (edit) |
10.1192/J.EURPSY.2022.1372 |
|
| 2022-06-01 |
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2806.212580 |
|
| 2022-05-31 |
In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-31 |
Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11030-022-10459-9 |
35639226 |
| 2022-05-31 |
Atomic-Resolution Structure of SARS-CoV-2 Nucleocapsid Protein N-Terminal Domain (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.2C03320 |
35638584 |
| 2022-05-31 |
High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-12032-8 |
35641545 |
| 2022-05-31 |
Mask wearing in community settings reduces SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2119266119 |
|
| 2022-05-31 |
Aerosol particle emission increases exponentially above moderate exercise intensity resulting in superemission during maximal exercise (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2202521119 |
35605123 |
| 2022-05-31 |
Genome Sequencing of Omicron Variants of SARS-CoV-2 Circulating in Bangladesh during the Third Wave of the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MRA.00381-22 |
|
| 2022-05-31 |
Analysis of SARS-CoV-2 High Infection Spread in India Based on SIRD Model and Structural Insights (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3523286.3524574 |
|
| 2022-05-31 |
Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010160 |
|
| 2022-05-31 |
Seeking antiviral drugs to inhibit SARS-CoV-2 RNA dependent RNA polymerase: A molecular docking analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0268909 |
35639751 |
| 2022-05-31 |
Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0269249 |
35639708 |
| 2022-05-31 |
Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10060850 |
|
| 2022-05-30 |
Phytochemistry, biological activities and in silico molecular docking studies of Oxalis pes-caprae L. compounds against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-30 |
Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S44197-022-00041-9 |
35635641 |
| 2022-05-30 |
Early detection and improved genomic surveillance of SARS-CoV-2 variants from deep sequencing data (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104487 |
35677393 |
| 2022-05-30 |
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-022-01135-7 |
35637329 |
| 2022-05-30 |
Cell response analysis in SARS-CoV-2 infected bronchial organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03499-2 |
35637255 |
| 2022-05-30 |
Vaccines Associated Cardiac Adverse Events, Including SARS-Cov-2 Myocarditis, Elevated Histamine Etiology Hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.54289/JVVD2200108 |
|
| 2022-05-29 |
Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-29 |
A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RVSC.2022.05.003 |
|
| 2022-05-29 |
Could the SARS-CoV-2 Outbreak Cause An Increase In Rickettsia Infection? North Cyprus Observation (edit) |
SARSコロナウイルス2 (edit) |
10.19127/MBSJOHS.1082154 |
|
| 2022-05-28 |
GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYMED.2022.154215 |
|
| 2022-05-28 |
Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-022-01827-W |
35643510 |
| 2022-05-27 |
Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-27 |
Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110952 |
35675811 |
| 2022-05-27 |
Transmission of SARS-CoV-2 from humans to animals and potential host adaptation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30698-6 |
35624123 |
| 2022-05-27 |
The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABO5083 |
35622909 |
| 2022-05-27 |
Assessing the impact of lateral flow testing strategies on within-school SARS-CoV-2 transmission and absences: A modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010158 |
|
| 2022-05-27 |
Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County—Results from a Population-Based Longitudinal Study in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14061168 |
|
| 2022-05-27 |
The COVID-19 pandemic: SARS-CoV-2, childhood hepatitis and monkeypox raise five new questions for the global health research community (edit) |
SARSコロナウイルス2 (edit) |
10.7189/JOGH.12.01002 |
|
| 2022-05-26 |
Parsing the role of NSP1 in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-26 |
Genomic surveillance of SARS-CoV-2 in a university community: insights into tracking variants, transmission, and spread of Gamma (P.1) variant (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-26 |
Reverse-zoonotic transmission of SARS-CoV-2 lineage alpha (B.1.1.7) to great apes and exotic felids in a zoo in the Czech Republic (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-022-05469-9 |
|
| 2022-05-26 |
Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVIROMET.2022.114553 |
|
| 2022-05-26 |
Incidence of SARS-CoV-2 over four epidemic waves in a low-resource community in Rio de Janeiro, Brazil: A prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2022.100283 |
|
| 2022-05-26 |
The emergence of variants with increased fitness accelerates the slowdown of genome sequence heterogeneity in the SARS-CoV-2 coronavirus (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.05.26.493529 |
|
| 2022-05-26 |
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PMED.1003987 |
35617363 |
| 2022-05-26 |
Excess Mortality on Italian Small Islands during the SARS-CoV-2 Pandemic: An Ecological Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IDR14030043 |
|
| 2022-05-25 |
Single-cell RNA sequencing reveals immunological rewiring at the maternal-fetal interface following asymptomatic/mild SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-25 |
A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00253-022-11988-X |
35612630 |
| 2022-05-25 |
SARS-CoV-2 transmission from infected owner to household dogs and cats is associated to food sharing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.05.049 |
35643308 |
| 2022-05-25 |
Long COVID after breakthrough SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-01840-0 |
|
| 2022-05-25 |
Quantitative and ultrasensitive in situ immunoassay technology for SARS-CoV-2 detection in saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABN3481 |
35613342 |
| 2022-05-25 |
Importance of the Precautionary Principle With Regard to the Risk of Exposure to Aerosols Containing Viral Loads of SARS-CoV-2 Present in Feces: In Perspective (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.892290 |
|
| 2022-05-24 |
SPIKES: Identification of physicochemical properties of spike proteins across diverse host species of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-24 |
Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-022-05483-X |
35606466 |
| 2022-05-24 |
Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S0950268822000966 |
35607808 |
| 2022-05-24 |
Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABQ4411 |
|
| 2022-05-24 |
The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266015 |
35609027 |
| 2022-05-24 |
Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0268389 |
35609034 |
| 2022-05-24 |
Epidemiological, virological and clinical features of SARS-CoV-2 among individuals during the first wave in Cameroon: Baseline analysis for the EDCTP PERFECT-Study RIA2020EF-3000 (edit) |
SARSコロナウイルス2 (edit) |
10.4081/JPHIA.2022.2142 |
|
| 2022-05-24 |
SARS-CoV-2 and the Vaccination Hype (edit) |
SARSコロナウイルス2 (edit) |
10.56098/IJVTPR.V2I1.34 |
|
| 2022-05-23 |
The effect of the probiotic consortia on SARS-CoV-2 infection in ferrets and on human immune cell response in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104445 |
35634575 |
| 2022-05-23 |
AB1163 ATTITUDES AND HESITANCY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES TOWARDS SARS-CoV-2 VACCINATION: A SINGLE-CENTER STUDY FROM BULGARIA (edit) |
SARSコロナウイルス2 (edit) |
10.1136/ANNRHEUMDIS-2022-EULAR.4447 |
|
| 2022-05-23 |
Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-022-13464-7 |
35606743 |
| 2022-05-23 |
Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0268093 |
35604947 |
| 2022-05-23 |
Characterization of the Interaction Between SARS-CoV-2 Membrane Protein (M) and Proliferating Cell Nuclear Antigen (PCNA) as a Potential Therapeutic Target (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.849017 |
35677658 |
| 2022-05-22 |
E2UbcH5B-derived peptide ligands target HECT E3-E2 binding site and block the Ub-dependent SARS-CoV-2 egression: A computational study (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-22 |
In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23105810 |
35628622 |
| 2022-05-21 |
チキサゲビマブおよびシルガビマブ (エバシェルド) は、B細胞除去剤による多発性硬化症患者のSARS-CoV-2に対する抗体レベルを高める (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MSARD.2022.103905 |
35661563 |
| 2022-05-20 |
Whole-genome sequencing of SARS-CoV-2 reveals diverse mutations in circulating Alpha and Delta variants during the first, second, and third waves of COVID-19 in South Kivu, east of the Democratic Republic of the Congo (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.05.041 |
35598737 |
| 2022-05-20 |
Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCONREL.2022.05.023 |
35577151 |
| 2022-05-20 |
A new RT-LAMP-on-a-Chip Instrument for SARS-CoV-2 diagnostics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICROC.2022.107600 |
35620142 |
| 2022-05-20 |
Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2022.04.014 |
35609600 |
| 2022-05-20 |
Lebanese SARS-CoV-2 genomics: 24 months of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198824 |
|
| 2022-05-20 |
Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2022.2076154 |
|
| 2022-05-20 |
Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050813 |
35632569 |
| 2022-05-19 |
Low expression of TMPRSS2-a SARS-CoV-2 internalization protease-associates with basal subtype of head and neck squamous cell carcinoma (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TRANON.2022.101458 |
35607455 |
| 2022-05-19 |
SARS-CoV-2 delta variant infection in domestic dogs and cats, Thailand (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-12468-Y |
35589808 |
| 2022-05-19 |
Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2202012119 |
35588457 |
| 2022-05-19 |
Clinical Validation of a Rapid Variant-Proof RT-RPA Assay for the Detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS12051263 |
|
| 2022-05-19 |
Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NANO12101735 |
35630957 |
| 2022-05-19 |
Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.75791 |
|
| 2022-05-19 |
Identification of vaccine targets & design of vaccine against SARS-CoV-2 coronavirus using computational and deep learning-based approaches (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13380 |
35611169 |
| 2022-05-18 |
Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104431 |
35607524 |
| 2022-05-18 |
Paving the way to point of care (POC) devices for SARS-CoV-2 detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TALANTA.2022.123542 |
35609482 |
| 2022-05-18 |
Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30518-X |
35585202 |
| 2022-05-18 |
Validation of a COVID-19 Job Exposure Matrix (COVID-19-JEM) for Occupational Risk of a SARS-CoV-2 Infection at Work: Using Data of Dutch Workers (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ANNWEH/WXAC032 |
35583140 |
| 2022-05-18 |
Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2022/8551576 |
|
| 2022-05-18 |
Distinguishing Admissions Specifically for COVID-19 From Incidental SARS-CoV-2 Admissions: National Retrospective Electronic Health Record Study (edit) |
SARSコロナウイルス2 (edit) |
10.2196/37931 |
35476727 |
| 2022-05-18 |
A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.820336 |
35663966 |
| 2022-05-18 |
Natural Polyphenols, 1,2,3,4,6-O-Pentagalloyglucose and Proanthocyanidins, as Broad-Spectrum Anticoronaviral Inhibitors Targeting Mpro and RdRp of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES10051170 |
35625907 |
| 2022-05-18 |
Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PH15050620 |
35631446 |
| 2022-05-18 |
Detecting Potentially Adaptive Mutations from the Parallel and Fixed Patterns in SARS-CoV-2 Evolution (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051087 |
35632828 |
| 2022-05-17 |
The impacts of gradually terminating nonpharmaceutical interventions for SARS-CoV-2: A mathematical modelling analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FMRE.2022.05.007 |
|
| 2022-05-17 |
Spectral and theoretical study of SARS-CoV-2 ORF10 protein interaction with endogenous and exogenous macroheterocyclic compounds (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SAA.2022.121403 |
35617836 |
| 2022-05-17 |
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100651 |
35654046 |
| 2022-05-17 |
Inactivation of SARS-CoV-2 by a chitosan/α-Ag2WO4 composite generated by femtosecond laser irradiation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-11902-5 |
35581241 |
| 2022-05-17 |
Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2123000119 |
35580180 |
| 2022-05-17 |
NGS data vectorization, clustering, and finding key codons in SARS-CoV-2 variations (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12859-022-04718-7 |
35581558 |
| 2022-05-17 |
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-022-00794-7 |
35581593 |
| 2022-05-17 |
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.883612 |
35655773 |
| 2022-05-17 |
Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19106110 |
|
| 2022-05-17 |
Molecular Analysis of SARS-CoV-2 Lineages in Armenia (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051074 |
35632815 |
| 2022-05-17 |
The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050794 |
35632550 |
| 2022-05-16 |
IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110904 |
35617962 |
| 2022-05-16 |
Multifaceted membrane binding head of the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRSTBI.2022.05.001 |
35602928 |
| 2022-05-16 |
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04856-1 |
|
| 2022-05-16 |
Development of a new antigen-based microarray platform for screening and detection of human IgG antibodies against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10823-7 |
35577791 |
| 2022-05-16 |
SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC) (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-11956-5 |
35577837 |
| 2022-05-16 |
RT-qPCR-based tests for SARS-CoV-2 detection in pooled saliva samples for massive population screening to monitor epidemics (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-12179-4 |
|
| 2022-05-16 |
Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12859-022-04724-9 |
35578172 |
| 2022-05-16 |
Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epidemic Season in Poland (edit) |
SARSコロナウイルス2 (edit) |
10.12659/MSM.936495 |
|
| 2022-05-16 |
Appropriate relaxation of non-pharmaceutical interventions minimizes the risk of a resurgence in SARS-CoV-2 infections in spite of the Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010054 |
|
| 2022-05-16 |
Six Feet under Microbiota: Microbiologic Contamination and Toxicity Profile in Three Urban Cemeteries from Lisbon, Portugal (edit) |
SARSコロナウイルス2 (edit) |
10.3390/TOXINS14050348 |
35622594 |
| 2022-05-16 |
Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050786 |
35632541 |
| 2022-05-14 |
Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107692 |
|
| 2022-05-14 |
Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? (edit) |
SARSコロナウイルス2 (edit) |
10.7189/JOGH.12.03023 |
|
| 2022-05-13 |
How Does Temperature Affect the Dynamics of SARS-CoV-2 M Proteins? Insights from Molecular Dynamics Simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00232-022-00244-Y |
35552785 |
| 2022-05-13 |
Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NEUROL.2022.03.014 |
35610098 |
| 2022-05-13 |
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2468-1253(22)00166-2 |
|
| 2022-05-13 |
Testing Affordable Strategies for the Computational Study of Reactivity in Cysteine Proteases: The Case of SARS-CoV-2 3CL Protease Inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.2C00294 |
|
| 2022-05-13 |
Correction to “Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern” (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.2C00364 |
|
| 2022-05-13 |
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S10020-022-00484-7 |
35562666 |
| 2022-05-13 |
Lactoferrin Inhibition of the Complex Formation between ACE2 Receptor and SARS CoV-2 Recognition Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23105436 |
35628247 |
| 2022-05-13 |
Clearance of Persistent SARS-CoV-2 RNA Detection in a NFκB-Deficient Patient in Association with the Ingestion of Human Breast Milk: A Case Report (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051042 |
35632784 |
| 2022-05-12 |
SARS-CoV-2 RNA and N Antigen Quantification via Wastewater at the Campus Level, Building Cluster Level, and Individual-Building Level (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-05-12 |
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00044-022-02903-0 |
35578732 |
| 2022-05-12 |
Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2022.166432 |
35568352 |
| 2022-05-12 |
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMET.2022.04.009 |
35561674 |
| 2022-05-12 |
Transmembrane Protease Serine 2 Proteolytic Cleavage of the SARS-CoV-2 Spike Protein: A Mechanistic Quantum Mechanics/Molecular Mechanics Study to Inspire the Design of New Drugs To Fight the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C01561 |
35549216 |
| 2022-05-12 |
Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral Duva florida, Displays Inhibition of the SARS-CoV-2 3CLpro Enzyme (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JNATPROD.2C00054 |
|
| 2022-05-12 |
The role of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04835-6 |
35551511 |
| 2022-05-12 |
Human-to-dog transmission of SARS-CoV-2, Colombia (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-11847-9 |
35551247 |
| 2022-05-12 |
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2120976119 |
35549549 |
| 2022-05-12 |
Structural dynamics of SARS-CoV-2 nucleocapsid protein induced by RNA binding (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010121 |
35551296 |
| 2022-05-12 |
B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051031 |
35632772 |
| 2022-05-12 |
Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050763 |
|
| 2022-05-12 |
Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050772 |
35632528 |
| 2022-05-11 |
Mechanisms underlying inactivation of SARS-CoV-2 by nano-sized electrostatic atomized water particles (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11051-022-05485-5 |
35573750 |
| 2022-05-11 |
Hybrid drug-screening strategy identifies potential SARS-CoV-2 cell-entry inhibitors targeting human transmembrane serine protease (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11224-022-01960-W |
35571866 |
| 2022-05-11 |
Consensus Receptor-Binding Domain-Targeted Aptamer Selection and Designing of a Photonic Crystal-Decorated Aptasensor for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.2C00937 |
35544380 |
| 2022-05-11 |
SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00594-22 |
35543509 |
| 2022-05-11 |
Shared genetic background between SARS-CoV-2 infection and large artery stroke (edit) |
SARSコロナウイルス2 (edit) |
10.1177/17474930221095696 |
|
| 2022-05-11 |
Assessing of Humoral Immunity to SARS-COV-2 in Residents of Orenburg During the Epidemic Period (edit) |
SARSコロナウイルス2 (edit) |
10.31631/20733046-2022-21-2-17-22 |
|
| 2022-05-11 |
The Biological Interaction of SARS-CoV-2 Infection and Osteoporosis: A Preliminary Study (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2022.917907 |
35646907 |
| 2022-05-11 |
Phase Separation Drives SARS-CoV-2 Replication: A Hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.893067 |
|
| 2022-05-11 |
Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051020 |
|
| 2022-05-11 |
Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14051029 |
35632769 |
| 2022-05-10 |
Mutations in the nonstructural proteins of SARS-CoV-2 may contribute to adverse clinical outcome in patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.05.010 |
35562044 |
| 2022-05-10 |
Phylogenetic and amino acid signature analysis of the SARS-CoV-2s lineages circulating in Tunisia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2022.105300 |
35552003 |
| 2022-05-10 |
Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30163-4 |
35538074 |
| 2022-05-10 |
Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.877813 |
35620103 |
| 2022-05-10 |
Sample Buffer Containing Guanidine-Hydrochloride Combines Biological Safety and RNA Preservation for SARS-CoV-2 Molecular Diagnostics (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS12051186 |
|
| 2022-05-09 |
Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2022.10880 |
|
| 2022-05-09 |
SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30195-W |
35534483 |
| 2022-05-09 |
A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42255-022-00567-Z |
|
| 2022-05-09 |
At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07377-4 |
35534836 |
| 2022-05-09 |
Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PGPH.0000412 |
|
| 2022-05-09 |
Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.876306 |
35615365 |
| 2022-05-09 |
Insights into the Antimicrobial, Antioxidant, Anti-SARS-CoV-2 and Cytotoxic Activities of Pistacia lentiscus Bark and Phytochemical Profile; In Silico and In Vitro Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX11050930 |
35624793 |
| 2022-05-09 |
The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response (edit) |
SARSコロナウイルス2 (edit) |
10.7150/THNO.73268 |
35664076 |
| 2022-05-08 |
Longitudinal analyses reveal distinct immune response landscapes in lung and intestinal tissues from SARS-CoV-2-infected rhesus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110864 |
35594870 |
| 2022-05-08 |
ADAM10 and ADAM17 promote SARS‐CoV‐2 cell entry and spike protein‐mediated lung cell fusion (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBR.202154305 |
35527514 |
| 2022-05-08 |
SARS-CoV-2 Envelope (E) Protein Binds and Activates TLR2 Pathway: A Novel Molecular Target for COVID-19 Interventions (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14050999 |
35632741 |
| 2022-05-07 |
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07418-Y |
35525973 |
| 2022-05-07 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11050551 |
|
| 2022-05-06 |
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.104025 |
35533497 |
| 2022-05-06 |
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2022.04.025 |
35526097 |
| 2022-05-06 |
Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30219-5 |
35523782 |
| 2022-05-06 |
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN4947 |
35289632 |
| 2022-05-06 |
Rapid response modeling of SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABP9498 |
|
| 2022-05-06 |
RHAMNETIN IS A BETTER INHIBITOR OF SARS-COV-2 2'-O-METHYLTRANSFERASE THAN DOLUTEGRAVIR: A COMPUTATIONAL PREDICTION (edit) |
SARSコロナウイルス2 (edit) |
10.21010/AJID.V16I2.9 |
35582066 |
| 2022-05-06 |
Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.884433 |
35603198 |
| 2022-05-06 |
Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2022.864972 |
|
| 2022-05-06 |
Determining the Efficacy of Various Governmental Interventions in Stemming the Spread of SARS-CoV-2 in Seven Locations (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.828090 |
|
| 2022-05-06 |
O efeito do vírus SARS-CoV-2 na audição de pacientes adultos / The effect of the SARS-CoV-2 virus on hearing in adult patients (edit) |
SARSコロナウイルス2 (edit) |
10.34119/BJHRV5N3-066 |
|
| 2022-05-05 |
Effects of spike protein and toxin-like peptides found in COVID-19 patients on human 3D neuronal/glial model undergoing differentiation: Possible implications for SARS-CoV-2 impact on brain development (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REPROTOX.2022.04.011 |
35525527 |
| 2022-05-05 |
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14992027.2022.2056721 |
|
| 2022-05-04 |
Synthesis, antimicrobial, molecular docking and molecular dynamics studies of lauroyl thymidine analogs against SARS-CoV-2: POM study and identification of the pharmacophore sites (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOORG.2022.105850 |
35533581 |
| 2022-05-04 |
Oral dysbiosis and its linkage with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICRES.2022.127055 |
35597076 |
| 2022-05-04 |
Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-30134-9 |
35508460 |
| 2022-05-04 |
Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-11103-0 |
|
| 2022-05-04 |
Comparison of the Prevalence of Antibodies to SARS-CoV-2 in 9954 Recruits in the Korean Army Training Center with the General Korean Population of Equivalent Age Between September and November, 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.12659/MSM.934926 |
35505583 |
| 2022-05-04 |
A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.855230 |
35603150 |
| 2022-05-04 |
Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.868724 |
35603169 |
| 2022-05-03 |
TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100640 |
35588734 |
| 2022-05-03 |
Nationwide Trends in COVID-19 Cases and SARS-CoV-2 RNA Wastewater Concentrations in the United States (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSESTWATER.1C00434 |
|
| 2022-05-03 |
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10987-2 |
35505068 |
| 2022-05-03 |
Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.807104 |
35592326 |
| 2022-05-02 |
Intensification of an Essential Tremor by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12311-022-01409-0 |
|
| 2022-05-02 |
Reply to “Intensification of an Essential Tremor by SARS-CoV-2” (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12311-022-01410-7 |
|
| 2022-05-02 |
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.04.035 |
35568035 |
| 2022-05-02 |
SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2022.109027 |
35513305 |
| 2022-05-02 |
Prediction of binding miRNAs involved with immune genes to the SARS-CoV-2 by using sequence features extraction and One-class SVM (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2022.100958 |
35528315 |
| 2022-05-02 |
Predictive Ability of the MEWS, REMS, and RAPS in Geriatric Patients With SARS-CoV-2 Infection in the Emergency Department (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.107 |
|
| 2022-05-02 |
SARS-CoV-2 omicron variant and the future of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.12968/DENU.2022.49.5.432 |
|
| 2022-05-01 |
Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JHA2.407 |
35602246 |
| 2022-05-01 |
Prospective Pilot Study Evaluating SARS-CoV-2 Transmission-Limiting Measures in an On-Site School (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACAP.2021.11.019 |
|
| 2022-05-01 |
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110829 |
|
| 2022-05-01 |
Vocal cord dysfunction/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (COVID-19) vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAIP.2022.02.025 |
|
| 2022-05-01 |
Calcitonin gene-related peptide: A biomarker for stroke in SARS-CoV-2 infection? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110807 |
|
| 2022-05-01 |
Pasteurization, storage conditions and viral concentration methods influence RT-qPCR detection of SARS-CoV-2 RNA in wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153228 |
|
| 2022-05-01 |
Factors influencing SARS-CoV-2 RNA concentrations in wastewater up to the sampling stage: A systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153290 |
|
| 2022-05-01 |
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2022.01.024 |
|
| 2022-05-01 |
Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0016-5085(22)63690-4 |
|
| 2022-05-01 |
Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41385-022-00511-0 |
35468942 |
| 2022-05-01 |
Reducing occupational exposure to SARS-CoV-2: a survey of changes in caseload and controls among medical examiner and coroners' offices in Pennsylvania during 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/15459624.2022.2050740 |
35254951 |
| 2022-05-01 |
Use of DFT Distance Metrics for Classification of SARS-CoV-2 Genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1089/CMB.2021.0229 |
|
| 2022-05-01 |
Unheeded SARS-CoV-2 proteins? A deep look into negative-sense RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BIB/BBAC045 |
35229157 |
| 2022-05-01 |
Risk of Healthcare-Associated Transmission of Sever Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Hospitalized Cancer Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB670 |
34329418 |
| 2022-05-01 |
Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers (edit) |
SARSコロナウイルス2 (edit) |
10.1093/GIGASCIENCE/GIAC045 |
35639883 |
| 2022-05-01 |
Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC045 |
36382127 |
| 2022-05-01 |
Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC049 |
35783502 |
| 2022-05-01 |
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC058 |
36713311 |
| 2022-05-01 |
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC067 |
36713328 |
| 2022-05-01 |
The Effect of Glycosylation Modulators on the Trafficking and Interaction of Spike Protein S1 Subunit and Angiotensin‐Converting Enzyme 2 (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R3340 |
|
| 2022-05-01 |
Synthesis of the transmembrane domain of the accessory protein ORF7a of SARS‐CoV‐2 using solid phase peptide synthesis and analyzing the oligomerization state (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R3870 |
|
| 2022-05-01 |
Variation in ORF3a Protein of SARS‐CoV‐2 Decreases The Severity of Host Cell Damage (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R4149 |
|
| 2022-05-01 |
Folding of the SARS‐CoV‐2 RNA Polymerase by the Cytosolic Chaperonin CCT (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R4318 |
|
| 2022-05-01 |
Recognition and Cleavage of Human tRNA Methyltransferase TRMT1 by the SARS‐CoV‐2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R4632 |
|
| 2022-05-01 |
Protease Activated Receptor‐2 (PAR‐2) Antagonist potentially ameliorates the SARS‐CoV‐2 virus‐induced Inflammatory Storm (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FASEBJ.2022.36.S1.R6372 |
|
| 2022-05-01 |
Immunological heterogeneity informs estimation of the durability of vaccine protection (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSIF.2022.0070 |
35611620 |
| 2022-05-01 |
Source terms for benchmarking models of SARS-CoV-2 transmission via aerosols and droplets (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.212022 |
|
| 2022-05-01 |
SARS-CoV-2 B.1.1.7 variant of concern detected in a pet dog and cat after exposure to a person with COVID-19, USA (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14122 |
33955193 |
| 2022-05-01 |
Human phospho-signaling networks of SARS-CoV-2 infection are rewired by population genetic variants (edit) |
SARSコロナウイルス2 (edit) |
10.15252/MSB.202110823 |
35579274 |
| 2022-05-01 |
Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1530/JME-21-0282 |
35521990 |
| 2022-05-01 |
SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1681/ASN.2021121587 |
|
| 2022-05-01 |
In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro) (edit) |
SARSコロナウイルス2 (edit) |
10.3390/COMPUTATION10050069 |
|
| 2022-05-01 |
Positive effects of the decrease of hydraulic dredging due to the SARS-CoV-2 pandemic on benthic fauna and clam harvesting in the northern Adriatic (Mediterranean Sea) (edit) |
SARSコロナウイルス2 (edit) |
10.35800/JASM.V10I1.37485 |
|
| 2022-05-01 |
Development of a multi-epitope spike glycoprotein vaccine to combat SARS-CoV-2 using the bioinformatics approach (edit) |
SARSコロナウイルス2 (edit) |
10.56499/JPPRES21.1210_10.3.445 |
|
| 2022-04-30 |
A new approach for determining SARS-CoV-2 epitopes using machine learning-based in silico methods (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107688 |
|
| 2022-04-29 |
Computational study and design of effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107687 |
|
| 2022-04-29 |
SARS-CoV-2 and other airborne respiratory viruses in outdoor aerosols in three Swiss cities before and during the first wave of the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVINT.2022.107266 |
35512527 |
| 2022-04-29 |
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTM.2022.04.013 |
35506060 |
| 2022-04-29 |
In silico evidence of antiviral activity against SARS-CoV-2 main protease of oligosaccharides from Porphyridium sp (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.155580 |
35500710 |
| 2022-04-29 |
Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-022-00409-Y |
35487885 |
| 2022-04-29 |
Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266958 |
35486622 |
| 2022-04-29 |
Wpływ pandemii Sars-CoV-2 na postrzeganie idei „Slow Food” przez studentów (edit) |
SARSコロナウイルス2 (edit) |
10.15199/65.2022.4.6 |
|
| 2022-04-29 |
Investigation of changes in protein stability and substrate affinity of 3CL-protease of SARS-CoV-2 caused by mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1590/1678-4685-GMB-2021-0404 |
35499274 |
| 2022-04-29 |
Would New SARS-CoV-2 Variants Change the War against COVID-19? (edit) |
SARSコロナウイルス2 (edit) |
10.3390/EPIDEMIOLOGIA3020018 |
36417254 |
| 2022-04-29 |
Could SARS-CoV-2 Have Bacteriophage Behavior or Induce the Activity of Other Bacteriophages? (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050708 |
35632464 |
| 2022-04-28 |
Comparative Analysis of RNA-Extraction Approaches and Associated Influences on RT-qPCR of the SARS-CoV-2 RNA in a University Residence Hall and Quarantine Location (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-04-28 |
SARS‐CoV‐2‐specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID‐19 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1002/EJI.202149771 |
|
| 2022-04-28 |
In silico bioprospecting of taraxerol as a main protease inhibitor of SARS-CoV-2 to develop therapy against COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11224-022-01943-X |
35502321 |
| 2022-04-28 |
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.03.038 |
35447072 |
| 2022-04-28 |
Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.2C02203 |
35530749 |
| 2022-04-28 |
Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41587-022-01280-8 |
|
| 2022-04-28 |
Circulating microRNA profiling is altered in the acute respiratory distress syndrome related to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10738-3 |
35484171 |
| 2022-04-28 |
All hands on deck: A multidisciplinary approach to SARS-CoV-2-associated MIS-C (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PCH/PXAB110 |
35620558 |
| 2022-04-28 |
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC042 |
36713312 |
| 2022-04-28 |
Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABO0718 |
35482820 |
| 2022-04-28 |
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010465 |
35482816 |
| 2022-04-28 |
The determination of haemagglutinin influenza antibodies in the Polish population in the epidemic season 2020/2021 during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.18388/ABP.2020_6015 |
|
| 2022-04-28 |
EU-Funded Telemedicine Projects – Assessment of, and Lessons Learned From, in the Light of the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2022.849998 |
|
| 2022-04-28 |
Impact of SARS-CoV-2 Mutations on PCR Assay Sequence Alignment (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.889973 |
35570946 |
| 2022-04-28 |
Do the Successive Waves of SARS-CoV-2, Vaccination Status and Place of Infection Influence the Clinical Picture and COVID-19 Severity among Patients with Persistent Clinical Symptoms? The Retrospective Study of Patients from the STOP-COVID Registry o (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JPM12050706 |
|
| 2022-04-27 |
Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105552 |
35508082 |
| 2022-04-27 |
Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104309 |
35502319 |
| 2022-04-27 |
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-00987-Z |
35478188 |
| 2022-04-27 |
Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10510-7 |
35477954 |
| 2022-04-27 |
Adenovirus 5 Vectors Expressing SARS-CoV-2 Proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00998-21 |
|
| 2022-04-27 |
Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Detect a SARS-CoV-2 Antibody Response (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01405-21 |
35266818 |
| 2022-04-27 |
First Identification of Reinfection by a Genetically Different Variant of SARS-CoV-2 in a Homeless Person from the Metropolitan Area of Santiago, Chile (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2022/3859071 |
35528635 |
| 2022-04-27 |
Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0263316 |
|
| 2022-04-27 |
ECG Utilization Patterns of Patients With Arrhythmias During COVID-19 Epidemic and Post-SARS-CoV-2 Eras in Shanghai, China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCVM.2022.829679 |
|
| 2022-04-27 |
Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PH15050539 |
35631364 |
| 2022-04-27 |
Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a Scaffold (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PH15050540 |
35631367 |
| 2022-04-26 |
SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.04.030 |
35495107 |
| 2022-04-26 |
Detection of SARS-CoV-2 in the air in Indian hospitals and houses of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAEROSCI.2022.106002 |
35495416 |
| 2022-04-26 |
In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2022.102049 |
35493709 |
| 2022-04-26 |
Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100634 |
35561673 |
| 2022-04-26 |
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-00992-2 |
|
| 2022-04-26 |
Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7117E3 |
35482574 |
| 2022-04-26 |
Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES10050996 |
35625733 |
| 2022-04-26 |
Chronic Exposure to the Food Additive tBHQ Modulates Expression of Genes Related to SARS-CoV-2 and Influenza Viruses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE12050642 |
35629310 |
| 2022-04-26 |
SARS-CoV-2 Omicron Variant in Croatia-Rapid Detection of the First Case and Cross-Border Spread (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11050511 |
35631032 |
| 2022-04-25 |
Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27789 |
35467028 |
| 2022-04-25 |
Genetic differentiation and diversity of SARS-CoV-2 omicron variant in Its early outbreak (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BSHEAL.2022.04.004 |
35496653 |
| 2022-04-25 |
Enrichment analysis on regulatory subspaces: A novel direction for the superior description of cellular responses to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105443 |
35533463 |
| 2022-04-25 |
Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29896-Z |
35469023 |
| 2022-04-25 |
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-022-00471-3 |
35468973 |
| 2022-04-25 |
Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07374-7 |
35468749 |
| 2022-04-25 |
Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusion (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PNTD.0010363 |
35468133 |
| 2022-04-25 |
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.863831 |
35547740 |
| 2022-04-25 |
Histamine Potentiates SARS-CoV-2 Spike Protein Entry Into Endothelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.872736 |
35548336 |
| 2022-04-25 |
Field Evaluation of the New Rapid NG-Test® SARS-CoV-2 Ag for Diagnosis of COVID-19 in the Emergency Department of an Academic Referral Hospital (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.840984 |
|
| 2022-04-25 |
Shell Disorder Models Detect That Omicron Has Harder Shells with Attenuation but Is Not a Descendant of the Wuhan-Hu-1 SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM12050631 |
35625559 |
| 2022-04-24 |
Probing the competitive inhibitor efficacy of frog-skin alpha helical AMPs identified against ACE2 binding to SARS-CoV-2 S1 spike protein as therapeutic scaffold to prevent COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00894-022-05117-8 |
35461388 |
| 2022-04-24 |
Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S43556-022-00074-3 |
35461370 |
| 2022-04-24 |
A human coronavirus OC43-derived polypeptide causes neuropathic pain (edit) |
ベータコロナウイルス１ (edit) |
10.15252/EMBR.202154069 |
35466531 |
| 2022-04-24 |
Risk mitigation and disease control challenges of SARS-CoV-2 multidirectional transmission at ski resorts (edit) |
SARSコロナウイルス2 (edit) |
10.21037/JPHE-21-112 |
|
| 2022-04-24 |
Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NEUROLINT14020032 |
|
| 2022-04-24 |
Phylodynamic Dispersal of SARS-CoV-2 Lineages Circulating across Polish–German Border Provinces (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14050884 |
|
| 2022-04-23 |
SARS-CoV-2 infection of human-induced pluripotent stem cells-derived lung lineage cells evokes inflammatory and chemosensory responses by targeting mitochondrial pathways (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JCP.30755 |
35460571 |
| 2022-04-23 |
SARS-COV-2 as potential microRNA sponge in COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12920-022-01243-7 |
35461273 |
| 2022-04-23 |
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS11091431 |
35563737 |
| 2022-04-22 |
RT- PCR testing of upper respiratory tract samples for diagnosis of SARS-CoV-2: Between justification and overestimation, a multi-center international study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TMAID.2022.102334 |
35470069 |
| 2022-04-22 |
Protocols for SARS-CoV-2 infection in primary ocular cells and eye organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2022.101383 |
35664254 |
| 2022-04-22 |
How time-scale differences in asymptomatic and symptomatic transmission shape SARS-CoV-2 outbreak dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.04.21.22274139 |
|
| 2022-04-22 |
Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.157597 |
35290246 |
| 2022-04-22 |
Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.157963 |
35316213 |
| 2022-04-22 |
Comparison of SARS-CoV-2 sequencing using the ONT GridION and the Illumina MiSeq (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12864-022-08541-5 |
35459088 |
| 2022-04-22 |
Anti-SARS-CoV-2 potential of Cissampelos pareira L. identified by connectivity map-based analysis and in vitro studies (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12906-022-03584-3 |
35459166 |
| 2022-04-22 |
The challenge of SARS-CoV-2 environmental monitoring in schools using floors and portable HEPA filtration units: Fresh or relic RNA? (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0267212 |
|
| 2022-04-21 |
Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110799 |
35523172 |
| 2022-04-21 |
SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.04.022 |
35474907 |
| 2022-04-21 |
Presumptive positive with the Cepheid Xpert Xpress SARS-CoV-2 assay due to N mutations in the Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2022.115699 |
35569431 |
| 2022-04-21 |
SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198785 |
|
| 2022-04-21 |
An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266844 |
35446879 |
| 2022-04-21 |
Human Wharton's Jelly Mesenchymal Stem Cells Secretome Inhibits Human SARS-CoV-2 and Avian Infectious Bronchitis Coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS11091408 |
35563714 |
| 2022-04-20 |
Evaluating the risk of SARS‐CoV‐2 transmission to bats in the context of wildlife research, rehabilitation, and control (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-04-20 |
Visibility, wind speed, and dew point temperature are important factors in SARS-CoV-2 transmissibility (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PUL2.12081 |
35514785 |
| 2022-04-20 |
Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.04.096 |
35460753 |
| 2022-04-20 |
Preclinical study of a DNA vaccine targeting SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RETRAM.2022.103348 |
35489099 |
| 2022-04-20 |
Development and validation of cost-effective one-step multiplex RT-PCR assay for detecting the SARS-CoV-2 infection using SYBR Green melting curve analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10413-7 |
35444203 |
| 2022-04-20 |
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.04.17.22273906 |
|
| 2022-04-20 |
Immunoinformatics approach of epitope prediction for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S43141-022-00344-1 |
35441904 |
| 2022-04-20 |
First Analytical Solution of Intracellular life Cycle of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.14302/ISSN.2643-2811.JMBR-22-4130 |
|
| 2022-04-20 |
Current Drug Targets for Gut Microbiota Biocorrection during the SARS-CoV-2 Pandemic: A Systematic Review (edit) |
SARSコロナウイルス2 (edit) |
10.2174/1389450123666220418094853 |
|
| 2022-04-20 |
SARS-CoV-2 Employ BSG/CD147 and ACE2 Receptors to Directly Infect Human Induced Pluripotent Stem Cell-Derived Kidney Podocytes (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2022.855340 |
35517495 |
| 2022-04-20 |
The Endolysosomal System: The Acid Test for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23094576 |
35562967 |
| 2022-04-20 |
Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14050847 |
35632589 |
| 2022-04-20 |
Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10050649 |
35632405 |
| 2022-04-19 |
Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110786 |
35477024 |
| 2022-04-19 |
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100603 |
35480625 |
| 2022-04-19 |
Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.2C00120 |
35439007 |
| 2022-04-19 |
Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29731-5 |
35440562 |
| 2022-04-19 |
First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09615-W |
35440789 |
| 2022-04-19 |
Shifts of SARS-CoV-2 exposure settings in the transmission clusters of 2 epidemic waves in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1080/09603123.2022.2064438 |
|
| 2022-04-19 |
The Potential of Eukaryotic Cell-Free Systems as a Rapid Response to Novel Zoonotic Pathogens: Analysis of SARS-CoV-2 Viral Proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FBIOE.2022.896751 |
|
| 2022-04-19 |
The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.848650 |
35521219 |
| 2022-04-19 |
Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19094930 |
|
| 2022-04-19 |
Efficacy of a “stay-at-home” policy on SARS-CoV-2 transmission in Toronto, Canada: a mathematical modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.9778/CMAJO.20200242 |
|
| 2022-04-18 |
The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2022.108193 |
35462185 |
| 2022-04-18 |
Occurrence of a novel cleavage site for cathepsin G adjacent to the polybasic sequence within the proteolytically sensitive activation loop of the SARS-CoV-2 Omicron variant: The amino acid substitution N679K and P681H of the spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0264723 |
35436320 |
| 2022-04-18 |
An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266412 |
35436306 |
| 2022-04-17 |
Clinically observed deletions in SARS-CoV-2 Nsp1 affect its stability and ability to inhibit translation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/1873-3468.14354 |
35434785 |
| 2022-04-17 |
Identification of Transcription Factors Regulating SARS-CoV-2 Tropism Factor Expression by Inferring Cell-Type-Specific Transcriptional Regulatory Networks in Human Lungs (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040837 |
35458567 |
| 2022-04-16 |
Control of common viral epidemics but not of SARS-CoV-2 through the application of hygiene and distancing measures (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2022.105163 |
|
| 2022-04-16 |
Electrochemical genosensor for the specific detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TALANTA.2022.123482 |
35462140 |
| 2022-04-15 |
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110757 |
35477023 |
| 2022-04-15 |
Detection of SARS-CoV-2 with RAPID: A prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104055 |
35291265 |
| 2022-04-15 |
Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-10293-X |
35440680 |
| 2022-04-15 |
One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABM5016 |
35427158 |
| 2022-04-15 |
COVID-profiler: a webserver for the analysis of SARS-CoV-2 sequencing data (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12859-022-04632-Y |
35428185 |
| 2022-04-15 |
Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study (edit) |
SARSコロナウイルス2 (edit) |
10.2169/INTERNALMEDICINE.8902-21 |
|
| 2022-04-15 |
MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIB11020027 |
|
| 2022-04-15 |
Reproduction Number of the Omicron Variant Triples That of the Delta Variant (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040821 |
35458551 |
| 2022-04-14 |
The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina sero-epidemiological survey (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11739-022-02975-1 |
|
| 2022-04-14 |
A magnetic bead immunoassay to detect high affinity human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42770-022-00753-X |
|
| 2022-04-14 |
Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2022.108194 |
35453047 |
| 2022-04-14 |
Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09845-Y |
35422113 |
| 2022-04-14 |
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC292 |
|
| 2022-04-14 |
Abnormal global alternative RNA splicing in COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PGEN.1010137 |
35421082 |
| 2022-04-14 |
Wastewater surveillance of SARS-CoV-2 mutational profiles at a university and its surrounding community reveals a 20G outbreak on campus (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266407 |
35421164 |
| 2022-04-14 |
Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010464 |
35421191 |
| 2022-04-14 |
Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.822599 |
35493733 |
| 2022-04-14 |
Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FVIRO.2022.854363 |
|
| 2022-04-14 |
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10040614 |
|
| 2022-04-14 |
Research on COVID-19, SARS-CoV-2 in dermatology journals: A brief bibliometric analysis based on PubMed (edit) |
SARSコロナウイルス2 (edit) |
10.4103/IJD.IJD_397_21 |
|
| 2022-04-13 |
Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2022.04.001 |
35434682 |
| 2022-04-13 |
Molecularly Imprinted Polymer Nanoparticles Enable Rapid, Reliable, and Robust Point-of-Care Thermal Detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSSENSORS.2C00100 |
35416035 |
| 2022-04-13 |
Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-022-00108-5 |
35603276 |
| 2022-04-13 |
Transcriptomic analysis of asymptomatic and symptomatic severe Turkish patients in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.14744/NCI.2022.28000 |
35582503 |
| 2022-04-13 |
Free PoC Testing for SARS-CoV-2 in Germany: Factors Expanding Access to Various Communities in a Medium-Sized City (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19084721 |
|
| 2022-04-13 |
Comparative Evaluation of Six SARS-CoV-2 Real-Time RT-PCR Diagnostic Approaches Shows Substantial Genomic Variant–Dependent Intra- and Inter-Test Variability, Poor Interchangeability of Cycle Threshold and Complementary Turn-Around Times (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS11040462 |
|
| 2022-04-13 |
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040800 |
35458530 |
| 2022-04-13 |
PipeCoV: a pipeline for SARS-CoV-2 genome assembly, annotation and variant identification (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13300 |
35437474 |
| 2022-04-12 |
SARS-CoV-2 monitoring by automated target-driven molecular machine-based engineering (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10311-022-01434-9 |
|
| 2022-04-12 |
Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.04.017 |
35427785 |
| 2022-04-12 |
Severe Adams-Oliver Syndrome after Maternal COVID-19 Infection Could Be Another Effect of the SARS-CoV-2 Inflammatory Storm? Case Report (edit) |
SARSコロナウイルス2 (edit) |
10.1080/15513815.2022.2064018 |
|
| 2022-04-12 |
SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCISIGNAL.ABG8744 |
35412852 |
| 2022-04-12 |
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02167-21 |
35412356 |
| 2022-04-12 |
[Geospatial models for SARS-CoV-2 outbreak control in Cartagena and Barranquilla, Colombia, 2020Modelos geoespaciais para controle de surtos de SARS-CoV-2 em Cartagena e Barranquilla, Colômbia, 2020] (edit) |
SARSコロナウイルス2 (edit) |
10.26633/RPSP.2022.26 |
35432500 |
| 2022-04-12 |
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2022.861209 |
35494659 |
| 2022-04-12 |
Identification of Neutrophil-Related Factor LCN2 for Predicting Severity of Patients With Influenza A Virus and SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.854172 |
35495713 |
| 2022-04-11 |
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADVS.202104333 |
35403837 |
| 2022-04-11 |
Structural and functional impact by SARS-CoV-2 Omicron spike mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110729 |
35452593 |
| 2022-04-11 |
Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104223 |
35434541 |
| 2022-04-11 |
Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.2C00708 |
35403431 |
| 2022-04-11 |
Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00629 |
35404564 |
| 2022-04-11 |
Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.15311 |
35403221 |
| 2022-04-11 |
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1010021 |
35404937 |
| 2022-04-11 |
Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010155 |
35404959 |
| 2022-04-11 |
Dentist’s Experiences and Perceptions One Year into the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.33140/JODH.05.04.03 |
|
| 2022-04-10 |
Increased close proximity airborne transmission of the SARS-CoV-2 Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.151499 |
34752865 |
| 2022-04-09 |
Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1002/MCO2.129 |
35434714 |
| 2022-04-09 |
Dynamic Ca2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110694 |
35397208 |
| 2022-04-09 |
MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105509 |
35421792 |
| 2022-04-09 |
Replication of the coronavirus genome: a paradox among positive-strand RNA viruses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2022.101923 |
35413290 |
| 2022-04-09 |
Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS11081274 |
35455955 |
| 2022-04-08 |
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.04.009 |
35523182 |
| 2022-04-08 |
Unveiling the nature's fruit basket to computationally identify Citrus sinensis csi-mir169-3p as a probable plant miRNA against Reference and Omicron SARS-CoV-2 genome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105502 |
35605482 |
| 2022-04-08 |
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29579-9 |
35396511 |
| 2022-04-08 |
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-022-00462-4 |
35396516 |
| 2022-04-08 |
Screening of wild deer populations for exposure to SARS‐CoV‐2 in the United Kingdom, 2020–2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14534 |
|
| 2022-04-08 |
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-056872 |
35396297 |
| 2022-04-08 |
Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009990 |
35395058 |
| 2022-04-08 |
SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS11081262 |
|
| 2022-04-08 |
Genome Profiling of SARS-CoV-2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040778 |
35458508 |
| 2022-04-07 |
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00018-022-04246-W |
35391601 |
| 2022-04-07 |
Interference of Chaga mushroom terpenoids with the attachment of SARS-CoV-2; in silico perspective (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105478 |
35421790 |
| 2022-04-07 |
Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2022.04.002 |
35483354 |
| 2022-04-07 |
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2022.04.003 |
35447092 |
| 2022-04-07 |
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29413-2 |
35393402 |
| 2022-04-07 |
Systematic evaluating and modeling of SARS-CoV-2 UVC disinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09930-2 |
35393480 |
| 2022-04-07 |
SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00037-22 |
35389264 |
| 2022-04-07 |
The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02240-21 |
35389245 |
| 2022-04-07 |
Inactivation of SARS-CoV-2 and influenza A virus by dry fogging hypochlorous acid solution and hydrogen peroxide solution (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0261802 |
35389997 |
| 2022-04-07 |
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266124 |
35390032 |
| 2022-04-06 |
Mathematical modeling and analysis of the SARS-Cov-2 disease with reinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107678 |
|
| 2022-04-06 |
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04702-4 |
|
| 2022-04-06 |
Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09664-1 |
35388061 |
| 2022-04-06 |
Prolonged and extended impacts of SARS-CoV-2 on the olfactory neurocircuit (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09731-7 |
35388072 |
| 2022-04-06 |
Evaluation of a machine learning approach utilizing wearable data for prediction of SARS-CoV-2 infection in healthcare workers (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JAMIAOPEN/OOAC041 |
|
| 2022-04-06 |
Small-Sample Estimation of the Mutational Support and Distribution of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1109/TCBB.2022.3165395 |
|
| 2022-04-06 |
Hospital Disaster and Emergency Plan in Biological Disasters (HDEP): Coronavirus (SARS-CoV-2) COVID-19 Pandemic System Model Example (edit) |
SARSコロナウイルス2 (edit) |
10.29333/JCONSEPH/11975 |
|
| 2022-04-06 |
Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.832223 |
35464437 |
| 2022-04-06 |
Biocompatible Films of Calcium Alginate Inactivate Enveloped Viruses Such as SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/POLYM14071483 |
35406356 |
| 2022-04-06 |
What Do We Know About the Impacts of Novel Coronavirus (SARS-Cov-2) on Freshwater Ecosystems? (edit) |
SARSコロナウイルス2 (edit) |
10.38125/OAJBS.000357 |
|
| 2022-04-05 |
Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.2C00139 |
35380435 |
| 2022-04-05 |
pH- and Calcium-Dependent Aromatic Network in the SARS-CoV-2 Envelope Protein (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.2C00973 |
35380805 |
| 2022-04-05 |
Characterisation and natural progression of SARS-CoV-2 infection in ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-08431-6 |
|
| 2022-04-05 |
A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2114397119 |
35312342 |
| 2022-04-05 |
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2117142119 |
35380892 |
| 2022-04-05 |
SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-057846 |
35383082 |
| 2022-04-05 |
Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.821730 |
35479098 |
| 2022-04-05 |
Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.857322 |
|
| 2022-04-05 |
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS11071235 |
35406799 |
| 2022-04-05 |
Safety of an Inactivated SARS-CoV-2 Vaccine Among Healthcare Workers in Turkey: An Online Survey (edit) |
SARSコロナウイルス2 (edit) |
10.4274/BALKANMEDJ.GALENOS.2022.2021-11-25 |
|
| 2022-04-05 |
Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study (edit) |
SARSコロナウイルス2 (edit) |
10.4274/BALKANMEDJ.GALENOS.2022.2021-8-131 |
|
| 2022-04-05 |
Comparison of Hematological and Biochemical Parameters of SARS-CoV-2-Positive and -Negative Neonates of COVID-19 Mothers in a COVID-19 Hospital, Odisha State (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.23859 |
|
| 2022-04-04 |
The Effects of Migration and Limited Medical Resources of the Transmission of SARS-CoV-2 Model with Two Patches (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11538-022-01010-W |
|
| 2022-04-04 |
Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110714 |
35421379 |
| 2022-04-04 |
Tracking of SARS-CoV-2 Alpha variant (B.1.1.7) in Palestine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2022.105279 |
35390503 |
| 2022-04-04 |
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2022.03.060 |
|
| 2022-04-04 |
Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSPTSCI.2C00026 |
35434531 |
| 2022-04-04 |
Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.21.21268143 |
35411350 |
| 2022-04-04 |
Meteorological factors and non-pharmaceutical interventions explain local differences in the spread of SARS-CoV-2 in Austria (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009973 |
|
| 2022-04-04 |
Comparison of different sequencing techniques for identification of SARS-CoV-2 variants of concern with multiplex real-time PCR (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0265220 |
35377884 |
| 2022-04-04 |
Genetic Surveillance of Five SARS-CoV-2 Clinical Samples in Henan Province Using Nanopore Sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.814806 |
35444655 |
| 2022-04-04 |
Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.836454 |
35444976 |
| 2022-04-02 |
Child transmission of SARS-CoV-2: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12887-022-03175-8 |
35365104 |
| 2022-04-02 |
mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040748 |
|
| 2022-04-01 |
Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTM2.802 |
35415890 |
| 2022-04-01 |
The variants of SARS-CoV-2 and the challenges of vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27513 |
34890492 |
| 2022-04-01 |
Pulmonary endothelial NEDD9 and the prothrombotic pathophenotype of acute respiratory distress syndrome due to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PUL2.12071 |
35599981 |
| 2022-04-01 |
Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B receptor antagonism (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00109-022-02182-7 |
35247068 |
| 2022-04-01 |
The Possible Role of Prion-Like Viral Protein Domains on the Emergence of Novel Viruses as SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00239-022-10054-4 |
|
| 2022-04-01 |
Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00345-021-03810-6 |
|
| 2022-04-01 |
Amplification-free detection of SARS-CoV-2 using gold nanotriangles functionalized with oligonucleotides (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00604-022-05272-Y |
35364748 |
| 2022-04-01 |
Circular RNA vaccines against SARS-CoV-2 and emerging variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.03.044 |
|
| 2022-04-01 |
Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2022.03.018 |
|
| 2022-04-01 |
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.103944 |
35465948 |
| 2022-04-01 |
ZERO projects in intensive care units: Challenges during SARS-CoV-2 pandemic and future recommendations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENFIE.2022.03.001 |
|
| 2022-04-01 |
Hygienic assessment of digestate from a high solids anaerobic co-digestion of sewage sludge with biowaste by testing Salmonella Typhimurium, Escherichia coli and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.112585 |
|
| 2022-04-01 |
Assessment of SARS-CoV-2 airborne infection transmission risk in public buses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GSF.2022.101398 |
37521135 |
| 2022-04-01 |
Link between SARS-CoV-2 emissions and airborne concentrations: Closing the gap in understanding (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHAZMAT.2022.128279 |
35063838 |
| 2022-04-01 |
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHEP.2022.03.040 |
35461912 |
| 2022-04-01 |
The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANWPC.2022.100389 |
35132397 |
| 2022-04-01 |
Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANWPC.2022.100393 |
35128500 |
| 2022-04-01 |
l-Methionine may modulate the assembly of SARS-CoV-2 by interfering with the mechanism of RNA polymerase (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110798 |
|
| 2022-04-01 |
Combatting future variants of SARS-CoV-2 using an in-silico peptide vaccine approach by targeting the spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110810 |
|
| 2022-04-01 |
All about that trait: Examining extraversion and state anxiety during the SARS-CoV-2 pandemic using a machine learning approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PAID.2021.111461 |
|
| 2022-04-01 |
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(22)00462-7 |
|
| 2022-04-01 |
CLOTH FACE COVERINGS FOR USE AS FACEMASKS DURING THE CORONAVIRUS (SARS-CoV-2) PANDEMIC: WHAT SCIENCE AND EXPERIENCE HAVE TAUGHT US (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2020.354 |
32921329 |
| 2022-04-01 |
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41565-022-01071-X |
|
| 2022-04-01 |
SARS-CoV-2 is associated with changes in brain structure in UK Biobank (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04569-5 |
35255491 |
| 2022-04-01 |
Antibody evasion properties of SARS-CoV-2 Omicron sublineages (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04594-4 |
35240676 |
| 2022-04-01 |
Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04653-W |
35332335 |
| 2022-04-01 |
Author Correction: T cell responses to SARS-CoV-2 spike cross-recognize Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04708-Y |
35396582 |
| 2022-04-01 |
Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2119467119 |
35363556 |
| 2022-04-01 |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC262 |
35380632 |
| 2022-04-01 |
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19? (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JPIDS/PIAC024 |
35394545 |
| 2022-04-01 |
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAC144 |
35244721 |
| 2022-04-01 |
Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.1097/TP.0000000000004044 |
34999659 |
| 2022-04-01 |
Portable air cleaners and residential exposure to SARS-CoV-2 aerosols: a real-world study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/INA.13029 |
35481935 |
| 2022-04-01 |
Salivary diagnostics of the novel corona virus SARS-CoV-2 (COVID-19) (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ODI.13729 |
33211392 |
| 2022-04-01 |
Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization (edit) |
SARSコロナウイルス2 (edit) |
10.1134/S0006297922040022 |
35527370 |
| 2022-04-01 |
Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJGAST-2022-000871 |
|
| 2022-04-01 |
Impact of air temperature and containment measures on mitigating the intrahousehold transmission of SARS-CoV-2: a data-based modelling analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-049383 |
|
| 2022-04-01 |
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry (edit) |
SARSコロナウイルス2 (edit) |
10.1136/RMDOPEN-2021-002187 |
35387864 |
| 2022-04-01 |
Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform (edit) |
SARSコロナウイルス2 (edit) |
10.1177/01926233221090518 |
35514116 |
| 2022-04-01 |
SARS-CoV-2 detection in multi-sample pools in a real pandemic scenario: A screening strategy of choice for active surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266408 |
35363805 |
| 2022-04-01 |
Triamcinolone as a potential inhibitor of SARS-CoV-2 main protease and cytokine storm: An in-silico study (edit) |
SARSコロナウイルス2 (edit) |
10.2174/1570180819666220401142351 |
|
| 2022-03-31 |
Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2022.105278 |
35367360 |
| 2022-03-31 |
Defining the risk of SARS-CoV-2 variants on immune protection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04690-5 |
35361968 |
| 2022-03-31 |
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-01780-9 |
|
| 2022-03-31 |
SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-09410-7 |
|
| 2022-03-31 |
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMOA2118691 |
|
| 2022-03-31 |
One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JOIM.13482 |
|
| 2022-03-31 |
A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07314-5 |
35361140 |
| 2022-03-31 |
Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3001592 |
35358182 |
| 2022-03-31 |
Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009964 |
|
| 2022-03-31 |
Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0266417 |
35358277 |
| 2022-03-31 |
The Finding of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in a Wild Eurasian River Otter (Lutra lutra) Highlights the Need for Viral Surveillance in Wild Mustelids (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FVETS.2022.826991 |
|
| 2022-03-30 |
Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105468 |
35390745 |
| 2022-03-30 |
Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00486 |
35352558 |
| 2022-03-30 |
Inferring age-specific differences in susceptibility to and infectiousness upon SARS-CoV-2 infection based on Belgian social contact data (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009965 |
|
| 2022-03-30 |
RNA editing increases the nucleotide diversity of SARS-CoV-2 in human host cells (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PGEN.1010130 |
35353808 |
| 2022-03-30 |
Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.847617 |
35432316 |
| 2022-03-29 |
Detection of SARS-CoV-2 Proteins in Wastewater Samples by Mass Spectrometry (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.EST.1C04705 |
|
| 2022-03-29 |
Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-022-00855-4 |
35352010 |
| 2022-03-29 |
In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-08320-Y |
35351926 |
| 2022-03-29 |
Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EMPH/EOAC010 |
35419205 |
| 2022-03-29 |
SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00221-22 |
35348367 |
| 2022-03-29 |
In vitro Suppression of SARS-CoV-2 Infection by Existing Kampo Formulas and Crude Constituent Drugs Used for Treatment of Common Cold Respiratory Symptoms (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.804103 |
|
| 2022-03-29 |
Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IDR14020029 |
35447881 |
| 2022-03-28 |
Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11845-022-02984-1 |
|
| 2022-03-28 |
SARS-CoV-2 3CLpro whole human proteome cleavage prediction and enrichment/depletion analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107671 |
35429835 |
| 2022-03-28 |
NGS analysis of nasopharyngeal microbiota in SARS-CoV-2 positive patients during the first year of the pandemic in the Campania Region of Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2022.105506 |
35358660 |
| 2022-03-28 |
Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2352-4642(22)00059-1 |
35358491 |
| 2022-03-28 |
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29288-3 |
35347138 |
| 2022-03-28 |
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04661-W |
35344983 |
| 2022-03-28 |
Global landscape of SARS-CoV-2 genomic surveillance and data sharing (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41588-022-01033-Y |
|
| 2022-03-28 |
Virucidal efficacy of laundry sanitizers against SARS-CoV-2 and other coronaviruses and influenza viruses (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-08259-0 |
35347149 |
| 2022-03-28 |
Molecular consequences of SARS-CoV-2 liver tropism (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42255-022-00552-6 |
35347318 |
| 2022-03-28 |
SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in Arf6-dependent manner (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2059403 |
|
| 2022-03-28 |
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00128-22 |
35343766 |
| 2022-03-28 |
Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00249-22 |
35343765 |
| 2022-03-28 |
Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.00402-22 |
|
| 2022-03-28 |
Phylogenetic analysis of 17271 Indian SARS-CoV-2 genomes to identify temporal and spatial hotspot mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0265579 |
|
| 2022-03-28 |
Identification of Potential Semisynthetic Andrographolide Derivatives to Combat COVID-19 by Targeting the SARS-COV-2 Spike Protein and Human ACE2 Receptor– An In-silico Approach (edit) |
SARSコロナウイルス2 (edit) |
10.33263/BRIAC132.155 |
|
| 2022-03-27 |
Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS‐CoV‐2 wild‐type and the variants of concern, viral cell‐entry process, and cytokine storm in COVID‐19 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JCB.30243 |
|
| 2022-03-27 |
RNA–protein interactomes as invaluable resources to study RNA viruses: Insights from SARS CoV‐2 studies (edit) |
SARSコロナウイルス2 (edit) |
10.1002/WRNA.1727 |
35343064 |
| 2022-03-27 |
What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection? (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23073673 |
35409036 |
| 2022-03-27 |
Emergence of Two Distinct SARS-CoV-2 Gamma Variants and the Rapid Spread of P.1-like-II SARS-CoV-2 during the Second Wave of COVID-19 in Santa Catarina, Southern Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040695 |
35458424 |
| 2022-03-26 |
Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105452 |
35364308 |
| 2022-03-26 |
Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EKIR.2022.03.020 |
35372734 |
| 2022-03-26 |
Phylogenetic-based inference reveals distinct transmission dynamics of SARS-CoV-2 lineages Gamma and P.2 in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104156 |
35368908 |
| 2022-03-26 |
BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era (edit) |
SARSコロナウイルス2 (edit) |
10.7189/JOGH.12.05008 |
35356660 |
| 2022-03-25 |
Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects (edit) |
SARSコロナウイルス2 (edit) |
10.1002/EJI.202149785 |
35312186 |
| 2022-03-25 |
Structural diversity of the SARS-CoV-2 Omicron spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLCEL.2022.03.028 |
35447081 |
| 2022-03-25 |
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABM0220 |
35333580 |
| 2022-03-25 |
Associations among eHealth literacy, social support, individual resilience, and emotional status in primary care providers during the outbreak of the SARS-CoV-2 Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1177/20552076221089789 |
|
| 2022-03-25 |
Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009978 |
|
| 2022-03-25 |
Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010181 |
35333914 |
| 2022-03-25 |
Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2022.866474 |
35401674 |
| 2022-03-25 |
The Molecular Basis of the Effect of Temperature on the Structure and Function of SARS-CoV-2 Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.794960 |
35463957 |
| 2022-03-25 |
Autoimmune Encephalitis in COVID-19 Infection: Our Experience and Systematic Review of the Literature (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES10040774 |
35453524 |
| 2022-03-25 |
Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm (edit) |
SARSコロナウイルス2 (edit) |
10.3390/LIFE12040478 |
|
| 2022-03-25 |
Survival and Fate of Novel Coronavirus (SARS-CoV-2) in Water and Wastewater: Possible Health Concerns (edit) |
SARSコロナウイルス2 (edit) |
10.5296/JEE.V13I1.19674 |
|
| 2022-03-24 |
SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEMCR.2022.02.015 |
35334213 |
| 2022-03-24 |
An extended conformation of SARS-CoV-2 main protease reveals allosteric targets (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2120913119 |
35324337 |
| 2022-03-24 |
EDGE COVID-19: a web platform to generate submission-ready genomes from SARS-CoV-2 sequencing efforts (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BIOINFORMATICS/BTAC176 |
|
| 2022-03-24 |
Plant-based expression and characterization of SARS-CoV-2 virus-like particles presenting a native spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1111/PBI.13813 |
35325498 |
| 2022-03-24 |
Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0264700 |
35324925 |
| 2022-03-24 |
Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010093 |
35325013 |
| 2022-03-24 |
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.824378 |
35401544 |
| 2022-03-24 |
Cannabidiol and SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.870787 |
|
| 2022-03-24 |
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.75433 |
35323111 |
| 2022-03-24 |
The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.75720 |
35323112 |
| 2022-03-23 |
A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTI2.1380 |
35356067 |
| 2022-03-23 |
Glycosylation is key for enhancing drug recognition into spike glycoprotein of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107668 |
|
| 2022-03-23 |
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.02077-21 |
35225672 |
| 2022-03-23 |
High Seroprevalence of SARS-CoV-2 in White-Tailed Deer (Odocoileus virginianus) at One of Three Captive Cervid Facilities in Texas (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00576-22 |
|
| 2022-03-23 |
Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1177/11779322221085077 |
35342288 |
| 2022-03-23 |
Tuftsin: A Natural Molecule Against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.859162 |
35402510 |
| 2022-03-23 |
Genomic Epidemiology of SARS-CoV-2 in Tocantins State and the Diffusion of P.1.7 and AY.99.2 Lineages in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14040659 |
35458389 |
| 2022-03-22 |
SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin (edit) |
MERSコロナウイルス (edit) |
10.1002/JMV.27734 |
35318674 |
| 2022-03-22 |
SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27734 |
35318674 |
| 2022-03-22 |
Generalized Methodology for the Quick Prediction of Variant SARS-CoV-2 Spike Protein Binding Affinities with Human Angiotensin-Converting Enzyme II (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.1C10718 |
35315274 |
| 2022-03-22 |
SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-022-00770-1 |
35317858 |
| 2022-03-22 |
In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM12040482 |
35454070 |
| 2022-03-22 |
E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13099 |
35341044 |
| 2022-03-22 |
The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13132 |
35341058 |
| 2022-03-21 |
Intra-protein interactions of SARS-CoV-2 and SARS: a bioinformatic analysis for plausible explanation regarding stability, divergency, and severity (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-03-21 |
Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.2C00100 |
35312321 |
| 2022-03-21 |
Genetic alteration of human MYH6 is mimicked by SARS-CoV-2 polyprotein: mapping viral variants of cardiac interest (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41420-022-00914-9 |
35314694 |
| 2022-03-21 |
The early SARS-CoV-2 epidemic in Senegal was driven by the local emergence of B.1.416 and the introduction of B.1.1.420 from Europe (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC025 |
35371561 |
| 2022-03-21 |
Comparison of Saliva and Midturbinate Swabs for Detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00128-22 |
35311575 |
| 2022-03-21 |
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00182-22 |
35311586 |
| 2022-03-21 |
SARS-CoV-2 Lineage Tracking, and Evolving Trends Seen during Three Consecutive Peaks of Infection in Delhi, India: a Clinico-Genomic Study (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02729-21 |
35311567 |
| 2022-03-21 |
No man is an island: management of the emergency response to the SARS-CoV-2 (COVID-19) outbreak in a large public decentralised service delivery organisation (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12913-022-07716-W |
|
| 2022-03-21 |
From Deer-to-Deer: SARS-CoV-2 is efficiently transmitted and presents broad tissue tropism and replication sites in white-tailed deer (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010197 |
35312736 |
| 2022-03-21 |
SARS-CoV-2 Mutations and COVID-19 Clinical Outcome: Mutation Global Frequency Dynamics and Structural Modulation Hold the Key (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.868414 |
35386683 |
| 2022-03-21 |
Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.850987 |
|
| 2022-03-21 |
The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.744439 |
|
| 2022-03-21 |
HSP90 Inhibitors Modulate SARS-CoV-2 Spike Protein Subunit 1-Induced Human Pulmonary Microvascular Endothelial Activation and Barrier Dysfunction (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHYS.2022.812199 |
35388292 |
| 2022-03-21 |
Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/GENES13030552 |
|
| 2022-03-19 |
SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2804.211961 |
|
| 2022-03-18 |
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.03.019 |
35429436 |
| 2022-03-18 |
Both simulation and sequencing data reveal coinfections with multiple SARS-CoV-2 variants in the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.03.011 |
35342534 |
| 2022-03-18 |
Metataxonomic Analysis of Milk Samples From SARS-CoV-2-Positive and SARS-CoV-2-Negative Women (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNUT.2022.853576 |
35369105 |
| 2022-03-17 |
Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBI.2022.03.006 |
35307504 |
| 2022-03-17 |
Immunoassay platform with surface-enhanced resonance Raman scattering for detecting trace levels of SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TALANTA.2022.123381 |
35364338 |
| 2022-03-17 |
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-29104-Y |
35301314 |
| 2022-03-17 |
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2119912 |
35081298 |
| 2022-03-17 |
Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC002 |
35310621 |
| 2022-03-17 |
Evolutionary history and introduction of SARS-CoV-2 Alpha VOC/B.1.1.7 in Pakistan through international travelers (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC020 |
35462736 |
| 2022-03-17 |
Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22) (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.865401 |
35371009 |
| 2022-03-17 |
Mutations and Phylogenetic Analyses of SARS-CoV-2 Among Imported COVID-19 From Abroad in Nanjing, China (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.851323 |
35369437 |
| 2022-03-17 |
The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES27061947 |
35335311 |
| 2022-03-16 |
SARS-CoV-2: Receptor and Co-receptor Tropism Probability (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00284-022-02807-7 |
35292865 |
| 2022-03-16 |
Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2022.101965 |
35313445 |
| 2022-03-16 |
The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2022.03.010 |
35313658 |
| 2022-03-16 |
Monitoring SARS-CoV-2 in wastewater during New York City's second wave of COVID-19: sewershed-level trends and relationships to publicly available clinical testing data (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1EW00747E |
|
| 2022-03-16 |
Sensitive, smartphone-based SARS-CoV-2 detection from clinical saline gargle samples (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC028 |
35450423 |
| 2022-03-16 |
Collaboration between Clinical and Academic Laboratories for Sequencing SARS-CoV-2 Genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.01288-21 |
|
| 2022-03-16 |
When Poly(A) Binding Proteins Meet Viral Infections, Including SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00136-22 |
35293770 |
| 2022-03-16 |
SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJ-2021-067696 |
35296519 |
| 2022-03-16 |
Free ISG15 and protein ISGylation emerging in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.2174/1389450123666220316094720 |
35297347 |
| 2022-03-16 |
SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape (edit) |
SARSコロナウイルス2 (edit) |
10.26508/LSA.202201415 |
35296517 |
| 2022-03-16 |
SARS-CoV-2 Nsp14 mediates the effects of viral infection on the host cell transcriptome (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.71945 |
35293857 |
| 2022-03-16 |
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.77444 |
35294338 |
| 2022-03-15 |
Isolation of Thioinosine and Butenolides from a Terrestrial Actinomycetes sp. GSCW-51 and Their in Silico Studies for Potential against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CBDV.202100843 |
35213767 |
| 2022-03-15 |
The importance of accessory protein variants in the pathogenicity of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ABB.2022.109124 |
35085577 |
| 2022-03-15 |
Virus blocking textile for SARS-CoV-2 using human body triboelectric energy harvesting (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRP.2022.100813 |
35309284 |
| 2022-03-15 |
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2122954119 |
35238654 |
| 2022-03-15 |
Characterization of Altered Oropharyngeal Microbiota in Hospitalized Patients With Mild SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.824578 |
35372134 |
| 2022-03-14 |
When cyclin‐dependent kinases meet viral infections, including SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27719 |
35288942 |
| 2022-03-14 |
SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.103940 |
35301181 |
| 2022-03-14 |
Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104075 |
35309726 |
| 2022-03-14 |
Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-022-00451-7 |
35288576 |
| 2022-03-14 |
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41579-022-00722-Z |
|
| 2022-03-14 |
Design of SARS-CoV-2 Variant-Specific PCR Assays Considering Regional and Temporal Characteristics (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AEM.02289-21 |
35285246 |
| 2022-03-14 |
Data on Transfer of Human Coronavirus SARS-CoV-2 from Foods and Packaging Materials to Gloves Indicate That Fomite Transmission Is of Minor Importance (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AEM.02338-21 |
35285254 |
| 2022-03-14 |
Would New SARS-CoV-2 Variants Change the War Against COVID-19? (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202203.0185.V1 |
|
| 2022-03-14 |
Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.799703 |
35372520 |
| 2022-03-13 |
Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SMSC.202100124 |
35600064 |
| 2022-03-13 |
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.103934 |
35290827 |
| 2022-03-12 |
Characterization of persons with reported SARS-CoV-2 infection in the Oklahoma City tri-county area: Evidence from the first 12 months of transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2022.03.007 |
35292299 |
| 2022-03-12 |
Risk of SARS-CoV-2 transmission upon return to work in RNA-positive healthcare workers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHIN.2022.02.024 |
35288252 |
| 2022-03-11 |
Persistence of Endogenous SARS-CoV-2 and Pepper Mild Mottle Virus RNA in Wastewater-Settled Solids (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-03-11 |
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.104043 |
35291264 |
| 2022-03-11 |
Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100583 |
35480627 |
| 2022-03-11 |
Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.1C01372 |
35275639 |
| 2022-03-11 |
ACE2-independent infection of T lymphocytes by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-00919-X |
|
| 2022-03-11 |
Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-08073-8 |
35277538 |
| 2022-03-11 |
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABL4292 |
35084937 |
| 2022-03-11 |
Indirect protection of children from SARS-CoV-2 infection through parental vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM3087 |
35084938 |
| 2022-03-11 |
The changing epidemiology of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM4915 |
35271324 |
| 2022-03-11 |
The immunology and immunopathology of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM8108 |
|
| 2022-03-11 |
Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0263671 |
35275926 |
| 2022-03-11 |
Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7110A3 |
35271558 |
| 2022-03-11 |
SARS-CoV-2 Incidence in K-12 School Districts with Mask-Required Versus Mask-Optional Policies - Arkansas, August-October 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7110E1 |
35271560 |
| 2022-03-11 |
Exploring Zebrafish Larvae as a COVID-19 Model: Probable Abortive SARS-CoV-2 Replication in the Swim Bladder (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2022.790851 |
35360100 |
| 2022-03-11 |
Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10030433 |
35335065 |
| 2022-03-10 |
SARS-CoV-2 B.1.214.1, B.1.214.2 and B.1.620 are predominant lineages between December 2020 and July 2021 in the Republic of Congo (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-03-10 |
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.03.009 |
35344711 |
| 2022-03-10 |
Structural basis of nanobodies neutralizing SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2022.02.011 |
35276082 |
| 2022-03-10 |
Histones released by NETosis enhance the infectivity of SARS-CoV-2 by bridging the spike protein subunit 2 and sialic acid on host cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-022-00845-6 |
35273357 |
| 2022-03-10 |
Divergent trajectories of antiviral memory after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28898-1 |
35273178 |
| 2022-03-10 |
Anti-SARS-CoV-2 equine F (Ab')2 immunoglobulin as a possible therapy for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-07793-1 |
35273234 |
| 2022-03-10 |
The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss (edit) |
SARSコロナウイルス2 (edit) |
10.1111/DTH.15433 |
|
| 2022-03-10 |
Stopping pandemics before they start: Lessons learned from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN1900 |
|
| 2022-03-10 |
Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ABO0535 |
35271298 |
| 2022-03-10 |
Unsupervised explainable AI for molecular evolutionary study of forty thousand SARS-CoV-2 genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12866-022-02484-3 |
|
| 2022-03-10 |
Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.17179/EXCLI2022-4721 |
35651657 |
| 2022-03-10 |
Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2022.27.10.2100815 |
35272744 |
| 2022-03-10 |
Overview SARS-CoV-2 Pandemic as January-February 2022: Likely Cometary Origin, Global Spread, Prospects for Future Vaccine Efficacy (edit) |
SARSコロナウイルス2 (edit) |
10.31038/IDT.2022311 |
|
| 2022-03-10 |
Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43 (edit) |
ベータコロナウイルス１ (edit) |
10.3389/FIMMU.2022.835333 |
35359936 |
| 2022-03-10 |
Decline in Respiratory Functions in Hospitalized SARS-CoV-2 Infected Cancer Patients Following Cytotoxic Chemotherapy-An Additional Risk for Post-chemotherapy Complications (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2022.835098 |
35360723 |
| 2022-03-10 |
SARS-CoV-2 infection in public hospital medical doctors in an Eastern Cape metro (edit) |
SARSコロナウイルス2 (edit) |
10.4102/SAJID.V37I1.335 |
35399560 |
| 2022-03-09 |
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJ-2021-069761 |
|
| 2022-03-09 |
In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S43141-022-00314-7 |
35262828 |
| 2022-03-09 |
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0261045 |
35263335 |
| 2022-03-09 |
RespiCoV: Simultaneous identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 46 respiratory tract viruses and bacteria by amplicon-based Oxford-Nanopore MinION sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0264855 |
35263362 |
| 2022-03-09 |
CovDif, a Tool to Visualize the Conservation between SARS-CoV-2 Genomes and Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14030561 |
|
| 2022-03-08 |
RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2022.02.008 |
35186439 |
| 2022-03-08 |
Ensemble cryo-EM reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication–transcription complex (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-022-00734-6 |
|
| 2022-03-08 |
An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-07867-0 |
35260703 |
| 2022-03-07 |
Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S15010-022-01777-Z |
|
| 2022-03-07 |
Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOMATERIALS.2022.121460 |
35286852 |
| 2022-03-07 |
Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110558 |
35303476 |
| 2022-03-07 |
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110561 |
35303475 |
| 2022-03-07 |
Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2022.03.003 |
35272059 |
| 2022-03-07 |
HLA-dependent variation in SARS-CoV-2 CD8 + T cell cross-reactivity with human coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IMM.13451 |
35143694 |
| 2022-03-07 |
Conserved Pattern and Potential Role of Recurrent Deletions in SARS-CoV-2 Evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02191-21 |
35254107 |
| 2022-03-07 |
Using genomic epidemiology of SARS-CoV-2 to support contact tracing and public health surveillance in rural Humboldt County, California (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-022-12790-0 |
35255849 |
| 2022-03-07 |
Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBR.202154199 |
35253970 |
| 2022-03-07 |
Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOPHYSIOLOGY29010009 |
35366292 |
| 2022-03-06 |
Effective and scalable clustering of SARS-CoV-2 sequences (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3505745.3505752 |
|
| 2022-03-06 |
An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages (edit) |
SARSコロナウイルス2 (edit) |
10.7150/THNO.66831 |
35401811 |
| 2022-03-05 |
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(22)00152-0 |
35202601 |
| 2022-03-04 |
Transport Safety Concerning a Patient Infected With SARS-CoV-2 and Emergency Service Officers in an Ambulance Accident—A Case Study (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.50 |
|
| 2022-03-04 |
Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAC033 |
|
| 2022-03-04 |
Determining the optimal SARS-CoV-2 mRNA vaccine dosing interval for maximum immunogenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.03.01.482592 |
|
| 2022-03-04 |
Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN2688 |
35143256 |
| 2022-03-03 |
CEBIT screening for inhibitors of the interaction between SARS-CoV-2 spike and ACE2 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-03-03 |
Truncating fined-tuned vision-based models to lightweight deployable diagnostic tools for SARS-CoV-2 infected chest X-rays and CT-scans (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11042-022-12484-0 |
35261555 |
| 2022-03-03 |
Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28882-9 |
35241675 |
| 2022-03-03 |
Viral load of SARS-CoV-2 in droplets and bioaerosols directly captured during breathing, speaking and coughing (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-07301-5 |
35241703 |
| 2022-03-03 |
SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and triggers sequential ER stress and inflammatory responses during SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1080/15548627.2022.2039992 |
35239449 |
| 2022-03-03 |
Statewide Evaluation of SARS-CoV-2 Diagnoses and Sexual Orientation and Gender Identity (edit) |
SARSコロナウイルス2 (edit) |
10.1177/00333549221077073 |
|
| 2022-03-03 |
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-022-02312-5 |
|
| 2022-03-03 |
Mini-XT, a miniaturized tagmentation-based protocol for efficient sequencing of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12967-022-03307-9 |
35241105 |
| 2022-03-02 |
Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28603-2 |
35236847 |
| 2022-03-02 |
Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009922 |
35235558 |
| 2022-03-02 |
Travel ban effects on SARS-CoV-2 transmission lineages in the UAE as inferred by genomic epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0264682 |
35235585 |
| 2022-03-02 |
Biocompatible Films of Calcium Alginate Inactivate Enveloped Viruses such as SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202203.0035.V1 |
|
| 2022-03-01 |
Comparison of anti-peptide and anti-protein antibody-based purification techniques for detection of SARS-CoV-2 by targeted LC-MS/MS (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-03-01 |
Characterization of a cluster of COVID-19 cases linked to the Omicron variant, in Mauritania. (edit) |
SARSコロナウイルス2 (edit) |
|
36005913 |
| 2022-03-01 |
Elucidating important structural features for the binding affinity of spike - SARS-CoV-2 neutralizing antibody complexes (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PROT.26277 |
34761442 |
| 2022-03-01 |
Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1β, IL-6, IL-15 and TNF-α (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12024-021-00414-9 |
34463916 |
| 2022-03-01 |
The effects of SARS-CoV-2 on hearing thresholds in COVID-19 patients with non-hospitalized mild disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJOTO.2021.103320 |
|
| 2022-03-01 |
SARS-CoV-2 vaccine-associated-tinnitus: A review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMSU.2022.103293 |
|
| 2022-03-01 |
Prevalence of current and past COVID-19 in Ohio adults (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANNEPIDEM.2021.11.009 |
34921991 |
| 2022-03-01 |
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2022.105268 |
35271914 |
| 2022-03-01 |
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110429 |
|
| 2022-03-01 |
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMI.2021.10.006 |
|
| 2022-03-01 |
Factors Responsible for Emergence of Novel Viruses: An emphasis on SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COESH.2022.100358 |
|
| 2022-03-01 |
Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105367 |
35247766 |
| 2022-03-01 |
Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.112092 |
34562480 |
| 2022-03-01 |
Existing human mobility data sources poorly predicted the spatial spread of SARS-CoV-2 in Madagascar (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EPIDEM.2021.100534 |
|
| 2022-03-01 |
Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDM.2021.11.002 |
|
| 2022-03-01 |
HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103856 |
|
| 2022-03-01 |
Experiences of the SARS-CoV-2 pandemic amongst Australian healthcare workers: from stressors to protective factors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHIN.2021.12.002 |
34902500 |
| 2022-03-01 |
Copper acetate aerosols: A possible tool complementary to vaccination in fight against SARS-CoV-2 and variants replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110775 |
|
| 2022-03-01 |
Mitochondrial hijacking: A potential mechanism for SARS-CoV-2 to impair female fertility (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2022.110778 |
|
| 2022-03-01 |
Potentialities of graphene and its allied derivatives to combat against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MTADV.2022.100208 |
|
| 2022-03-01 |
SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2022.01.003 |
|
| 2022-03-01 |
FOLLOW-UP OF HOSPITALIZED COVID-19 SURVIVORS: ASSESSMENT OF SHORT AND LONG-TERM CARDIOVASCULAR SEQUELAE AFTER SARS-COV-2 INFECTION (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0735-1097(22)03148-5 |
|
| 2022-03-01 |
T cell responses to SARS-CoV-2 spike cross-recognize Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04460-3 |
35102311 |
| 2022-03-01 |
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04465-Y |
35102312 |
| 2022-03-01 |
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-01704-7 |
35051989 |
| 2022-03-01 |
The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-022-00735-5 |
|
| 2022-03-01 |
Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03084-7 |
|
| 2022-03-01 |
Laboratory study of physical barrier efficiency for worker protection against SARS-CoV-2 while standing or sitting (edit) |
SARSコロナウイルス2 (edit) |
10.1080/02786826.2021.2020210 |
35677842 |
| 2022-03-01 |
Feasibility of a high-volume filter sampler for detecting SARS-CoV-2 RNA in COVID-19 patient rooms (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ANNWEH/WXAB100 |
34791020 |
| 2022-03-01 |
Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAC120 |
35234938 |
| 2022-03-01 |
Coupling freedom from disease principles and early warning from wastewater surveillance to improve health security (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC001 |
36712792 |
| 2022-03-01 |
Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PNASNEXUS/PGAC018 |
36712796 |
| 2022-03-01 |
Risk of SARS‐CoV‐2 in a car cabin assessed through 3D CFD simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1111/INA.13012 |
35347787 |
| 2022-03-01 |
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03705-21 |
35229634 |
| 2022-03-01 |
Waiting for the truth: is reluctance in accepting an early origin hypothesis for SARS-CoV-2 delaying our understanding of viral emergence? (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJGH-2021-008386 |
|
| 2022-03-01 |
Impact of residual risk messaging to reduce false reassurance following test-negative results from asymptomatic coronavirus (SARS-CoV-2) testing: an online experimental study of a hypothetical test (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-056533 |
|
| 2022-03-01 |
Histopathology and localization of SARS-CoV-2 and its host cell entry receptor ACE2 in tissues from naturally infected US-farmed mink (Neovison vison) (edit) |
SARSコロナウイルス2 (edit) |
10.1177/03009858221079665 |
|
| 2022-03-01 |
The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression (edit) |
SARSコロナウイルス2 (edit) |
10.1261/RNA.079086.121 |
|
| 2022-03-01 |
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021109622 |
35178710 |
| 2022-03-01 |
Does SARS-CoV-2 affect cochlear functions in children? (edit) |
SARSコロナウイルス2 (edit) |
10.15537/SMJ.2022.43.3.20210782 |
|
| 2022-03-01 |
Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.2217/FMB-2021-0286 |
|
| 2022-03-01 |
Restaurant-Based Measures to Control Community Transmission of COVID-19, Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2803.211015 |
35202535 |
| 2022-03-01 |
Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2803.211885 |
35202525 |
| 2022-03-01 |
Impact of SARS-CoV-2 Infection Among Non-Invasive Ventilated ALS Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3233/JND-210733 |
|
| 2022-02-28 |
The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immuno-escaping ability (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27663 |
35174519 |
| 2022-02-28 |
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2022.105271 |
35240221 |
| 2022-02-28 |
Optimizing peptide inhibitors of SARS-Cov-2 nsp10/nsp16 methyltransferase predicted through molecular simulation and machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2022.100886 |
35252541 |
| 2022-02-28 |
SARS-CoV-2 nucleocapsid protein targets a conserved surface groove of the NTF2-like domain of G3BP1 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2022.167516 |
35240128 |
| 2022-02-27 |
The Incidence of Diabetes Among 2,808,106 Veterans With and Without Recent SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.2337/DC21-1686 |
|
| 2022-02-26 |
Comparison of analytical sensitivity and efficiency for SARS-CoV-2 primer sets by TaqMan-based and SYBR Green-based RT-qPCR (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00253-022-11822-4 |
35218386 |
| 2022-02-26 |
Machine learning prediction of 3CL SARS-CoV-2 docking scores (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2022.107656 |
|
| 2022-02-26 |
Prodrug Therapies for Infectious and Neurodegenerative Diseases (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACEUTICS14030518 |
35335894 |
| 2022-02-25 |
The first baseline of ALDFG generated by the artisanal fishery during the SARS-CoV-2 pandemic on the north coast of Pernambuco, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MARPOLBUL.2022.113470 |
35245765 |
| 2022-02-25 |
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03090-9 |
35217718 |
| 2022-02-25 |
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN8652 |
35076256 |
| 2022-02-25 |
Index-Based Policy to Guide Mask-Wearing for SARS-CoV-2 and Other Pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4039299 |
|
| 2022-02-25 |
Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.3168/JDS.2021-21247 |
35221061 |
| 2022-02-25 |
Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.835686 |
35281029 |
| 2022-02-25 |
Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.838985 |
|
| 2022-02-25 |
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23052558 |
35269703 |
| 2022-02-24 |
Viroporins: structure, function, and their role in the life cycle of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOCEL.2022.106185 |
35219876 |
| 2022-02-24 |
Insights into Binding of Single-Stranded Viral RNA Template to the Replication-Transcription Complex of SARS-CoV-2 for the Priming Reaction from Molecular Dynamics Simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.1C00755 |
35199520 |
| 2022-02-24 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.0C01140 |
33186044 |
| 2022-02-24 |
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-022-00630-0 |
|
| 2022-02-24 |
Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-022-01736-Z |
|
| 2022-02-24 |
Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facility (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06873-6 |
35210470 |
| 2022-02-24 |
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2804.211907 |
35203113 |
| 2022-02-23 |
Neuropilin‐1‐Mediated SARS‐CoV‐2 Infection in Bone Marrow‐Derived Macrophages Inhibits Osteoclast Differentiation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADBI.202200007 |
35195371 |
| 2022-02-23 |
The stalk domain of SARS-CoV-2 NSP13 is essential for its helicase activity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2022.02.068 |
35245742 |
| 2022-02-23 |
Detection of SARS-CoV-2 RNA throughout wastewater treatment plants and a modeling approach to understand COVID-19 infection dynamics in Winnipeg, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153906 |
35218826 |
| 2022-02-23 |
Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28508-0 |
35197461 |
| 2022-02-23 |
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-022-00450-8 |
35197485 |
| 2022-02-23 |
Evaluation of Swab-Seq as a scalable, sensitive assay for community surveillance of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06901-5 |
|
| 2022-02-23 |
Evaluation of the Performance of a Multiplexed Serological Assay in the Detection of SARS-CoV-2 Infections in a Predominantly Vaccinated Population (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01454-21 |
35196794 |
| 2022-02-23 |
Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections—an Open Observational Study in Lower Saxony, Germany (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01512-21 |
|
| 2022-02-23 |
Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02366-21 |
35196783 |
| 2022-02-23 |
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02513-21 |
|
| 2022-02-23 |
Limited Recognition of Highly Conserved Regions of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.02780-21 |
35196796 |
| 2022-02-23 |
Is heparan sulfate a target for inhibition of RNA virus infection? (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPCELL.00028.2022 |
|
| 2022-02-23 |
Serially passaged, conditionally reprogrammed nasal epithelial cells as a model to study epithelial functions and SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPCELL.00363.2021 |
35196166 |
| 2022-02-23 |
Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.832501 |
35281023 |
| 2022-02-23 |
Interactions of Severe Acute Respiratory Syndrome Coronavirus 2 Protein E With Cell Junctions and Polarity PSD-95/Dlg/ZO-1-Containing Proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.829094 |
35283834 |
| 2022-02-23 |
Stillbirth after COVID-19 in Unvaccinated Mothers Can Result from SARS-CoV-2 Placentitis, Placental Insufficiency, and Hypoxic Ischemic Fetal Demise, Not Direct Fetal Infection: Potential Role of Maternal Vaccination in Pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14030458 |
35336864 |
| 2022-02-23 |
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study (edit) |
SARSコロナウイルス2 (edit) |
10.5603/CJ.A2021.0148 |
34787891 |
| 2022-02-22 |
The SARS‐CoV‐2 Spike Glycoprotein Directly Binds Exogeneous Sialic Acids: A NMR View (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ANIE.202201432 |
|
| 2022-02-22 |
Multi-omics evaluation of SARS-CoV-2 infected mouse lungs reveals dynamics of host responses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103967 |
35224468 |
| 2022-02-22 |
A cell-based system combined with flow cytometry to evaluate antibody responses against SARS-CoV-2 transmembrane proteins in patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2022.101229 |
35287269 |
| 2022-02-22 |
Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28654-5 |
35194049 |
| 2022-02-22 |
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03101-9 |
35194144 |
| 2022-02-22 |
BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-022-00083-X |
35465056 |
| 2022-02-22 |
Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.02.19.481107 |
|
| 2022-02-22 |
Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-022-00647-6 |
35193695 |
| 2022-02-22 |
Shedding Light on SARS-CoV-2, COVID-19, COVID-19 Vaccination, and Auditory Symptoms: Causality or Spurious Conjunction? (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2022.837513 |
|
| 2022-02-21 |
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12185-022-03300-4 |
35190963 |
| 2022-02-21 |
SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110503 |
35235832 |
| 2022-02-21 |
Limited extent and consequences of pancreatic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110508 |
35247306 |
| 2022-02-21 |
Active site prediction of phosphorylated SARS-CoV-2 N-Protein using molecular simulation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2022.100889 |
35224174 |
| 2022-02-21 |
Decoupling SARS-CoV-2 ORF6 localization and interferon antagonism (edit) |
SARSコロナウイルス2 (edit) |
10.1242/JCS.259666 |
35187564 |
| 2022-02-21 |
Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19042392 |
|
| 2022-02-19 |
How tetraspanin-mediated cell entry of SARS-CoV-2 can dysregulate the shedding of the ACE2 receptor by ADAM17 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2022.01.038 |
35063769 |
| 2022-02-19 |
Can spike fragments of SARS-CoV-2 induce genomic instability and DNA damage in the guppy, Poecilia reticulate? An unexpected effect of the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153988 |
35192827 |
| 2022-02-18 |
Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-022-05385-Y |
35178586 |
| 2022-02-18 |
SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12015-021-10322-8 |
35181867 |
| 2022-02-18 |
Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2022.105253 |
35189404 |
| 2022-02-18 |
Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06752-0 |
35181735 |
| 2022-02-18 |
Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.02.17.480845 |
|
| 2022-02-18 |
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM5835 |
35076281 |
| 2022-02-18 |
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN7760 |
35050643 |
| 2022-02-18 |
A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-022-02290-8 |
35177066 |
| 2022-02-18 |
Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention — New York City, November–December 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7107A4 |
|
| 2022-02-17 |
Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CMDC.202100782 |
35112482 |
| 2022-02-17 |
Identification of a Potential mRNA-based Vaccine Candidate against the SARS-CoV-2 Spike Glycoprotein: A Reverse Vaccinology Approach (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SLCT.202103903 |
35601809 |
| 2022-02-17 |
Impacts of the SARS-CoV-2 pandemic on the global demand for exotic pets: An expert elicitation approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GECCO.2022.E02067 |
|
| 2022-02-17 |
SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103934 |
35194575 |
| 2022-02-17 |
Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103939 |
35194576 |
| 2022-02-17 |
The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCRC.2022.154010 |
35183892 |
| 2022-02-17 |
Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLLIQ.2022.118775 |
35194277 |
| 2022-02-17 |
Detecting SARS-CoV-2 lineages and mutational load in municipal wastewater and a use-case in the metropolitan area of Thessaloniki, Greece (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06625-6 |
35177697 |
| 2022-02-17 |
Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010343 |
35176124 |
| 2022-02-17 |
Sensitivity and efficiency of RNA sample pooling for real-time quantitative polymerase chain reaction testing for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.21037/JPHE-21-97 |
|
| 2022-02-17 |
A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pa (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10020314 |
35214772 |
| 2022-02-16 |
Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LFS.2022.120411 |
35181310 |
| 2022-02-16 |
Bat coronaviruses related to SARS-CoV-2 and infectious for human cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04532-4 |
|
| 2022-02-16 |
Reproduction Numbers of SARS-CoV-2 Variants: A Systematic Review and Meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAC137 |
35171991 |
| 2022-02-16 |
Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00681-21 |
35170989 |
| 2022-02-16 |
Lipid and Nucleocapsid N-Protein Accumulation in COVID-19 Patient Lung and Infected Cells (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01271-21 |
35171025 |
| 2022-02-16 |
Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12865-022-00480-W |
35172720 |
| 2022-02-16 |
Bayes Lines Tool (BLT): a SQL-script for analyzing diagnostic test results with an application to SARS-CoV-2-testing (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.51061.3 |
|
| 2022-02-16 |
Infection clusters can elevate risk of diagnostic target failure for detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0264008 |
35171960 |
| 2022-02-16 |
A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.811430 |
35250984 |
| 2022-02-16 |
Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.828053 |
35251012 |
| 2022-02-16 |
Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies (edit) |
SARSコロナウイルス2 (edit) |
10.4049/IMMUNOHORIZONS.2200005 |
35173021 |
| 2022-02-15 |
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100529 |
35233550 |
| 2022-02-15 |
Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06306-4 |
35169179 |
| 2022-02-15 |
SARS-CoV-2 RNA is enriched by orders of magnitude in primary settled solids relative to liquid wastewater at publicly owned treatment works (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1EW00826A |
35433013 |
| 2022-02-15 |
Unrecognized introductions of SARS-CoV-2 into the US state of Georgia shaped the early epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC011 |
35317348 |
| 2022-02-15 |
Inhibition of Protein Glycosylation Blocks SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03718-21 |
35164559 |
| 2022-02-15 |
Assessment of performance and implementation characteristics of rapid point of care SARS-CoV-2 antigen testing (edit) |
SARSコロナウイルス2 (edit) |
10.12688/AASOPENRES.13323.1 |
|
| 2022-02-15 |
Operationalizing a routine wastewater monitoring laboratory for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PWAT.0000007 |
|
| 2022-02-15 |
Rapid SARS-CoV-2 Intra-Host and Within-Household Emergence of Novel Haplotypes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14020399 |
|
| 2022-02-14 |
Strikingly Different Roles of SARS-CoV-2 Fusion Peptides Uncovered by Neutron Scattering (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.1C09856 |
35157798 |
| 2022-02-14 |
Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28446-X |
35165285 |
| 2022-02-14 |
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-04952-2 |
35165301 |
| 2022-02-14 |
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41746-022-00561-5 |
|
| 2022-02-14 |
Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2106379119 |
35165203 |
| 2022-02-14 |
Structural polymorphism of coiled‐coils from the stalk domain of SARS‐CoV‐2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FJ.202101670R |
35157347 |
| 2022-02-14 |
Real world data on cardiometabolic diseases in U.S. adults during the SARS-CoV-2 pandemic: a decentralized registry study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12933-022-01462-3 |
35164745 |
| 2022-02-14 |
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2: a case report (edit) |
SARSコロナウイルス2 (edit) |
10.12809/HKMJ219689 |
|
| 2022-02-14 |
Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262399 |
|
| 2022-02-14 |
SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.798813 |
35237261 |
| 2022-02-14 |
Post SARS-CoV-2 Urban India: Computing Air Quality Health Indicators (AQHI) for Gurugram City to Assess Imminent Threats to Public Health (edit) |
SARSコロナウイルス2 (edit) |
10.53550/EEC.2022.V28I01S.027 |
|
| 2022-02-13 |
Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PEP.2022.106071 |
35172194 |
| 2022-02-13 |
Use of ozonation technology to combat viruses and bacteria in aquatic environments: problems and application perspectives for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/09593330.2022.2034981 |
|
| 2022-02-13 |
Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans (edit) |
SARSコロナウイルス2 (edit) |
10.1124/DMD.121.000801 |
|
| 2022-02-12 |
Structure and dynamics of the SARS‐CoV ‐2 envelope protein monomer (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PROT.26317 |
|
| 2022-02-12 |
Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMETH.2022.02.004 |
35167916 |
| 2022-02-12 |
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2022.02.013 |
35167974 |
| 2022-02-11 |
SARS‐CoV‐2 Omicron variant: A next phase of the COVID‐19 pandemic and a call to arms for system sciences and precision medicine (edit) |
SARSコロナウイルス2 (edit) |
10.1002/MCO2.119 |
|
| 2022-02-11 |
SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2022.101724 |
35157849 |
| 2022-02-11 |
Evaluation of Interactions between SARS-CoV-2 RBD and Full-Length ACE2 with Coarse-Grained Molecular Dynamics Simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C01306 |
35147419 |
| 2022-02-11 |
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABN7591 |
35040667 |
| 2022-02-11 |
Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots (edit) |
SARSコロナウイルス2 (edit) |
10.3791/63395 |
|
| 2022-02-10 |
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YMTHE.2022.02.011 |
35151843 |
| 2022-02-10 |
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.1C08402 |
35142215 |
| 2022-02-10 |
Plasma Neutralization of the SARS-CoV-2 Omicron Variant (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2119641 |
35030645 |
| 2022-02-10 |
Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2022.2026739 |
|
| 2022-02-10 |
Factors affecting the transmission of SARS-CoV-2 in school settings (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IRV.12968 |
35146922 |
| 2022-02-10 |
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients (edit) |
SARSコロナウイルス2 (edit) |
10.1152/JAPPLPHYSIOL.00015.2022 |
35142560 |
| 2022-02-10 |
Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07102-1 |
35144550 |
| 2022-02-10 |
Predicted impact of the viral mutational landscape on the cytotoxic response against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009726 |
35143484 |
| 2022-02-10 |
The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009914 |
35143587 |
| 2022-02-10 |
A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010265 |
35143592 |
| 2022-02-10 |
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.820126 |
|
| 2022-02-09 |
Structure‐ and Interaction‐Based Design of Anti‐SARS‐CoV‐2 Aptamers (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CHEM.202104481 |
|
| 2022-02-09 |
Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRSTBI.2022.01.002 |
35156058 |
| 2022-02-09 |
Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2022.101710 |
35150743 |
| 2022-02-09 |
Selection of surrogate viruses for process control in detection of SARS-CoV-2 in wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153737 |
35149069 |
| 2022-02-09 |
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28544-W |
35140233 |
| 2022-02-09 |
Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJ-2021-068414 |
|
| 2022-02-09 |
Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-053237 |
35140153 |
| 2022-02-09 |
The atlas of ACE2 expression in fetal and adult human hearts reveals the potential mechanism of heart-injured patients infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPCELL.00169.2021 |
35138176 |
| 2022-02-09 |
Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-022-00750-5 |
35139909 |
| 2022-02-08 |
B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ANA.26309 |
35067959 |
| 2022-02-08 |
Human SARS-CoV-2 has evolved to increase U content and reduce genome size (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.02.034 |
35149094 |
| 2022-02-08 |
Effects of theaflavin-gallate in-silico binding with different proteins of SARS-CoV-2 and host inflammation and vasoregulations referring an experimental rat-lung injury (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYPLU.2022.100237 |
35403090 |
| 2022-02-08 |
Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PRRV.2022.01.008 |
35227628 |
| 2022-02-08 |
Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.1C00786 |
|
| 2022-02-08 |
Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27942-W |
35136068 |
| 2022-02-08 |
Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28324-6 |
35136050 |
| 2022-02-08 |
Genomic epidemiology of SARS-CoV-2 under an elimination strategy in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28420-7 |
35136039 |
| 2022-02-08 |
Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-06091-0 |
35136154 |
| 2022-02-08 |
An extended motif in the SARS-CoV-2 spike modulates binding and release of host coatomer in retrograde trafficking (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03063-Y |
35136165 |
| 2022-02-08 |
Subcellular Detection of SARS-CoV-2 RNA in Human Tissue Reveals Distinct Localization in Alveolar Type 2 Pneumocytes and Alveolar Macrophages (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03751-21 |
35130722 |
| 2022-02-08 |
SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03788-21 |
35130727 |
| 2022-02-08 |
Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-055474 |
35135773 |
| 2022-02-08 |
The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0263684 |
|
| 2022-02-08 |
SARS-CoV-2 Spike Glycoprotein Binds Heparan Sulfate Chains and N-Glycans in Psoriatic Keratinocytes: A Hypothesis. (edit) |
SARSコロナウイルス2 (edit) |
10.33425/2690-537X.1019 |
|
| 2022-02-07 |
Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CLPro) of SARS-CoV-2: in silico study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11224-022-01887-2 |
35153452 |
| 2022-02-07 |
Cryo-EM structure of the SARS-CoV-2 Omicron spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110428 |
35172173 |
| 2022-02-07 |
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJCA.2022.01.019 |
35248840 |
| 2022-02-07 |
The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2022.101695 |
35143839 |
| 2022-02-07 |
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04482-X |
|
| 2022-02-07 |
Anti-SARS-CoV-2 antibodies among indigenous populations of the Brazilian Amazon: a cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-054271 |
|
| 2022-02-07 |
Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka (edit) |
SARSコロナウイルス2 (edit) |
10.12688/WELLCOMEOPENRES.16768.2 |
|
| 2022-02-07 |
Omicron Variant (B.1.1.529) of SARS-CoV-2, A Worldwide Public Health Emergency! (edit) |
SARSコロナウイルス2 (edit) |
10.24018/CLINICMED.2022.3.1.159 |
|
| 2022-02-07 |
Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.786233 |
|
| 2022-02-06 |
Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JFBC.14085 |
35128681 |
| 2022-02-05 |
Spatiotemporal clustering patterns and sociodemographic determinants of COVID-19 (SARS-CoV-2) infections in Helsinki, Finland (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-02-05 |
Tracing the SARS-CoV-2 infection on the ocular surface: Overview and preliminary corneoscleral transcriptome sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EXER.2022.108975 |
35134391 |
| 2022-02-05 |
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103880 |
35156006 |
| 2022-02-05 |
Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2022.100195 |
35156075 |
| 2022-02-05 |
Escherichia coli recombinant expression of SARS-CoV-2 protein fragments (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12934-022-01753-0 |
|
| 2022-02-04 |
SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2022.100873 |
35136832 |
| 2022-02-04 |
Limited genomic reconstruction of SARS-CoV-2 transmission history within local epidemiological clusters (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAC008 |
35242361 |
| 2022-02-04 |
Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S41231-022-00109-5 |
35136839 |
| 2022-02-04 |
Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.798538 |
35185890 |
| 2022-02-04 |
SARS-CoV-2 Dysregulates Neutrophil Degranulation and Reduces Lymphocyte Counts (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES10020382 |
|
| 2022-02-04 |
Secondary Structure of Subgenomic RNA M of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14020322 |
35215915 |
| 2022-02-04 |
Biomimetic Alveolus-on-a-Chip for SARS-CoV-2 Infection Recapitulation (edit) |
SARSコロナウイルス2 (edit) |
10.34133/2022/9819154 |
35224503 |
| 2022-02-03 |
Designed SARS-CoV-2 receptor binding domain variants form stable monomers (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BIOT.202100422 |
35078277 |
| 2022-02-03 |
Omicron (B.1.1.529) variant of SARS-CoV-2 – Concerns, challenges and recent updates (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27633 |
|
| 2022-02-03 |
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2022.01.004 |
35132398 |
| 2022-02-03 |
Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28246-3 |
|
| 2022-02-03 |
Myeloid cell interferon responses correlate with clearance of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28315-7 |
35115549 |
| 2022-02-03 |
The Slowing Rate of CpG Depletion in SARS-CoV-2 Genomes Is Consistent with Adaptations to the Human Host (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAC029 |
|
| 2022-02-03 |
Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2022.768356 |
35186917 |
| 2022-02-03 |
Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.817905 |
35185909 |
| 2022-02-02 |
Mass spectrometry and proteome analysis to identify SARS-CoV-2 protein from COVID-19 patient swab samples (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-02-02 |
Glucosinolates and their hydrolysis products as potential nutraceuticals to combat cytokine storm in SARS-COV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40199-022-00435-X |
|
| 2022-02-02 |
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.01.027 |
35202565 |
| 2022-02-02 |
Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2022.01.011 |
35134624 |
| 2022-02-02 |
A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28113-1 |
35110538 |
| 2022-02-02 |
Host cellular RNA helicases regulate SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00002-22 |
|
| 2022-02-02 |
The outbreak of the SARS‐CoV‐2 Omicron variant make imperative the adoption of telerehabilitation in the Bulgarian health care system (edit) |
SARSコロナウイルス2 (edit) |
10.4081/EJTM.2022.10355 |
|
| 2022-02-01 |
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMAINTERNMED.2021.7382 |
|
| 2022-02-01 |
SARS-CoV-2 Variant Tracking and Mitigation During In-Person Learning at a Midwestern University in the 2020-2021 School Year (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2021.46805 |
35113163 |
| 2022-02-01 |
Comparison of SARS-CoV-2 Test Positivity in NCAA Division I Student Athletes vs Nonathletes at 12 Institutions (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2021.47805 |
35138397 |
| 2022-02-01 |
Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach (edit) |
SARSコロナウイルス2 (edit) |
10.1002/OPEN.202100248 |
35103413 |
| 2022-02-01 |
SARS-CoV-2 Inhibitors from Nigella Sativa (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12010-021-03790-8 |
35102539 |
| 2022-02-01 |
An update on COVID-19 and pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2021.08.054 |
34534497 |
| 2022-02-01 |
Dysphagia Characteristics of Patients Post SARS-CoV-2 During Inpatient Rehabilitation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.APMR.2021.10.007 |
|
| 2022-02-01 |
Rapid detection of novel coronavirus SARS-CoV-2 by RT-LAMP coupled solid-state nanopores (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOS.2021.113759 |
|
| 2022-02-01 |
Multi-color super-resolution imaging to study human coronavirus RNA during cellular infection (edit) |
ヒトコロナウイルス229E (edit) |
10.1016/J.CRMETH.2022.100170 |
35128513 |
| 2022-02-01 |
Evaluation of observed and unobserved self-collection of saline gargle samples for the detection of SARS-CoV-2 in outpatients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2021.115566 |
34781164 |
| 2022-02-01 |
SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.103861 |
|
| 2022-02-01 |
Corrigendum to “Error rates in SARS-CoV-2 testing examined with Bayes' theorem” [Heliyon 7, (4), (April 2021), Article e06905] (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2022.E08836 |
|
| 2022-02-01 |
Impaired hearing following SARS-CoV-2 vaccinations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.12.317 |
|
| 2022-02-01 |
A Case Report of Pediatric Germinoma With SARS-CoV-2: Lessons Learned From an Academic Tertiary Referral Hospital in Asian COVID Epicentrum (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJSCR.2022.106774 |
35070644 |
| 2022-02-01 |
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJSU.2022.106233 |
|
| 2022-02-01 |
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIAC.2021.10.026 |
|
| 2022-02-01 |
A SARS-CoV-2 Delta variant containing mutation in the probe binding region used for RT-qPCR test in Japan exhibited atypical PCR amplification and might induce false negative result (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIAC.2022.01.019 |
35144878 |
| 2022-02-01 |
Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.09.019 |
|
| 2022-02-01 |
Dynamics of Reverse Transcription-Polymerase Chain Reaction and Serologic Test Results in Children with SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPEDS.2021.09.029 |
|
| 2022-02-01 |
Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110750 |
|
| 2022-02-01 |
SARS-CoV-2 might transmit through the skin while the skin barrier function could be the mediator (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110752 |
35002019 |
| 2022-02-01 |
A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110754 |
|
| 2022-02-01 |
Alimentation et risque d’infection par le SARS-CoV-2 : étude prospective dans la cohorte NutriNet-Santé (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NUPAR.2021.12.065 |
|
| 2022-02-01 |
Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEMCR.2022.01.014 |
35180394 |
| 2022-02-01 |
The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41429-021-00491-6 |
|
| 2022-02-01 |
SARS-CoV-2 genomes from Saudi Arabia implicate nucleocapsid mutations in host response and increased viral load (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-022-28287-8 |
35105893 |
| 2022-02-01 |
Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04342-0 |
34937050 |
| 2022-02-01 |
SARS-CoV-2 infection in free-ranging white-tailed deer (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04353-X |
34942632 |
| 2022-02-01 |
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04462-1 |
35104835 |
| 2022-02-01 |
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04474-X |
35104837 |
| 2022-02-01 |
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04479-6 |
|
| 2022-02-01 |
SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43587-022-00170-7 |
37117754 |
| 2022-02-01 |
Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21655979.2022.2027181 |
35048792 |
| 2022-02-01 |
Expression of recombinant SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro) in Escherichia coli RIPL (edit) |
SARSコロナウイルス2 (edit) |
10.1088/1755-1315/976/1/012033 |
|
| 2022-02-01 |
Spatio-temporal dynamics of intra-host variability in SARS-CoV-2 genomes (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB1297 |
35048970 |
| 2022-02-01 |
Testing for SARS-CoV-2 in symptomatic vaccinated and unvaccinated health care workers during the Delta variant surge (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JOM.0000000000002431 |
34775397 |
| 2022-02-01 |
The E3 Ubiquitin Ligase RNF5 Facilitates SARS-CoV-2 Membrane Protein-Mediated Virion Release (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03168-21 |
35100873 |
| 2022-02-01 |
Ethnobotany in the Andes and the Amazon in a world of Nagoya Protocol and post SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1139/CJB-2021-0062 |
|
| 2022-02-01 |
Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1165/RCMB.2021-0292OC |
34731594 |
| 2022-02-01 |
Early Evidence of Circulating SARS-CoV-2 in Unvaccinated and Vaccinated Measles Patients, September 2019–February 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.2147/IDR.S344437 |
|
| 2022-02-01 |
Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2802.211938 |
34852213 |
| 2022-02-01 |
Pathophysiological Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy Enables Rapid and Robust Saliva Screening for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES10020351 |
35203562 |
| 2022-02-01 |
The nsp15 Nuclease as a Good Target to Combat SARS-CoV-2: Mechanism of Action and Its Inactivation with FDA-Approved Drugs (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS10020342 |
|
| 2022-02-01 |
Microplastics and Macroplastic Debris as Potential Physical Vectors of SARS-CoV-2: A Hypothetical Overview with Implications for Public Health (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROPLASTICS1010010 |
|
| 2022-02-01 |
Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.34133/2022/9781758 |
35198984 |
| 2022-02-01 |
Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex (edit) |
SARSコロナウイルス2 (edit) |
10.4274/TJPS.GALENOS.2021.56957 |
35227055 |
| 2022-02-01 |
A COVID-19 T-Cell Response Detection Method Based on a Newly Identified Human CD8+ T Cell Epitope from SARS-CoV-2 - Hubei Province, China, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.46234/CCDCW2021.258 |
35186375 |
| 2022-01-31 |
Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti-SARS-CoV-2 Activity (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CMDC.202100732 |
35099120 |
| 2022-01-31 |
Virus interactions with the actin cytoskeleton—what we know and do not know about SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-022-05366-1 |
35102456 |
| 2022-01-31 |
Item-level analysis of mental health symptom trajectories during the COVID-19 pandemic in the UK: Associations with age, sex and pre-existing psychiatric conditions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPPSYCH.2022.152298 |
35123177 |
| 2022-01-31 |
SARS-CoV-2 in Egypt: epidemiology, clinical characterization and bioinformatics analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2022.E08864 |
35128118 |
| 2022-01-31 |
The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103854 |
35128349 |
| 2022-01-31 |
Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCT.2022.01.019 |
35092892 |
| 2022-01-31 |
In silico, in vitro screening of plant extracts for anti-SARS-CoV-2 activity and evaluation of their acute and sub-acute toxicity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYPLU.2022.100233 |
35403091 |
| 2022-01-31 |
An in silico analysis identifies drugs potentially modulating the cytokine storm triggered by SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-05597-X |
35102208 |
| 2022-01-31 |
SARS-CoV-2 S Protein Subunit 1 Elicits Ca2+ Influx - Dependent Ca2+ Signals in Pancreatic Stellate Cells and Macrophages In Situ (edit) |
SARSコロナウイルス2 (edit) |
10.1093/FUNCTION/ZQAC002 |
35284826 |
| 2022-01-31 |
Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.29.478316 |
|
| 2022-01-31 |
Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-022-02243-1 |
|
| 2022-01-31 |
Sulfated Polysaccharide from Marine Red Microalga Porphyridium against SARS-CoV-2 - A Mini-Review (edit) |
SARSコロナウイルス2 (edit) |
10.31080/ASMI.2022.05.1012 |
|
| 2022-01-30 |
Inhibitory efficacy of 2, 4-diacetylphloroglucinol against SARS-COV-2 proteins: in silico study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11756-021-00979-4 |
35125499 |
| 2022-01-29 |
The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2022.01.106 |
35123263 |
| 2022-01-29 |
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.01.024 |
35126884 |
| 2022-01-29 |
Persistence of SARS-CoV-2 RNA in wastewater after the end of the COVID-19 epidemics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHAZMAT.2022.128358 |
|
| 2022-01-29 |
The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2022.01.029 |
35277373 |
| 2022-01-29 |
Early introduction, dispersal and evolution of Delta SARS-CoV-2 in Southern Brazil, late predominance of AY.99.2 and AY.101 related lineages (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198702 |
35104582 |
| 2022-01-29 |
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(22)00017-4 |
35065011 |
| 2022-01-29 |
SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB394 |
33949665 |
| 2022-01-28 |
Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27596 |
35032057 |
| 2022-01-28 |
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103818 |
35106453 |
| 2022-01-28 |
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04466-X |
35090164 |
| 2022-01-28 |
Antiviral activities of natural compounds and ionic liquids to inhibit the Mpro of SARS-CoV-2: a computational approach (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA08604A |
35425367 |
| 2022-01-28 |
Factors Associated With SARS-CoV-2 Attack Rates in Aged Care—A Meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAC033 |
|
| 2022-01-28 |
Impact of voluntary risk-mitigation behaviour on transmission of the Omicron SARS-CoV-2 variant in England (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.26.22269540 |
|
| 2022-01-28 |
Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-022-07045-7 |
35090398 |
| 2022-01-28 |
Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020-January 2022 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7104E4 |
35085225 |
| 2022-01-28 |
SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.732197 |
35154090 |
| 2022-01-27 |
Effectiveness of Disinfectants Suitable for Inactivating SARS-CoV-2 at Cold-Chain Temperature (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12560-022-09509-0 |
|
| 2022-01-27 |
Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-05349-X |
35087077 |
| 2022-01-27 |
Effect of SARS-CoV-2 spike mutations on its activation by TMPRSS2 and TMPRSS13 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.26.477969 |
|
| 2022-01-27 |
Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1146/ANNUREV-MED-042220-023859 |
|
| 2022-01-27 |
Genome-scale CRISPR screens identify host factors that promote human coronavirus infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13073-022-01013-1 |
35086559 |
| 2022-01-27 |
Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.751705 |
35154094 |
| 2022-01-27 |
Integrated Analysis Reveals the Characteristics and Effects of SARS-CoV-2 Maternal-Fetal Transmission (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.813187 |
35154056 |
| 2022-01-26 |
Trypsin enhances SARS-CoV-2 infection by facilitating viral entry (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00705-021-05343-0 |
35079901 |
| 2022-01-26 |
Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A medicinal chemistry approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2022.105235 |
35123137 |
| 2022-01-26 |
Inhalable SARS-CoV-2 Mimetic Particles Induce Pleiotropic Antigen Presentation (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOMAC.1C01447 |
35080884 |
| 2022-01-26 |
Despite the odds: formation of the SARS-CoV-2 methylation complex (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.25.477673 |
|
| 2022-01-26 |
A Structurally Conserved RNA Element within SARS-CoV-2 ORF1a RNA and S mRNA Regulates Translation in Response to Viral S Protein-Induced Signaling in Human Lung Cells (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01678-21 |
34757848 |
| 2022-01-26 |
Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.02184-21 |
35080423 |
| 2022-01-26 |
Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.02216-21 |
35080424 |
| 2022-01-26 |
Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-022-02235-1 |
|
| 2022-01-26 |
End-to-end system for rapid and sensitive early-detection of SARS-CoV-2 for resource-poor and field-test environments using a $51 lab-in-a-backpack (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0259886 |
35081119 |
| 2022-01-25 |
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.01.018 |
35148837 |
| 2022-01-25 |
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.01.019 |
|
| 2022-01-25 |
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110368 |
35123652 |
| 2022-01-25 |
Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2022.01.003 |
35134333 |
| 2022-01-25 |
Characteristics of SARS-CoV-2 transmission in a medium-sized city with traditional communities during the early COVID-19 epidemic in China (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRS.2022.01.030 |
|
| 2022-01-25 |
Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-05342-4 |
35079083 |
| 2022-01-25 |
Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2113874119 |
35078919 |
| 2022-01-25 |
Residual antimicrobial coating efficacy against SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JAM.15437 |
|
| 2022-01-25 |
N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03662-21 |
35073761 |
| 2022-01-25 |
Nanobubble Ozone Stored in Hyaluronic Acid Decorated Liposomes: Antibacterial, Anti-SARS-CoV-2 Effect and Biocompatibility Tests (edit) |
SARSコロナウイルス2 (edit) |
10.2147/IJN.S328090 |
35115773 |
| 2022-01-24 |
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-24 |
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.01.015 |
35139340 |
| 2022-01-24 |
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2022.100527 |
35233548 |
| 2022-01-24 |
Protocol for structure determination of SARS-CoV-2 main protease at near-physiological-temperature by serial femtosecond crystallography (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2022.101158 |
35194584 |
| 2022-01-24 |
SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-00878-3 |
35075101 |
| 2022-01-24 |
Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010255 |
35073387 |
| 2022-01-24 |
Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.830527 |
35140714 |
| 2022-01-23 |
Development and Evaluation of Peptidomimetic Compounds Against SARS-CoV-2 Spike Protein: an In Silico and In Vitro Study (edit) |
SARSコロナウイルス2 (edit) |
10.1002/MINF.202100231 |
35068079 |
| 2022-01-22 |
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2022.103818 |
35078012 |
| 2022-01-22 |
Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2022.112720 |
35074352 |
| 2022-01-22 |
Insights into the specificity for the interaction of the promiscuous SARS-CoV-2 nucleocapsid protein N-terminal domain with deoxyribonucleic acids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.01.121 |
35077748 |
| 2022-01-22 |
HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSAMI.1C19541 |
35067058 |
| 2022-01-22 |
An investigation for the interaction of gamma oryzanol with the Mpro of SARS-CoV-2 to combat COVID-19: DFT, molecular docking, ADME and molecular dynamics simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2022.2029770 |
|
| 2022-01-21 |
Operational Constraints of Detecting SARS-CoV-2 on Passive Samplers using Electronegative Filters: A Kinetic and Equilibrium Analysis (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-21 |
Patients’ perspective about speech, swallowing and hearing status post-SARS-CoV-2 (COVID-19) recovery: E-survey (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00405-021-07217-2 |
|
| 2022-01-21 |
Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2022.01.006 |
35150638 |
| 2022-01-21 |
Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.01.021 |
35096288 |
| 2022-01-21 |
Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103589 |
34909610 |
| 2022-01-21 |
ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103720 |
35005526 |
| 2022-01-21 |
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04441-6 |
35062015 |
| 2022-01-21 |
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04442-5 |
|
| 2022-01-21 |
Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-04950-4 |
35064154 |
| 2022-01-21 |
Tracking the circulating SARS-CoV-2 variant of concern in South Africa using wastewater-based epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-05110-4 |
35064174 |
| 2022-01-21 |
Genomic and transcriptomic characterization of Delta SARS-CoV-2 infection in free-ranging white-tailed deer ( Odocoileus virginianus ) (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.20.476458 |
|
| 2022-01-21 |
The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABM4034 |
35044811 |
| 2022-01-21 |
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM0620 |
34735261 |
| 2022-01-21 |
Studies reveal dangers of SARS-CoV-2 infection in pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ADA0233 |
|
| 2022-01-21 |
Identification of Marine Fungi-Based Antiviral Agents as Potential Inhibitors of SARS-CoV-2 by Molecular Docking, ADMET and Molecular Dynamic Study (edit) |
SARSコロナウイルス2 (edit) |
10.1142/S2737416522500065 |
|
| 2022-01-21 |
Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.811952 |
35126396 |
| 2022-01-20 |
SARS-CoV-2 spike protein inhibits growth of prostate cancer: a potential role of the COVID-19 vaccine killing two birds with one stone (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12032-021-01628-1 |
35059896 |
| 2022-01-20 |
SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110336 |
35090596 |
| 2022-01-20 |
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEMCR.2021.12.011 |
35063125 |
| 2022-01-20 |
Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA07447D |
35425333 |
| 2022-01-20 |
RNA reference materials with defined viral RNA loads of SARS-CoV-2-A useful tool towards a better PCR assay harmonization (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262656 |
35051208 |
| 2022-01-20 |
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.74153 |
|
| 2022-01-19 |
Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110344 |
35093235 |
| 2022-01-19 |
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110345 |
35090598 |
| 2022-01-19 |
Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2022.105404 |
35065253 |
| 2022-01-19 |
The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-022-00874-7 |
35046385 |
| 2022-01-19 |
Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41589-021-00965-6 |
35046611 |
| 2022-01-19 |
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01678-Y |
35046573 |
| 2022-01-19 |
Tissue-level alveolar epithelium model for recapitulating SARS-CoV-2 infection and cellular plasticity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-022-03026-3 |
35046486 |
| 2022-01-19 |
Impact of social distancing on early SARS‐CoV‐2 transmission in the United States (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ZPH.12909 |
|
| 2022-01-19 |
Extended ensemble simulations of a SARS-CoV-2 nsp1-5'-UTR complex (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009804 |
35045069 |
| 2022-01-19 |
Genomic surveillance of SARS-CoV-2 in the state of Delaware reveals tremendous genomic diversity (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262573 |
35045124 |
| 2022-01-19 |
Pregnancy Associated SARS-CoV-2 and Zika Infectious Conditions – Recent Data and Outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.31926/BUT.MS.2022.64.15.1.6 |
|
| 2022-01-19 |
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.811020 |
35126395 |
| 2022-01-19 |
Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14020187 |
35215783 |
| 2022-01-18 |
Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2021.21921 |
34860253 |
| 2022-01-18 |
Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent 1-year global expansion (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27580 |
35001392 |
| 2022-01-18 |
Sequence analysis for SNP detection and phylogenetic reconstruction of SARS-cov-2 isolated from Nigerian COVID-19 cases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NMNI.2022.100955 |
35070322 |
| 2022-01-18 |
Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27745-Z |
35042863 |
| 2022-01-18 |
Early-stage spatial disease surveillance of novel SARS-CoV-2 variants of concern in Germany with crowdsourced data (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-04573-1 |
|
| 2022-01-18 |
Two short low complexity regions (LCRs) are hallmark sequences of the Delta SARS-CoV-2 variant spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-022-04976-8 |
35042962 |
| 2022-01-18 |
JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03377-21 |
35038906 |
| 2022-01-18 |
Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection In Vitro, despite Eliciting a Prolonged Antiviral Response (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.03436-21 |
35038898 |
| 2022-01-18 |
Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report (edit) |
SARSコロナウイルス2 (edit) |
10.12659/AJCR.934220 |
|
| 2022-01-18 |
Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262657 |
35041700 |
| 2022-01-18 |
SARS-CoV-2 antibody seroprevalence in healthcare personnel during the pandemics peak: The experience of single hospital (edit) |
SARSコロナウイルス2 (edit) |
10.5455/MEDSCIENCE.2021.09.294 |
|
| 2022-01-17 |
Competing endogenous RNA network mediated by circ_3205 in SARS-CoV-2 infected cells (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00018-021-04119-8 |
35039944 |
| 2022-01-17 |
Screening and identification of B cell epitope of the nucleocapsid protein in SARS-CoV-2 using the monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00253-022-11769-6 |
35037999 |
| 2022-01-17 |
Detection of homologous recombination events in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10529-021-03218-7 |
35037234 |
| 2022-01-17 |
Methyl β-D-galactopyranoside esters as potential inhibitors for SARS-CoV-2 protease enzyme: synthesis, antimicrobial, PASS, molecular docking, molecular dynamics simulations and quantum computations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10719-021-10039-3 |
35037163 |
| 2022-01-17 |
Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2022.01.094 |
35051498 |
| 2022-01-17 |
Factors associated with SARS-CoV-2 test positivity in long-term care homes: A population-based cohort analysis using machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2021.100146 |
35072145 |
| 2022-01-17 |
Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2022.153171 |
35051459 |
| 2022-01-17 |
Purifying Selection Determines the Short-Term Time Dependency of Evolutionary Rates in SARS-CoV-2 and pH1N1 Influenza (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAC009 |
|
| 2022-01-17 |
Characterization of the SARS-CoV-2 ExoN (nsp14ExoN–nsp10) complex: implications for its role in viral genome stability and inhibitor identification (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB1303 |
35037045 |
| 2022-01-17 |
Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.785941 |
35111156 |
| 2022-01-17 |
Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.796094 |
35111161 |
| 2022-01-16 |
Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2022.115636 |
35219552 |
| 2022-01-15 |
Automatic system for high-throughput and high-sensitivity diagnosis of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00449-021-02674-9 |
35031864 |
| 2022-01-15 |
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRVIRO.2022.100019 |
35072124 |
| 2022-01-15 |
SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCLINEPI.2022.01.002 |
|
| 2022-01-14 |
Detection and discrimination of SARS-CoV-2 spike protein-derived peptides using THz metamaterials (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOS.2022.113981 |
35086028 |
| 2022-01-14 |
Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use (edit) |
SARSコロナウイルス2 (edit) |
10.1017/DMP.2022.15 |
|
| 2022-01-14 |
4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABJ5508 |
34855509 |
| 2022-01-14 |
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM0811 |
|
| 2022-01-14 |
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-021-02228-6 |
35027067 |
| 2022-01-14 |
Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7102E2 |
|
| 2022-01-14 |
In Silico Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.794780 |
35095870 |
| 2022-01-14 |
Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.808932 |
35095897 |
| 2022-01-14 |
Fatal Pneumonia Associated With a Novel Genotype of Human Coronavirus OC43 (edit) |
ベータコロナウイルス１ (edit) |
10.3389/FMICB.2021.795449 |
|
| 2022-01-14 |
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14010144 |
35062348 |
| 2022-01-13 |
Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJMECH.2022.114121 |
35114539 |
| 2022-01-13 |
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-01113-X |
|
| 2022-01-13 |
The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster model (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.12.476031 |
|
| 2022-01-13 |
A short plus long-amplicon based sequencing approach improves genomic coverage and variant detection in the SARS-CoV-2 genome (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0261014 |
35025877 |
| 2022-01-13 |
Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.812176 |
|
| 2022-01-12 |
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.12.004 |
34953513 |
| 2022-01-12 |
Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NANTOD.2022.101393 |
35035515 |
| 2022-01-12 |
SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41418-022-00928-X |
35022571 |
| 2022-01-12 |
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02983-5 |
35022513 |
| 2022-01-12 |
Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2113118119 |
35022216 |
| 2022-01-12 |
SNX27 suppresses SARS-CoV-2 infection by inhibiting viral lysosome/late endosome entry (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2117576119 |
35022217 |
| 2022-01-12 |
Wildlife in Cameroon harbor diverse coronaviruses, including many closely related to human coronavirus 229E (edit) |
ヒトコロナウイルス229E (edit) |
10.1093/VE/VEAB110 |
35233291 |
| 2022-01-12 |
Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.02186-21 |
35019723 |
| 2022-01-12 |
Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPLUNG.00397.2021 |
|
| 2022-01-12 |
Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant's Superior Transmission (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS23020796 |
35054983 |
| 2022-01-11 |
Spatially refined time-varying reproduction numbers of SARS-CoV-2 in Arkansas and Kentucky and their relationship to population size and public health policy, March - November 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANNEPIDEM.2021.12.012 |
35031444 |
| 2022-01-11 |
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2022.110318 |
35090597 |
| 2022-01-11 |
Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMBIOL.2021.11.006 |
35021060 |
| 2022-01-11 |
Exploring the Local Determinants of SARS-CoV-2 Transmission and Control via an Exposure-Based Model (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.EST.1C05633 |
|
| 2022-01-11 |
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-021-00836-Z |
|
| 2022-01-11 |
Structural insights in cell-type specific evolution of intra-host diversity by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27881-6 |
35017512 |
| 2022-01-11 |
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.11.22269045 |
|
| 2022-01-11 |
Alpha-Soluble NSF Attachment Protein Prevents the Cleavage of the SARS-CoV-2 Spike Protein by Functioning as an Interferon-Upregulated Furin Inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02443-21 |
|
| 2022-01-11 |
Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database (edit) |
SARSコロナウイルス2 (edit) |
10.2217/CER-2021-0208 |
35014556 |
| 2022-01-11 |
SARS-CoV-2 Saliva Mass Screening in Primary Schools: A 10-Week Sentinel Surveillance Study in Munich, Germany (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS12010162 |
|
| 2022-01-10 |
Phenotypic analysis of the pediatric immune response to SARS-CoV-2 by flow cytometry (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CYTO.A.24528 |
34953025 |
| 2022-01-10 |
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00018-021-04085-1 |
35013790 |
| 2022-01-10 |
The discovery of herbal drugs and natural compounds as inhibitors of SARS-CoV-2 infection in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11418-021-01596-W |
35006524 |
| 2022-01-10 |
Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11756-021-01004-4 |
35034970 |
| 2022-01-10 |
'All In One' SARS-CoV-2 variant recognition platform: Machine learning-enabled point of care diagnostics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOSX.2022.100105 |
35036904 |
| 2022-01-10 |
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CCELL.2021.12.003 |
34895486 |
| 2022-01-10 |
Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2022.01.006 |
35017107 |
| 2022-01-10 |
Ozone for SARS-CoV-2 inactivation on surfaces and in liquid cell culture media (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHAZMAT.2022.128251 |
35032958 |
| 2022-01-10 |
Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2022.198674 |
35021068 |
| 2022-01-10 |
Robust and durable serological response following pediatric SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27595-9 |
35013206 |
| 2022-01-10 |
Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27669-8 |
35013235 |
| 2022-01-10 |
Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27717-3 |
35013229 |
| 2022-01-10 |
A global assessment of the impact of school closure in reducing COVID-19 spread (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSTA.2021.0124 |
34802277 |
| 2022-01-10 |
Identification and characterisation of SARS-CoV-2 and Human alphaherpesvirus 1 from a productive coinfection in a fatal COVID-19 case (edit) |
SARSコロナウイルス2 (edit) |
10.1590/0074-02760210176 |
35019069 |
| 2022-01-10 |
The Potential Mechanism of Cancer Patients Appearing More Vulnerable to SARS-CoV-2 and Poor Outcomes: A Pan-Cancer Bioinformatics Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.804387 |
35082790 |
| 2022-01-10 |
Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2021.801763 |
|
| 2022-01-10 |
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10010099 |
35062760 |
| 2022-01-09 |
Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00431-021-04345-Z |
|
| 2022-01-09 |
Seasonal Betacoronavirus Antibodies' Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10875-021-01190-5 |
35000058 |
| 2022-01-09 |
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13045-021-01219-7 |
|
| 2022-01-09 |
Tokophobia and Anxiety in Pregnant Women during the SARS-CoV-2 Pandemic in Poland-A Prospective Cross-Sectional Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19020714 |
35055536 |
| 2022-01-08 |
UV and violet light can Neutralize SARS-CoV-2 Infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPAP.2021.100107 |
35036965 |
| 2022-01-08 |
Potential of phytocompounds from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structural and molecular insights (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2022.132369 |
35034979 |
| 2022-01-08 |
SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41418-021-00916-7 |
|
| 2022-01-08 |
Ferrets are valuable models for SARS-CoV-2 research (edit) |
SARSコロナウイルス2 (edit) |
10.1177/03009858211071012 |
35001763 |
| 2022-01-07 |
Point-of-Care Platform for Rapid Multiplexed Detection of SARS-CoV-2 Variants and Respiratory Pathogens (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADMT.202101013 |
35441089 |
| 2022-01-07 |
Predicting SARS-CoV-2 infection duration at hospital admission:a deep learning solution (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11517-021-02479-8 |
|
| 2022-01-07 |
Immunity to SARS-CoV-2 up to 15 months after infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2022.103743 |
35018336 |
| 2022-01-07 |
A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIM.2022.113216 |
35007561 |
| 2022-01-07 |
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1038/D41586-021-03832-5 |
|
| 2022-01-07 |
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04411-Y |
35042229 |
| 2022-01-07 |
Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-04360-Y |
34997166 |
| 2022-01-07 |
A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABH3827 |
34995117 |
| 2022-01-07 |
Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABJ4526 |
34995115 |
| 2022-01-07 |
Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12860-021-00403-4 |
34991443 |
| 2022-01-07 |
Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH (edit) |
SARSコロナウイルス2 (edit) |
10.26508/LSA.202101124 |
|
| 2022-01-07 |
Financial Burden and Shortage of Respiratory Rehabilitation for SARS-CoV-2 Survivors: The Next Step of the Pandemic? (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JRFM15010020 |
|
| 2022-01-07 |
SARS-CoV-2 NSP13 Inhibits Type I IFN Production by Degradation of TBK1 via p62-Dependent Selective Autophagy (edit) |
SARSコロナウイルス2 (edit) |
10.4049/JIMMUNOL.2100684 |
|
| 2022-01-07 |
Antigenic properties of the SARS-CoV-2 nucleoprotein are altered by the RNA admixture (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.12751 |
35036106 |
| 2022-01-06 |
Worsening of Essential Tremor After SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12311-022-01366-8 |
|
| 2022-01-06 |
Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13167-021-00267-W |
35013687 |
| 2022-01-06 |
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2022.01.001 |
35093192 |
| 2022-01-06 |
Palindromic target site identification in SARS-CoV-2, MERS-CoV and SARS-CoV-1 by adopting CRISPR-Cas technique (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GENE.2021.146136 |
34999179 |
| 2022-01-06 |
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C01451 |
|
| 2022-01-06 |
Inferring the stabilization effects of SARS-CoV-2 variants on the binding with ACE2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02946-W |
34992214 |
| 2022-01-05 |
Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.04.474958 |
|
| 2022-01-05 |
Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01438-21 |
34985323 |
| 2022-01-05 |
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01504-21 |
34985303 |
| 2022-01-05 |
Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-1207071/V1 |
35018372 |
| 2022-01-05 |
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines (edit) |
SARSコロナウイルス2 (edit) |
10.31083/J.FBL2701003 |
|
| 2022-01-04 |
Computational Prediction of the Potential Target of SARS‐CoV‐2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM‐PBSA Calculations (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CBDV.202100719 |
|
| 2022-01-04 |
Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12033-021-00432-6 |
34981440 |
| 2022-01-04 |
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.12.046 |
35081335 |
| 2022-01-04 |
SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2111199119 |
34930824 |
| 2022-01-04 |
SARS-CoV-2 spreads through cell-to-cell transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2111400119 |
34937699 |
| 2022-01-04 |
IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262162 |
|
| 2022-01-04 |
A Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study (edit) |
SARSコロナウイルス2 (edit) |
10.2196/32564 |
34803022 |
| 2022-01-04 |
Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10010075 |
|
| 2022-01-03 |
Impact of the COVID-19 pandemic on the oncologic activities (diagnosis, treatment, clinical trials enrollment) of a general hospital in a district with high prevalence of SARS-COV-2 in Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00520-021-06667-Y |
34977981 |
| 2022-01-03 |
Viral Prefusion Targeting Using Entry Inhibitor Peptides: The Case of SARS-CoV-2 and Influenza A virus (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10989-021-10357-Y |
35002586 |
| 2022-01-03 |
Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2021.101810 |
35002180 |
| 2022-01-03 |
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1084/JEM.20211818 |
34757384 |
| 2022-01-03 |
Sequencing SARS-CoV-2 genomes from saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAB098 |
35542310 |
| 2022-01-03 |
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2022.01.03.21268111 |
|
| 2022-01-03 |
Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.775420 |
35046939 |
| 2022-01-03 |
Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10010072 |
|
| 2022-01-02 |
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SLASD.2021.12.005 |
35086793 |
| 2022-01-02 |
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.20.21268048 |
34981067 |
| 2022-01-02 |
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14010078 |
|
| 2022-01-01 |
Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Proteomic and Metabolomic Signatures Associated With the Immune Response in Healthy Individuals Immunized With an Inactivated SARS-CoV-2 Vaccine (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
SARS-CoV-2 productively infects human brain microvascular endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Prediction of SARS-CoV-2-positivity from million-scale complete blood counts using machine learning (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
High throughput SARS-CoV-2 variant analysis using molecular barcodes coupled with next generation sequencing (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Binding and structural basis of equine ACE2 to RBDs from SARS-CoV, SARS-CoV-2 and related coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
A Rapid, Whole Genome Sequencing Assay for Detection and Characterization of Novel Coronavirus (SARS-CoV-2) Clinical Specimens Using Nanopore Sequencing (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Characteristics of 24 SARS-CoV-2-Sequenced Reinfection Cases in a Tertiary Hospital in Spain (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins—A Possible Signature of Adaptive Selection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Saliva molecular testing bypassing RNA extraction is suitable for monitoring and diagnosing SARS-CoV-2 infection in children (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Prediction of the effects of the top 10 nonsynonymous variants from 30229 SARS-CoV-2 strains on their proteins [version 2; peer review: 2 approved] (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Sequencing SARS-CoV-2 from antigen tests (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Influence of atmospheric environment on SARS-CoV-2 transmission: A review (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Research progress and intervention strategies against SARS-CoV-2 viral entry (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Application of Nanotechnology for Virus Inactivation in Water: Implications for Transmission-Blocking of the Novel Coronavirus SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Research Progress on Nano Photonics Technology-based SARS-CoV-2 Detection (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Inorganic-based Surface Materials with Anti-SARS-CoV-2 Properties and Their Mechanisms of Action (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Q122122936 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Q122123383 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Q122133593 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Q122133791 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
Q122133923 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2022-01-01 |
The aging lung face to COVID-19. (edit) |
SARSコロナウイルス2 (edit) |
|
35852241 |
| 2022-01-01 |
Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series. (edit) |
SARSコロナウイルス2 (edit) |
|
36155902 |
| 2022-01-01 |
Clinical and computed tomography features of patients suspected of COVID-19 in the university hospital of Oran, Algeria. (edit) |
SARSコロナウイルス2 (edit) |
|
36206086 |
| 2022-01-01 |
Wastewater-Based Epidemiology: Detection of SARS-CoV-2 RNA in Different Stages of Domestic Wastewater Treatment in Santa Fe, Argentina (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11270-022-05772-W |
36090741 |
| 2022-01-01 |
Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40883-021-00234-X |
34746370 |
| 2022-01-01 |
Reduced Requests for Medical Rehabilitation Because of the SARS-CoV-2 Pandemic: A Difference-in-Differences Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.APMR.2021.07.791 |
34371015 |
| 2022-01-01 |
Pathophysiological and molecular considerations of viral and bacterial infections during maternal-fetal and –neonatal interactions of SARS-CoV-2, Zika, and Mycoplasma infectious diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166285 |
34624499 |
| 2022-01-01 |
D155Y substitution of SARS-CoV-2 ORF3a weakens binding with Caveolin-1 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.01.017 |
35126886 |
| 2022-01-01 |
Whole-body metabolic modelling predicts isoleucine dependency of SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2022.07.019 |
|
| 2022-01-01 |
Accuracy and ease-of-use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103774 |
|
| 2022-01-01 |
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.11.040 |
34863925 |
| 2022-01-01 |
SARS-CoV-2 infection enhances mitochondrial PTP complex activity to perturb cardiac energetics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103722 |
35005527 |
| 2022-01-01 |
First evidence of SARS-CoV-2 genome detection in zebra mussel (Dreissena polymorpha) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JENVMAN.2021.113866 |
|
| 2022-01-01 |
Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.07.008 |
|
| 2022-01-01 |
Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.07.032 |
|
| 2022-01-01 |
Impact of the Alpha VOC on disease severity in SARS-CoV-2-positive adults in Sweden (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.08.043 |
34474056 |
| 2022-01-01 |
An easy pipeline for one-step purification of SARS-CoV-2 nucleocapsid protein from insect cell suspension culture (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVIROMET.2021.114341 |
34699776 |
| 2022-01-01 |
Are there medium to short-term multifaceted effects of the airborne pollutant PM2.5 determining the emergence of SARS-CoV-2 variants? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110718 |
|
| 2022-01-01 |
Nicotinic receptors as SARS-CoV-2 spike co-receptors? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110741 |
|
| 2022-01-01 |
SARS-CoV-2 RNA concentrations in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.150121 |
|
| 2022-01-01 |
Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2021.11.051 |
|
| 2022-01-01 |
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00460-6 |
|
| 2022-01-01 |
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(21)00275-5 |
|
| 2022-01-01 |
Air exchanges, climate change, and severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Results from a survey of the Society of Healthcare Epidemiology of America Research Network (SRN) (edit) |
SARSコロナウイルス2 (edit) |
10.1017/ASH.2021.256 |
|
| 2022-01-01 |
Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S0950268822000267 |
|
| 2022-01-01 |
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04186-8 |
34758478 |
| 2022-01-01 |
Identification of fragments binding to SARS-CoV-2 nsp10 reveals ligand-binding sites in conserved interfaces between nsp10 and nsp14/nsp16 (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1CB00135C |
35128408 |
| 2022-01-01 |
Structure of the 5′ untranslated region in SARS-CoV-2 genome and its specific recognition by innate immune system via the human oligoadenylate synthase 1 (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1CC07006A |
|
| 2022-01-01 |
Grammatical evolution-based design of SARS-CoV-2 main protease inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1CP04159B |
|
| 2022-01-01 |
Site-specific recognition of SARS-CoV-2 nsp1 protein with a tailored titanium dioxide nanoparticle – elucidation of the complex structure using NMR data and theoretical calculation (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1NA00855B |
|
| 2022-01-01 |
Design of a multi-epitope vaccine against SARS-CoV-2: immunoinformatic and computational methods (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA06532G |
35425433 |
| 2022-01-01 |
Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D2CC00121G |
35380569 |
| 2022-01-01 |
Targeting proteases involved in the viral replication of SARS-CoV-2 by sesquiterpene lactones from chicory (Cichorium intybus L.) (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D2FO00933A |
|
| 2022-01-01 |
Ångstrom-scale silver particles potently combat SARS-CoV-2 infection by suppressing the ACE2 expression and inflammatory responses (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D2TB00336H |
|
| 2022-01-01 |
Agro-tourism Structures, SARS-CoV-2: the Role of Water (edit) |
SARSコロナウイルス2 (edit) |
10.1051/MATECCONF/202235400070 |
|
| 2022-01-01 |
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/19420862.2022.2047144 |
35289719 |
| 2022-01-01 |
A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/19490976.2022.2073131 |
35574937 |
| 2022-01-01 |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB380 |
33906227 |
| 2022-01-01 |
Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CVR/CVAB322 |
34647998 |
| 2022-01-01 |
Future-proofing and maximizing the utility of metadata: The PHA4GE SARS-CoV-2 contextual data specification package (edit) |
SARSコロナウイルス2 (edit) |
10.1093/GIGASCIENCE/GIAC003 |
|
| 2022-01-01 |
The Impact of Cocirculating Pathogens on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Coronavirus Disease 2019 Surveillance: How Concurrent Epidemics May Introduce Bias and Decrease the Observed SARS-CoV-2 Percentage Positivity (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB459 |
34514500 |
| 2022-01-01 |
Proteolytic activation of SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1111/1348-0421.12945 |
34561887 |
| 2022-01-01 |
Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.14907 |
33993490 |
| 2022-01-01 |
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ANAE.15563 |
34428858 |
| 2022-01-01 |
COVID-19 in children: I. Epidemiology, prevention and indirect impacts (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JPC.15791 |
34643307 |
| 2022-01-01 |
COVID-19 in children. II: Pathogenesis, disease spectrum and management (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JPC.15811 |
34694037 |
| 2022-01-01 |
RNAscope in situ hybridization and RT‐PCR for detection of SARS‐CoV‐2 in chilblain‐like lesions: A clinical, laboratory and histopathological study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/PDE.14903 |
|
| 2022-01-01 |
Study protocol for monitoring SARS-CoV-2 infection and its determinants in Catalonia (Spain): an observational and participatory research approach in a Sentinel Network of Schools (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-055649 |
|
| 2022-01-01 |
Short- and Long-Term Self-Reported Audiovestibular Symptoms of SARS-CoV-2 Infection in Hospitalized and Nonhospitalized Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1159/000521963 |
|
| 2022-01-01 |
Assessment of SARS-CoV-2 seroprevalence by community survey and residual specimens, Denver, Colorado, July-August 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/00333549211055137 |
34752156 |
| 2022-01-01 |
Computational Structural and Functional Analyses of ORF10 in Novel Coronavirus SARS-CoV-2 Variants to Understand Evolutionary Dynamics (edit) |
SARSコロナウイルス2 (edit) |
10.1177/11769343221108218 |
|
| 2022-01-01 |
A case of sudden mixed hearing loss in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/2050313X221080642 |
|
| 2022-01-01 |
Impact of COVID-19 on the Endocrine System: A Mini-review (edit) |
SARSコロナウイルス2 (edit) |
10.1210/ENDOCR/BQAB203 |
34543404 |
| 2022-01-01 |
How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262114 |
35061758 |
| 2022-01-01 |
Are We Hearing Right? The Negative Impact of New SARS-CoV-2 Preventive Measures and Prolonged Use of Treatment Modalities during Orthodontic Treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1590/PBOCI.2022.023 |
|
| 2022-01-01 |
COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan (edit) |
SARSコロナウイルス2 (edit) |
10.1620/TJEM.2022.J067 |
|
| 2022-01-01 |
Infection control practices of medical practitioners at a large urban public hospital in South Africa during the SARS-COV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.18772/26180197.2022.V4N2A4 |
|
| 2022-01-01 |
Detecting Time-Evolving Phenotypic Components of Adverse Reactions Against BNT162b2 mRNA SARS-CoV-2 Vaccine Via Non-Negative Tensor Factorization (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4041409 |
|
| 2022-01-01 |
Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4059223 |
|
| 2022-01-01 |
Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4075484 |
|
| 2022-01-01 |
Seroprevalence of Exposure to SARS-CoV-2 in Domestic Dogs and Cats and its Relationship with COVID-19 Cases in the City of Villavicencio, Colombia (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4156064 |
|
| 2022-01-01 |
SARS-CoV-2 Disease in Cameroon:& Theoretical and Computational Analysis of a Delayed SIQR Model with Optimal Control (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4229706 |
|
| 2022-01-01 |
Impact of a Non-Invasive Respiratory Support Strategy and Switches in Therapy During Acute Respiratory Failure Due to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.4313559 |
|
| 2022-01-01 |
Identification of Potential Vaccine Candidates Against SARS-CoV-2 to Fight COVID-19: Reverse Vaccinology Approach (edit) |
SARSコロナウイルス2 (edit) |
10.2196/32401 |
35506029 |
| 2022-01-01 |
On the Treatment of SARS-COV-2 Including Omicron Type (edit) |
SARSコロナウイルス2 (edit) |
10.23880/OAJMMS-16000156 |
|
| 2022-01-01 |
SARS-CoV-2 antibody screening in healthcare workers: lessons learned from the first months of COVID-19 outbreak in Europe. Significance of serology testing for effective pandemic management and reduction of the occupational risk (edit) |
SARSコロナウイルス2 (edit) |
10.2478/PJPH-2022-0001 |
|
| 2022-01-01 |
Using Open-Source Bioinformatics and Visualization Tools to Explore the Structure and Function of SARS-CoV-2 Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.24918/CS.2022.5 |
|
| 2022-01-01 |
SARS-CoV-2 and Environment: Transmission and Green Combat (edit) |
SARSコロナウイルス2 (edit) |
10.31632/IJALSR.2022.V05I02.001 |
|
| 2022-01-01 |
Multistate outbreak of SARS-CoV-2 infections, including vaccine breakthrough infections, associated with large public gatherings, United States (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2801.212220 |
34793690 |
| 2022-01-01 |
Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.821595 |
35154139 |
| 2022-01-01 |
Emerging Insights on Caspases in COVID-19 Pathogenesis, Sequelae, and Directed Therapies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2022.842740 |
35265086 |
| 2022-01-01 |
Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2022.854567 |
35356515 |
| 2022-01-01 |
Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2022.804109 |
35495619 |
| 2022-01-01 |
Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2022.1043714 |
36699057 |
| 2022-01-01 |
A Systemic Review and Meta-analysis of the Effect of SARS-CoV-2 Infection on Sperm Parameters (edit) |
SARSコロナウイルス2 (edit) |
10.34133/2022/9835731 |
|
| 2022-01-01 |
Return visit characteristics of SARS-CoV-2 PCR-positive cases in a pediatric emergency department (edit) |
SARSコロナウイルス2 (edit) |
10.3906/SAG-2102-281 |
|
| 2022-01-01 |
Identification of transmission rates and reproduction number in a SARS-CoV-2 epidemic model (edit) |
SARSコロナウイルス2 (edit) |
10.3934/DCDSS.2022128 |
|
| 2022-01-01 |
A systematic study on the binding affinity of SARS-CoV-2 spike protein to antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.3934/MICROBIOL.2022038 |
36694585 |
| 2022-01-01 |
Persisting, unilateral tinnitus 22 days after first dose of an mRNA-based SARS-CoV-2 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.4103/JFMPC.JFMPC_1927_21 |
|
| 2022-01-01 |
CHANGES IN CARDIO-PHYSIOLOGICAL PARAMETERS ANALYZED WITH BRUCE PROTOCOL FOLLOWING SARS-COV-2 INFECTION IN SOCCER PLAYERS (edit) |
SARSコロナウイルス2 (edit) |
10.53582/AMJ2222025M |
|
| 2022-01-01 |
SARS-Cov-2 and hearing loss: Two sibling cases (edit) |
SARSコロナウイルス2 (edit) |
10.5455/MEDSCIENCE.2021.09.295 |
|
| 2022-01-01 |
Assessment of cochlear functions in hospitalized patients with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.5455/MEDSCIENCE.2022.07.154 |
|
| 2022-01-01 |
Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.5603/CJ.A2021.0122 |
34642923 |
| 2022-01-01 |
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.7150/THNO.65563 |
34987630 |
| 2022-01-01 |
Seroprevalence of SARS-CoV-2 antibodies among Jordanian citizens: A cross-sectional study of the demographic and clinical factors that ameliorate serum IgG concentration (edit) |
SARSコロナウイルス2 (edit) |
10.7324/JAPS.2022.121116 |
|
| 2022-01-01 |
An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.13136 |
35341060 |
| 2021-12-31 |
Establishment of Human Pluripotent Stem Cell‐Derived Skin Organoids Enabled Pathophysiological Model of SARS‐CoV‐2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADVS.202104192 |
|
| 2021-12-31 |
Modelling policy combinations of vaccination and transmission suppression of SARS-CoV-2 in Rio de Janeiro, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IDM.2021.12.007 |
35005325 |
| 2021-12-31 |
SARS-CoV-2 causes a significant stress response mediated by small RNAs in the blood of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2021.12.034 |
35003892 |
| 2021-12-31 |
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-022-04399-5 |
|
| 2021-12-31 |
In silico bioprospecting of antiviral compounds from marine fungi and mushroom for rapid development of nutraceuticals against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.2023048 |
|
| 2021-12-31 |
Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene (edit) |
SARSコロナウイルス2 (edit) |
10.1080/15476286.2021.2010959 |
34904915 |
| 2021-12-31 |
Active environmental surveillance of SARS-CoV-2 in Midwestern United States meatpacking plants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0261704 |
|
| 2021-12-31 |
The evaluation of the utility of the GENECUBE HQ SARS-CoV-2 for anterior nasal samples and saliva samples with a new rapid examination protocol (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0262159 |
|
| 2021-12-31 |
Evaluation of test to stay strategy on secondary and tertiary transmission of SARS-CoV-2 in K-12 schools - Lake County, Illinois, August 9-October 29, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM705152E2 |
34968375 |
| 2021-12-31 |
AB035. Comparative sensitivity of different self-sampling methods for SARS-CoV-2 RT-PCR testing (edit) |
SARSコロナウイルス2 (edit) |
10.21037/JPHE-21-AB035 |
|
| 2021-12-31 |
Microsecond molecular dynamics simulations revealed the inhibitory potency of amiloride analogs against SARS-CoV-2 E viroporin (edit) |
SARSコロナウイルス2 (edit) |
10.5808/GI.21040 |
35172476 |
| 2021-12-31 |
High-performance computing for SARS-CoV-2 RNAs clustering: a data science‒based genomics approach (edit) |
SARSコロナウイルス2 (edit) |
10.5808/GI.21056 |
35012291 |
| 2021-12-30 |
Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-04108-8 |
|
| 2021-12-30 |
A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BIB/BBAB526 |
|
| 2021-12-30 |
Diagnostic Value of Nucleocapsid Protein in Blood for SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CLINCHEM/HVAB148 |
34358289 |
| 2021-12-30 |
Interactome profiling reveals interaction of SARS-CoV-2 NSP13 with host factor STAT1 to suppress interferon signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAB068 |
34687317 |
| 2021-12-30 |
Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.29.474402 |
|
| 2021-12-30 |
Morbidity, Clinical Course and Vaccination against SARS-CoV-2 Virus in Patients with Duchenne Muscular Dystrophy: A Patient Reported Survey (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19010406 |
35010666 |
| 2021-12-29 |
Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1002/IID3.583 |
34965032 |
| 2021-12-29 |
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.27.474288 |
|
| 2021-12-29 |
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010203 |
34965282 |
| 2021-12-29 |
Hypothetical Immunological and Immunogenetic Model of Heterogenous Effects of BCG Vaccination in SARS-CoV-2 Infections: BCG-induced Trained and Heterologous Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.20883/MEDICAL.E551 |
|
| 2021-12-28 |
LinearTurboFold: Linear-time global prediction of conserved structures for RNA homologs with applications to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2116269118 |
34887342 |
| 2021-12-28 |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
ヒトコロナウイルス229E (edit) |
10.1371/JOURNAL.PBIO.3001490 |
|
| 2021-12-28 |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
MERSコロナウイルス (edit) |
10.1371/JOURNAL.PBIO.3001490 |
|
| 2021-12-28 |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3001490 |
|
| 2021-12-28 |
Intranasal inhibitor blocks omicron and other variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-1196079/V1 |
|
| 2021-12-28 |
Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2021.757826 |
35028304 |
| 2021-12-28 |
DETECTION OF SARS-COV-2 FROM SURFACE OF PATIENTS’ LEFTOVER FOOD PACKAGES AT A COVID-19 QUARANTINE CENTRE (edit) |
SARSコロナウイルス2 (edit) |
10.37268/MJPHM/VOL.21/NO.3/ART.1205 |
|
| 2021-12-27 |
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27526 |
|
| 2021-12-27 |
Development of SARS-CoV-2 packaged RNA reference material for nucleic acid testing (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-021-03846-Y |
34958396 |
| 2021-12-27 |
Spatial and temporal effects on severe acute respiratory coronavirus virus 2 (SARS-CoV-2) contamination of the healthcare environment (edit) |
SARSコロナウイルス2 (edit) |
10.1017/ICE.2021.530 |
34955111 |
| 2021-12-27 |
Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.23.21268040 |
|
| 2021-12-27 |
SARS-CoV-2 Omicron VOC Transmission in Danish Households (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.27.21268278 |
|
| 2021-12-27 |
The interactions of ZDHHC5/GOLGA7 with SARS-CoV-2 spike (S) protein and their effects on S protein's subcellular localization, palmitoylation and pseudovirus entry (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-021-01722-W |
34961524 |
| 2021-12-27 |
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-1175516/V1 |
34981042 |
| 2021-12-25 |
SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEM.2021.12.010 |
35032430 |
| 2021-12-24 |
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JGG.2021.12.003 |
34954396 |
| 2021-12-24 |
Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-04133-7 |
34952919 |
| 2021-12-24 |
Molecular interactions of the M and E integral membrane proteins of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1FD00031D |
34543372 |
| 2021-12-24 |
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.2023329 |
|
| 2021-12-24 |
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABL4784 |
34726479 |
| 2021-12-24 |
Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABL6184 |
|
| 2021-12-24 |
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABL8506 |
|
| 2021-12-24 |
Learning From Biological and Computational Machines: Importance of SARS-CoV-2 Genomic Surveillance, Mutations and Risk Stratification (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.783961 |
35047415 |
| 2021-12-24 |
Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.810047 |
35003140 |
| 2021-12-24 |
Stress and Coping Strategies of Nurses Working with Patients Infected with and Not Infected with SARS-CoV-2 Virus (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH19010195 |
35010454 |
| 2021-12-24 |
SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES10010018 |
35062679 |
| 2021-12-23 |
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.12.026 |
35026152 |
| 2021-12-23 |
Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANWPC.2021.100360 |
34961854 |
| 2021-12-23 |
A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105195 |
34954105 |
| 2021-12-23 |
Comprehensive serologic profile and specificity of maternal and neonatal cord blood SARS-CoV-2 antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XAGR.2021.100046 |
34961853 |
| 2021-12-23 |
Evolution of enhanced innate immune evasion by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04352-Y |
34942634 |
| 2021-12-23 |
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04385-3 |
35016194 |
| 2021-12-23 |
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04386-2 |
35016195 |
| 2021-12-23 |
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04388-0 |
|
| 2021-12-23 |
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04389-Z |
|
| 2021-12-23 |
Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.21.473268 |
|
| 2021-12-23 |
Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.22.473914 |
34981061 |
| 2021-12-23 |
Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009735 |
|
| 2021-12-23 |
Critical Role of the Subways in the Initial Spread of SARS-CoV-2 in New York City (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2021.754767 |
35004575 |
| 2021-12-23 |
Comparison of Antigen Tests and qPCR in Rapid Diagnostics of Infections Caused by SARS-CoV-2 Virus (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V14010017 |
35062221 |
| 2021-12-22 |
SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110242 |
34998467 |
| 2021-12-22 |
Local and systemic responses to SARS-CoV-2 infection in children and adults (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04345-X |
34937051 |
| 2021-12-22 |
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease (edit) |
SARSコロナウイルス2 (edit) |
10.1042/CS20210735 |
34807265 |
| 2021-12-22 |
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.20.473557 |
34981056 |
| 2021-12-22 |
Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01969-21 |
34935438 |
| 2021-12-22 |
PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.146701 |
|
| 2021-12-21 |
Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOORG.2021.105574 |
34971947 |
| 2021-12-21 |
Toxicity of spike fragments SARS-CoV-2 S protein for zebrafish: A tool to study its hazardous for human health? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.152345 |
34942250 |
| 2021-12-21 |
Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-03731-9 |
34934117 |
| 2021-12-21 |
Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02756-21 |
|
| 2021-12-21 |
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02975-21 |
34781736 |
| 2021-12-21 |
The Impact of the SARS-CoV-2 (COVID-19) Coronavirus Pandemic on Ecological Security and the Development of International Environmental Policy (edit) |
SARSコロナウイルス2 (edit) |
10.5604/01.3001.0015.6476 |
|
| 2021-12-20 |
Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101518 |
34942146 |
| 2021-12-20 |
Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JKSUS.2021.101773 |
34955621 |
| 2021-12-20 |
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.15.21267805 |
34931200 |
| 2021-12-20 |
Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S10020-021-00424-X |
34930105 |
| 2021-12-20 |
SARS-CoV-2 infection and persistence throughout the human body and brain (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-1139035/V1 |
|
| 2021-12-20 |
METHYLENE BLUE INHIBITS THE INTERACTION BETWEEN HEPARAN SULFATE AND SARS-COV-2 SPIKE PROTEIN; A REVIEW OF EVIDENCE FOR A HYPOTHESIS. (edit) |
SARSコロナウイルス2 (edit) |
10.31674/MJMR.2021.V05I04.002 |
|
| 2021-12-20 |
Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.12595 |
|
| 2021-12-18 |
Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CPLETT.2021.139294 |
34961797 |
| 2021-12-18 |
Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105192 |
34933126 |
| 2021-12-18 |
SARS-CoV-2 and COVID-19: revisiting the most important research questions (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-021-00730-1 |
|
| 2021-12-18 |
The experience of the ethics committee in research in human beings in times of pandemic COVID-19 (SARS-CoV-2) (edit) |
SARSコロナウイルス2 (edit) |
10.54448/MDNT21634 |
|
| 2021-12-17 |
Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105155 |
34942397 |
| 2021-12-17 |
The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101507 |
34929169 |
| 2021-12-17 |
Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105191 |
34923158 |
| 2021-12-17 |
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00849-0 |
34921131 |
| 2021-12-17 |
QTQTN motif upstream of the furin-cleavage site plays key role in SARS-CoV-2 infection and pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.15.472450 |
|
| 2021-12-17 |
Current attitude to deferral of cellular therapy or non‐transplant chemotherapy due to SARS‐CoV‐2 asymptomatic infection: survey of Infectious Diseases Working Party EBMT (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TID.13773 |
|
| 2021-12-17 |
An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-021-00609-4 |
34920753 |
| 2021-12-17 |
Geographical Landscape and Transmission Dynamics of SARS-CoV-2 Variants Across India: A Longitudinal Perspective (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2021.753648 |
|
| 2021-12-16 |
Synthetic Coumarin Derivatives as SARS‐CoV‐2 Major Protease Inhibitors: Design, Synthesis, Bioevaluation and Molecular Docking (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SLCT.202103658 |
|
| 2021-12-16 |
SARS-CoV-2 loads in urine, sera and stool specimens in association with clinical features of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCVP.2021.100059 |
35262032 |
| 2021-12-16 |
Modeling the number of people infected with SARS-COV-2 from wastewater viral load in Northwest Spain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.152334 |
34921882 |
| 2021-12-16 |
Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27611-Y |
34916516 |
| 2021-12-16 |
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2114706 |
34731554 |
| 2021-12-16 |
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) (edit) |
SARSコロナウイルス2 (edit) |
10.1177/09612033211062523 |
|
| 2021-12-16 |
Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009629 |
|
| 2021-12-16 |
A virus‐derived microRNA targets immune response genes during SARS‐CoV‐2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBR.202154341 |
34914162 |
| 2021-12-16 |
Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.50.2101146 |
|
| 2021-12-16 |
Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.50.2101147 |
34915975 |
| 2021-12-15 |
Transmission of SARS-CoV-2 from humans to a 16-year-old domestic cat with comorbidities in Pennsylvania, USA (edit) |
SARSコロナウイルス2 (edit) |
10.1002/VMS3.695 |
34910368 |
| 2021-12-15 |
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110210 |
34971573 |
| 2021-12-15 |
Genomic characterization of SARS-CoV-2 and its association with clinical outcomes: a 1-year longitudinal study of the pandemic in Colombia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.12.326 |
34920122 |
| 2021-12-15 |
Highly conserved s2m element of SARS-CoV-2 dimerizes via a kissing complex and interacts with host miRNA-1307-3p (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB1226 |
34908151 |
| 2021-12-15 |
Identification of a novel SARS-CoV-2 P.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAB091 |
35039782 |
| 2021-12-15 |
Heptad stereotypy, S/Q layering, and remote origin of the SARS-CoV-2 fusion core (edit) |
SARSコロナウイルス2 (edit) |
10.1093/VE/VEAB097 |
35039783 |
| 2021-12-15 |
Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.14.472513 |
|
| 2021-12-15 |
Spatial epidemiology and genetic diversity of SARS-CoV-2 and related coronaviruses in domestic and wild animals (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260635 |
34910734 |
| 2021-12-15 |
Reconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0261422 |
34910769 |
| 2021-12-15 |
Comment on “Comparison of two pandemics: H1N1 and SARS-CoV-2” (edit) |
SARSコロナウイルス2 (edit) |
10.1590/1806-9282.20210756 |
|
| 2021-12-15 |
Understanding Gene Expression and Transcriptome Profiling of COVID-19: An Initiative Towards the Mapping of Protective Immunity Genes Against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.724936 |
34975833 |
| 2021-12-15 |
Cryptocurrency as Epidemiologically Safe Means of Transactions: Diminishing Risk of SARS-CoV-2 Spread (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MATH9243263 |
|
| 2021-12-14 |
Vaccine breakthrough and the invasion dynamics of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.13.21267725 |
|
| 2021-12-14 |
The atomic portrait of SARS‐CoV‐2 as captured by cryo‐electron microscopy (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JCMM.17103 |
34904376 |
| 2021-12-14 |
Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260850 |
34905589 |
| 2021-12-14 |
Digital Image Encryption Using Double Crossover Approach for SARS-CoV-2 Infected Lungs in a Blockchain Framework (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FBLOC.2021.771241 |
|
| 2021-12-14 |
Inflammasomes and SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13122513 |
34960782 |
| 2021-12-13 |
Host Manipulation Mechanisms of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10441-021-09425-Z |
34902063 |
| 2021-12-13 |
Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCME.2021.12.002 |
34926189 |
| 2021-12-13 |
Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27202-X |
34903718 |
| 2021-12-13 |
Predicting infectivity: comparing four PCR-based assays to detect culturable SARS-CoV-2 in clinical samples (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMMM.202115290 |
34862752 |
| 2021-12-13 |
Seroprevalence of SARS-CoV-2 (COVID-19) among Health Care Workers in Three Health Facilities of Yaounde, Center Region of Cameroon (edit) |
SARSコロナウイルス2 (edit) |
10.24018/EJMED.2021.3.6.1109 |
|
| 2021-12-13 |
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.766821 |
34966387 |
| 2021-12-11 |
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(21)02758-6 |
34871545 |
| 2021-12-11 |
Combination of cycle threshold time, absolute lymphocyte count and neutrophil:lymphocyte ratio is predictive of hypoxia in patients with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/TRSTMH/TRAB182 |
34894631 |
| 2021-12-11 |
Risk-focused differences in molecular processes implicated in SARS-CoV-2 infection: corollaries in DNA methylation and gene expression (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13072-021-00428-1 |
34895312 |
| 2021-12-10 |
Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103748 |
34902788 |
| 2021-12-10 |
Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLIMM.2021.12.006 |
34915268 |
| 2021-12-10 |
Design, synthesis and in silico screening of benzoxazole-thiazolidinone hybrids as potential inhibitors of SARS-CoV-2 proteases (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA07504G |
35492479 |
| 2021-12-10 |
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.07.470392 |
|
| 2021-12-10 |
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABL9463 |
|
| 2021-12-10 |
Insights into the Binding of Receptor-Binding Domain (RBD) of SARS-CoV-2 Wild Type and B.1.620 Variant with hACE2 Using Molecular Docking and Simulation Approaches (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOLOGY10121310 |
|
| 2021-12-09 |
Superspreading of SARS-CoV-2 infections: A Systematic Review and Meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.09.21267507 |
|
| 2021-12-09 |
Numbers of close contacts of individuals infected with SARS-CoV-2 and their association with government intervention strategies (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12889-021-12318-Y |
34886842 |
| 2021-12-09 |
Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010085 |
|
| 2021-12-09 |
Evidence of SARS-CoV-2-Specific T-Cell-Mediated Myocarditis in a MIS-A Case (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.779026 |
34956207 |
| 2021-12-09 |
SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.798859 |
34956236 |
| 2021-12-09 |
Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2021.784303 |
34957216 |
| 2021-12-09 |
SARS-CoV-2 ORF3a Induces Incomplete Autophagy via the Unfolded Protein Response (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13122467 |
34960736 |
| 2021-12-08 |
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110143 |
34919799 |
| 2021-12-08 |
Detection of N6-methyladenosine in SARS-CoV-2 RNA by methylated RNA immunoprecipitation sequencing (MeRIP-Seq) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.101067 |
34901888 |
| 2021-12-08 |
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.1C00882 |
34878788 |
| 2021-12-08 |
Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-01655-Y |
34880279 |
| 2021-12-08 |
Persimmon-derived tannin has antiviral effects and reduces the severity of infection and transmission of SARS-CoV-2 in a Syrian hamster model (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-03149-3 |
|
| 2021-12-08 |
TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABI6802 |
34878838 |
| 2021-12-08 |
Possibilities for the Entrance of SARS-Cov-2 as an Archaeal Vi-rus into the Ecosystem (edit) |
SARSコロナウイルス2 (edit) |
10.18502/IJPH.V50I12.7948 |
|
| 2021-12-08 |
B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-1148985/V1 |
|
| 2021-12-07 |
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.12.005 |
34965382 |
| 2021-12-07 |
VDA-RWLRLS: An anti-SARS-CoV-2 drug prioritizing framework combining an unbalanced bi-random walk and Laplacian regularized least squares (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105119 |
34902608 |
| 2021-12-07 |
Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105122 |
34896886 |
| 2021-12-07 |
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIPH.2021.12.002 |
34952247 |
| 2021-12-07 |
Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27318-0 |
34876592 |
| 2021-12-07 |
A single-cell transcriptomic landscape of the lungs of patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41556-021-00796-6 |
34876692 |
| 2021-12-07 |
Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04280-X |
34875673 |
| 2021-12-07 |
N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-02904-W |
34876606 |
| 2021-12-07 |
How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2108395118 |
34873059 |
| 2021-12-07 |
In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2111477118 |
34857628 |
| 2021-12-07 |
Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.04.471200 |
|
| 2021-12-07 |
Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.06.471389 |
|
| 2021-12-07 |
International risk of SARS-CoV-2 Omicron variant importations originating in South Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.07.21267410 |
34909796 |
| 2021-12-07 |
Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects (edit) |
SARSコロナウイルス2 (edit) |
10.18632/ONCOTARGET.28088 |
34917266 |
| 2021-12-07 |
Death in Times of SARS-CoV-2 Pandemic. Legal Regulations of the Burial of the COVID-19 Deceased in Poland (edit) |
SARSコロナウイルス2 (edit) |
10.31743/RECL.13024 |
|
| 2021-12-07 |
IL1β Promotes TMPRSS2 Expression and SARS-CoV-2 Cell Entry Through the p38 MAPK-GATA2 Axis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.781352 |
34950146 |
| 2021-12-07 |
Production of SARS-CoV-2 N Protein-Specific Monoclonal Antibody and Its Application in an ELISA-Based Detection System and Targeting the Interaction Between the Spike C-Terminal Domain and N Protein (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.726231 |
34950112 |
| 2021-12-06 |
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CMDC.202100483 |
34382337 |
| 2021-12-06 |
Front Cover: Bithiazole Inhibitors of Phosphatidylinositol 4‐Kinase (PI4KIIIβ) as Broad‐Spectrum Antivirals Blocking the Replication of SARS‐CoV‐2, Zika Virus, and Human Rhinoviruses (ChemMedChem 23/2021) (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CMDC.202100724 |
|
| 2021-12-06 |
Modelling the spreading of the SARS-CoV-2 in presence of the lockdown and quarantine measures by a kinetic-type reactions approach (edit) |
SARSコロナウイルス2 (edit) |
10.1093/IMAMMB/DQAB017 |
|
| 2021-12-06 |
A Cross-Disciplinary View of Testing and Bioinformatic Analysis of SARS-CoV-2 and Other Human Respiratory Viruses in Pandemic Settings (edit) |
SARSコロナウイルス2 (edit) |
10.1109/ACCESS.2021.3133417 |
35582017 |
| 2021-12-06 |
Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260438 |
34871297 |
| 2021-12-06 |
Forced association of SARS-CoV-2 proteins with the yeast proteome perturb vesicle trafficking (edit) |
SARSコロナウイルス2 (edit) |
10.15698/MIC2021.12.766 |
34909432 |
| 2021-12-06 |
Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.773198 |
34938188 |
| 2021-12-06 |
SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kB pathway (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.68563 |
34866574 |
| 2021-12-05 |
Extracellular Vimentin as a Target Against SARS‐CoV‐2 Host Cell Invasion (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SMLL.202105640 |
34866333 |
| 2021-12-04 |
A structural view of the SARS-CoV-2 virus and its assembly (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COVIRO.2021.11.011 |
34915287 |
| 2021-12-04 |
SARS-CoV-2 Nucleocapsid protein attenuates stress granules and interacts with mRNAs to impair host stress response (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103562 |
34901782 |
| 2021-12-04 |
Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers (edit) |
SARSコロナウイルス2 (edit) |
10.1177/07487304211059315 |
|
| 2021-12-03 |
Roles of antiviral sensing and type I interferon signaling in the restriction of SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103553 |
34877479 |
| 2021-12-03 |
Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2021.10.016 |
34692233 |
| 2021-12-03 |
Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.1C00965 |
|
| 2021-12-03 |
Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.01.470748 |
|
| 2021-12-03 |
SARS-CoV-2 wildlife surveillance in Ontario and Québec, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.12.02.470924 |
|
| 2021-12-03 |
Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010118 |
34860860 |
| 2021-12-03 |
Acceptance, Use, and Barriers of Telemedicine in Transgender Health Care in Times of SARS-CoV-2: Nationwide Cross-sectional Survey (edit) |
SARSコロナウイルス2 (edit) |
10.2196/30278 |
|
| 2021-12-03 |
Exosomes/microvesicles target SARS-CoV-2 via innate and RNA-induced immunity with PIWI-piRNA system (edit) |
SARSコロナウイルス2 (edit) |
10.26508/LSA.202101240 |
|
| 2021-12-03 |
SARS-CoV-2 Nsp5 Protein Causes Acute Lung Inflammation, A Dynamical Mathematical Model (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FSYSB.2021.764155 |
|
| 2021-12-02 |
Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-021-16356-2 |
|
| 2021-12-02 |
Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.11.151 |
34863825 |
| 2021-12-02 |
Contrasting SARS-CoV-2 epidemics in Singapore: cohort studies in migrant workers and the general population (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.11.043 |
|
| 2021-12-02 |
Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02885-6 |
34857854 |
| 2021-12-02 |
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable? (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21645515.2021.2007015 |
34898381 |
| 2021-12-02 |
Patient health records and whole viral genomes from an early SARS-CoV-2 outbreak in a Quebec hospital reveal features associated with favorable outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260714 |
34855869 |
| 2021-12-02 |
Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.795741 |
34925381 |
| 2021-12-02 |
The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM11121812 |
34944456 |
| 2021-12-02 |
The Correlation between Nurses' COVID-19 Infections and Their Emotional State and Work Conditions during the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH182312715 |
34886440 |
| 2021-12-01 |
Highly accurate whole-genome imputation of SARS-CoV-2 from partial or low-quality sequences (edit) |
SARSコロナウイルス2 (edit) |
|
34865008 |
| 2021-12-01 |
Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JEV2.12170 |
34874124 |
| 2021-12-01 |
SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27244 |
34324210 |
| 2021-12-01 |
Modeling SARS-CoV-2 proteins in the CASP-commons experiment (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PROT.26231 |
34462960 |
| 2021-12-01 |
D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00253-021-11676-2 |
34755213 |
| 2021-12-01 |
Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40121-021-00493-9 |
34302258 |
| 2021-12-01 |
Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40199-021-00422-8 |
34762250 |
| 2021-12-01 |
SARS-CoV-2 and the subsequent development of preeclampsia and preterm birth: evidence of a dose-response relationship supporting causality (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJOG.2021.08.020 |
34454898 |
| 2021-12-01 |
Computational screening and biochemical analysis of Pistacia integerrima and Pandanus odorifer plants to find effective inhibitors against Receptor-Binding domain (RBD) of the spike protein of SARS-Cov-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARABJC.2021.103600 |
34909068 |
| 2021-12-01 |
SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166264 |
34481867 |
| 2021-12-01 |
The spike protein of SARS-CoV-2 virus induces heme oxygenase-1: Pathophysiologic implications (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166322 |
34920080 |
| 2021-12-01 |
Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2021.107613 |
|
| 2021-12-01 |
Impact of cobas PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2021.115521 |
|
| 2021-12-01 |
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJMECH.2021.114030 |
34883292 |
| 2021-12-01 |
Bacille Calmette-Guérin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection — Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.03.060 |
|
| 2021-12-01 |
Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.09.066 |
34597761 |
| 2021-12-01 |
Pannexin-1 channel opening is critical for COVID-19 pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103478 |
34841222 |
| 2021-12-01 |
A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2021.105050 |
34883405 |
| 2021-12-01 |
A solution scan of societal options to reduce transmission and spread of respiratory viruses: SARS-CoV-2 as a case study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JOBB.2021.08.003 |
|
| 2021-12-01 |
Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTBI.2021.110895 |
34499915 |
| 2021-12-01 |
Clinical utility of novel biosensing platform: Diagnosis of coronavirus SARS-CoV-2 at point of care (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MATLET.2021.130612 |
34381287 |
| 2021-12-01 |
Models for SARS-CoV-2 associated thrombocytopenia associated with hemophagocytic histiocytes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110700 |
|
| 2021-12-01 |
Molecular docking of SARS-COV-2 Spike epitope sequences identifies heterodimeric peptide-protein complex formation with human Zo-1, TLR8 and brain specific glial proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110706 |
|
| 2021-12-01 |
SARS-CoV-2 mutational cascades and the risk of hyper-exponential growth (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2021.105237 |
|
| 2021-12-01 |
Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ONEHLT.2021.100352 |
|
| 2021-12-01 |
Production of full-length SARS-CoV-2 nucleocapsid protein from Escherichia coli optimized by native hydrophobic interaction chromatography hyphenated to multi-angle light scattering detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TALANTA.2021.122691 |
|
| 2021-12-01 |
Normalization of SARS-CoV-2 viral load via RT-qPCR provides higher-resolution data for comparison across time and between patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198604 |
|
| 2021-12-01 |
UnCovid: A versatile, low-cost, and open-source protocol for SARS-CoV-2 RNA detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.100878 |
|
| 2021-12-01 |
SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00357-Z |
34903715 |
| 2021-12-01 |
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-021-00794-6 |
34782760 |
| 2021-12-01 |
The short isoform of the host antiviral protein ZAP acts as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27431-0 |
34893599 |
| 2021-12-01 |
Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27511-1 |
34907161 |
| 2021-12-01 |
Genomic reconstruction of the SARS-CoV-2 epidemic in England (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04069-Y |
34649268 |
| 2021-12-01 |
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04117-7 |
34670266 |
| 2021-12-01 |
Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02866-9 |
34853399 |
| 2021-12-01 |
SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications (edit) |
SARSコロナウイルス2 (edit) |
10.1080/01652176.2021.1921311 |
33892621 |
| 2021-12-01 |
Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21505594.2021.1911477 |
34030593 |
| 2021-12-01 |
The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21505594.2021.1964329 |
34494942 |
| 2021-12-01 |
The antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1888660 |
33560940 |
| 2021-12-01 |
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1898291 |
33666147 |
| 2021-12-01 |
The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1899770 |
33691601 |
| 2021-12-01 |
Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1902755 |
33704002 |
| 2021-12-01 |
Mining of linear B cell epitopes of SARS-CoV-2 ORF8 protein from COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1931465 |
34003073 |
| 2021-12-01 |
Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1932607 |
34013835 |
| 2021-12-01 |
Lentil lectin derived from exhibit broad antiviral activities against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1957720 |
34278967 |
| 2021-12-01 |
A novel SARS-CoV-2 related coronavirus with complex recombination isolated from bats in Yunnan province, China (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1964925 |
34348599 |
| 2021-12-01 |
Host-dependent editing of SARS-CoV-2 in COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1080/22221751.2021.1969868 |
34402744 |
| 2021-12-01 |
405 Myopericarditis after SARS-CoV-2 MRNA vaccination: casual or causal relationship? (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EURHEARTJ/SUAB135.025 |
|
| 2021-12-01 |
A Daily-Updated Database and Tools for Comprehensive SARS-CoV-2 Mutation-Annotated Trees (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAB264 |
34469548 |
| 2021-12-01 |
Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children (edit) |
SARSコロナウイルス2 (edit) |
10.1097/MOP.0000000000001061 |
34534994 |
| 2021-12-01 |
Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABJ1476 |
34851667 |
| 2021-12-01 |
Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00711-21 |
34851166 |
| 2021-12-01 |
Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.49.2002005 |
34886945 |
| 2021-12-01 |
Sampling for SARS-CoV-2 aerosols in hospital patient rooms (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13122347 |
34960615 |
| 2021-12-01 |
Future medico-legal implications on Obstetrics and Gynaecology practice in the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.36129/JOG.33.04.07 |
|
| 2021-12-01 |
Deploying a rapid point-of-care polymerase chain reaction test for SARS-CoV-2 in a clinical research unit to ensure healthy volunteer safety (edit) |
SARSコロナウイルス2 (edit) |
10.4155/BIO-2021-0079 |
|
| 2021-12-01 |
The discovery, origins and evolution of SARS-CoV-2 (COVID-19) (edit) |
SARSコロナウイルス2 (edit) |
10.5962/P.361973 |
|
| 2021-11-30 |
Dynamics of spreading of SARS-CoV-2 in a Belgian hemodialysis facility: The importance of the analysis of viral strains (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27471 |
34811754 |
| 2021-11-30 |
Severity of SARS-CoV-2 infection is linked to double-negative (CD27- IgD-) B cell subset numbers (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00011-021-01525-3 |
34850243 |
| 2021-11-30 |
Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27325-1 |
34848718 |
| 2021-11-30 |
A hydrated 2,3-diaminophenazinium chloride as a promising building block against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-02280-5 |
34848758 |
| 2021-11-30 |
Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02858-9 |
|
| 2021-11-30 |
Did social distancing measures deployed for SARS-CoV-2/COVID-19 control have an impact on invasive meningococcal disease? (edit) |
SARSコロナウイルス2 (edit) |
10.1080/20477724.2021.1995657 |
|
| 2021-11-30 |
Multiplex Gene Tagging with CRISPR-Cas9 for Live-Cell Microscopy and Application to Study the Role of SARS-CoV-2 Proteins in Autophagy, Mitochondrial Dynamics, and Cell Growth (edit) |
SARSコロナウイルス2 (edit) |
10.1089/CRISPR.2021.0041 |
34847745 |
| 2021-11-30 |
A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB938 |
34849655 |
| 2021-11-30 |
Is cardiac involvement prevalent in highly trained athletes after SARS-CoV-2 infection? A cardiac magnetic resonance study using sex-matched and age-matched controls (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BJSPORTS-2021-104576 |
34848398 |
| 2021-11-30 |
EpiCurator: an immunoinformatic workflow to predict and prioritize SARS-CoV-2 epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.12548 |
34909278 |
| 2021-11-29 |
Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101190 |
34870134 |
| 2021-11-29 |
Mechanistic Insights into SARS-CoV-2 Main Protease Inhibition Reveals Hotspot Residues (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C00928 |
|
| 2021-11-29 |
SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-021-00807-4 |
34845370 |
| 2021-11-29 |
Immune response against SARS-CoV-2 variants: the role of neutralization assays (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-021-00404-6 |
34845231 |
| 2021-11-29 |
A 3D structural SARS-CoV-2-human interactome to explore genetic and drug perturbations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41592-021-01318-W |
34845387 |
| 2021-11-29 |
The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB1160 |
34850141 |
| 2021-11-29 |
Crystal structure of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) frameshifting pseudoknot (edit) |
SARSコロナウイルス2 (edit) |
10.1261/RNA.078825.121 |
|
| 2021-11-29 |
Intra-Familial Transmission Patterns of COVID-19 Infection among the Rural Residents of Ahmedabad, Gujarat, during an Epidemic of SARS-CoV-2 in India (edit) |
SARSコロナウイルス2 (edit) |
10.7883/YOKEN.JJID.2021.267 |
|
| 2021-11-27 |
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.11.033 |
34914922 |
| 2021-11-27 |
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.11.013 |
34921776 |
| 2021-11-27 |
A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JHAZMAT.2021.127923 |
34906876 |
| 2021-11-27 |
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2021.11.008 |
34871905 |
| 2021-11-27 |
The Differences in the Level of Anti-SARS-CoV-2 Antibodies after mRNA Vaccine between Convalescent and Non-Previously Infected People Disappear after the Second Dose-Study in Healthcare Workers Group in Poland (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9121402 |
34960148 |
| 2021-11-26 |
Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10822-021-00432-3 |
34825285 |
| 2021-11-26 |
Binder design for targeting SARS-CoV-2 spike protein: An in silico perspective (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GENREP.2021.101452 |
34849425 |
| 2021-11-26 |
Oxidative stress transforms 3CLpro into an insoluble and more active form to promote SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REDOX.2021.102199 |
34847508 |
| 2021-11-26 |
Development of a Rapid and Sensitive CasRx-Based Diagnostic Assay for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSSENSORS.1C01088 |
34714054 |
| 2021-11-26 |
Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00595-6 |
34837059 |
| 2021-11-26 |
Epidemiological associations with genomic variation in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-02548-W |
34837008 |
| 2021-11-26 |
Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABL6096 |
34826236 |
| 2021-11-26 |
The vaccination threshold for SARS-CoV-2 depends on the indoor setting and room ventilation (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06884-0 |
34836502 |
| 2021-11-26 |
COVID-19–Associated Deaths After SARS-CoV-2 Infection During Pregnancy — Mississippi, March 1, 2020–October 6, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7047E2 |
|
| 2021-11-26 |
Major Complex Trait for Early De Novo Programming ‘CoV-MAC-TED’ Detected in Human Nasal Epithelial Cells Infected by Two SARS-CoV-2 Variants Is Promising to Help in Designing Therapeutic Strategies (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9121399 |
|
| 2021-11-25 |
Novel dynamic residue network analysis approaches to study allosteric modulation: SARS-CoV-2 Mpro and its evolutionary mutations as a case study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.11.016 |
34849191 |
| 2021-11-25 |
Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103712 |
34839261 |
| 2021-11-25 |
Mitochondrial DNA and TLR9 activation contribute to SARS-CoV-2-induced endothelial cell damage (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VPH.2021.106946 |
34838735 |
| 2021-11-25 |
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04266-9 |
34823256 |
| 2021-11-25 |
Epidemic size, trend and spatiotemporal mapping of SARS-CoV-2 using geographical information system in Alborz Province, Iran (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06870-6 |
34823478 |
| 2021-11-25 |
Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.733539 |
34899693 |
| 2021-11-24 |
A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110112 |
34863353 |
| 2021-11-24 |
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110114 |
34883043 |
| 2021-11-24 |
A comparison of precipitation and filtration-based SARS-CoV-2 recovery methods and the influence of temperature, turbidity, and surfactant load in urban wastewater (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.151916 |
34826466 |
| 2021-11-24 |
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04245-0 |
34818667 |
| 2021-11-24 |
Glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01626-21 |
34817202 |
| 2021-11-24 |
Whole-Genome Sequences of SARS-CoV-2 Isolates from the Dominican Republic (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MRA.00952-21 |
34817214 |
| 2021-11-24 |
Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009587 |
|
| 2021-11-24 |
Non-Woven Infection Prevention Fabrics Coated with Biobased Cranberry Extracts Inactivate Enveloped Viruses Such as SARS-CoV-2 and Multidrug-Resistant Bacteria (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS222312719 |
34884521 |
| 2021-11-23 |
SARS‐CoV‐2 N Protein Induces Acute Kidney Injury via Smad3‐Dependent G1 Cell Cycle Arrest Mechanism (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADVS.202103248 |
34813685 |
| 2021-11-23 |
COVID-19 and Gynecologic Oncology: What Have We Learned? (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11864-021-00905-5 |
34812973 |
| 2021-11-23 |
Performance of a computer aided diagnosis system for SARS-CoV-2 pneumonia based on ultrasound images (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJRAD.2021.110066 |
34902668 |
| 2021-11-23 |
Low-Cost Optodiagnostic for Minute-Time Scale Detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSNANO.1C03236 |
34669371 |
| 2021-11-23 |
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-04232-5 |
34814158 |
| 2021-11-23 |
An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-02266-3 |
34815498 |
| 2021-11-23 |
Spatiotemporal interactions of a novel mesocarnivore community in an urban environment before and during SARS-CoV-2 lockdown (edit) |
SARSコロナウイルス2 (edit) |
10.1111/1365-2656.13635 |
34775595 |
| 2021-11-23 |
Comprehensive occupational health services for healthcare workers in Zimbabwe during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260261 |
34813627 |
| 2021-11-23 |
Methodological problems of SARS-CoV-2 rapid point-of-care tests when used in mass testing (edit) |
SARSコロナウイルス2 (edit) |
10.3934/PUBLICHEALTH.2022007 |
35071670 |
| 2021-11-22 |
Sequence Similarity Analysis between SARS-CoV-2 and Other Viruses Based on Variant Logic Framework and Topological Entropy (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3482632.3487471 |
|
| 2021-11-22 |
SARS-CoV-2 Infection Fatality Rates in India: Systematic Review, Meta-analysis and Model-based Estimation (edit) |
SARSコロナウイルス2 (edit) |
10.1177/23210222211054324 |
|
| 2021-11-22 |
Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0258649 |
34807925 |
| 2021-11-22 |
TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009820 |
34807954 |
| 2021-11-22 |
Seroepidemiological Survey on the Impact of Smoking on SARS-CoV-2 Infection and COVID-19 Outcomes: Protocol for the Troina Study (edit) |
SARSコロナウイルス2 (edit) |
10.2196/32285 |
|
| 2021-11-20 |
SARS-CoV-2: Can sunlight exposure reduce the risk of developing severe consequences of COVID-19? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2021.107602 |
|
| 2021-11-20 |
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105049 |
34823857 |
| 2021-11-20 |
Symptomatic and asymptomatic transmission of SARS-CoV-2 in K-12 schools, British Columbia, April to June 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.15.21266284 |
|
| 2021-11-19 |
SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-19 |
In silico validation of anti-viral drugs obtained from marine sources as a potential target against SARS-CoV-2 Mpro (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-19 |
SARS-CoV-2 triggers DNA damage response in Vero E6 cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2021.09.024 |
34600299 |
| 2021-11-19 |
Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.11.026 |
34910927 |
| 2021-11-19 |
Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26498-Z |
34799561 |
| 2021-11-19 |
SARS-CoV-2 infection generates tissue-localized immunological memory in humans (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIIMMUNOL.ABL9105 |
34618554 |
| 2021-11-19 |
Association between ambient air pollutants and meteorological factors with SARS-CoV-2 transmission and mortality in India: an exploratory study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12940-021-00804-0 |
34794454 |
| 2021-11-19 |
Phosphatidylserine receptors enhance SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009743 |
34797899 |
| 2021-11-19 |
Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.748291 |
|
| 2021-11-19 |
Psychiatric hospitalization during the two SARS-CoV-2 pandemic waves: New warnings for acute psychotic episodes and suicidal behaviors (edit) |
SARSコロナウイルス2 (edit) |
10.5498/WJP.V11.I11.1095 |
|
| 2021-11-18 |
Backbone and Ile, Leu, Val methyl group resonance assignment of CoV-Y domain of SARS-CoV-2 non-structural protein 3 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12104-021-10059-Y |
34792756 |
| 2021-11-18 |
Critical timing and extent of public health interventions to control outbreaks dominated by SARS-CoV-2 variants in Australia: a mathematical modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.11.024 |
|
| 2021-11-18 |
Genome-wide identification and prediction of SARS-CoV-2 mutations show an abundance of variants: Integrated study of bioinformatics and deep neural learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2021.100798 |
34812411 |
| 2021-11-18 |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103469 |
34812415 |
| 2021-11-18 |
Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105153 |
34801754 |
| 2021-11-18 |
Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PATTER.2021.100407 |
34812427 |
| 2021-11-18 |
Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCHEMBIO.1C00756 |
34792325 |
| 2021-11-18 |
Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-27040-X |
34795285 |
| 2021-11-18 |
The role of cell surface sialic acids for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/GLYCOB/CWAB032 |
33909065 |
| 2021-11-18 |
COVID-19 and vertical transmission: assessing the expression of ACE2/TMPRSS2 in the human fetus and placenta to assess the risk of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1111/1471-0528.16974 |
34735736 |
| 2021-11-18 |
Dissecting the early COVID-19 cases in Wuhan (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABM4454 |
34793199 |
| 2021-11-18 |
Nanopore metagenomic sequencing for detection and characterization of SARS-CoV-2 in clinical samples (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0259712 |
34793508 |
| 2021-11-18 |
Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0260283 |
34793553 |
| 2021-11-18 |
Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.753444 |
34869063 |
| 2021-11-18 |
Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.768993 |
34869070 |
| 2021-11-18 |
Optimization and Clinical Validation of Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification, a Fast, Highly Sensitive and Specific COVID-19 Molecular Diagnostic Tool That Is Robust to Detect SARS-CoV-2 Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.713713 |
|
| 2021-11-17 |
Identification of Key Pathways and Genes in SARS-CoV-2 Infecting Human Intestines by Bioinformatics Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10528-021-10144-W |
34787756 |
| 2021-11-17 |
SARS-CoV-2 introduction and lineage dynamics across three epidemic peaks in Southern Brazil: massive spread of P.1. (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105144 |
34798321 |
| 2021-11-17 |
SARS-CoV-2–Associated New Dysphagia in Parkinson’s Disease Requires Exclusion of Differentials (edit) |
SARSコロナウイルス2 (edit) |
10.1097/PHM.0000000000001927 |
|
| 2021-11-17 |
Response to the Letter to the Editor “SARS-CoV-2–Associated New Dysphagia in Parkinson’s Disease Requires Exclusion of Differentials” (edit) |
SARSコロナウイルス2 (edit) |
10.1097/PHM.0000000000001928 |
|
| 2021-11-17 |
Tunneling nanotubes provide a novel route for SARS-CoV-2 spreading between permissive cells and to non-permissive neuronal cells (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.15.468633 |
|
| 2021-11-17 |
The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.16.468777 |
|
| 2021-11-17 |
A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01131-21 |
34787485 |
| 2021-11-17 |
Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMMM.202114544 |
|
| 2021-11-17 |
A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.747816 |
34869058 |
| 2021-11-17 |
Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9111347 |
34835278 |
| 2021-11-16 |
Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADHM.202101714 |
34755476 |
| 2021-11-16 |
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110020 |
34762851 |
| 2021-11-16 |
SARS-CoV-2 infection and replication in human gastric organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26762-2 |
34785679 |
| 2021-11-16 |
The Critical Need for Pooled Data on Coronavirus Disease 2019 in African Children: An AFREhealth Call for Action Through Multicountry Research Collaboration (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB142 |
33580256 |
| 2021-11-16 |
Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02315-21 |
34781748 |
| 2021-11-16 |
A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02936-21 |
34781739 |
| 2021-11-16 |
Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10113187 |
|
| 2021-11-16 |
A Comparative Study between Spanish and British SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB43030140 |
34889898 |
| 2021-11-15 |
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BIT.27945 |
34585736 |
| 2021-11-15 |
SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high density lipoprotein to exchange lipids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCIS.2021.06.056 |
34157514 |
| 2021-11-15 |
The existence, spread, and strategies for environmental monitoring and control of SARS-CoV-2 in environmental media (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.148949 |
34252782 |
| 2021-11-15 |
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(21)00267-6 |
|
| 2021-11-15 |
Targeted Detection of SARS-CoV-2 Nucleocapsid Sequence Variants by Mass Spectrometric Analysis of Tryptic Peptides (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.1C00613 |
34779632 |
| 2021-11-15 |
The glycosylation in SARS-CoV-2 and its receptor ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00809-8 |
34782609 |
| 2021-11-15 |
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26910-8 |
34782627 |
| 2021-11-15 |
Nanometer-resolution in situ structure of the SARS-CoV-2 postfusion spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2112703118 |
34782481 |
| 2021-11-15 |
Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CANCERS13225718 |
34830872 |
| 2021-11-14 |
Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3748/WJG.V27.I42.7271 |
|
| 2021-11-13 |
Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.11.005 |
34822776 |
| 2021-11-13 |
A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRSTBI.2021.11.002 |
34806033 |
| 2021-11-13 |
SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NBD.2021.105561 |
34780863 |
| 2021-11-13 |
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BJS/ZNAB336 |
|
| 2021-11-13 |
In depth analysis of Cyprus-specific mutations of SARS-CoV-2 strains using computational approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12863-021-01007-9 |
34773976 |
| 2021-11-13 |
Identification of Cellular Factors Required for SARS-CoV-2 Replication (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10113159 |
34831382 |
| 2021-11-12 |
Assessing the efficacy of interventions to control indoor SARS-Cov-2 transmission: An agent-based modeling approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EPIDEM.2021.100524 |
34798545 |
| 2021-11-12 |
Disulfide bonds play a critical role in the structure and function of the receptor-binding domain of the SARS-CoV-2 Spike antigen (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167357 |
34780781 |
| 2021-11-12 |
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00278 |
34658235 |
| 2021-11-12 |
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26803-W |
34772941 |
| 2021-11-12 |
Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-00684-X |
34772947 |
| 2021-11-12 |
The Emergence of the Spike Furin Cleavage Site in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAB327 |
34788836 |
| 2021-11-12 |
Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PNTD.0009945 |
|
| 2021-11-12 |
Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NU13114047 |
|
| 2021-11-11 |
Dresdner Kinder und Corona - kein schöne(s)r Land zu dieser Zeit: Eine Beobachtung aus Prohlis (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-11 |
Meine Kindheit mit Corona: Bericht einer Zehnjährigen (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-11 |
Epigenetic glycosylation of SARS-CoV-2 impact viral infection through DC&L-SIGN receptors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103426 |
34786539 |
| 2021-11-11 |
Dietary polyphenols mitigate SARS-CoV-2 main protease (Mpro)-Molecular dynamics, molecular mechanics, and density functional theory investigations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2021.131879 |
34785822 |
| 2021-11-11 |
Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A.23.1 identified in Uganda (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.30.450632 |
34230931 |
| 2021-11-11 |
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.11.21266068 |
|
| 2021-11-11 |
Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0259165 |
34762662 |
| 2021-11-11 |
Evolutionary and Antigenic Profiling of the Tendentious D614G Mutation of SARS-CoV-2 in Gujarat, India (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2021.764927 |
34858480 |
| 2021-11-11 |
Research progress of human coronaviruses and associated eye diseases (edit) |
SARSコロナウイルス2 (edit) |
10.3760/CMA.J.CN112142-20210426-00190 |
34743475 |
| 2021-11-10 |
Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.11.004 |
34838159 |
| 2021-11-10 |
Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103412 |
34786537 |
| 2021-11-10 |
Close proximity risk assessment for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.148749 |
34225157 |
| 2021-11-10 |
The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.09.467693 |
|
| 2021-11-10 |
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00965-21 |
34756082 |
| 2021-11-10 |
In Silico Identification and Clinical Validation of a Novel Long Non-Coding RNA/mRNA/miRNA Molecular Network for Potential Biomarkers for Discriminating SARS CoV-2 Infection Severity (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10113098 |
|
| 2021-11-09 |
Molecular dynamic study of SARS-CoV-2 with various S protein mutations and their effect on thermodynamic properties (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105025 |
34772510 |
| 2021-11-09 |
Discovery of Camellia sinensis catechins as SARS-CoV-2 3CL protease inhibitors through molecular docking, intra and extra cellular assays (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYMED.2021.153853 |
34799184 |
| 2021-11-09 |
Transparent Polymeric Formulations Effective against SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSAMI.1C10404 |
34752084 |
| 2021-11-09 |
A novel SARS-CoV-2 related coronavirus in bats from Cambodia (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26809-4 |
|
| 2021-11-09 |
Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41589-021-00924-1 |
34754101 |
| 2021-11-09 |
Candidate genes of SARS-CoV-2 gender susceptibility (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-01131-7 |
34753980 |
| 2021-11-09 |
CCR2 Signaling Restricts SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02749-21 |
|
| 2021-11-09 |
Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16) (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S43141-021-00273-5 |
34751829 |
| 2021-11-08 |
Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.11.007 |
34777716 |
| 2021-11-08 |
Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-01410-3 |
34750486 |
| 2021-11-08 |
Correction: Collaboration in the time of COVID: a scientometric analysis of multidisciplinary SARS-CoV-2 research (edit) |
SARSコロナウイルス2 (edit) |
10.1057/S41599-021-00957-W |
|
| 2021-11-08 |
Adaptive trends of sequence compositional complexity over pandemic time in the SARS-CoV-2 coronavirus (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.11.06.467547 |
|
| 2021-11-08 |
Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1010053 |
34748603 |
| 2021-11-08 |
Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13112239 |
34835045 |
| 2021-11-07 |
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103675 |
34758415 |
| 2021-11-06 |
Aging whole blood transcriptome reveals candidate genes for SARS-CoV-2-related vascular and immune alterations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00109-021-02161-4 |
34741638 |
| 2021-11-06 |
Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105128 |
34752930 |
| 2021-11-06 |
Surveillance and control of SARS-CoV-2 in mustelids: An evolutionary perspective (edit) |
SARSコロナウイルス2 (edit) |
10.1111/EVA.13310 |
34899977 |
| 2021-11-06 |
Strategy to Develop and Evaluate a Multiplex RT-ddPCR in Response to SARS-CoV-2 Genomic Evolution (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CIMB43030134 |
34889894 |
| 2021-11-05 |
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-021-03721-W |
34739558 |
| 2021-11-05 |
Phylogenetic and Ancestral Sequence Reconstruction of SARS-CoV-2 Reveals Latent Capacity to Bind Human ACE2 Receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00239-021-10034-0 |
34739551 |
| 2021-11-05 |
Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13337-021-00747-7 |
34754886 |
| 2021-11-05 |
Predicting COVID-19 cases in diverse population groups using SARS-CoV-2 wastewater monitoring across Oklahoma City (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.151431 |
34748841 |
| 2021-11-05 |
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26760-4 |
34741049 |
| 2021-11-05 |
Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-01081-0 |
34741079 |
| 2021-11-05 |
Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-01217-2 |
34741071 |
| 2021-11-05 |
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOOD-2021-153901 |
|
| 2021-11-04 |
CTD of SARS‐CoV‐2 N protein is a cryptic domain for binding ATP and nucleic acid that interplay in modulating phase separation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PRO.4221 |
34734665 |
| 2021-11-04 |
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2021.105024 |
34781240 |
| 2021-11-04 |
SARS-CoV-2 can infect and propagate in human placenta explants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100456 |
34751258 |
| 2021-11-04 |
In Silico End-to-End Protein-Ligand Interaction Characterization Pipeline: The Case of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSSYNBIO.1C00368 |
34736321 |
| 2021-11-04 |
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26602-3 |
34737266 |
| 2021-11-04 |
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3001284 |
34735434 |
| 2021-11-03 |
Risk of chlorine dioxide as emerging contaminant during SARS-CoV-2 pandemic: enzyme, cardiac, and behavior effects on amphibian tadpoles (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-03 |
Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.10.027 |
34798069 |
| 2021-11-03 |
Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.105017 |
34758907 |
| 2021-11-03 |
Comprehensive investigation of SARS-CoV-2 fate in wastewater and finding the virus transfer and destruction route through conventional activated sludge and sequencing batch reactor (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.151391 |
34740662 |
| 2021-11-03 |
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1470-2045(21)00573-8 |
|
| 2021-11-03 |
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.1C01494 |
34730959 |
| 2021-11-03 |
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00810-1 |
34732694 |
| 2021-11-03 |
The COVID-19 pandemic as a challenge and opportunity for registries in health services research: experiences from the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) (edit) |
SARSコロナウイルス2 (edit) |
10.1055/A-1655-8705 |
|
| 2021-11-03 |
Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2109905118 |
34732583 |
| 2021-11-03 |
Insights on the SARS-CoV-2 genome variability: the lesson learned in Brazil and its impacts on the future of pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1099/MGEN.0.000656 |
|
| 2021-11-03 |
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13112209 |
34835015 |
| 2021-11-02 |
RNA-extraction-free diagnostic method to detect SARS-CoV-2: an assessment from two states, India (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-11-02 |
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109928 |
34706271 |
| 2021-11-02 |
A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.10.038 |
34745450 |
| 2021-11-02 |
Metabologenomics approach to the discovery of novel compounds from Streptomyces sp. GMR22 as anti-SARS-CoV-2 drugs (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E08308 |
34746476 |
| 2021-11-02 |
Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2107148118 |
34702738 |
| 2021-11-02 |
Bilateral giant cell arteritis with skin necrosis following SARS‐CoV‐2 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1111/BJD.20824 |
|
| 2021-11-01 |
SARS-CoV-2 Antibodies in Breast Milk After Vaccination (edit) |
SARSコロナウイルス2 (edit) |
|
34408089 |
| 2021-11-01 |
The evaluation of potential global impact of the N501Y mutation in SARS-COV-2 positive patients (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27413 |
34676574 |
| 2021-11-01 |
Dominant clade‐featured SARS‐CoV‐2 co‐occurring mutations reveal plausible epistasis: An in silico based hypothetical model (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27416 |
|
| 2021-11-01 |
In response to the letter to the editor regarding SARS-CoV-2 Presence in the Saliva, Tears, and Cerumen of COVID-19 Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1002/LARY.29723 |
34216142 |
| 2021-11-01 |
In Reference to "SARS-CoV-2 presence in the saliva, tears and cerumen of COVID-19 patients" (edit) |
SARSコロナウイルス2 (edit) |
10.1002/LARY.29727 |
34216143 |
| 2021-11-01 |
Zn‐Induced Interactions Between SARS‐CoV‐2 orf7a and BST2/Tetherin (edit) |
SARSコロナウイルス2 (edit) |
10.1002/OPEN.202100217 |
34791819 |
| 2021-11-01 |
SARS-CoV-2 research using human pluripotent stem cells and organoids (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SCTM.21-0183 |
34302450 |
| 2021-11-01 |
Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00296-021-04932-1 |
34259880 |
| 2021-11-01 |
Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12031-020-01767-6 |
33464535 |
| 2021-11-01 |
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13238-021-00836-9 |
33864621 |
| 2021-11-01 |
A framework for monitoring population immunity to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANNEPIDEM.2021.08.013 |
34425208 |
| 2021-11-01 |
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.APSB.2021.10.026 |
34745850 |
| 2021-11-01 |
Membranotropic and biological activities of the membrane fusion peptides from SARS-CoV spike glycoprotein: The importance of the complete internal fusion peptide domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAMEM.2021.183697 |
34274319 |
| 2021-11-01 |
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOMATERIALS.2021.121159 |
|
| 2021-11-01 |
Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.110049 |
34788596 |
| 2021-11-01 |
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.10.003 |
|
| 2021-11-01 |
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2021.108871 |
|
| 2021-11-01 |
Dysphagia and mechanical ventilation in SARS-COV-2 pneumonia: It's real (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLNU.2021.11.018 |
|
| 2021-11-01 |
Emerging SARS-CoV-2 variants expand species tropism to murines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103643 |
34689086 |
| 2021-11-01 |
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101174 |
34746725 |
| 2021-11-01 |
Water-sanitation-health nexus in the Indus-Ganga-Brahmaputra River Basin: need for wastewater surveillance of SARS-CoV-2 for preparedness during the future waves of pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECOHYD.2021.11.001 |
|
| 2021-11-01 |
Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJMECH.2021.113966 |
34749200 |
| 2021-11-01 |
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103353 |
34729465 |
| 2021-11-01 |
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2021.08.016 |
34492260 |
| 2021-11-01 |
In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LFS.2021.119881 |
34389403 |
| 2021-11-01 |
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105038 |
34403832 |
| 2021-11-01 |
Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110681 |
|
| 2021-11-01 |
Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SAA.2021.120595 |
34815178 |
| 2021-11-01 |
Spatially resolved qualified sewage spot sampling to track SARS-CoV-2 dynamics in Munich - One year of experience (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.149031 |
|
| 2021-11-01 |
SARS-CoV-2 viral RNA levels are not 'viral load' (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TIM.2021.08.008 |
|
| 2021-11-01 |
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2021.09.001 |
34536797 |
| 2021-11-01 |
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00289-9 |
|
| 2021-11-01 |
High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2214-109X(21)00355-7 |
34678195 |
| 2021-11-01 |
Virus detective: searching for Zika, dengue and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/D41586-021-03001-8 |
|
| 2021-11-01 |
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00570-1 |
34584244 |
| 2021-11-01 |
Structural biology of SARS-CoV-2 and implications for therapeutic development (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41579-021-00630-8 |
34535791 |
| 2021-11-01 |
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03944-Y |
34488225 |
| 2021-11-01 |
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01540-1 |
34588689 |
| 2021-11-01 |
Whole genome sequencing for revealing the point mutations of SARS-CoV-2 genome in Bangladeshi isolates and their structural effects on viral proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA05327B |
35493250 |
| 2021-11-01 |
In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA07845C |
35493238 |
| 2021-11-01 |
Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2114390118 |
34702736 |
| 2021-11-01 |
189. Potential Tiger-to-Human Transmission of SARS-CoV-2 at a Tennessee Zoo: A One Health Approach to Outbreak Investigation (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB466.189 |
|
| 2021-11-01 |
297. Infectious Complications Associated with Tocilizumab Use in Patients Infected with SARS-CoV-2 at a Mid-Atlantic Hospital Consortium (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB466.499 |
|
| 2021-11-01 |
347. SARS-CoV-2 and Acute Otitis Media in Children: A Case Series (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB466.548 |
|
| 2021-11-01 |
A hybrid PDE–ABM model for viral dynamics with application to SARS-CoV-2 and influenza (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.210787 |
|
| 2021-11-01 |
Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography (edit) |
SARSコロナウイルス2 (edit) |
10.1107/S2052252521010113 |
34804549 |
| 2021-11-01 |
SARS-CoV-2 infection in pregnancy in Denmark-characteristics and outcomes after confirmed infection in pregnancy: A nationwide, prospective, population-based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/AOGS.14252 |
34467518 |
| 2021-11-01 |
Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TRF.16672 |
34549821 |
| 2021-11-01 |
Spectra of Photobiological Inactivation of SARS-CoV-2 by Solar UVB Radiation (280–320 nm) (edit) |
SARSコロナウイルス2 (edit) |
10.1134/S1024856021060191 |
|
| 2021-11-01 |
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI146408 |
|
| 2021-11-01 |
Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM (edit) |
SARSコロナウイルス2 (edit) |
10.1192/BJO.2021.1037 |
|
| 2021-11-01 |
Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets (edit) |
SARSコロナウイルス2 (edit) |
10.15252/MSB.202110260 |
34709707 |
| 2021-11-01 |
SARS-CoV-2-host proteome interactions for antiviral drug discovery (edit) |
SARSコロナウイルス2 (edit) |
10.15252/MSB.202110396 |
34709727 |
| 2021-11-01 |
Detection of SARS-CoV-2 in the sewerage system in Tunisia: a promising tool to confront COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.2217/FVL-2021-0050 |
|
| 2021-11-01 |
The high diversity of SARS-CoV-2-related coronaviruses in pangolins alerts potential ecological risks (edit) |
SARSコロナウイルス2 (edit) |
10.24272/J.ISSN.2095-8137.2021.334 |
34766482 |
| 2021-10-31 |
Structural basis for the interaction of SARS‐CoV‐2 virulence factor nsp1 with DNA Polymerase a ‐ Primase (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PRO.4220 |
34719824 |
| 2021-10-31 |
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01416-21 |
34704808 |
| 2021-10-30 |
Analysis on genome variation of SARS-CoV-2 circulating in the world (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-10-30 |
Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10875-021-01142-Z |
34716845 |
| 2021-10-30 |
Multiplex PCR Assays for Identifying All Major SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.10.28.21263107 |
|
| 2021-10-30 |
Clinical and Epidemiological Characteristics of 1283 Pediatric Patients with Coronavirus Disease 2019 during the First and Second Waves of the Pandemic-Results of the Pediatric Part of a Multicenter Polish Register SARSTer (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM10215098 |
34768620 |
| 2021-10-29 |
Evaluation of virucidal activity of residual quaternary ammonium-treated surfaces on SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2021.10.021 |
34756967 |
| 2021-10-29 |
SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.10.112 |
34743814 |
| 2021-10-29 |
Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.10.019 |
34788600 |
| 2021-10-29 |
SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101371 |
34756892 |
| 2021-10-29 |
BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCLINEPI.2021.10.011 |
34715314 |
| 2021-10-29 |
In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SJBS.2021.10.060 |
34729030 |
| 2021-10-29 |
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00648-4 |
|
| 2021-10-29 |
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-01068-Z |
34716452 |
| 2021-10-29 |
Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-021-00044-W |
|
| 2021-10-29 |
Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7043E1 |
34710076 |
| 2021-10-29 |
The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13112182 |
|
| 2021-10-28 |
A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101362 |
34756886 |
| 2021-10-28 |
RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.WATRES.2021.117808 |
34753092 |
| 2021-10-28 |
Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YGENO.2021.10.015 |
34718131 |
| 2021-10-28 |
Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(21)02276-5 |
|
| 2021-10-28 |
Quantification of airborne SARS-CoV-2 genomic particles in different hospital settings (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-00761-1 |
34711888 |
| 2021-10-28 |
The intersection of COVID-19 and autoimmunity (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI154886 |
34710063 |
| 2021-10-28 |
Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.770066 |
|
| 2021-10-27 |
Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100452 |
|
| 2021-10-27 |
The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100453 |
34723226 |
| 2021-10-27 |
Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.1C01475 |
|
| 2021-10-27 |
Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSNANO.1C06839 |
|
| 2021-10-27 |
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43018-021-00274-W |
34950880 |
| 2021-10-27 |
qNMR characterization of potential peptide calibrators for isotope dilution LC–MS quantification of a SARS-CoV-2 IgG monoclonal antibody (edit) |
SARSコロナウイルス2 (edit) |
10.1088/1361-6501/AC2FE9 |
|
| 2021-10-27 |
Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JPM11111098 |
34834450 |
| 2021-10-26 |
Garcinia kola and garcinoic acid suppress SARS-CoV-2 spike glycoprotein S1-induced hyper-inflammation in human PBMCs through inhibition of NF-κB activation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PTR.7315 |
34697842 |
| 2021-10-26 |
Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109881 |
34655519 |
| 2021-10-26 |
Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL substrate degradome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109892 |
34672947 |
| 2021-10-26 |
Polymorphic landscape of SARS-CoV-2 genomes isolated from Indian population in 2020 demonstrates rapid evolution in ORF3a, ORF8, nucleocapsid phosphoprotein and spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2021.107594 |
34736125 |
| 2021-10-26 |
Analysis of 329,942 SARS-CoV-2 records retrieved from GISAID database (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104981 |
34735950 |
| 2021-10-26 |
SARS-CoV-2 exploits host DGAT and ADRP for efficient replication (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00338-2 |
34702802 |
| 2021-10-26 |
Detailed phylogenetic analysis tracks transmission of distinct SARS-COV-2 variants from China and Europe to West Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-00267-W |
34702899 |
| 2021-10-26 |
Data-driven analysis of amino acid change dynamics timely reveals SARS-CoV-2 variant emergence (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-00496-Z |
|
| 2021-10-26 |
Distant residues modulate conformational opening in SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2100943118 |
34615730 |
| 2021-10-26 |
A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1080/00365521.2021.1993328 |
|
| 2021-10-26 |
Betacoronavirus Assembly: Clues and Perspectives for Elucidating SARS-CoV-2 Particle Formation and Egress (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02371-21 |
34579570 |
| 2021-10-26 |
Diurnal Variation in SARS-CoV-2 PCR Test Results: Test Accuracy May Vary by Time of Day (edit) |
SARSコロナウイルス2 (edit) |
10.1177/07487304211051841 |
|
| 2021-10-26 |
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.750386 |
34764961 |
| 2021-10-26 |
OM-85 Broncho-Vaxom, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES9111544 |
34829773 |
| 2021-10-25 |
De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104967 |
34739968 |
| 2021-10-25 |
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100450 |
|
| 2021-10-25 |
Stuck between a rock and a hard place: The clinical conundrum of managing cardiac surgical patients during the SARS‐CoV‐2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JOCS.16111 |
|
| 2021-10-25 |
Transmission dynamics and susceptibility patterns of SARS‐CoV‐2 in domestic, farmed and wild animals: Sustainable One Health surveillance for conservation and public health to prevent future epidemics and pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.14356 |
|
| 2021-10-25 |
Structure-Based Primer Design Minimizes the Risk of PCR Failure Caused by SARS-CoV-2 Mutations (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.741147 |
34760717 |
| 2021-10-24 |
Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103341 |
34723159 |
| 2021-10-23 |
New approach in SARS-CoV-2 surveillance using biosensor technology: a review (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-021-17096-Z |
|
| 2021-10-23 |
SARS-CoV-2 Spike Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11481-021-10029-0 |
34687399 |
| 2021-10-23 |
DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103331 |
34723158 |
| 2021-10-23 |
SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JACI.2021.10.014 |
34695490 |
| 2021-10-22 |
COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-bi (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BIES.202100158 |
34677872 |
| 2021-10-22 |
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13238-021-00883-2 |
34687004 |
| 2021-10-22 |
Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRPHAR.2021.100065 |
34870160 |
| 2021-10-22 |
Allotypic variation in antigen processing controls antigenic peptide generation from SARS-CoV-2 S1 spike glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101329 |
34688668 |
| 2021-10-22 |
Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2021.10.005 |
34700068 |
| 2021-10-22 |
Genomic epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely collected surveillance data (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2214-109X(21)00434-4 |
34695371 |
| 2021-10-22 |
A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABJ4336 |
34672751 |
| 2021-10-22 |
De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2021/8400842 |
|
| 2021-10-22 |
Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13112127 |
34834934 |
| 2021-10-22 |
Evolutionary Perspective and Theories on the Possible Origin of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.18981 |
34820236 |
| 2021-10-21 |
Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27405 |
34672376 |
| 2021-10-21 |
Design and synthesis of heterocyclic azole based bioactive compounds: Molecular structures, quantum simulation, and mechanistic studies through docking as multi-target inhibitors of SARS-CoV-2 and cytotoxicity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2021.131782 |
34697505 |
| 2021-10-21 |
The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41593-021-00926-1 |
34675436 |
| 2021-10-21 |
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2113468 |
|
| 2021-10-21 |
Are antigen tests useful as screening for the identification of SARS-CoV-2 in emergency rooms? (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EURPUB/CKAB164.813 |
|
| 2021-10-21 |
High-throughput virtual screening of small molecule inhibitors for SARS-CoV-2 protein targets with deep fusion models (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3458817.3476193 |
|
| 2021-10-21 |
Micronucleus production, activation of DNA damage response and cGAS-STING signaling in syncytia induced by SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13062-021-00305-7 |
34674770 |
| 2021-10-21 |
Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PMED.1003807 |
|
| 2021-10-21 |
Pathology and Immunity After SARS-CoV-2 Infection in Male Ferrets Is Affected by Age and Inoculation Route (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.750229 |
34745122 |
| 2021-10-21 |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CANCERS13215276 |
|
| 2021-10-21 |
A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PHARMACEUTICS13111759 |
34834174 |
| 2021-10-20 |
Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound (edit) |
SARSコロナウイルス2 (edit) |
10.1002/FSN3.2576 |
34900242 |
| 2021-10-20 |
Deciphering the link between Diabetes mellitus and SARS-CoV-2 infection through differential targeting of microRNAs in the human pancreas (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40618-021-01693-3 |
34669152 |
| 2021-10-20 |
An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMBIOL.2021.10.008 |
34672954 |
| 2021-10-20 |
Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101290 |
34678315 |
| 2021-10-20 |
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26354-0 |
|
| 2021-10-20 |
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26401-W |
34671049 |
| 2021-10-20 |
An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-021-00390-9 |
34671047 |
| 2021-10-20 |
An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2110817118 |
34670842 |
| 2021-10-20 |
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01110-21 |
34668774 |
| 2021-10-20 |
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.01298-21 |
34668728 |
| 2021-10-20 |
Mechanisms of Immunothrombosis by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM11111550 |
34827548 |
| 2021-10-20 |
Associations between Genetic Variants in the Vitamin D Metabolism Pathway and Severity of COVID-19 among UAE Residents (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NU13113680 |
34835935 |
| 2021-10-20 |
Direct RNA Sequencing Reveals SARS-CoV-2 m6A Sites and Possible Differential DRACH Motif Methylation among Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13112108 |
34834915 |
| 2021-10-19 |
Compartmentalization-aided interaction screening reveals extensive high-order complexes within the SARS-CoV-2 proteome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109778 |
34686343 |
| 2021-10-19 |
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103637 |
34678613 |
| 2021-10-19 |
Evaluation of SARS-CoV-2 main protease and inhibitor interactions using dihedral angle distributions and radial distribution function (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E08220 |
34693066 |
| 2021-10-19 |
Collaboration in the time of COVID: a scientometric analysis of multidisciplinary SARS-CoV-2 research (edit) |
SARSコロナウイルス2 (edit) |
10.1057/S41599-021-00922-7 |
|
| 2021-10-19 |
Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00921-21 |
34379531 |
| 2021-10-19 |
Computational Analysis of Missense Variants in the Human Transmembrane Protease Serine 2 (TMPRSS2) and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2021/9982729 |
34692848 |
| 2021-10-19 |
Factors affecting aerosol SARS-CoV-2 transmission via HVAC systems; a modeling study (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009474 |
|
| 2021-10-19 |
COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.15252/MSB.202110387 |
34664389 |
| 2021-10-19 |
How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13102106 |
|
| 2021-10-18 |
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00578-7 |
34663909 |
| 2021-10-18 |
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-01035-8 |
34663977 |
| 2021-10-17 |
Viruscape: A Microscopic Adventure Game to Guide Conceptual Learning of SARS-CoV-2 Mechanisms (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3450337.3483490 |
|
| 2021-10-15 |
Sequence complementarity between human noncoding RNAs and SARS-CoV-2 genes: What are the implications for human health? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166291 |
34662705 |
| 2021-10-15 |
Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2021.08.036 |
34425281 |
| 2021-10-15 |
An airway organoid-based screen identifies a role for the HIF1α-glycolysis axis in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109920 |
34731648 |
| 2021-10-15 |
Sweet Drugs for Bad Bugs: A Glycomimetic Strategy against the DC-SIGN-Mediated Dissemination of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.1C06778 |
|
| 2021-10-15 |
Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI148036 |
|
| 2021-10-14 |
Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26267-Y |
34650062 |
| 2021-10-14 |
Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99642-W |
34650130 |
| 2021-10-14 |
Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99661-7 |
|
| 2021-10-14 |
Integrin activation is an essential component of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99893-7 |
34650161 |
| 2021-10-14 |
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13073-021-00985-W |
34649620 |
| 2021-10-13 |
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27376 |
|
| 2021-10-13 |
Host genetic factors determining COVID-19 susceptibility and severity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103629 |
34655949 |
| 2021-10-13 |
The effect of glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103272 |
34661088 |
| 2021-10-13 |
A cross-sectional analysis of meteorological factors and SARS-CoV-2 transmission in 409 cities across 26 countries (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25914-8 |
34645794 |
| 2021-10-13 |
Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02728-4 |
34645933 |
| 2021-10-13 |
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S43856-021-00039-7 |
35602204 |
| 2021-10-13 |
Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA04134G |
35497518 |
| 2021-10-13 |
Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABI6533 |
34644111 |
| 2021-10-13 |
Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00055-21 |
34643448 |
| 2021-10-13 |
Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PNTD.0009835 |
34644287 |
| 2021-10-13 |
Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.765039 |
34722346 |
| 2021-10-13 |
Children and Adults in a Household Cohort Study Have Robust Longitudinal Immune Responses Following SARS-CoV-2 Infection or Exposure (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.741639 |
34721408 |
| 2021-10-13 |
Strategy and Performance Evaluation of Low-Frequency Variant Calling for SARS-CoV-2 Using Targeted Deep Illumina Sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.747458 |
34721349 |
| 2021-10-13 |
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13102056 |
34696485 |
| 2021-10-12 |
Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PTR.7302 |
34643000 |
| 2021-10-12 |
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109825 |
34614392 |
| 2021-10-12 |
Crippling SARS-CoV-2 vaccine supply crunch, vaccination target and scope in Bangladesh (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HPOPEN.2021.100054 |
|
| 2021-10-12 |
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.08.016 |
34481543 |
| 2021-10-12 |
Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYTOCHEM.2021.112984 |
34757253 |
| 2021-10-12 |
Computational Study on the Function of Palmitoylation on the Envelope Protein in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.1C00359 |
34516136 |
| 2021-10-12 |
Dietary stigmastane-type saponins as promising dual-target directed inhibitors of SARS-CoV-2 proteases: a structure-based screening (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA05976A |
35497510 |
| 2021-10-12 |
Construction and Investigation of Competing Endogenous RNA Networks and Candidate Genes Involved in SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.2147/IJGM.S335162 |
34675627 |
| 2021-10-12 |
Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FENDO.2021.714909 |
34712201 |
| 2021-10-11 |
In silico screening, SAR and kinetic studies of naturally occurring flavonoids against SARS CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARABJC.2021.103473 |
34909065 |
| 2021-10-11 |
ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DEVCEL.2021.10.006 |
34706264 |
| 2021-10-11 |
Identification of Berbamine, Oxyacanthine and Rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: An in silico study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2021.108028 |
34649146 |
| 2021-10-11 |
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2108728118 |
34635581 |
| 2021-10-11 |
The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JTM/TAAB124 |
34369565 |
| 2021-10-11 |
SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3001425 |
34634033 |
| 2021-10-11 |
Direct and Indirect Proof of SARS-CoV-2 Infections in Indigenous Wiwa Communities in North-Eastern Colombia—A Cross-Sectional Assessment Providing Preliminary Surveillance Data (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9101120 |
|
| 2021-10-09 |
A student led computational screening of peptide inhibitors against main protease of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BMB.21580 |
34626436 |
| 2021-10-09 |
Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first 6 months of the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PROT.26250 |
34580920 |
| 2021-10-08 |
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans (edit) |
SARSコロナウイルス2 (edit) |
10.1002/EJI.202149535 |
34580856 |
| 2021-10-08 |
SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1002/MCO2.92 |
34909756 |
| 2021-10-08 |
Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109882 |
34653416 |
| 2021-10-08 |
Study of perinatal transmission of SARS-CoV-2 in a Mexican public hospital (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.10.006 |
34628021 |
| 2021-10-08 |
SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99404-8 |
34625610 |
| 2021-10-08 |
Compelling Evidence Suggesting the Codon Usage of SARS-CoV-2 Adapts to Human After the Split From RaTG13 (edit) |
SARSコロナウイルス2 (edit) |
10.1177/11769343211052013 |
34646060 |
| 2021-10-08 |
Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy) (edit) |
SARSコロナウイルス2 (edit) |
10.2196/27739 |
34533472 |
| 2021-10-08 |
Inhibition Potencies of Phytochemicals Derived from Sesame Against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2021.744376 |
34692642 |
| 2021-10-08 |
Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.693462 |
34691016 |
| 2021-10-08 |
Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.753435 |
34691072 |
| 2021-10-08 |
Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13102021 |
|
| 2021-10-07 |
A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2021.105183 |
34626674 |
| 2021-10-07 |
Airborne microplastics and SARS-CoV-2 in total suspended particles in the area surrounding the largest medical centre in Latin America (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVPOL.2021.118299 |
34626707 |
| 2021-10-07 |
A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.NBT.2021.10.002 |
34628049 |
| 2021-10-07 |
Domain-specific biochemical and serological characterization of SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.100906 |
34642671 |
| 2021-10-07 |
Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSNANO.1C01243 |
34618423 |
| 2021-10-07 |
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26117-X |
34620860 |
| 2021-10-07 |
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26178-Y |
34620866 |
| 2021-10-07 |
Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99431-5 |
34620951 |
| 2021-10-07 |
Nutritional behaviors of women and men in Poland during confinement related to the SARS-CoV-2 epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99561-W |
34620981 |
| 2021-10-07 |
Genome Sequences of Community SARS-CoV-2 B.1.526 and P.1 Variants Circulating in the Dominican Republic (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MRA.00744-21 |
34617785 |
| 2021-10-07 |
Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1192/BJO.2021.1030 |
|
| 2021-10-07 |
Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.750725 |
34691002 |
| 2021-10-07 |
l-Arginine Improves Solubility and ANTI SARS-CoV-2 Mpro Activity of Rutin but Not the Antiviral Activity in Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MOLECULES26196062 |
34641606 |
| 2021-10-07 |
Turnover of SARS-CoV-2 Lineages Shaped the Pandemic and Enabled the Emergence of New Variants in the State of Rio de Janeiro, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13102013 |
34696443 |
| 2021-10-07 |
Evolution of SARS-CoV-2 Key Mutations in Vienna Detected by Large Scale Screening Program (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13102014 |
|
| 2021-10-07 |
Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.70968 |
34617885 |
| 2021-10-06 |
Superspreading events of SARS-CoV-2 in Paris: A retrospective analysis of data from the first wave of COVID-19 in 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIPH.2021.10.001 |
34715427 |
| 2021-10-06 |
SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25946-0 |
34615863 |
| 2021-10-06 |
Transcriptomic analysis revealed increased expression of genes involved in keratinization in the tears of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99344-3 |
34615949 |
| 2021-10-06 |
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IJCP.14882 |
34529866 |
| 2021-10-06 |
Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01368-21 |
34613786 |
| 2021-10-06 |
Rapid and High-Throughput Reverse Transcriptase Quantitative PCR (RT-qPCR) Assay for Identification and Differentiation between SARS-CoV-2 Variants B.1.1.7 and B.1.351 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00506-21 |
34612692 |
| 2021-10-06 |
Averting an Outbreak of SARS-CoV-2 in a University Residence Hall through Wastewater Surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00792-21 |
|
| 2021-10-06 |
Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DIAGNOSTICS11101843 |
|
| 2021-10-05 |
Novel Molecules derived from 3-O-(6-galloylglucoside) inhibit Main Protease of SARS-CoV 2 In Silico (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11696-021-01899-Y |
34629698 |
| 2021-10-05 |
Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109771 |
34587480 |
| 2021-10-05 |
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109784 |
34592170 |
| 2021-10-05 |
In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109838 |
34648735 |
| 2021-10-05 |
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MCPRO.2021.100159 |
34619366 |
| 2021-10-05 |
Mechanisms of SARS-CoV-2 entry into cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41580-021-00418-X |
34611326 |
| 2021-10-05 |
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02473-21 |
34607456 |
| 2021-10-05 |
UK Research Ethics Committee’s review of the global first SARS-CoV-2 human infection challenge studies (edit) |
SARSコロナウイルス2 (edit) |
10.1136/MEDETHICS-2021-107709 |
|
| 2021-10-05 |
A Bioinformatics Approach for the Prediction of Immunogenic Properties and Structure of the SARS-COV-2 B.1.617.1 Variant Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2021/7251119 |
34651048 |
| 2021-10-05 |
Tailoring Our Approach in Response to the SARS-CoV-2 Pandemic and Transcending Science Outreach Modalities for Native American Students in a Cancer Research Education Program (edit) |
SARSコロナウイルス2 (edit) |
10.15695/JSTEM/V4I4.08 |
|
| 2021-10-05 |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.746203 |
34675930 |
| 2021-10-05 |
HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.67397 |
|
| 2021-10-04 |
The acid sphingomyelinase/ceramide system in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41380-021-01309-5 |
34608263 |
| 2021-10-04 |
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs (edit) |
SARSコロナウイルス2 (edit) |
10.1084/JEM.20211211 |
34357402 |
| 2021-10-04 |
The early interferon catches the SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1084/JEM.20211667 |
34424267 |
| 2021-10-04 |
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.741502 |
34671355 |
| 2021-10-02 |
Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11481-021-10015-6 |
34599743 |
| 2021-10-02 |
The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103215 |
34632327 |
| 2021-10-02 |
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review (edit) |
SARSコロナウイルス2 (edit) |
10.1093/RHEUMATOLOGY/KEAB026 |
|
| 2021-10-02 |
SARS‐CoV‐2 Alpha, Beta and Delta variants display enhanced Spike‐mediated Syncytia Formation (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021108944 |
34601723 |
| 2021-10-01 |
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMA.2021.15125 |
34459863 |
| 2021-10-01 |
Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2021.28568 |
34643720 |
| 2021-10-01 |
SARS-CoV-2 Delta variant infects ACE2 primary human bronchial epithelial cells more efficiently than other variants (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27372 |
34596249 |
| 2021-10-01 |
SARS-CoV-2 infects an upper airway model derived from induced pluripotent stem cells (edit) |
SARSコロナウイルス2 (edit) |
10.1002/STEM.3422 |
34152044 |
| 2021-10-01 |
Lesson by SARS-CoV-2 disease (COVID-19): whole-body CT angiography detection of "relevant" and "other/incidental" systemic vascular findings (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00330-021-07904-Y |
33864140 |
| 2021-10-01 |
Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00403-020-02156-0 |
33159236 |
| 2021-10-01 |
H, C and N Backbone chemical shift assignments of the n-terminal and central intrinsically disordered domains of SARS-CoV-2 nucleoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12104-021-10014-X |
33730325 |
| 2021-10-01 |
H, C and N assignment of stem-loop SL1 from the 5'-UTR of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12104-021-10047-2 |
34453696 |
| 2021-10-01 |
A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12250-021-00385-9 |
33999369 |
| 2021-10-01 |
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2021.105167 |
34450201 |
| 2021-10-01 |
The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AUTREV.2021.102909 |
34274539 |
| 2021-10-01 |
Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166198 |
|
| 2021-10-01 |
Kawasaki Disease Shock Syndrome vs Classical Kawasaki Disease: A Meta-analysis and Comparison With SARS-CoV-2 Multisystem Inflammatory Syndrome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CJCA.2021.05.014 |
|
| 2021-10-01 |
Proteases and variants: context matters for SARS-CoV-2 entry assays (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COVIRO.2021.07.004 |
34365113 |
| 2021-10-01 |
S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DEVCEL.2021.09.016 |
34599882 |
| 2021-10-01 |
Modeling viral dynamics in SARS-CoV-2 infection based on differential equations and numerical analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E08207 |
|
| 2021-10-01 |
SARS-CoV-2 and dengue virus coinfection in an adult with beta-thalassemia (trait): A case report from Bangladesh with literature review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E08229 |
|
| 2021-10-01 |
APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.10.004 |
|
| 2021-10-01 |
6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103213 |
34632326 |
| 2021-10-01 |
Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101202 |
34537245 |
| 2021-10-01 |
The mechanism and consequences of SARS-CoV-2 spike-mediated fusion and syncytia formation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167280 |
34606831 |
| 2021-10-01 |
Motor skills dysfunction and fatigue persist after mild infection by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JNS.2021.119920 |
|
| 2021-10-01 |
Application of a novel mathematical model to identify intermediate hosts of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTBI.2021.110761 |
|
| 2021-10-01 |
Complementation of contact tracing by mass testing for successful containment of beta COVID-19 variant (SARS-CoV-2 VOC B.1.351) epidemic in Hong Kong (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANWPC.2021.100281 |
34611629 |
| 2021-10-01 |
High intelligence may exacerbate paediatric inflammatory response to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110677 |
|
| 2021-10-01 |
OntoRepliCov: an Ontology-Based Approach for Modeling the SARS-CoV-2 Replication Process (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PROCS.2021.08.050 |
34630741 |
| 2021-10-01 |
[SARS-CoV-2 infection and ischemic stroke] (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SEMERG.2020.09.007 |
33218946 |
| 2021-10-01 |
Structural modelling of SARS-CoV-2 alpha variant (B.1.1.7) suggests enhanced furin binding and infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198522 |
|
| 2021-10-01 |
Weather, air pollution, and SARS-CoV-2 transmission: a global analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2542-5196(21)00202-3 |
|
| 2021-10-01 |
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(21)00129-4 |
34258603 |
| 2021-10-01 |
Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(21)00146-4 |
|
| 2021-10-01 |
Will prenatal exposure to SARS-CoV-2 define a birth cohort with accelerated aging in the century ahead? (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S204017442000104X |
33168125 |
| 2021-10-01 |
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41375-021-01332-Z |
34163002 |
| 2021-10-01 |
SARS-CoV-2 N501Y variants of concern and their potential transmission by mouse (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41418-021-00846-4 |
34389814 |
| 2021-10-01 |
O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an "O-Follow-N" rule (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00545-2 |
34341488 |
| 2021-10-01 |
Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00555-0 |
34433900 |
| 2021-10-01 |
Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-26055-8 |
34599175 |
| 2021-10-01 |
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA04820A |
35493159 |
| 2021-10-01 |
Highly active engineered IgG3 antibodies against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2107249118 |
34599091 |
| 2021-10-01 |
Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2020.1802345 |
32752944 |
| 2021-10-01 |
Increased platelet activation in SARS-CoV-2 infected non-hospitalised children and adults, and their household contacts (edit) |
SARSコロナウイルス2 (edit) |
10.1111/BJH.17629 |
34101171 |
| 2021-10-01 |
Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort (edit) |
SARSコロナウイルス2 (edit) |
10.1183/23120541.00384-2021 |
|
| 2021-10-01 |
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe (edit) |
SARSコロナウイルス2 (edit) |
10.1183/23120541.00411-2021 |
|
| 2021-10-01 |
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-021-02103-4 |
34593004 |
| 2021-10-01 |
The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009412 |
34597346 |
| 2021-10-01 |
Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021108375 |
34375000 |
| 2021-10-01 |
Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2710.211427 |
34289335 |
| 2021-10-01 |
The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2021.745310 |
34660520 |
| 2021-10-01 |
The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS221910636 |
|
| 2021-10-01 |
High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review) (edit) |
SARSコロナウイルス2 (edit) |
10.3892/ETM.2021.10616 |
34475972 |
| 2021-10-01 |
Estimating the effect of timetabling decisions on the spread of SARS-CoV-2 in medium-to-large engineering schools in Canada: an agent-based modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.9778/CMAJO.20200280 |
34933883 |
| 2021-09-30 |
No increase in anti-A isohemagglutinin titer after SARS-CoV-2 infection: A retrospective cohort analysis of group O apheresis platelet donors (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JCA.21942 |
34590725 |
| 2021-09-30 |
Cell death mechanisms involved in cell injury caused by SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/RMV.2292 |
34590761 |
| 2021-09-30 |
The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.09.003 |
34537136 |
| 2021-09-30 |
Role of miR-2392 in driving SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109839 |
34624208 |
| 2021-09-30 |
The N-terminal domain of SARS-CoV-2 nsp1 plays key roles in suppression of cellular gene expression and preservation of viral gene expression (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109841 |
34624207 |
| 2021-09-30 |
Theoretical and experimental study of interaction of macroheterocyclic compounds with ORF3a of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-99072-8 |
34593970 |
| 2021-09-30 |
Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2113401118 |
34593624 |
| 2021-09-30 |
Identification of potent inhibitors against transmembrane serine protease 2 for developing therapeutics against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1980109 |
34590967 |
| 2021-09-30 |
Analysis of SARS-CoV-2 haplotypes and genomic sequences during 2020 in Victoria, Australia, in the context of putative deficits in innate immune deaminase anti-viral responses (edit) |
SARSコロナウイルス2 (edit) |
10.1111/SJI.13100 |
34940992 |
| 2021-09-30 |
Aerosol SARS-CoV-2 in hospitals and long-term care homes during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0258151 |
|
| 2021-09-30 |
Expansion of a SARS-CoV-2 Delta variant with an 872 nt deletion encompassing ORF7a, ORF7b and ORF8, Poland, July to August 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.39.2100902 |
34596017 |
| 2021-09-29 |
SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103185 |
34604721 |
| 2021-09-29 |
The roles of lipids in SARS-CoV-2 viral replication and the host immune response (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JLR.2021.100129 |
34599996 |
| 2021-09-29 |
Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYPLU.2021.100135 |
35403085 |
| 2021-09-29 |
Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of incoming travelers on lineage diversity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25985-7 |
34588460 |
| 2021-09-29 |
Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2106480118 |
34588290 |
| 2021-09-29 |
Metabolic snapshot of plasma samples reveals new pathways implicated in SARS-CoV-2 pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.09.29.462326 |
|
| 2021-09-29 |
Critical Capability Needs for Reduction of Transmission of SARS-CoV-2 Indoors (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FBIOE.2021.641599 |
34660544 |
| 2021-09-29 |
Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM10194493 |
|
| 2021-09-29 |
Active site-specific quantum tunneling of hACE2 receptor to assess its complexing poses with selective bioactive compounds in co-suppressing SARS-CoV-2 influx and subsequent cardiac injury (edit) |
SARSコロナウイルス2 (edit) |
10.5455/JAVAR.2021.H544 |
35106293 |
| 2021-09-29 |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.69375 |
|
| 2021-09-28 |
Instant determination of the artemisinin from various Artemisia annua L. extracts by LC‐ESI‐MS/MS and their in‐silico modelling and in vitro antiviral activity studies against SARS‐CoV‐2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PCA.3088 |
|
| 2021-09-28 |
Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100421 |
34604819 |
| 2021-09-28 |
In vivo structure and dynamics of the SARS-CoV-2 RNA genome (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25999-1 |
|
| 2021-09-28 |
Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOODADVANCES.2021004977 |
|
| 2021-09-28 |
Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0257784 |
34582497 |
| 2021-09-28 |
Representing COVID-19 information in collaborative knowledge graphs: the case of Wikidata (edit) |
SARSコロナウイルス2 (edit) |
10.3233/SW-210444 |
|
| 2021-09-28 |
ORF3a Protein of Severe Acute Respiratory Syndrome Coronavirus 2 Inhibits Interferon-Activated Janus Kinase/Signal Transducer and Activator of Transcription Signaling via Elevating Suppressor of Cytokine Signaling 1 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.752597 |
34650546 |
| 2021-09-28 |
Autoimmune Disorders & COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MEDICINES8100055 |
34677484 |
| 2021-09-27 |
High throughput nanopore sequencing of SARS-CoV-2 viral genomes from patient samples (edit) |
SARSコロナウイルス2 (edit) |
|
34631911 |
| 2021-09-27 |
The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12250-021-00452-1 |
|
| 2021-09-27 |
Identifying Distinct Structural Features of the SARS-CoV-2 Spike Protein Fusion Domain Essential for Membrane Interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.1C00543 |
|
| 2021-09-27 |
Machine Learning Models Identify Inhibitors of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C00683 |
34387990 |
| 2021-09-27 |
Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25903-X |
34580297 |
| 2021-09-27 |
Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25997-3 |
34580306 |
| 2021-09-27 |
AGO CLIP-based imputation of potent siRNA sequences targeting SARS-CoV-2 with antifibrotic miRNA-like activity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-98708-Z |
34580386 |
| 2021-09-27 |
Viral S protein histochemistry reveals few potential SARS-CoV-2 entry sites in human ocular tissues (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-98709-Y |
34580409 |
| 2021-09-27 |
Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42255-021-00479-4 |
34580494 |
| 2021-09-27 |
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BJS/ZNAB101 |
33761533 |
| 2021-09-27 |
Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB719 |
34403466 |
| 2021-09-27 |
Targeting novel coronavirus SARS-CoV-2 spike protein with phytoconstituents of Momordica charantia (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13048-021-00872-3 |
34579761 |
| 2021-09-27 |
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0249254 |
34570776 |
| 2021-09-27 |
Characterization of Phytochemicals in Ulva intestinalis L. and Their Action Against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2021.735768 |
34650958 |
| 2021-09-27 |
New Tetramic Acid Derivatives From the Deep-Sea-Derived Fungus Penicillium sp. SCSIO06868 With SARS-CoV-2 Mpro Inhibitory Activity Evaluation (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.730807 |
34646250 |
| 2021-09-27 |
A meta-analysis for the risk and prevalence of preeclampsia among pregnant women with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.4274/TJOD.GALENOS.2021.66750 |
34580872 |
| 2021-09-27 |
Meta-analysis of the frequency of intrauterine growth restriction and preterm premature rupture of the membranes in pregnant women with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.4274/TJOD.GALENOS.2021.74829 |
34580931 |
| 2021-09-26 |
A multicenter survey on the aspects of everyday life in adult patients with primary antibody deficiencies treated with immunoglobulin G replacement during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1177/20587384211044344 |
34565194 |
| 2021-09-25 |
Serological assay for anti-SARS-CoV-2 antibodies improves sensitivity of diagnosis of COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00430-021-00721-6 |
|
| 2021-09-25 |
Reinfection cases by closely related SARS-CoV-2 lineages in Southern Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42770-021-00621-0 |
34562232 |
| 2021-09-25 |
Role of microRNAs in COVID-19 with implications for therapeutics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOPHA.2021.112247 |
34601190 |
| 2021-09-25 |
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109822 |
34610292 |
| 2021-09-25 |
The nasal symbiont Staphylococcus species restricts the transcription of SARS-CoV-2 entry factors in human nasal epithelium (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103172 |
34604720 |
| 2021-09-25 |
Analytical performance comparison of four SARS-CoV-2 RT-qPCR primer-probe sets for wastewater samples (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.150572 |
34582851 |
| 2021-09-25 |
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00760-8 |
34564690 |
| 2021-09-25 |
Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and thrombosis (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.09.24.461743 |
|
| 2021-09-25 |
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13101927 |
34696358 |
| 2021-09-25 |
Lack of Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spillover in Free-Living Neotropical Non-Human Primates, Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13101933 |
34696363 |
| 2021-09-24 |
Implications derived from S-protein variants of SARS-CoV-2 from six continents (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.09.080 |
34571123 |
| 2021-09-24 |
Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102941 |
34368648 |
| 2021-09-24 |
D614G mutation in the SARS-CoV-2 spike protein enhances viral fitness by desensitizing it to temperature-dependent denaturation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101238 |
34563540 |
| 2021-09-24 |
Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00562-1 |
34561618 |
| 2021-09-24 |
Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants (edit) |
SARSコロナウイルス2 (edit) |
10.1093/GLYCOB/CWAB102 |
|
| 2021-09-24 |
Vaccine nationalism and the dynamics and control of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABJ7364 |
34404735 |
| 2021-09-24 |
Azithromycin: characteristics and clinical indications for bacterial and virus infections, including SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.33448/RSD-V10I12.19864 |
|
| 2021-09-24 |
A Linkage-specific Sialic Acid Labeling Strategy Reveals Different Site-specific Glycosylation Patterns in SARS-CoV-2 Spike Protein Produced in CHO and HEK Cell Substrates (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCHEM.2021.735558 |
34631661 |
| 2021-09-24 |
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.725240 |
34630400 |
| 2021-09-24 |
α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.757691 |
34630436 |
| 2021-09-23 |
Palmitoylation of SARS‐CoV‐2 S protein is critical for S‐mediated syncytia formation and virus entry (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27339 |
34528721 |
| 2021-09-23 |
SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2021.09.053 |
34592572 |
| 2021-09-23 |
A robust high-throughput fluorescent polarization assay for the evaluation and screening of SARS-CoV-2 fusion inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BIOORG.2021.105362 |
34598089 |
| 2021-09-23 |
SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25949-X |
34556667 |
| 2021-09-22 |
In silico targeting SARS-CoV-2 spike protein and main protease by biochemical compounds (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11756-021-00881-Z |
34565804 |
| 2021-09-22 |
"SARS-CoV-2 is transmitted by particulate air pollution": Misinterpretations of statistical data, skewed citation practices, and misuse of specific terminology spreading the misconception (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.112116 |
34562486 |
| 2021-09-22 |
Mechanisms of Antiviral Immune Evasion of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167265 |
34562466 |
| 2021-09-22 |
Identification of SARS-CoV-2 S RBD escape mutants using yeast screening and deep mutational scanning (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.100869 |
34568839 |
| 2021-09-22 |
SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00749-3 |
|
| 2021-09-22 |
Destruction mechanisms of ozone over SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-97860-W |
34552128 |
| 2021-09-22 |
Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-98308-X |
34552127 |
| 2021-09-22 |
Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA04107J |
35496863 |
| 2021-09-22 |
Investigating the structure-activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1RA05817G |
35496831 |
| 2021-09-22 |
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMOA2113017 |
34551225 |
| 2021-09-22 |
Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.15066 |
34453317 |
| 2021-09-22 |
Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABH2848 |
34550739 |
| 2021-09-22 |
RNA Viromics of Southern California Wastewater and Detection of SARS-CoV-2 Single-Nucleotide Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AEM.01448-21 |
34550753 |
| 2021-09-22 |
Whole-Genome Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq Panel and Comparison with the Illumina MiSeq ARTIC Protocol (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00649-21 |
34550806 |
| 2021-09-22 |
Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01396-21 |
34549987 |
| 2021-09-22 |
Good Cholesterol Gone Bad? HDL and COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS221910182 |
34638523 |
| 2021-09-22 |
Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS221910188 |
34638527 |
| 2021-09-22 |
Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NCRNA7040060 |
34698261 |
| 2021-09-21 |
A highly potent antibody effective against SARS-CoV-2 variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109814 |
34599871 |
| 2021-09-21 |
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.09.011 |
34614412 |
| 2021-09-21 |
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25796-W |
34548480 |
| 2021-09-21 |
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-021-00972-2 |
34548634 |
| 2021-09-21 |
SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02335-21 |
34544279 |
| 2021-09-21 |
Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA—the CHASING COVID Cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-048778 |
|
| 2021-09-21 |
Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.707977 |
34621266 |
| 2021-09-21 |
Impact of Two Different Recruitment Procedures (Random vs. Volunteer Selection) on the Results of Seroepidemiological Study (SARS-CoV-2) (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH18189928 |
|
| 2021-09-21 |
Intent to Vaccinate SARS-CoV-2 Infected Children in US Households: A Survey (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9091049 |
34579286 |
| 2021-09-20 |
On the weak binding and spectroscopic signature of SARS‐CoV‐2 nsp14 interaction with RNA (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CBIC.202100486 |
|
| 2021-09-20 |
SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10719-021-10021-Z |
34542788 |
| 2021-09-20 |
Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02640-X |
34545191 |
| 2021-09-20 |
The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AAC.00772-21 |
34543092 |
| 2021-09-20 |
Mathematical models of the spread and consequences of the SARS-CoV-2 pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13362-021-00111-W |
|
| 2021-09-20 |
Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009436 |
34543264 |
| 2021-09-20 |
SAS: A Platform of Spike Antigenicity for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2021.713188 |
34616728 |
| 2021-09-19 |
SARS-CoV-2 pandemic and its threats to humans and animals (edit) |
SARSコロナウイルス2 (edit) |
10.21521/MW.6593 |
|
| 2021-09-17 |
Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJPS.2021.106012 |
34543728 |
| 2021-09-17 |
Complete genome sequencing and molecular characterization of SARS-COV-2 from COVID-19 cases in Alborz province in Iran (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E08027 |
34549097 |
| 2021-09-17 |
Structural and kinetic analyses of holothurian sulfated glycans suggest potential treatment for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101207 |
34537241 |
| 2021-09-17 |
Spatial and temporal variability and data bias in wastewater surveillance of SARS-CoV-2 in a sewer system (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.150390 |
34818797 |
| 2021-09-17 |
A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25729-7 |
|
| 2021-09-17 |
The biological and clinical significance of emerging SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41576-021-00408-X |
34535792 |
| 2021-09-17 |
Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-97667-9 |
|
| 2021-09-17 |
Prolyl isomerase Pin1 plays an essential role in SARS-CoV-2 proliferation, indicating its possibility as a novel therapeutic target (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-97972-3 |
34535740 |
| 2021-09-17 |
Arjunetin as a promising drug candidate against SARS-CoV-2: molecular dynamics simulation studies (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1970627 |
34533107 |
| 2021-09-17 |
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB368 |
34260717 |
| 2021-09-17 |
SARS-CoV-2 Epidemiology on a Public University Campus in Washington State (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB464 |
|
| 2021-09-17 |
Prevention of SARS-CoV-2 (COVID-19) transmission in residential aged care using ultraviolet light (PETRA): a two-arm crossover randomised controlled trial protocol (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06659-7 |
34535091 |
| 2021-09-17 |
Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12920-021-01079-7 |
34535131 |
| 2021-09-17 |
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009929 |
34534263 |
| 2021-09-17 |
Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years — Long Beach, California, April 1–December 10, 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7037A2 |
34529639 |
| 2021-09-17 |
Enisamium Inhibits SARS-CoV-2 RNA Synthesis (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES9091254 |
34572438 |
| 2021-09-16 |
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.07.025 |
34332650 |
| 2021-09-16 |
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPHA.2021.09.006 |
34545316 |
| 2021-09-16 |
Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCME.2021.09.002 |
34549024 |
| 2021-09-16 |
Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVE.2021.100054 |
34548928 |
| 2021-09-16 |
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.1C00552 |
|
| 2021-09-16 |
S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00756-4 |
34531369 |
| 2021-09-16 |
In silico approach to design a multi-epitopic vaccine candidate targeting the non-mutational immunogenic regions in envelope protein and surface glycoprotein of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1977702 |
34528491 |
| 2021-09-16 |
Case report: change of dominant strain during dual SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06664-W |
|
| 2021-09-16 |
Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-021-00560-4 |
34530915 |
| 2021-09-16 |
Ozone Treatment Is Insufficient to Inactivate SARS-CoV-2 Surrogate under Field Conditions (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX10091480 |
34573110 |
| 2021-09-16 |
Technical Data of Heterologous Expression and Purification of SARS-CoV-2 Proteases Using Escherichia coli System (edit) |
SARSコロナウイルス2 (edit) |
10.3390/DATA6090099 |
|
| 2021-09-16 |
In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS9091967 |
|
| 2021-09-15 |
Case-control study evaluating risk factors for SARS-CoV-2 outbreak amongst healthcare personnel at a tertiary care center (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJIC.2021.09.004 |
34536502 |
| 2021-09-15 |
First reported nosocomial SARS-CoV-2 outbreak in a hospital-based laundry facility (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S0950268821002016 |
34521489 |
| 2021-09-15 |
Nanopore Dwell Time Analysis Permits Sequencing and Conformational Assignment of Pseudouridine in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCENTSCI.1C00788 |
34729414 |
| 2021-09-15 |
The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01257-21 |
34523966 |
| 2021-09-15 |
SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021108249 |
34296442 |
| 2021-09-14 |
Characteristics and outcomes of pregnant women with SARS-CoV-2 infection and other severe acute respiratory infections (SARI) in Brazil from January to November 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BJID.2021.101620 |
34563490 |
| 2021-09-14 |
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.08.015 |
34453881 |
| 2021-09-14 |
Honey bee (Apis mellifera L.) colonies as bioindicators of environmental SARS-CoV-2 occurrence (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.150327 |
|
| 2021-09-14 |
Rapid Detection of SARS-CoV-2 Antigens and Antibodies Using OFET Biosensors Based on a Soft and Stretchable Semiconducting Polymer (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSBIOMATERIALS.1C00727 |
|
| 2021-09-14 |
Antiviral Face Mask Functionalized with Solidified Hand Soap: Low-Cost Infection Prevention Clothing against Enveloped Viruses Such as SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.1C03511 |
34514272 |
| 2021-09-14 |
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01507-2 |
34522051 |
| 2021-09-14 |
MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity (edit) |
MERSコロナウイルス (edit) |
10.1128/MBIO.01316-21 |
34517762 |
| 2021-09-14 |
MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01316-21 |
34517762 |
| 2021-09-14 |
High-Frequency, High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned Treatment Works in Northern California Shows Strong Association with COVID-19 Incidence (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSYSTEMS.00829-21 |
34519528 |
| 2021-09-13 |
SARS-COV-2 Mpro conformational changes induced by covalently bound ligands (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1970626 |
|
| 2021-09-13 |
On the timing of interventions to preserve hospital capacity: lessons to be learned from the Belgian SARS-CoV-2 pandemic in 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13690-021-00685-2 |
|
| 2021-09-13 |
Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-021-00574-Y |
|
| 2021-09-13 |
Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009384 |
34516563 |
| 2021-09-12 |
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11239-021-02558-5 |
34510337 |
| 2021-09-12 |
Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12539-021-00477-W |
34510373 |
| 2021-09-12 |
A nanoenzyme linked immunochromatographic sensor for rapid and quantitative detection of SARS-CoV-2 nucleocapsid protein in human blood (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SNB.2021.130718 |
34539081 |
| 2021-09-12 |
Infection and transmission of SARS‐CoV‐2 depends on heparan sulfate proteoglycans (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2020106765 |
34510494 |
| 2021-09-11 |
5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103120 |
34541466 |
| 2021-09-11 |
The Challenge of Using an Antigen Test as a Screening Tool for SARS-CoV-2 Infection in an Emergency Department: Experience of a Tertiary Care Hospital in Southern Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2021/3893733 |
34527736 |
| 2021-09-10 |
Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27331 |
|
| 2021-09-10 |
Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.09.018 |
34517025 |
| 2021-09-10 |
Monitoring SARS-CoV-2 in sewage: Toward sentinels with analytical accuracy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.150244 |
34798752 |
| 2021-09-10 |
Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.1C00414 |
34506130 |
| 2021-09-10 |
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-97658-W |
34508172 |
| 2021-09-10 |
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABG7996 |
34516768 |
| 2021-09-10 |
Estimating the impact of reopening schools on the reproduction number of SARS-CoV-2 in England, using weekly contact survey data (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-021-02107-0 |
34503493 |
| 2021-09-09 |
Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CLIM.2021.108850 |
34506944 |
| 2021-09-09 |
Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25589-1 |
34504087 |
| 2021-09-09 |
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00685-21 |
34287040 |
| 2021-09-09 |
Interleukin-1RA Mitigates SARS-CoV-2–Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1161/ATVBAHA.121.316925 |
|
| 2021-09-09 |
Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI150613 |
34499051 |
| 2021-09-09 |
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S10020-021-00356-6 |
34503440 |
| 2021-09-09 |
Machine Learning augmented docking studies of aminothioureas at the SARS-CoV-2-ACE2 interface (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0256834 |
34499662 |
| 2021-09-09 |
Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22189746 |
|
| 2021-09-08 |
A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109754 |
34547223 |
| 2021-09-08 |
Structure of SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COVIRO.2021.08.010 |
34534731 |
| 2021-09-08 |
The dual role of phytochemicals on SARS-CoV-2 inhibition by targeting host and viral proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTCME.2021.09.001 |
34513611 |
| 2021-09-08 |
Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals of Nigella sativa: An in silico approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SJBS.2021.09.002 |
34518755 |
| 2021-09-08 |
Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41374-021-00663-W |
|
| 2021-09-08 |
SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.09.08.459464 |
|
| 2021-09-08 |
A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIADV.ABH1547 |
34516878 |
| 2021-09-08 |
Complete Analysis of the Epidemiological Scenario around a SARS-CoV-2 Reinfection: Previous Infection Events and Subsequent Transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00596-21 |
34494886 |
| 2021-09-08 |
In vitro efficacy of Artemisia extracts against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12985-021-01651-8 |
34496903 |
| 2021-09-08 |
SARS-CoV-2, Trait Anxiety, and the Microbiome (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPSYT.2021.720082 |
|
| 2021-09-08 |
Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS10091155 |
34578187 |
| 2021-09-07 |
Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-97267-7 |
34493762 |
| 2021-09-07 |
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2103154118 |
34417349 |
| 2021-09-07 |
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2105815118 |
34413211 |
| 2021-09-07 |
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2106845118 |
34493582 |
| 2021-09-07 |
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2111172118 |
34426525 |
| 2021-09-07 |
Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009380 |
34491988 |
| 2021-09-07 |
Outbreaks of SARS-CoV-2 in naturally infected mink farms: Impact, transmission dynamics, genetic patterns, and environmental contamination (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009883 |
34492088 |
| 2021-09-07 |
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.2174/1389450122666210120142746 |
|
| 2021-09-07 |
Evaluation of Capillary Blood Gases in Medical Personnel Caring for Patients Isolated Due to SARS-CoV-2 in Intensive Care Units before and after Using Enhanced Filtration Masks: A Prospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH18189425 |
34574350 |
| 2021-09-06 |
Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101175 |
34499924 |
| 2021-09-06 |
SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00719-9 |
34489403 |
| 2021-09-06 |
Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1SC02775A |
34777769 |
| 2021-09-06 |
Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1965028 |
34486937 |
| 2021-09-06 |
In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1968497 |
34486935 |
| 2021-09-06 |
Emotional Control among Nurses against Work Conditions and the Support Received during the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH18179415 |
34502006 |
| 2021-09-05 |
Genome-scale metabolic modelling of SARS-CoV-2 in cancer cells reveals an increased shift to glycolytic energy production (edit) |
SARSコロナウイルス2 (edit) |
10.1002/1873-3468.14180 |
34409594 |
| 2021-09-05 |
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.12.456173 |
34462752 |
| 2021-09-05 |
How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.25.21262155 |
|
| 2021-09-05 |
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.09.02.21261735 |
|
| 2021-09-04 |
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27285 |
34415583 |
| 2021-09-04 |
Exploration of In-silico screening of therapeutic agents against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMPHYS.2021.111354 |
34511699 |
| 2021-09-04 |
The epidemiology of hospital inpatient exposure to SARS-CoV-2: A cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.INFPIP.2021.100173 |
34514365 |
| 2021-09-04 |
The dominant strain of SARS-CoV-2 is a mosaicism (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198553 |
|
| 2021-09-04 |
Analysis of Intermediate Hosts and Susceptible Animals of SARS-CoV-2 by Computational Methods (edit) |
SARSコロナウイルス2 (edit) |
10.15212/ZOONOSES-2021-0010 |
|
| 2021-09-03 |
A Proposed Functional Analysis of Transmission Prevention Behaviors for a Respiratory Virus (SARS-CoV-2) (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42822-021-00055-1 |
|
| 2021-09-03 |
Computational insights into the membrane fusion mechanism of SARS-CoV-2 at the cellular level (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.08.053 |
34540146 |
| 2021-09-03 |
SARS-CoV-2 3C-like protease antagonizes interferon-beta production by facilitating the degradation of IRF3 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CYTO.2021.155697 |
34509038 |
| 2021-09-03 |
Inhibition of SARS-CoV-2 infection by human defensin HNP1 and retrocyclin RC-101 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167225 |
34487793 |
| 2021-09-03 |
Refining the N-Termini of the SARS-CoV-2 Spike Protein and Its Discrete Receptor-Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.1C00349 |
34379411 |
| 2021-09-03 |
Understanding the Barriers to Pooled SARS-CoV-2 Testing in the United States (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00312-21 |
|
| 2021-09-03 |
SARS-CoV-2 Initiates Programmed Cell Death in Platelets (edit) |
SARSコロナウイルス2 (edit) |
10.1161/CIRCRESAHA.121.319117 |
34293929 |
| 2021-09-03 |
Ethacridine inhibits SARS-CoV-2 by inactivating viral particles (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009898 |
|
| 2021-09-03 |
Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.7150/IJBS.53312 |
34671200 |
| 2021-09-02 |
Percepción del riesgo ante el virus SARS-CoV-2: el caso de conductores de taxi en Zumpango, Estado de México (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-09-02 |
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/14651858.CD013825.PUB2 |
|
| 2021-09-02 |
Potential Achilles heels of SARS-CoV-2 are best displayed by the base order-dependent component of RNA folding energy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2021.107570 |
|
| 2021-09-02 |
Predicted pH-dependent stability of SARS-CoV-2 spike protein trimer from interfacial acidic groups (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.08.049 |
34490059 |
| 2021-09-02 |
High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.08.062 |
34481966 |
| 2021-09-02 |
Activation Pathways and Free Energy Landscapes of the SARS-CoV-2 Spike Protein (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.1C03384 |
34514271 |
| 2021-09-02 |
Effectiveness of an Inactivated SARS-CoV-2 Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJME2111165 |
34469651 |
| 2021-09-02 |
Comparative phylogenetic analysis of SARS-CoV-2 spike protein-possibility effect on virus spillover (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BIB/BBAB144 |
33885726 |
| 2021-09-02 |
Modeling transmission dynamics and effectiveness of worker screening programs for SARS-CoV-2 in pork processing plants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0249143 |
|
| 2021-09-02 |
Self-collection and pooling of samples as resources-saving strategies for RT-PCR-based SARS-CoV-2 surveillance, the example of travelers in French Polynesia (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0256877 |
|
| 2021-09-01 |
Bioinformatics analysis of SARS-CoV-2 infection-associated immune injury and therapeutic prediction for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-09-01 |
SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMAOPHTHALMOL.2020.5464 |
33662099 |
| 2021-09-01 |
SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: Frequency and association with inflammatory and tissue-damage biomarkers (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27300 |
34449894 |
| 2021-09-01 |
Lipid-based therapies against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1002/RMV.2214 |
34546604 |
| 2021-09-01 |
Die Rolle der Epidemiologie in der SARS-CoV-2-Pandemie: Bedeutung, Aufgaben, Methoden und Erkenntnisse (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00103-021-03399-6 |
|
| 2021-09-01 |
Association of CXCR6 with COVID-19 severity: delineating the host genetic factors in transcriptomic regulation (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00439-021-02305-Z |
34155559 |
| 2021-09-01 |
The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12275-021-1348-5 |
34449057 |
| 2021-09-01 |
Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies? (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S40268-021-00349-0 |
34106430 |
| 2021-09-01 |
Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2021.105142 |
34303749 |
| 2021-09-01 |
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMI.2021.05.004 |
|
| 2021-09-01 |
The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103544 |
34419925 |
| 2021-09-01 |
Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101064 |
34401689 |
| 2021-09-01 |
Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101069 |
34377969 |
| 2021-09-01 |
Wastewater monitoring as a supplementary surveillance tool for capturing SARS-COV-2 community spread. A case study in two Greek municipalities (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.111749 |
34310965 |
| 2021-09-01 |
Approximative He Hamiltonian in descriptive multidimensional scaling statistics of RNA contained information with application to SARS-CoV-2 Spike mRNA and 7SLRNA, RN7SL2 and RN7SL3 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GENREP.2021.101203 |
|
| 2021-09-01 |
Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.06.019 |
|
| 2021-09-01 |
The Relationship Between GI symptoms, State and Trait Anxiety, and Lifestyle Factors in Males and Females During the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAND.2021.06.101 |
|
| 2021-09-01 |
The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101041 |
34358560 |
| 2021-09-01 |
SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2021.104914 |
34304088 |
| 2021-09-01 |
Comparison of approaches to quantify SARS-CoV-2 in wastewater using RT-qPCR: Results and implications from a collaborative inter-laboratory study in Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JES.2021.01.029 |
34412784 |
| 2021-09-01 |
Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.KINT.2021.06.033 |
|
| 2021-09-01 |
The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: A population based ecological study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2021.100021 |
|
| 2021-09-01 |
Investigating the possible origin and transmission routes of SARS-CoV-2 genomes and variants of concern in Bangladesh (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105057 |
34481060 |
| 2021-09-01 |
A scoping review of the experience of implementing population testing for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PUHE.2021.06.012 |
34352612 |
| 2021-09-01 |
Citizen volunteers detect SARS-CoV-2 RNA from outdoor urban fomites (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.147719 |
|
| 2021-09-01 |
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STEMCR.2021.08.018 |
34525378 |
| 2021-09-01 |
Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2021.07.093 |
34393019 |
| 2021-09-01 |
Zoonotic and Reverse Zoonotic Transmissibility of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198473 |
34118360 |
| 2021-09-01 |
Wastewater surveillance of SARS-CoV-2 across 40 U.S. states from February to June 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.WATRES.2021.117400 |
|
| 2021-09-01 |
Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(21)01786-4 |
|
| 2021-09-01 |
Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2589-7500(21)00115-1 |
34305035 |
| 2021-09-01 |
SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCIM.1C00857 |
34468141 |
| 2021-09-01 |
Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00734-W |
34471088 |
| 2021-09-01 |
A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00742-W |
34471099 |
| 2021-09-01 |
Cellular host factors for SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41564-021-00958-0 |
34471255 |
| 2021-09-01 |
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-01028-7 |
34471264 |
| 2021-09-01 |
A human three-dimensional neural-perivascular 'assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01443-1 |
34244682 |
| 2021-09-01 |
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01472-W |
|
| 2021-09-01 |
Manipulation of autophagy by SARS-CoV-2 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1080/15548627.2021.1953847 |
34281462 |
| 2021-09-01 |
Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAB281 |
33857303 |
| 2021-09-01 |
EpiSurf: metadata-driven search server for analyzing amino acid changes within epitopes of SARS-CoV-2 and other viral species (edit) |
SARSコロナウイルス2 (edit) |
10.1093/DATABASE/BAAB059 |
|
| 2021-09-01 |
Single-cell RNA sequencing of SARS-CoV-2 cell entry factors in the preconceptional human endometrium (edit) |
SARSコロナウイルス2 (edit) |
10.1093/HUMREP/DEAB183 |
34329437 |
| 2021-09-01 |
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JALM/JFAB080 |
34170314 |
| 2021-09-01 |
Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice (edit) |
SARSコロナウイルス2 (edit) |
10.1096/FJ.202002742RR |
34365657 |
| 2021-09-01 |
Targeting neuropilins as a viable SARS-CoV-2 treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1111/FEBS.16096 |
34185437 |
| 2021-09-01 |
Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva (edit) |
SARSコロナウイルス2 (edit) |
10.1111/IMM.13349 |
33932228 |
| 2021-09-01 |
Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A (edit) |
SARSコロナウイルス2 (edit) |
10.1111/PDE.14780 |
|
| 2021-09-01 |
Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1681/ASN.2020111546 |
34112705 |
| 2021-09-01 |
Is Environmental Pollen Concentration a Risk Factor for SARS-CoV-2 Infection? (edit) |
SARSコロナウイルス2 (edit) |
10.18176/JIACI.0743 |
|
| 2021-09-01 |
Comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India: a modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-855843/V1 |
|
| 2021-09-01 |
An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.2144/FSOA-2021-0064 |
|
| 2021-09-01 |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients (edit) |
SARSコロナウイルス2 (edit) |
10.2147/JIR.S322430 |
34511970 |
| 2021-09-01 |
Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.22092/ARI.2020.351202.1517 |
34824739 |
| 2021-09-01 |
SARS-CoV-2 Wastewater Surveillance for Public Health Action (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2709.210753 |
34424162 |
| 2021-09-01 |
Network-Based Identification and Experimental Validation of Drug Candidates Toward SARS-CoV-2 via Targeting Virus-Host Interactome (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2021.728960 |
34539756 |
| 2021-09-01 |
Antimicrobial Face Shield: Next Generation of Facial Protective Equipment against SARS-CoV-2 and Multidrug-Resistant Bacteria (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22179518 |
34502431 |
| 2021-09-01 |
Direct detection of SARS-CoV-2 RNA using high-contrast pH-sensitive dyes (edit) |
SARSコロナウイルス2 (edit) |
10.7171/JBT.21-3203-007 |
35027870 |
| 2021-09-01 |
Loop-Mediated Isothermal Amplification Detection of SARS-CoV-2 and Myriad Other Applications (edit) |
SARSコロナウイルス2 (edit) |
10.7171/JBT.21-3203-017 |
35136384 |
| 2021-08-31 |
The nucleotide addition cycle of the SARS-CoV-2 polymerase (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109650 |
34433083 |
| 2021-08-31 |
Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101151 |
34478710 |
| 2021-08-31 |
Genome-wide association study of COVID-19 severity among the Chinese population (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00318-6 |
|
| 2021-08-31 |
Mechanical activation of spike fosters SARS-CoV-2 viral infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00558-X |
34465913 |
| 2021-08-31 |
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03925-1 |
|
| 2021-08-31 |
Trans-ethnic genome-wide association study of severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02549-5 |
|
| 2021-08-31 |
Correction for Benton et al., The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2112850118 |
34426505 |
| 2021-08-31 |
Papulo‐purpuric dermatitis of childhood: a distinct PLEVA‐like eruption associated to SARS‐CoV‐2 infection. Clinical, histopathological and immunohistochemical study of 10 cases (edit) |
SARSコロナウイルス2 (edit) |
10.1111/PDE.14777 |
|
| 2021-08-31 |
D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.00587-21 |
34311586 |
| 2021-08-31 |
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.00970-21 |
34340553 |
| 2021-08-31 |
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01067-21 |
34225491 |
| 2021-08-31 |
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01140-21 |
34465019 |
| 2021-08-31 |
Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01590-21 |
34340537 |
| 2021-08-31 |
Origin of imported SARS-CoV-2 strains in The Gambia identified from whole genome sequences (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0241942 |
34464385 |
| 2021-08-31 |
Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0251114 |
34460832 |
| 2021-08-31 |
Higher entropy observed in SARS-CoV-2 genomes from the first COVID-19 wave in Pakistan (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0256451 |
34464419 |
| 2021-08-31 |
SARS-CoV-2 Lambda Variant: Spatiotemporal Distribution and Potential Public Health Impact (edit) |
SARSコロナウイルス2 (edit) |
10.15212/ZOONOSES-2021-0009 |
|
| 2021-08-31 |
The Clinical Impact and Cost Effectiveness of Intervention Policies Against the SARS-CoV-2 Pandemic: A Mathematical Modelling Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.2139/SSRN.3911364 |
|
| 2021-08-31 |
Non-Coding RNAs in COVID-19: Emerging Insights and Current Questions (edit) |
SARSコロナウイルス2 (edit) |
10.3390/NCRNA7030054 |
34564316 |
| 2021-08-31 |
Sterically confined rearrangements of SARS-CoV-2 Spike protein control cell invasion (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.70362 |
|
| 2021-08-30 |
Alternative Covid-19 mitigation measures in school classrooms: analysis using an agent-based model of SARS-CoV-2 transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.30.21262826 |
|
| 2021-08-30 |
Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-021-00680-8 |
34461999 |
| 2021-08-30 |
Airborne transmission of SARS-CoV-2: ventilation improvement strategies in preparation for school re-opening (edit) |
SARSコロナウイルス2 (edit) |
10.12809/HKMJ215122 |
|
| 2021-08-30 |
SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses (edit) |
SARSコロナウイルス2 (edit) |
10.3390/HEALTHCARE9091132 |
|
| 2021-08-30 |
Substrate Specificity of SARS-CoV-2 Nsp10-Nsp16 Methyltransferase (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13091722 |
34578302 |
| 2021-08-30 |
In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry (edit) |
SARSコロナウイルス2 (edit) |
10.3906/BIY-2012-52 |
34803446 |
| 2021-08-30 |
Genomic chronicle of SARS-CoV-2: a mutational analysis with over 1 million genome sequences (edit) |
SARSコロナウイルス2 (edit) |
10.3906/BIY-2106-8 |
34803444 |
| 2021-08-30 |
Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.52142/OMUJECM.38.4.44 |
|
| 2021-08-28 |
Ultrasensitive Detection of Dopamine, IL-6 and SARS-CoV-2 Proteins on Crumpled Graphene FET Biosensor (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADMT.202100712 |
34901384 |
| 2021-08-28 |
In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104818 |
34481181 |
| 2021-08-28 |
Diagnostic performance of a colorimetric RT -LAMP for the identification of SARS-CoV-2: A multicenter prospective clinical evaluation in sub-Saharan Africa (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101101 |
34476394 |
| 2021-08-28 |
In-silico immunoinformatic analysis of SARS-CoV-2 virus for the development of putative vaccine construct (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMBIO.2021.152134 |
34474252 |
| 2021-08-28 |
SARS-CoV-2 in residential rooms of two self-isolating persons with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAEROSCI.2021.105870 |
34483358 |
| 2021-08-28 |
SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2021.100046 |
34485969 |
| 2021-08-28 |
Assessing the extent of community spread caused by mink-derived SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XINN.2021.100128 |
34124706 |
| 2021-08-28 |
Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase (edit) |
SARSコロナウイルス2 (edit) |
10.1080/07391102.2021.1970024 |
|
| 2021-08-28 |
Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications (edit) |
SARSコロナウイルス2 (edit) |
10.1093/PCMEDI/PBAB022 |
34993416 |
| 2021-08-28 |
Development of a Web GIS for small-scale detection and analysis of COVID-19 (SARS-CoV-2) cases based on volunteered geographic information for the city of Cologne, Germany, in July/August 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12942-021-00290-0 |
34454536 |
| 2021-08-28 |
Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung (edit) |
SARSコロナウイルス2 (edit) |
10.7150/IJBS.61320 |
34671199 |
| 2021-08-27 |
SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBADIS.2021.166260 |
34461258 |
| 2021-08-27 |
Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109708 |
34506741 |
| 2021-08-27 |
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00475-8 |
34461056 |
| 2021-08-27 |
Host ADP-ribosylation and the SARS-CoV-2 macrodomain (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BST20201212 |
34351418 |
| 2021-08-27 |
A Dedicated SARS-CoV-2 Testing Center for Public Service Agency Personnel: Implementation, Results, and Impact on Human Resources (edit) |
SARSコロナウイルス2 (edit) |
10.1080/10903127.2021.1973627 |
|
| 2021-08-27 |
Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.731828 |
34512357 |
| 2021-08-27 |
Anti-clustering in the national SARS-CoV-2 daily infection counts (edit) |
SARSコロナウイルス2 (edit) |
10.7717/PEERJ.11856 |
|
| 2021-08-26 |
Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00237 |
34437808 |
| 2021-08-26 |
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25479-6 |
34446720 |
| 2021-08-26 |
5α-Reductase Inhibitors are Associated with Reduced Risk of SARS-COV-2 Infection: A Matched-Pair, Registry-Based Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JU.0000000000002180 |
|
| 2021-08-26 |
A Remote Control System for Emergency Ventilators During SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1109/LES.2021.3107837 |
35582518 |
| 2021-08-26 |
Investigation of Interaction between the Spike Protein of SARS-CoV-2 and ACE2-Expressing Cells Using an In Vitro Cell Capturing System (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12575-021-00153-9 |
34433426 |
| 2021-08-26 |
Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.72914.1 |
|
| 2021-08-26 |
Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22179233 |
34502139 |
| 2021-08-26 |
Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study (edit) |
SARSコロナウイルス2 (edit) |
10.7759/CUREUS.17455 |
34513523 |
| 2021-08-25 |
In silico molecular docking of SARS-CoV-2 surface proteins with microbial non-ribosomal peptides: identification of potential drugs (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S42485-021-00072-Z |
34456530 |
| 2021-08-25 |
Distinct weather conditions and human mobility impacts on the SARS-CoV-2 outbreak in Colombia: Application of an artificial neural network approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJHEH.2021.113833 |
34461424 |
| 2021-08-25 |
The low contagiousness and new A958D mutation of SARS-CoV-2 in children: An observational cohort study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.08.036 |
34454120 |
| 2021-08-25 |
Extraction-Free Rapid Cycle Quantitative RT-PCR and Extreme RT-PCR for SARS-CoV-2 Virus Detection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMOLDX.2021.08.004 |
34454108 |
| 2021-08-25 |
Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25357-1 |
|
| 2021-08-25 |
A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25361-5 |
|
| 2021-08-25 |
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00275-21 |
34431693 |
| 2021-08-25 |
Oligonucleotide capture sequencing of the SARS-CoV-2 genome and subgenomic fragments from COVID-19 individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0244468 |
34432798 |
| 2021-08-25 |
Spatial scales, patterns, and positivity trends of SARS-CoV-2 pandemics in mass rapid antigen testing in Slovakia (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0256669 |
|
| 2021-08-25 |
SARS-CoV-2 Membrane Glycoprotein M Triggers Apoptosis With the Assistance of Nucleocapsid Protein N in Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.706252 |
34513728 |
| 2021-08-25 |
Preliminary Findings on the Association of the Lipid Peroxidation Product 4-Hydroxynonenal with the Lethal Outcome of Aggressive COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/ANTIOX10091341 |
34572973 |
| 2021-08-25 |
Molecular Pathology Demonstration of SARS-CoV-2 in Cytotrophoblast from Placental Tissue with Chronic Histiocytic Intervillositis, Trophoblast Necrosis and COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JDB9030033 |
34449643 |
| 2021-08-24 |
Binding of boswellic acids to functional proteins of the SARS-CoV-2 virus: Bioinformatic studies (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ARDP.202100160 |
34427335 |
| 2021-08-24 |
Autoimmune Complications of COVID‐19 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27292 |
34427929 |
| 2021-08-24 |
A next generation sequencing (NGS) analysis to reveal genomic and proteomic mutation landscapes of SARS-CoV-2 in South Asia (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRMICR.2021.100065 |
34841355 |
| 2021-08-24 |
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.08.025 |
34508662 |
| 2021-08-24 |
Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00310-0 |
34429403 |
| 2021-08-24 |
Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of three proteins from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2103554118 |
34373319 |
| 2021-08-24 |
Reply to Betsch and Sprengholz: Higher SARS-CoV-2 infection numbers related to more airborne pollen, regardless of testing frequency (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2110982118 |
34400507 |
| 2021-08-24 |
Critically ill COVID-19 patients exhibit hyperactive cytokine responses associated with effector exhausted senescent T cells in acute infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB425 |
34427670 |
| 2021-08-23 |
Potential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga Halymenia durvillei (Rhodophyta) - A computational study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARABJC.2021.103393 |
34909061 |
| 2021-08-23 |
Multiple Roles of SARS-CoV-2 N Protein Facilitated by Proteoform-Specific Interactions with RNA, Host Proteins, and Convalescent Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACSAU.1C00139 |
34462738 |
| 2021-08-23 |
Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-021-00653-Y |
|
| 2021-08-23 |
Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.20.21262389 |
34462757 |
| 2021-08-23 |
Integrative approach identifies SLC6A20 and CXCR6 as putative causal genes for the COVID-19 GWAS signal in the 3p21.31 locus (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13059-021-02454-4 |
|
| 2021-08-23 |
Acute SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight transmission bottlenecks (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009849 |
34424945 |
| 2021-08-23 |
Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.692937 |
34497604 |
| 2021-08-22 |
Cell-Free Hemoglobin Does Not Attenuate the Effects of SARS-CoV-2 Spike Protein S1 Subunit in Pulmonary Endothelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22169041 |
34445747 |
| 2021-08-21 |
Molecular characterization of SARS-CoV-2 from Bangladesh: implications in genetic diversity, possible origin of the virus, and functional significance of the mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E07866 |
34458642 |
| 2021-08-21 |
HLA repertoire of 115 UAE nationals infected with SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HUMIMM.2021.08.012 |
34462158 |
| 2021-08-21 |
Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICINF.2021.104880 |
34425246 |
| 2021-08-21 |
Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41385-021-00437-Z |
34420043 |
| 2021-08-21 |
Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40249-021-00895-4 |
|
| 2021-08-21 |
SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22169035 |
34445741 |
| 2021-08-20 |
Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11427-021-1990-5 |
34431042 |
| 2021-08-20 |
Low SARS-CoV-2 seroprevalence but high perception of risk among healthcare workers at children's hospital before second pandemic wave in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12519-021-00447-8 |
34415560 |
| 2021-08-20 |
CovidPhy: A tool for phylogeographic analysis of SARS-CoV-2 variation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.111909 |
34419470 |
| 2021-08-20 |
Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.103006 |
34430803 |
| 2021-08-20 |
The Prevention of Common Respiratory Virus Epidemics in 2020-21 during the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: An Unexpected Benefit of the Implementation of Public Health Measures (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANA.2021.100043 |
|
| 2021-08-20 |
Enumerating asymptomatic COVID-19 cases and estimating SARS-CoV-2 fecal shedding rates via wastewater-based epidemiology (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.149794 |
34467933 |
| 2021-08-20 |
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-01021-0 |
|
| 2021-08-20 |
Management of SARS-CoV-2 in the Military and Lessons for Future Pandemics (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MILMED/USAB337 |
|
| 2021-08-20 |
Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level (edit) |
SARSコロナウイルス2 (edit) |
10.20411/PAI.V6I2.460 |
34541432 |
| 2021-08-20 |
Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMED.2021.737007 |
34490316 |
| 2021-08-20 |
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.69091 |
34414884 |
| 2021-08-19 |
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPC.2021.106677 |
34428682 |
| 2021-08-19 |
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103519 |
34419923 |
| 2021-08-19 |
Wastewater-based SARS-CoV-2 environmental monitoring for Piedmont, Italy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.111901 |
|
| 2021-08-19 |
Association of Apolipoprotein e polymorphism with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.105043 |
34419671 |
| 2021-08-19 |
Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend tracker and variants in Ohio, United States (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.149757 |
34467932 |
| 2021-08-19 |
A glycan gate controls opening of the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41557-021-00758-3 |
34413500 |
| 2021-08-19 |
SARS-CoV-2 infection initiates interleukin-17-enriched transcriptional response in different cells from multiple organs (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-96110-3 |
34413339 |
| 2021-08-19 |
A Community-Adapted Approach to SARS-CoV-2 Testing for Medically Underserved Populations, Rhode Island, USA (edit) |
SARSコロナウイルス2 (edit) |
10.3201/EID2709.204874 |
|
| 2021-08-18 |
Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJPHARM.2021.121023 |
34416332 |
| 2021-08-18 |
Co-expression of the SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in human ovaries: Identification of cell types and trends with age (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.YGENO.2021.08.012 |
34418496 |
| 2021-08-18 |
HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00726-W |
34408131 |
| 2021-08-18 |
Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41587-021-01037-9 |
|
| 2021-08-18 |
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABH0755 |
|
| 2021-08-18 |
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00975-21 |
34406858 |
| 2021-08-18 |
Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve In Vitro to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01357-21 |
34406867 |
| 2021-08-18 |
A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06528-3 |
34407759 |
| 2021-08-18 |
Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0256141 |
34407143 |
| 2021-08-18 |
Wide Application of Minimally Processed Saliva on Multiple RT-qPCR Kits for SARS-CoV-2 Detection in Indonesia (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.691538 |
34485174 |
| 2021-08-18 |
SARS-CoV-2 Viral Load Is Correlated With the Disease Severity and Mortality in Patients With Cancer (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FONC.2021.715794 |
34490115 |
| 2021-08-18 |
Group Testing for SARS-CoV-2 Allows for Up to 10-Fold Efficiency Increase Across Realistic Scenarios and Testing Strategies (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2021.583377 |
|
| 2021-08-18 |
Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13081635 |
|
| 2021-08-17 |
Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11756-021-00866-Y |
34421121 |
| 2021-08-17 |
Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.08.014 |
34499854 |
| 2021-08-17 |
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.08.013 |
34464596 |
| 2021-08-17 |
“Armed for the future Coronavirus pandemic”: a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00721-1 |
|
| 2021-08-17 |
Molecular determinants for regulation of G3BP1/2 phase separation by the SARS-CoV-2 nucleocapsid protein (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00306-W |
34400613 |
| 2021-08-17 |
SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25156-8 |
34404778 |
| 2021-08-17 |
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25331-X |
34404805 |
| 2021-08-17 |
No evidence of SARS-CoV-2 reverse transcription and integration as the origin of chimeric transcripts in patient tissues (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2109066118 |
34344759 |
| 2021-08-17 |
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.02094-21 |
34399606 |
| 2021-08-17 |
Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1136/THORAXJNL-2021-217561 |
|
| 2021-08-17 |
Rapid Global Spread of the SARS-CoV-2 Delta (B.1.617.2) Variant: Spatiotemporal Variation and Public Health Impact (edit) |
SARSコロナウイルス2 (edit) |
10.15212/ZOONOSES-2021-0005 |
|
| 2021-08-17 |
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.69719 |
34402426 |
| 2021-08-16 |
Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMAPEDIATRICS.2021.2770 |
34398179 |
| 2021-08-16 |
Structure and Function of N-Terminal Zinc Finger Domain of SARS-CoV-2 NSP2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12250-021-00431-6 |
34398430 |
| 2021-08-16 |
Trends in Pediatric Viral Symptoms, Influenza Testing, and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium, January 2017 to July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACAP.2021.08.008 |
34411765 |
| 2021-08-16 |
Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2021.07.007 |
34403647 |
| 2021-08-16 |
SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.TRANSPROCEED.2021.08.019 |
34551880 |
| 2021-08-16 |
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VACCINE.2021.07.034 |
34304928 |
| 2021-08-16 |
Ultrarapid detection of SARS-CoV-2 RNA using a reverse transcription–free exponential amplification reaction, RTF-EXPAR (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2100347118 |
34400545 |
| 2021-08-16 |
Molecular docking and dynamic simulation of conserved B cell epitope of SARS-CoV-2 glycoprotein Indonesian isolates: an immunoinformatic approach (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.54258.1 |
|
| 2021-08-16 |
Antimicrobial Face Shield: Next Generation of Facial Protective Equipment against SARS-CoV-2 and Multidrug-Resistant Bacteria (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202108.0329.V1 |
|
| 2021-08-16 |
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.722027 |
34489971 |
| 2021-08-15 |
EVOLUTION OF THE INFECTION OF THE SARS-COV-2 IN ITALY, GENERAL EPIDEMIOLOGICAL RESULTS AND NEW STRADEGIC HYPOTHESES RELATED TO TERRESTRIAL CLIMATE (edit) |
SARSコロナウイルス2 (edit) |
10.26821/IJSRC.9.8.2021.9822 |
|
| 2021-08-14 |
Comparison of positive SARS-CoV-2 incidence rate with environmental and socioeconomic factors in northern Illinois (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E07806 |
34414309 |
| 2021-08-14 |
Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MCPRO.2021.100134 |
34400346 |
| 2021-08-14 |
A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEDJ.2021.08.002 |
34414385 |
| 2021-08-14 |
Does face mask use elicit risk-compensation? Quasi-experimental evidence from Denmark during the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EURPUB/CKAB136 |
|
| 2021-08-14 |
Recovery of Deleted Deep Sequencing Data Sheds More Light on the Early Wuhan SARS-CoV-2 Epidemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAB246 |
|
| 2021-08-14 |
An overview of the COVID-19 related content of Wikimedia projects (edit) |
SARSコロナウイルス2 (edit) |
10.5281/ZENODO.5201623 |
|
| 2021-08-13 |
A distinct ssDNA/RNA binding interface in the Nsp9 protein from SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PROT.26205 |
34369011 |
| 2021-08-13 |
The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-021-03601-3 |
34389878 |
| 2021-08-13 |
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.08.001 |
34453880 |
| 2021-08-13 |
The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00131 |
34152728 |
| 2021-08-13 |
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABH1139 |
34016740 |
| 2021-08-13 |
Tibetan Medical Paradigms for the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1163/15734218-12341485 |
|
| 2021-08-13 |
The effect of SARS-CoV-2 on the nervous system: a review of neurological impacts caused by human coronaviruses (edit) |
SARSコロナウイルス2 (edit) |
10.1515/REVNEURO-2021-0041 |
34388333 |
| 2021-08-13 |
Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.706901 |
34483914 |
| 2021-08-13 |
Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence (edit) |
SARSコロナウイルス2 (edit) |
10.4049/JIMMUNOL.2100465 |
34389625 |
| 2021-08-12 |
Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78, a co-receptor for SARS-CoV-2, in COVID-19 autopsies (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12192-021-01230-4 |
34382151 |
| 2021-08-12 |
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CRPHAR.2021.100045 |
34870151 |
| 2021-08-12 |
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103524 |
34391096 |
| 2021-08-12 |
Systems level insights into the impact of airborne exposure on SARS-CoV-2 pathogenesis and COVID-19 outcome - A multi-omics big data study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.GENREP.2021.101312 |
34401607 |
| 2021-08-12 |
Dynamics of SARS-CoV-2 in wastewater in three districts of the Buenos Aires metropolitan region, Argentina, throughout nine months of surveillance: A pilot study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.149578 |
34426365 |
| 2021-08-12 |
Perturbation of ACE2 Structural Ensembles by SARS-CoV-2 Spike Protein Binding (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.1C00325 |
|
| 2021-08-12 |
Role of ATP in the RNA Translocation Mechanism of SARS-CoV-2 NSP13 Helicase (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.1C04528 |
34328740 |
| 2021-08-12 |
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41375-021-01374-3 |
34385593 |
| 2021-08-12 |
Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-021-00652-Z |
|
| 2021-08-12 |
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2107799 |
34233096 |
| 2021-08-12 |
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.11.455956 |
34401880 |
| 2021-08-12 |
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABJ4176 |
34385356 |
| 2021-08-12 |
SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12916-021-02072-8 |
34384441 |
| 2021-08-12 |
Identification of Natural Inhibitors Against SARS-CoV-2 Drugable Targets Using Molecular Docking, Molecular Dynamics Simulation, and MM-PBSA Approach (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.730288 |
34458164 |
| 2021-08-11 |
Distinct Lipid Metabolic Dysregulation in Asymptomatic COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102974 |
34396083 |
| 2021-08-11 |
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.RETRAM.2021.103309 |
34418758 |
| 2021-08-11 |
Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.1C02713 |
34328324 |
| 2021-08-11 |
Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00716-Y |
34381015 |
| 2021-08-11 |
Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25166-6 |
34381037 |
| 2021-08-11 |
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-021-00651-0 |
|
| 2021-08-11 |
A computational study of cooperative binding to multiple SARS-CoV-2 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-95826-6 |
34381116 |
| 2021-08-11 |
Multiplexed detection of SARS-CoV-2 genomic and subgenomic RNA using hybridization (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.08.11.455959 |
34401878 |
| 2021-08-11 |
SARS-CoV-2 Genome Sequencing Methods Differ in Their Abilities To Detect Variants from Low-Viral-Load Samples (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.01046-21 |
34379527 |
| 2021-08-11 |
A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00592-21 |
34379509 |
| 2021-08-11 |
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351) (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00472-21 |
34378968 |
| 2021-08-11 |
Mild and Severe SARS-CoV-2 Infection Induces Respiratory and Intestinal Microbiome Changes in the K18-hACE2 Transgenic Mouse Model (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00536-21 |
34378965 |
| 2021-08-11 |
Sex differences in a cohort of COVID-19 Italian patients hospitalized during the first and second pandemic waves (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13293-021-00386-Z |
34380555 |
| 2021-08-11 |
Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0253574 |
34379620 |
| 2021-08-11 |
Detection of SARS-CoV-2 Derived Small RNAs and Changes in Circulating Small RNAs Associated with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13081593 |
34452458 |
| 2021-08-11 |
Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9080887 |
|
| 2021-08-10 |
Determination of vulnerable regions of SARS-CoV-2 in Malaysia using meteorology and air quality data (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10668-021-01719-Z |
34393622 |
| 2021-08-10 |
Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104759 |
34403938 |
| 2021-08-10 |
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.06.015 |
34246326 |
| 2021-08-10 |
Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101065 |
34384783 |
| 2021-08-10 |
Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25137-X |
34376689 |
| 2021-08-10 |
Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-95733-W |
34376762 |
| 2021-08-10 |
Cold atmospheric plasma: A non-negligible strategy for viral RNA inactivation to prevent SARS-CoV-2 environmental transmission (edit) |
SARSコロナウイルス2 (edit) |
10.1063/5.0060530 |
34413992 |
| 2021-08-10 |
Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2109229118 |
|
| 2021-08-10 |
Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00402-21 |
34133899 |
| 2021-08-10 |
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10082047 |
34440816 |
| 2021-08-10 |
Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS9081700 |
34442779 |
| 2021-08-09 |
Online bioinformatics teaching practice: Comparison of popular docking programs using SARS-CoV-2 spike RBD-ACE2 complex as a benchmark (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BMB.21566 |
34369638 |
| 2021-08-09 |
Direct Comparison of N-Glycans and Their Isomers Derived from Spike Glycoprotein 1 of MERS-CoV, SARS-CoV-1, and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPROTEOME.1C00323 |
34369795 |
| 2021-08-09 |
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25168-4 |
34373458 |
| 2021-08-09 |
Quantifying SARS-CoV-2 viral load: current status and future prospects (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14737159.2021.1962709 |
34369836 |
| 2021-08-09 |
Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection and Escherichia coli Sepsis (edit) |
SARSコロナウイルス2 (edit) |
10.1097/RHU.0000000000001783 |
|
| 2021-08-09 |
Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021107985 |
34302370 |
| 2021-08-09 |
A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.707194 |
34434902 |
| 2021-08-07 |
HD5 and LL-37 Inhibit SARS-CoV and SARS-CoV-2 Binding to Human ACE2 by Molecular Simulation (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12539-021-00462-3 |
34363600 |
| 2021-08-06 |
Structural dynamics of single SARS-CoV-2 pseudoknot molecules reveal topologically distinct conformers (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25085-6 |
34362921 |
| 2021-08-06 |
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI6226 |
34168071 |
| 2021-08-06 |
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI9745 |
|
| 2021-08-06 |
Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13073-021-00943-6 |
34362430 |
| 2021-08-06 |
Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40001-021-00558-Y |
|
| 2021-08-06 |
Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7031E2 |
34351882 |
| 2021-08-06 |
The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.660490 |
34421587 |
| 2021-08-05 |
Previous vitamin D status and total cholesterol are associated with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CCA.2021.08.003 |
34364853 |
| 2021-08-05 |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.06.020 |
34242578 |
| 2021-08-05 |
Possible therapeutic targets and promising drugs based on unsymmetrical hetaryl-substituted porphyrins to combat SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPHA.2021.08.003 |
34377564 |
| 2021-08-05 |
Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2021.06.002 |
34161756 |
| 2021-08-05 |
Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198532 |
34363852 |
| 2021-08-05 |
SARS-CoV-2 Unrevealed: Ultrastructural and Nanomechanical Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.LANGMUIR.1C01488 |
34351770 |
| 2021-08-05 |
Real-time SARS-CoV-2 diagnostic and variants tracking over multiple candidates using nanopore DNA sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-95563-W |
34354202 |
| 2021-08-05 |
NMPylation and de-NMPylation of SARS-CoV-2 nsp9 by the NiRAN domain (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB677 |
34352100 |
| 2021-08-05 |
Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PCBI.1009286 |
|
| 2021-08-04 |
Par ici la sortie ! Le SARS-CoV-2 utilise les lysosomes pour sortir de la cellule infectée (edit) |
SARSコロナウイルス2 (edit) |
10.1051/MEDSCI/2021100 |
|
| 2021-08-04 |
Overlapping of Independent SARS-CoV-2 Nosocomial Transmissions in a Complex Outbreak (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00389-21 |
34346709 |
| 2021-08-04 |
Auditory Disturbances and SARS-CoV-2 Infection: Brain Inflammation or Cochlear Affection? Systematic Review and Discussion of Potential Pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNEUR.2021.707207 |
|
| 2021-08-03 |
Mass Spectrometry Analysis of SARS-CoV-2 Nucleocapsid Protein Reveals Camouflaging Glycans and Unique Post-Translational Modifications (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-08-03 |
Transient and stabilized complexes of Nsp7, Nsp8, and Nsp12 in SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2021.06.006 |
34197805 |
| 2021-08-03 |
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109479 |
34320401 |
| 2021-08-03 |
Predicting the SARS-CoV-2 effective reproduction number using bulk contact data from mobile phones (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2026731118 |
34261775 |
| 2021-08-03 |
Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2103272118 |
34312227 |
| 2021-08-03 |
Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase (edit) |
SARSコロナウイルス2 (edit) |
10.1080/17460441.2021.1909566 |
|
| 2021-08-03 |
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21645515.2021.1901545 |
33847226 |
| 2021-08-03 |
Catching SARS-CoV-2 by Sequence Hybridization: a Comparative Analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSYSTEMS.00392-21 |
34342536 |
| 2021-08-03 |
N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCELL.2021.697035 |
34414185 |
| 2021-08-03 |
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.3390/VACCINES9080848 |
34451973 |
| 2021-08-03 |
SARS-COV-2 invasion in lakes: A rare transferability of the dreaded virus by nature or manmade (edit) |
SARSコロナウイルス2 (edit) |
10.4314/JAS.V36I1.3 |
|
| 2021-08-02 |
Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics (edit) |
SARSコロナウイルス2 (edit) |
|
34128960 |
| 2021-08-02 |
Quantification of Specific Antibodies Against SARS-CoV-2 in Breast Milk of Lactating Women Vaccinated With an mRNA Vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1001/JAMANETWORKOPEN.2021.20575 |
34379127 |
| 2021-08-02 |
An optimized, amplicon-based approach for sequencing of SARS-CoV-2 from patient samples using COVIDSeq assay on Illumina MiSeq sequencing platforms (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.100755 |
34368787 |
| 2021-08-02 |
Why All the Fury over Furin? (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.1C00518 |
34340303 |
| 2021-08-02 |
SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-25015-6 |
34341353 |
| 2021-08-02 |
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB247 |
33961695 |
| 2021-08-02 |
Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.30.454402 |
|
| 2021-08-02 |
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0255622 |
34339474 |
| 2021-08-02 |
SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021107826 |
34101213 |
| 2021-08-02 |
The Emergence and Spread of Novel SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPUBH.2021.696664 |
34409009 |
| 2021-08-01 |
MUC1-C influences cell survival in lung adenocarcinoma Calu-3 cells after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
|
33832550 |
| 2021-08-01 |
Future developments in biosensors for field-ready SARS-CoV-2 virus diagnostics (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BAB.2033 |
32970352 |
| 2021-08-01 |
Predictable fold switching by the SARS-CoV-2 protein ORF9b (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PRO.4097 |
33934422 |
| 2021-08-01 |
p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PRP2.798 |
34128351 |
| 2021-08-01 |
Air pollution particulate matter as a potential carrier of SARS-CoV-2 to the nervous system and/or neurological symptom enhancer: arguments in favor (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-020-11183-3 |
33051841 |
| 2021-08-01 |
French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACCPM.2021.100931 |
|
| 2021-08-01 |
Mortality after surgery with SARS-CoV-2 infection in England: a population-wide epidemiological study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BJA.2021.05.018 |
34148733 |
| 2021-08-01 |
ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CCA.2021.04.024 |
33957095 |
| 2021-08-01 |
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.06.021 |
34242577 |
| 2021-08-01 |
The Origins of SARS-CoV-2: A Critical Review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.08.017 |
|
| 2021-08-01 |
Novel SARS-CoV-2 variants: the pandemics within the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CMI.2021.05.022 |
34015535 |
| 2021-08-01 |
Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CPLETT.2021.138727 |
33994552 |
| 2021-08-01 |
The conundrum of current anti-SARS-CoV-2 vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CYTOGFR.2021.03.001 |
|
| 2021-08-01 |
Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.101028 |
34308321 |
| 2021-08-01 |
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HEALUN.2021.05.004 |
|
| 2021-08-01 |
Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.100925 |
34214498 |
| 2021-08-01 |
S-acylation of SARS-CoV-2 Spike Protein: Mechanistic Dissection, In Vitro Reconstitution and Role in Viral Infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.101112 |
|
| 2021-08-01 |
Rapid SARS-CoV-2 variant monitoring using PCR confirmed by whole genome sequencing in a high-volume diagnostic laboratory (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2021.104906 |
34273860 |
| 2021-08-01 |
Rapid antigen test for SARS-CoV-2 and primary health care (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.05.001 |
|
| 2021-08-01 |
Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.05.017 |
|
| 2021-08-01 |
Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.05.018 |
34044037 |
| 2021-08-01 |
Real-Life Head-to-Head Comparison of Performance of Two High-Throughput Automated Assays for the Detection of SARS-CoV-2 RNA in Nasopharyngeal Swabs (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMOLDX.2021.05.003 |
|
| 2021-08-01 |
Mental health, substance use, and suicidal ideation during a prolonged COVID-19-related lockdown in a region with low SARS-CoV-2 prevalence (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JPSYCHIRES.2021.05.080 |
34174556 |
| 2021-08-01 |
Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JVIROMET.2021.114174 |
33984396 |
| 2021-08-01 |
Development and validation of a new triplex real-time quantitative reverse Transcriptase-PCR assay for the clinical detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MCP.2021.101744 |
34089805 |
| 2021-08-01 |
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEEGID.2021.104869 |
33915216 |
| 2021-08-01 |
Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110622 |
|
| 2021-08-01 |
Carpal, cubital or tarsal tunnel syndrome after SARS-CoV-2 infection: A causal link? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110638 |
|
| 2021-08-01 |
B cell receptor (BCR) guided mechanotransduction: Critical hypothesis to instruct SARS-CoV-2 specific B cells to trigger proximal signalling and antibody reshaping (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110640 |
|
| 2021-08-01 |
Highly expressed ACE-2 receptors during pregnancy: A protective factor for SARS-COV-2 infection? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MEHY.2021.110641 |
|
| 2021-08-01 |
Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PBIOMOLBIO.2021.02.002 |
33636189 |
| 2021-08-01 |
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00287-5 |
34051887 |
| 2021-08-01 |
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03739-1 |
34192737 |
| 2021-08-01 |
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01410-W |
34108716 |
| 2021-08-01 |
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41591-021-01413-7 |
34127854 |
| 2021-08-01 |
SARS-CoV-2-Impfstoffe und Reaktion des Immunsystems. Kann die epidemische Ausbreitung des Virus durch Impfung verhindert werden? (edit) |
SARSコロナウイルス2 (edit) |
10.1055/A-1550-0001 |
|
| 2021-08-01 |
Comparison of SARS-CoV-2 Variants of Concern 202012/01 (U.K. Variant) and D614G Variant Transmission by Different Routes in Syrian Hamsters (edit) |
SARSコロナウイルス2 (edit) |
10.1089/VBZ.2021.0032 |
|
| 2021-08-01 |
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB256 |
33978762 |
| 2021-08-01 |
On the Sensitivity and Specificity of Postmortem Upper Respiratory Tract Testing for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB270 |
33999152 |
| 2021-08-01 |
Proposed framework for considering SARS-CoV-2 antigen testing of unexposed asymptomatic workers in selected workplaces (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JOM.0000000000002269 |
34016912 |
| 2021-08-01 |
SARS-CoV-2 infection in UK university students: lessons from September-December 2020 and modelling insights for future student return (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSOS.210310 |
34386249 |
| 2021-08-01 |
SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009800 |
34437657 |
| 2021-08-01 |
Phylogenetic pattern of SARS-CoV-2 from COVID-19 patients from Bosnia and Herzegovina: lessons learned to optimize future molecular and epidemiological approaches (edit) |
SARSコロナウイルス2 (edit) |
10.17305/BJBMS.2020.5381 |
33577445 |
| 2021-08-01 |
In Silico Identification of Potential Inhibitors of SARS-CoV-2 Papain-like Protease From Natural Sources: A Natural Weapon to Fight COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.2174/2666796701999201203211330 |
|
| 2021-08-01 |
Why Are Physicists Involved in the Studies on the Origin of SARS-CoV-2? (edit) |
SARSコロナウイルス2 (edit) |
10.31661/JBPE.V0I0.2106-1361 |
|
| 2021-08-01 |
Rapid diagnostics for SARS-CoV-2 virus: point-of-care testing and lessons learned during the pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.4155/BIO-2021-0100 |
|
| 2021-07-31 |
Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.04.148 |
33915212 |
| 2021-07-31 |
An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.28.21261232 |
|
| 2021-07-31 |
Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Measure SARS-CoV-2 Humoral Immunogenicity (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.29.21261156 |
|
| 2021-07-31 |
Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10081952 |
34440721 |
| 2021-07-30 |
Quantum simulations of SARS-CoV-2 main protease M enable high-quality scoring of diverse ligands (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10822-021-00412-7 |
34328586 |
| 2021-07-30 |
"Bucket brigade" using lysine residues in RNA-dependent RNA polymerase of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2021.07.026 |
34339634 |
| 2021-07-30 |
An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104703 |
34352457 |
| 2021-07-30 |
JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102928 |
34345808 |
| 2021-07-30 |
Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2021.105114 |
34333072 |
| 2021-07-30 |
Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIRUSRES.2021.198526 |
|
| 2021-07-30 |
Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24887-Y |
34330917 |
| 2021-07-30 |
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24905-Z |
|
| 2021-07-30 |
SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BSR20210611 |
34328172 |
| 2021-07-30 |
The household secondary attack rate of SARS-CoV-2: A rapid review (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CID/CIAA1558 |
33045075 |
| 2021-07-30 |
Synthesis of Hetaryl-Substituted Asymmetric Porphyrins and Their Affinity to SARS-CoV-2 Helicase (edit) |
SARSコロナウイルス2 (edit) |
10.1134/S1070363221060098 |
34345157 |
| 2021-07-30 |
Occupational and environmental exposure to SARS-CoV-2 in and around infected mink farms (edit) |
SARSコロナウイルス2 (edit) |
10.1136/OEMED-2021-107443 |
34330815 |
| 2021-07-30 |
Computational modeling of SARS-CoV-2 Nsp1 binding to human ribosomal 40S complex (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3459930.3469554 |
|
| 2021-07-30 |
Kutatásetika és kutatásszervezés a SARS-CoV-2 vírus okozta világjárványban (edit) |
SARSコロナウイルス2 (edit) |
10.1556/112.2021.00008 |
|
| 2021-07-29 |
The genetic structure of SARS‐CoV‐2 is consistent with both natural or laboratory origin: Response to Tyshkovskiy and Panchin (10.1002/bies.202000325) (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BIES.202100137 |
|
| 2021-07-29 |
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00712-2 |
34326308 |
| 2021-07-29 |
SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24938-4 |
34326343 |
| 2021-07-29 |
Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 MPRO (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-94951-6 |
34326429 |
| 2021-07-29 |
Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S42003-021-02453-Y |
34326460 |
| 2021-07-29 |
Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/FEBS.16114 |
34228902 |
| 2021-07-29 |
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABJ0299 |
|
| 2021-07-29 |
Computational Prediction of N6-methyladenosine (m6A) RNA Methylation in SARS-CoV-2 Viral Transcripts (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3469678.3469689 |
|
| 2021-07-29 |
SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOOD.2021010685 |
34075401 |
| 2021-07-29 |
Modeling neutral viral mutations in the spread of SARS-CoV-2 epidemics (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0255438 |
|
| 2021-07-29 |
Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.30.2100673 |
|
| 2021-07-29 |
Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.719077 |
34394127 |
| 2021-07-29 |
Localization of SARS-CoV-2 Capping Enzymes Revealed by an Antibody against the nsp10 Subunit (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13081487 |
34452352 |
| 2021-07-29 |
Detection of IFNγ-Secreting CD4 and CD8 Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13081490 |
34452355 |
| 2021-07-28 |
Structure-based study of immune receptors as eligible binding targets of coronavirus SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2021.107997 |
34343818 |
| 2021-07-28 |
CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCENTSCI.0C01537 |
34341769 |
| 2021-07-28 |
IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24817-Y |
34321474 |
| 2021-07-28 |
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03841-4 |
|
| 2021-07-28 |
Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.01010-21 |
34319784 |
| 2021-07-28 |
Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets (edit) |
SARSコロナウイルス2 (edit) |
10.1182/BLOOD.2021011871 |
34315173 |
| 2021-07-28 |
poreCov-An Easy to Use, Fast, and Robust Workflow for SARS-CoV-2 Genome Reconstruction via Nanopore Sequencing (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FGENE.2021.711437 |
34394197 |
| 2021-07-28 |
Sewage Systems Surveillance for SARS-CoV-2: Identification of Knowledge Gaps, Emerging Threats, and Future Research Needs (edit) |
SARSコロナウイルス2 (edit) |
10.3390/PATHOGENS10080946 |
34451410 |
| 2021-07-27 |
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate? (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27210 |
34260088 |
| 2021-07-27 |
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109452 |
34289385 |
| 2021-07-27 |
SARS-CoV-2 airborne transmission: A validated sampling and analytical method (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2021.111783 |
34324848 |
| 2021-07-27 |
Emerging mutations in envelope protein of SARS-CoV-2 and their effect on thermodynamic properties (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2021.100675 |
34337139 |
| 2021-07-27 |
N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00704-2 |
34315847 |
| 2021-07-27 |
Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00295-W |
34315862 |
| 2021-07-27 |
Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24807-0 |
34315893 |
| 2021-07-27 |
Determination of the characteristic inactivation fluence for SARS-CoV-2 under UV-C radiation considering light absorption in culture media (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-94648-W |
34315976 |
| 2021-07-27 |
Minute-scale detection of SARS-CoV-2 using a low-cost biosensor composed of pencil graphite electrodes (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2106724118 |
34244421 |
| 2021-07-27 |
Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI9310 |
34315827 |
| 2021-07-27 |
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABI4547 |
|
| 2021-07-27 |
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01386-21 |
|
| 2021-07-27 |
COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.147472 |
|
| 2021-07-27 |
SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block (edit) |
SARSコロナウイルス2 (edit) |
10.1261/RNA.078923.121 |
34315815 |
| 2021-07-27 |
Non-RBM Mutations Impaired SARS-CoV-2 Spike Protein Regulated to the ACE2 Receptor Based on Molecular Dynamic Simulation (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2021.614443 |
34386518 |
| 2021-07-27 |
Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOMEDICINES9080899 |
34440103 |
| 2021-07-26 |
Results of the Genetic Counselor SARS‐CoV‐2 Impact Survey from the National Society of Genetic Counselors: Progress and penalty during the COVID‐19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JGC4.1484 |
|
| 2021-07-26 |
A realistic transfer method reveals low risk of SARS-CoV-2 transmission via contaminated euro coins and banknotes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102908 |
34337354 |
| 2021-07-26 |
Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping' (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24730-4 |
34312385 |
| 2021-07-26 |
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24909-9 |
34312390 |
| 2021-07-26 |
S494 O-glycosylation site on the SARS-CoV-2 RBD affects the virus affinity to ACE2 and its infectivity; a molecular dynamics study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-94602-W |
34312429 |
| 2021-07-26 |
The Truth about SARS-CoV-2 Cycle Threshold Values Is Rarely Pure and Never Simple (edit) |
SARSコロナウイルス2 (edit) |
10.1093/CLINCHEM/HVAB146 |
|
| 2021-07-26 |
N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.26.453787 |
|
| 2021-07-26 |
Emergence of Unique SARS-CoV-2 ORF10 Variants and Their Impact on Protein Structure and Function (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202107.0554.V1 |
|
| 2021-07-25 |
Target-Based In Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12539-021-00461-4 |
34308530 |
| 2021-07-24 |
Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22157919 |
34360686 |
| 2021-07-23 |
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.07.023 |
34352228 |
| 2021-07-23 |
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109504 |
34352226 |
| 2021-07-23 |
Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104668 |
34340124 |
| 2021-07-23 |
Target capture sequencing of SARS-CoV-2 genomes using the ONETest Coronaviruses Plus (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.DIAGMICROBIO.2021.115508 |
34391075 |
| 2021-07-23 |
ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102770 |
34189428 |
| 2021-07-23 |
Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167058 |
34023401 |
| 2021-07-23 |
The Inherent Dynamics and Interaction Sites of the SARS-CoV-2 Nucleocapsid N-Terminal Region (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMB.2021.167108 |
34161778 |
| 2021-07-23 |
RBM15-mediated N6-methyladenosine modification affects COVID-19 severity by regulating the expression of multitarget genes (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41419-021-04012-Z |
34301919 |
| 2021-07-23 |
Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EHJCVP/PVAA105 |
33155016 |
| 2021-07-23 |
Lung Ultrasound Examination in Patients with SARS-CoV-2 Infection: Multicenter Study (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM10153255 |
34362039 |
| 2021-07-23 |
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13081439 |
34452305 |
| 2021-07-23 |
SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.4049/JIMMUNOL.2100272 |
|
| 2021-07-22 |
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.06.005 |
34192529 |
| 2021-07-22 |
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EJPHAR.2021.174374 |
34303662 |
| 2021-07-22 |
Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JARE.2021.07.007 |
35116175 |
| 2021-07-22 |
Binding of SARS-CoV-2 Fusion Peptide to Host Endosome and Plasma Membrane (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.1C04176 |
34255499 |
| 2021-07-22 |
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41401-021-00732-2 |
34294887 |
| 2021-07-22 |
Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41522-021-00232-5 |
34294722 |
| 2021-07-22 |
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-021-00352-1 |
|
| 2021-07-22 |
Influenza-like illness among personnel responding to U.S. quarantine of cruise ship passengers exposed to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1097/JOM.0000000000002335 |
34310544 |
| 2021-07-22 |
Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.21.21260926 |
|
| 2021-07-22 |
L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.148999 |
34291736 |
| 2021-07-22 |
Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-021-00644-Y |
34294141 |
| 2021-07-21 |
Classification of SARS-CoV-2 and non-SARS-CoV-2 using machine learning algorithms (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104650 |
34329865 |
| 2021-07-21 |
Decrypting the role of predicted SARS-CoV-2 miRNAs in COVID-19 pathogenesis: A bioinformatics approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104669 |
34320442 |
| 2021-07-21 |
Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104671 |
34332348 |
| 2021-07-21 |
In-Silico analysis reveals lower transcription efficiency of C241T variant of SARS-CoV-2 with host replication factors MADP1 and hnRNP-1 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2021.100670 |
34307830 |
| 2021-07-21 |
A benchmarking study of SARS-CoV-2 whole-genome sequencing protocols using COVID-19 patient samples (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102892 |
34308277 |
| 2021-07-21 |
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCENTSCI.1C00596 |
|
| 2021-07-21 |
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41423-021-00728-2 |
34290398 |
| 2021-07-21 |
Lipid bilayer degradation induced by SARS-CoV-2 spike protein as revealed by neutron reflectometry (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93996-X |
34290262 |
| 2021-07-21 |
The virological impacts of SARS-CoV-2 D614G mutation (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAB045 |
34289053 |
| 2021-07-20 |
Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00604-021-04896-W |
34282508 |
| 2021-07-20 |
Flavonoids from Siparuna cristata as Potential Inhibitors of SARS-CoV-2 Replication (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S43450-021-00162-5 |
34305198 |
| 2021-07-20 |
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109415 |
34270919 |
| 2021-07-20 |
Shedding light on toxicity of SARS-CoV-2 peptides in aquatic biota: A study involving neotropical mosquito larvae (Diptera: Culicidae) (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVPOL.2021.117818 |
|
| 2021-07-20 |
Comprehensive O-Glycosylation Analysis of the SARS-CoV-2 Spike Protein with Biomimetic Trp-Arg Materials (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.ANALCHEM.0C04634 |
|
| 2021-07-20 |
To Knot or Not to Knot: Multiple Conformations of the SARS-CoV-2 Frameshifting RNA Element (edit) |
SARSコロナウイルス2 (edit) |
10.1021/JACS.1C03003 |
34283611 |
| 2021-07-20 |
Solar UV-B/A radiation is highly effective in inactivating SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-94417-9 |
34285313 |
| 2021-07-20 |
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity (edit) |
SARSコロナウイルス2 (edit) |
10.1136/ANNRHEUMDIS-2021-220781 |
34285048 |
| 2021-07-20 |
A Comparative Study of the Inhibitory Effects of Rheum palmatum L. and Isatis Indigotica Root, on 3CLpro from SARS-CoV-2 Using Both Cell-based and Cell-free Assay Models (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3460238.3461671 |
|
| 2021-07-20 |
Phytochemicals as potential inhibitors for novel coronavirus 2019-nCoV/SARS-CoV-2: a graph-based computational analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3468784.3468886 |
|
| 2021-07-20 |
Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.647693 |
|
| 2021-07-20 |
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS9071542 |
34361977 |
| 2021-07-19 |
Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTI2.1312 |
34295471 |
| 2021-07-19 |
Identifying potential human and medicinal plant microRNAs against SARS-CoV-2 3'UTR region: A computational genomics assessment (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104662 |
34311261 |
| 2021-07-19 |
Traces of SARS-CoV-2 RNA in Peripheral Blood Cells of Patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1089/OMI.2021.0068 |
34280038 |
| 2021-07-19 |
Using a household-structured branching process to analyse contact tracing in the SARS-CoV-2 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSTB.2020.0267 |
|
| 2021-07-19 |
Estimates of regional infectivity of COVID-19 in the United Kingdom following imposition of social distancing measures (edit) |
SARSコロナウイルス2 (edit) |
10.1098/RSTB.2020.0280 |
34053251 |
| 2021-07-19 |
Endemic SARS-CoV-2 Polymorphisms Can Cause a Higher Diagnostic Target Failure Rate than Estimated by Aggregate Global Sequencing Data (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JCM.00913-21 |
33972454 |
| 2021-07-19 |
SARS-CoV-2: from its discovery to genome structure, transcription, and replication (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-021-00643-Z |
34281608 |
| 2021-07-19 |
Whole-genome sequencing of SARS-CoV-2 in Uganda: implementation of the low-cost ARTIC protocol in resource-limited settings (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.53567.1 |
34457243 |
| 2021-07-19 |
Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.669357 |
34349756 |
| 2021-07-19 |
Role of Laboratory Medicine in SARS-CoV-2 Diagnostics. Lessons Learned from a Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/HEALTHCARE9070915 |
|
| 2021-07-18 |
Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ADMA.202101707 |
34278613 |
| 2021-07-18 |
The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.KINT.2021.07.005 |
34284044 |
| 2021-07-18 |
Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM/GBSA and molecular dynamics simulation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2021.131124 |
34305175 |
| 2021-07-18 |
Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study (edit) |
SARSコロナウイルス2 (edit) |
10.1053/J.GASTRO.2021.07.010 |
34284037 |
| 2021-07-18 |
Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.14.21260497 |
|
| 2021-07-17 |
HAVoC, a bioinformatic pipeline for reference-based consensus assembly and lineage assignment for SARS-CoV-2 sequences (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12859-021-04294-2 |
34273961 |
| 2021-07-17 |
SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10071814 |
34359983 |
| 2021-07-16 |
Genomic characterization of SARS-CoV-2 isolates from patients in Turkey reveals the presence of novel mutations in spike and nsp12 proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27188 |
34241906 |
| 2021-07-16 |
Updated SARS-CoV-2 single nucleotide variants and mortality association (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27191 |
34245452 |
| 2021-07-16 |
On the origin of SARS-CoV-2—The blind watchmaker argument (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11427-021-1972-1 |
|
| 2021-07-16 |
Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104654 |
34346317 |
| 2021-07-16 |
Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JCV.2021.104897 |
34304089 |
| 2021-07-16 |
Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLSTRUC.2021.131113 |
34305174 |
| 2021-07-16 |
Conformational Variability Correlation Prediction of Transmissibility and Neutralization Escape Ability for Multiple Mutation SARS-CoV-2 Strains using SSSCPreds (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.1C03055 |
34337269 |
| 2021-07-16 |
SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24521-X |
34272374 |
| 2021-07-16 |
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93361-Y |
34272426 |
| 2021-07-16 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BCJ20210199 |
34198324 |
| 2021-07-16 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BCJ20210201 |
34198322 |
| 2021-07-16 |
Patterns of SARS-CoV-2 exposure and mortality suggest endemic infections, in addition to space and population factors, shape dynamics across countries (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.12.21260394 |
|
| 2021-07-16 |
Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AAC.00491-21 |
34001511 |
| 2021-07-16 |
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0253364 |
34270554 |
| 2021-07-16 |
Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009715 |
34270613 |
| 2021-07-16 |
High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.694243 |
34335605 |
| 2021-07-15 |
Prospects for controlling future pandemics of SARS in highlights of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13337-021-00715-1 |
|
| 2021-07-15 |
Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S13337-021-00720-4 |
34307771 |
| 2021-07-15 |
SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MATPR.2021.07.163 |
34307057 |
| 2021-07-15 |
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41422-021-00531-8 |
34267349 |
| 2021-07-15 |
A hybrid computational framework for intelligent inter-continent SARS-CoV-2 sub-strains characterization and prediction (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93757-W |
34267263 |
| 2021-07-15 |
Sex and age bias viral burden and interferon responses during SARS-CoV-2 infection in ferrets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93855-9 |
34267262 |
| 2021-07-14 |
Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ARABJC.2021.103315 |
34909064 |
| 2021-07-14 |
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.05.004 |
34022154 |
| 2021-07-14 |
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHOM.2021.06.006 |
34171266 |
| 2021-07-14 |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJID.2021.07.014 |
34273511 |
| 2021-07-14 |
The Strand-biased Transcription of SARS-CoV-2 and Unbalanced Inhibition by Remdesivir (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102857 |
34278249 |
| 2021-07-14 |
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.LANEPE.2021.100164 |
34278371 |
| 2021-07-14 |
SARS-CoV-2 detection in wastewater using multiplex quantitative PCR (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.148890 |
34298359 |
| 2021-07-14 |
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00689-Y |
|
| 2021-07-14 |
Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24467-0 |
34262047 |
| 2021-07-14 |
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03807-6 |
|
| 2021-07-14 |
Rapid Base-Specific Calling of SARS-CoV-2 Variants of Concern Using Combined RT-PCR Melting Curve Screening and SIRPH Technology (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB364 |
34409122 |
| 2021-07-14 |
SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00862-21 |
|
| 2021-07-14 |
SARS-CoV-2: is there neuroinvasion? (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12987-021-00267-Y |
|
| 2021-07-14 |
Implementation of an open-source robotic platform for SARS-CoV-2 testing by real-time RT-PCR (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PONE.0252509 |
|
| 2021-07-13 |
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BMCL.2021.128263 |
34271072 |
| 2021-07-13 |
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109364 |
34214467 |
| 2021-07-13 |
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109385 |
34237284 |
| 2021-07-13 |
Computational and network pharmacology studies of Phyllanthus emblica to tackle SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.PHYPLU.2021.100095 |
35399824 |
| 2021-07-13 |
SARS-CoV-2 test positivity rate in Reno, Nevada: association with PM2.5 during the 2020 wildfire smoke events in the western United States (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41370-021-00366-W |
|
| 2021-07-13 |
Placental response to maternal SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93931-0 |
34257394 |
| 2021-07-13 |
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABI8452 |
|
| 2021-07-13 |
RNA-Protein Interaction Analysis of SARS-CoV-2 5' and 3' Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSYSTEMS.00643-21 |
34254825 |
| 2021-07-13 |
What Impact Have SARS-CoV-2/Covid-19 Pandemic induced lockdown on the number of OPD patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology in India during the lockdown months ( (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-708392/V1 |
|
| 2021-07-13 |
In Silico Studies on Binding of Vernonia Amygdalina Phytochemicals to Main Protease (Mpro) of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.23880/JONAM-16000318 |
|
| 2021-07-13 |
What Impact has lockdown on SARS-CoV-2/COVID-19 incidence, prevalence and mortality during second wave of pandemic in 2021: - observational analysis of Bihar (edit) |
SARSコロナウイルス2 (edit) |
10.32388/KWXMBG |
|
| 2021-07-13 |
COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street? (edit) |
SARSコロナウイルス2 (edit) |
10.3390/BIOM11071020 |
34356644 |
| 2021-07-12 |
The limits of SARS-CoV-2 predictability (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41559-021-01514-Z |
|
| 2021-07-12 |
Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93608-8 |
34253751 |
| 2021-07-12 |
Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.28.21258780 |
34268529 |
| 2021-07-12 |
Host-Virus Chimeric Events in SARS-CoV-2-Infected Cells Are Infrequent and Artifactual (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00294-21 |
33980601 |
| 2021-07-12 |
ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00327-21 |
33963054 |
| 2021-07-12 |
Emerging SARS-CoV-2 variants of concern and potential intervention approaches (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13054-021-03662-X |
34253247 |
| 2021-07-12 |
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009706 |
|
| 2021-07-12 |
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMMM.202114122 |
34170074 |
| 2021-07-12 |
What Impact Have SARS-CoV-2/Covid-19 Pandemic induced lockdown on the number of OPD patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology in India during the lockdown months ( (edit) |
SARSコロナウイルス2 (edit) |
10.31219/OSF.IO/ENAFH |
|
| 2021-07-12 |
SARS-CoV-2 Crisis Management With a Wastewater Early-Warning System in the Bavarian District of Berchtesgadener Land, Germany (edit) |
SARSコロナウイルス2 (edit) |
10.3238/ARZTEBL.M2021.0261 |
|
| 2021-07-12 |
What Impact Have SARS-CoV-2/Covid-19 Pandemic induced lockdown on the number of OPD patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology in India during the lockdown months ( (edit) |
SARSコロナウイルス2 (edit) |
10.32388/8I2HH5 |
|
| 2021-07-12 |
Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMOLB.2021.648232 |
34322517 |
| 2021-07-12 |
Viral MicroRNAs Encoded by Nucleocapsid Gene of SARS-CoV-2 Are Detected during Infection, and Targeting Metabolic Pathways in Host Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/CELLS10071762 |
34359932 |
| 2021-07-12 |
Role of Extracellular Vimentin in Cancer-Cell Functionality and Its Influence on Cell Monolayer Permeability Changes Induced by SARS-CoV-2 Receptor Binding Domain (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22147469 |
34299089 |
| 2021-07-10 |
Investigations into the origin of SARS-CoV-2: an update (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-07-10 |
Exploiting the molecular basis of age and gender differences in outcomes of SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.07.002 |
34306570 |
| 2021-07-10 |
RAAS, ACE2 and COVID-19; a mechanistic review (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SJBS.2021.07.003 |
34305426 |
| 2021-07-10 |
Investigations into the Origin of SARS-CoV-2: An Update (edit) |
SARSコロナウイルス2 (edit) |
10.18520/CS/V121/I1/77-84 |
|
| 2021-07-10 |
Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22147425 |
|
| 2021-07-09 |
Supramolecular Cylinders Target Bulge Structures in the 5′ UTR of the RNA Genome of SARS‐CoV‐2 and Inhibit Viral Replication** (edit) |
SARSコロナウイルス2 (edit) |
10.1002/ANGE.202104179 |
|
| 2021-07-09 |
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JMEDCHEM.1C00616 |
34242027 |
| 2021-07-09 |
Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JTH.15455 |
34242469 |
| 2021-07-09 |
Estimating infectiousness throughout SARS-CoV-2 infection course (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI5273 |
|
| 2021-07-09 |
Efficacy of portable air cleaners and masking for reducing indoor exposure to simulated exhaled SARS-CoV-2 aerosols - United States, 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.15585/MMWR.MM7027E1 |
34237047 |
| 2021-07-09 |
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.PEX-1338/V3 |
|
| 2021-07-09 |
Evaluation of Screening Tests in Bavarian Healthcare Facilities during the Second Wave of the SARS-CoV-2 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH18147371 |
|
| 2021-07-09 |
SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review (edit) |
SARSコロナウイルス2 (edit) |
10.5492/WJCCM.V10.I4.132 |
|
| 2021-07-08 |
Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JTEMB.2021.126818 |
34274845 |
| 2021-07-08 |
First detection and molecular analysis of SARS-CoV-2 from a naturally infected cat from Argentina (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VETMIC.2021.109179 |
34271305 |
| 2021-07-08 |
Targeting liquid–liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41556-021-00710-0 |
34239064 |
| 2021-07-08 |
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03777-9 |
|
| 2021-07-08 |
SARS-CoV-2 Variants and Vaccines (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMSR2105280 |
34161052 |
| 2021-07-08 |
REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.08.21260185 |
|
| 2021-07-08 |
Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients (edit) |
SARSコロナウイルス2 (edit) |
10.1183/13993003.00918-2021 |
|
| 2021-07-08 |
Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13104-021-05652-2 |
34238344 |
| 2021-07-08 |
Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S40794-021-00147-1 |
34238372 |
| 2021-07-07 |
Glycosylation of SARS-CoV-2: structural and functional insights (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-021-03499-X |
34235568 |
| 2021-07-07 |
A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.07.007 |
34289344 |
| 2021-07-07 |
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109432 |
34270918 |
| 2021-07-07 |
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109433 |
34273271 |
| 2021-07-07 |
Low-cost biosensor for rapid detection of SARS-CoV-2 at the point of care (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MATT.2021.05.003 |
33997767 |
| 2021-07-07 |
Zinc-Embedded Polyamide Fabrics Inactivate SARS-CoV-2 and Influenza A Virus (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSAMI.1C04412 |
34180223 |
| 2021-07-07 |
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41392-021-00686-1 |
34234102 |
| 2021-07-07 |
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24435-8 |
34234131 |
| 2021-07-07 |
Determination of intermediate state structures in the opening pathway of SARS-CoV-2 spike using cryo-electron microscopy (edit) |
SARSコロナウイルス2 (edit) |
10.1039/D1SC00244A |
34276947 |
| 2021-07-07 |
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2024302118 |
|
| 2021-07-07 |
SARS-CoV-2 Nsp3 unique domain SUD interacts with guanine quadruplexes and G4-ligands inhibit this interaction (edit) |
SARSコロナウイルス2 (edit) |
10.1093/NAR/GKAB571 |
34232992 |
| 2021-07-07 |
Correction to: Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S12879-021-06358-3 |
34233629 |
| 2021-07-07 |
Interactomes of SARS-CoV-2 and human coronaviruses reveal host factors potentially affecting pathogenesis (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021107776 |
34232536 |
| 2021-07-07 |
ROS/RNS Balancing, Aerobic Fermentation Regulation and Cell Cycle Control - a Complex Early Trait ('CoV-MAC-TED') for Combating SARS-CoV-2-Induced Cell Reprogramming (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.673692 |
34305903 |
| 2021-07-07 |
Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.710778 |
34305617 |
| 2021-07-06 |
Prevalence of SARS-CoV-2 genes in water reclamation facilities: From influent to anaerobic digester (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCITOTENV.2021.148905 |
34271386 |
| 2021-07-06 |
Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JPCB.1C03639 |
34228472 |
| 2021-07-06 |
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41418-021-00817-9 |
34230615 |
| 2021-07-06 |
SARS-CoV-2 infection in the mouse olfactory system (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41421-021-00290-1 |
34230457 |
| 2021-07-06 |
First molecular-based detection of SARS-CoV-2 virus in the field-collected houseflies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93439-7 |
34230585 |
| 2021-07-06 |
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants (edit) |
SARSコロナウイルス2 (edit) |
10.1080/21645515.2021.1940652 |
34228597 |
| 2021-07-06 |
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score (edit) |
SARSコロナウイルス2 (edit) |
10.1093/BJS/ZNAB183 |
34227657 |
| 2021-07-06 |
Kidney injury molecule-1 is a potential receptor for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAB003 |
33493263 |
| 2021-07-06 |
Entry, egress and vertical transmission of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAB013 |
33677567 |
| 2021-07-06 |
What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JMCB/MJAB016 |
33693723 |
| 2021-07-06 |
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/OFID/OFAB358 |
|
| 2021-07-06 |
Mechanisms of immunothrombosis in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1097/MOH.0000000000000666 |
34232139 |
| 2021-07-06 |
Lockdowns exert selection pressure on overdispersion of SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.30.21259771 |
|
| 2021-07-06 |
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PMED.1003656 |
34228725 |
| 2021-07-06 |
Mendelian randomization analysis provides causality of smoking on the expression of ACE2, a putative SARS-CoV-2 receptor (edit) |
SARSコロナウイルス2 (edit) |
10.7554/ELIFE.64188 |
34227468 |
| 2021-07-05 |
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation (edit) |
SARSコロナウイルス2 (edit) |
10.1002/CTI2.1306 |
34257967 |
| 2021-07-05 |
Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00018-021-03889-5 |
34223911 |
| 2021-07-05 |
Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00395-021-00882-8 |
34224022 |
| 2021-07-05 |
In silico analysis of the aggregation propensity of the SARS-CoV-2 proteome: Insight into possible cellular pathologies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAPAP.2021.140693 |
34237472 |
| 2021-07-05 |
Recombinant SARS-CoV-2 envelope protein traffics to the trans-Golgi network following amphipol-mediated delivery into human cells (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.100940 |
34237302 |
| 2021-07-05 |
SARS-COV-2 seroprevalence among employees of a University Hospital in Belgium during the 2020 COVID-19 outbreak (COVEMUZ-study) (edit) |
SARSコロナウイルス2 (edit) |
10.1017/S0950268821001540 |
34219629 |
| 2021-07-05 |
SARS-CoV-2 respiratory screening of asymptomatic stem cell donors on day of collection; to test or not to test. UK Aligned Stem Cell Donor Registry (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41409-021-01379-7 |
34226667 |
| 2021-07-05 |
COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.01.21259833 |
|
| 2021-07-05 |
Early detection of SARS-CoV-2 P.1 variant in Southern Brazil and reinfection of the same patient by P.2. (edit) |
SARSコロナウイルス2 (edit) |
10.1590/S1678-9946202163058 |
34231823 |
| 2021-07-05 |
Personal protective equipment waste potentially infected with SARS-CoV-2 – a new global challenge for biological safety (edit) |
SARSコロナウイルス2 (edit) |
10.17816/PHF71586 |
|
| 2021-07-05 |
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.714511 |
34290717 |
| 2021-07-04 |
Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S41207-021-00263-6 |
|
| 2021-07-04 |
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCHEMBIO.1C00272 |
|
| 2021-07-03 |
Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CYTO.2021.155637 |
34242899 |
| 2021-07-03 |
A mass spectrometry-based targeted assay for detection of SARS-CoV-2 antigen from clinical specimens (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.EBIOM.2021.103465 |
34229274 |
| 2021-07-03 |
The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigen (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.29.21259605 |
|
| 2021-07-03 |
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.02.450959 |
|
| 2021-07-03 |
SARS-CoV-2 Infection Remodels the Phenotype and Promotes Angiogenesis of Primary Human Lung Endothelial Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3390/MICROORGANISMS9071438 |
34361874 |
| 2021-07-02 |
Recent advances in developing small-molecule inhibitors against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.APSB.2021.06.016 |
34249607 |
| 2021-07-02 |
Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.BIOCHEM.1C00279 |
34213308 |
| 2021-07-02 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BCJ20210198 |
34198326 |
| 2021-07-02 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BCJ20210219 |
|
| 2021-07-02 |
An all-out assault on SARS-CoV-2 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1042/BCJ20210256 |
|
| 2021-07-02 |
Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2’ by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.07.02.450896 |
|
| 2021-07-02 |
ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009723 |
34214142 |
| 2021-07-01 |
A weak COPI binding motif in the cytoplasmic tail of SARS-CoV-2 spike glycoprotein is necessary for its cleavage, glycosylation, and localization (edit) |
SARSコロナウイルス2 (edit) |
10.1002/1873-3468.14109 |
33991349 |
| 2021-07-01 |
SARS-CoV-2's claimed natural origin is undermined by issues with genome sequences of its relative strains: Coronavirus sequences RaTG13, MP789 and RmYN02 raise multiple questions to be critically addressed by the scientific community (edit) |
SARSコロナウイルス2 (edit) |
10.1002/BIES.202100015 |
34046923 |
| 2021-07-01 |
Mutations in SARS-CoV-2 nsp7 and nsp8 proteins and their predicted impact on replication/transcription complex structure (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.26791 |
33433004 |
| 2021-07-01 |
Fetal and placental infection with SARS-CoV-2 in early pregnancy (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.26965 |
33764543 |
| 2021-07-01 |
Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target (edit) |
SARSコロナウイルス2 (edit) |
10.1002/JMV.27009 |
33837972 |
| 2021-07-01 |
Salivary glands are a target for SARS-CoV-2: a source for saliva contamination (edit) |
SARSコロナウイルス2 (edit) |
10.1002/PATH.5679 |
33834497 |
| 2021-07-01 |
Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment (edit) |
SARSコロナウイルス2 (edit) |
10.1002/RMV.2194 |
33205496 |
| 2021-07-01 |
Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00381-021-05104-Z |
33751228 |
| 2021-07-01 |
The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10741-020-10066-6 |
33404999 |
| 2021-07-01 |
Transmission of SARS-CoV-2 virus and ambient temperature: a critical review (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S11356-021-14625-8 |
34053039 |
| 2021-07-01 |
Decontamination of respirators amid shortages due to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S43630-021-00064-4 |
34118013 |
| 2021-07-01 |
Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AJPATH.2021.04.006 |
33894177 |
| 2021-07-01 |
Evaluation of cochlear functions in infants exposed to SARS-CoV-2 intrauterine (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.AMJOTO.2021.102982 |
|
| 2021-07-01 |
The SARS-CoV-2 envelope (E) protein has evolved towards membrane topology robustness (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBAMEM.2021.183608 |
33771486 |
| 2021-07-01 |
SARS-Cov-2 spike protein fragment 674–685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBRC.2021.05.018 |
34000512 |
| 2021-07-01 |
Variations in Orf3a protein of SARS-CoV-2 alter its structure and function (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BBREP.2021.100933 |
33527091 |
| 2021-07-01 |
Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BCP.2021.114424 |
33482149 |
| 2021-07-01 |
Compartmentalization-aided interaction screening reveals extensive high-order complexes within the SARS-CoV-2 proteome (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109482 |
34297909 |
| 2021-07-01 |
The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CUB.2021.06.049 |
|
| 2021-07-01 |
Evolution and spread of SARS-CoV-2 likely to be affected by climate (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECOCHG.2021.100005 |
|
| 2021-07-01 |
How to study SARS-CoV-2 in soils? (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ENVRES.2020.110464 |
33188764 |
| 2021-07-01 |
Hearing screening outcomes in neonates of SARS-CoV-2 positive pregnant women (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJPORL.2021.110754 |
|
| 2021-07-01 |
Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMMUNI.2021.06.002 |
34174183 |
| 2021-07-01 |
Role of host factors in SARS-CoV-2 entry (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.100847 |
34058196 |
| 2021-07-01 |
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JIM.2021.113046 |
33775672 |
| 2021-07-01 |
Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interface (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JINF.2021.04.020 |
33895226 |
| 2021-07-01 |
SARS-CoV-2 and hearing: An audiometric analysis of COVID-19 hospitalized patients (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JOTO.2021.01.005 |
|
| 2021-07-01 |
Inflammatory cytokine storms severity may be fueled by interactions of micronuclei and RNA viruses such as COVID-19 virus SARS-CoV-2. A hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MRREV.2021.108395 |
|
| 2021-07-01 |
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MSARD.2021.102947 |
33979771 |
| 2021-07-01 |
SARS-CoV-2 (COVID-19) pneumonia: Incidental finding on 18F-FDG PET/CT study for vasculitis diagnosis (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.REMNIE.2020.08.004 |
|
| 2021-07-01 |
Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.STR.2021.05.014 |
34111408 |
| 2021-07-01 |
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.THROMRES.2021.05.010 |
|
| 2021-07-01 |
The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2021.03.009 |
33774551 |
| 2021-07-01 |
Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XCRM.2021.100359 |
|
| 2021-07-01 |
Science, not speculation, is essential to determine how SARS-CoV-2 reached humans (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(21)01419-7 |
|
| 2021-07-01 |
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00224-3 |
33930320 |
| 2021-07-01 |
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S2666-5247(21)00082-3 |
33870240 |
| 2021-07-01 |
SARS-CoV-2 variants, spike mutations and immune escape (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41579-021-00573-0 |
34075212 |
| 2021-07-01 |
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03570-8 |
33915569 |
| 2021-07-01 |
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41586-021-03676-Z |
34098567 |
| 2021-07-01 |
Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-91662-W |
34210996 |
| 2021-07-01 |
The RNA sensor MDA5 detects SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92940-3 |
34211037 |
| 2021-07-01 |
Demonstrated SARS-CoV-2 surface disinfection using ozone (edit) |
SARSコロナウイルス2 (edit) |
10.1080/01919512.2020.1863770 |
|
| 2021-07-01 |
An Evolutionary Portrait of the Progenitor SARS-CoV-2 and Its Dominant Offshoots in COVID-19 Pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1093/MOLBEV/MSAB118 |
33942847 |
| 2021-07-01 |
Potential zoonotic sources of SARS-CoV-2 infections (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TBED.13872 |
33034151 |
| 2021-07-01 |
The role of the SARS-CoV-2 envelope protein as a pH-dependent cation channel (edit) |
SARSコロナウイルス2 (edit) |
10.1113/JP281785 |
34089533 |
| 2021-07-01 |
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI7994 |
|
| 2021-07-01 |
SARS-CoV-2 transmission during rugby league matches: do players become infected after participating with SARS-CoV-2 positive players? (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BJSPORTS-2020-103714 |
33574043 |
| 2021-07-01 |
Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-051484 |
|
| 2021-07-01 |
Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2021-053245 |
|
| 2021-07-01 |
Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI148517 |
34003804 |
| 2021-07-01 |
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI148635 |
34196300 |
| 2021-07-01 |
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors (edit) |
SARSコロナウイルス2 (edit) |
10.1177/24725552211026261 |
34192965 |
| 2021-07-01 |
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009544 |
34265018 |
| 2021-07-01 |
Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009759 |
34320031 |
| 2021-07-01 |
Saliva Testing is a Robust Non-Invasive Method for SARS-CoV-2 RNA Detection (edit) |
SARSコロナウイルス2 (edit) |
10.2147/IDR.S314491 |
|
| 2021-07-01 |
Assessment of weather and atmospheric pollution as a co-factor in the spread of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.23750/ABM.V92I3.11354 |
34212907 |
| 2021-07-01 |
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.27.2100568 |
34240697 |
| 2021-07-01 |
Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021 (edit) |
SARSコロナウイルス2 (edit) |
10.2807/1560-7917.ES.2021.26.27.2100570 |
34240695 |
| 2021-07-01 |
What Impact has lockdown on SARS-CoV-2/COVID-19 incidence, prevalence and mortality during second wave of pandemic in 2021: - observational & statistical analysis of Bihar-version 2 (edit) |
SARSコロナウイルス2 (edit) |
10.31219/OSF.IO/63WJ5 |
|
| 2021-07-01 |
AmpliCoV: Rapid Whole-Genome Sequencing Using Multiplex PCR Amplification and Real-Time Oxford Nanopore MinION Sequencing Enables Rapid Variant Identification of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.651151 |
34276587 |
| 2021-07-01 |
Expansion of SARS-CoV-2 sequencing capacity globally is vital for future control of the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.4038/SLJM.V30I1.273 |
|
| 2021-07-01 |
SARS-CoV-2 transmission in kindergarten to grade 12 schools in the Vancouver Coastal Health region: a descriptive epidemiologic study (edit) |
SARSコロナウイルス2 (edit) |
10.9778/CMAJO.20210106 |
34429325 |
| 2021-06-30 |
Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IJBIOMAC.2021.03.199 |
33862077 |
| 2021-06-30 |
Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLIMM.2021.06.021 |
34242919 |
| 2021-06-30 |
Binding of the SARS-CoV-2 spike protein to glycans (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.SCIB.2021.01.010 |
33495714 |
| 2021-06-30 |
SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24377-1 |
34193870 |
| 2021-06-30 |
Symptom-based early-stage differentiation between SARS-CoV-2 versus other respiratory tract infections-Upper Silesia pilot study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-93046-6 |
34193945 |
| 2021-06-30 |
Exploitation of the Secretory Pathway by SARS-CoV-2 Envelope (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.30.450614 |
|
| 2021-06-30 |
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCITRANSLMED.ABI9915 |
34103407 |
| 2021-06-30 |
Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00180-21 |
34190583 |
| 2021-06-30 |
Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2- and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MSPHERE.00270-21 |
34160239 |
| 2021-06-30 |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.658519 |
34276652 |
| 2021-06-30 |
Enhanced Expression of Autoantigens During SARS-CoV-2 Viral Infection (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.686462 |
34276672 |
| 2021-06-30 |
Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of M and Its Antiviral Activity in Cells against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22137048 |
34208928 |
| 2021-06-29 |
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109292 |
34166617 |
| 2021-06-29 |
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109414 |
34260965 |
| 2021-06-29 |
Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.1C01797 |
34235330 |
| 2021-06-29 |
Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92941-2 |
34188167 |
| 2021-06-29 |
Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2023947118 |
34172581 |
| 2021-06-29 |
AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2 (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2025879118 |
34185681 |
| 2021-06-29 |
Absolute quantitation of individual SARS-CoV-2 RNA molecules: a new paradigm for infection dynamics and variant differences (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.29.450133 |
|
| 2021-06-29 |
Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.00788-21 |
|
| 2021-06-29 |
Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides (edit) |
SARSコロナウイルス2 (edit) |
10.1128/MBIO.01423-21 |
34154407 |
| 2021-06-29 |
Team Sport Risk Exposure Framework-2 (TS-REF-2) to identify sports activities and contacts at increased SARS-CoV-2 transmission risk during the COVID-19 pandemic (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BJSPORTS-2021-104225 |
|
| 2021-06-29 |
Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months (edit) |
SARSコロナウイルス2 (edit) |
10.1136/BMJOPEN-2020-048142 |
34187827 |
| 2021-06-29 |
Relevant SARS-CoV-2 Genome Variation through Six Months of Worldwide Monitoring (edit) |
SARSコロナウイルス2 (edit) |
10.1155/2021/5553173 |
34258267 |
| 2021-06-29 |
IL-13 is a driver of COVID-19 severity (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.150107 |
34185704 |
| 2021-06-29 |
Production of SARS-CoV-2 Specific IFN-γ/IL-10 Co-producing CD4 T Cells from Convalescent Donors to Treat COVID-19: A Hypothesis (edit) |
SARSコロナウイルス2 (edit) |
10.14218/ERHM.2021.00008 |
|
| 2021-06-29 |
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.676314 |
34267735 |
| 2021-06-29 |
Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13071263 |
|
| 2021-06-28 |
SARS-CoV-2 signaling pathway map: A functional landscape of molecular mechanisms in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
|
34181169 |
| 2021-06-28 |
Dynamics of the SARS-CoV-2 nucleoprotein N-terminal domain triggers RNA duplex destabilization (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.BPJ.2021.06.003 |
34197802 |
| 2021-06-28 |
Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.VIROL.2021.06.009 |
34217923 |
| 2021-06-28 |
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S1473-3099(21)00319-4 |
34197764 |
| 2021-06-28 |
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24285-4 |
34183681 |
| 2021-06-28 |
A STING in the tail for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41590-021-00971-9 |
|
| 2021-06-28 |
A SARS-CoV-2 mini-genome assay based on negative-sense RNA to study replication inhibitors and emerging mutations (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.28.450211 |
|
| 2021-06-28 |
One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-Cov-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1111/ALL.14991 |
34180546 |
| 2021-06-28 |
The endogenous cellular protease inhibitor SPINT2 controls SARS-CoV-2 viral infection and is associated to disease severity (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PPAT.1009687 |
34181691 |
| 2021-06-28 |
What Impact has lockdown on SARS-CoV-2/COVID-19 incidence, prevalence and mortality during second wave of pandemic in 2021: - observational analysis of Bihar (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-635528/V2 |
|
| 2021-06-27 |
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ECLINM.2021.100993 |
|
| 2021-06-27 |
Variants in SARS-CoV-2 associated with mild or severe outcome (edit) |
SARSコロナウイルス2 (edit) |
10.1093/EMPH/EOAB019 |
34447577 |
| 2021-06-26 |
Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELREP.2021.109391 |
34242574 |
| 2021-06-26 |
Upregulation of oxidative stress gene markers during SARS-COV-2 viral infection (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.FREERADBIOMED.2021.06.018 |
34186206 |
| 2021-06-26 |
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness (edit) |
SARSコロナウイルス2 (edit) |
10.1016/S0140-6736(21)01358-1 |
34139198 |
| 2021-06-26 |
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13071237 |
34206727 |
| 2021-06-25 |
SARS-CoV-2–Related Acute Respiratory Distress Syndrome Uncovers a Patient with Severe Combined Immunodeficiency Disease (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S10875-021-01063-X |
|
| 2021-06-25 |
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMBIOL.2021.05.018 |
34174194 |
| 2021-06-25 |
Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102523 |
33997662 |
| 2021-06-25 |
Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ISCI.2021.102681 |
34095780 |
| 2021-06-25 |
Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92740-9 |
34172783 |
| 2021-06-25 |
Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ABT/TBAB013 |
34286216 |
| 2021-06-25 |
Averting an outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a university residence hall through wastewater surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.23.21259176 |
|
| 2021-06-25 |
Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus and Viral RNA in Relation to Surface Type and Contamination Concentration (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AEM.00526-21 |
33962986 |
| 2021-06-25 |
Quantification of SARS-CoV-2 variant mutations (HV69-70 and E484K/N501Y) in settled solids using digital RT-PCR v1 (edit) |
SARSコロナウイルス2 (edit) |
10.17504/PROTOCOLS.IO.BV5BN82N |
|
| 2021-06-24 |
Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S43440-021-00300-9 |
34165771 |
| 2021-06-24 |
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.04.025 |
33991487 |
| 2021-06-24 |
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CELL.2021.05.032 |
34139176 |
| 2021-06-24 |
Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CSBJ.2021.06.037 |
34188776 |
| 2021-06-24 |
In silico study of medicinal plants with cyclodextrin inclusion complex as the potential inhibitors against SARS-CoV-2 main protease (Mpro) and spike (S) receptor (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.IMU.2021.100645 |
34189252 |
| 2021-06-24 |
A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.OMTN.2021.06.014 |
34188971 |
| 2021-06-24 |
The architecture of the SARS-CoV-2 RNA genome inside virion (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-22785-X |
|
| 2021-06-24 |
Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.15.448419 |
34159331 |
| 2021-06-24 |
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.21.21258528 |
|
| 2021-06-24 |
Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication (edit) |
SARSコロナウイルス2 (edit) |
10.1101/GAD.348320.121 |
34168039 |
| 2021-06-24 |
Human Nasal and Lung Tissues Infected with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00130-21 |
33893170 |
| 2021-06-24 |
Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00663-21 |
33963053 |
| 2021-06-24 |
Autoantibodies stabilize neutrophil extracellular traps in COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1172/JCI.INSIGHT.150111 |
|
| 2021-06-24 |
The Role of Neuropilin-1 (NRP-1) in SARS-CoV-2 Infection: Review (edit) |
SARSコロナウイルス2 (edit) |
10.3390/JCM10132772 |
34202613 |
| 2021-06-23 |
In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOMED.2021.104591 |
34216889 |
| 2021-06-23 |
Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCENTSCI.1C00010 |
34235261 |
| 2021-06-23 |
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24078-9 |
34162869 |
| 2021-06-23 |
Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92641-X |
34162970 |
| 2021-06-23 |
Nsp2 has the potential to be a drug target revealed by global identification of SARS-CoV-2 Nsp2-interacting proteins (edit) |
SARSコロナウイルス2 (edit) |
10.1093/ABBS/GMAB088 |
|
| 2021-06-23 |
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post–COVID-19 Convalescent Samples (edit) |
SARSコロナウイルス2 (edit) |
10.1093/INFDIS/JIAB333 |
|
| 2021-06-23 |
SARS-CoV-2 spike protein induces paracrine senescence and leukocyte adhesion in endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00794-21 |
|
| 2021-06-23 |
Deletion of ER-retention motif on SARS-CoV-2 spike protein reduces cell hybrid during cell–cell fusion (edit) |
SARSコロナウイルス2 (edit) |
10.1186/S13578-021-00626-0 |
|
| 2021-06-23 |
TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells (edit) |
SARSコロナウイルス2 (edit) |
10.15252/EMBJ.2021107821 |
34159616 |
| 2021-06-23 |
Interfering Reactive Cysteine Proteome in Covid-19 Disease (edit) |
SARSコロナウイルス2 (edit) |
10.2174/0929867328666210623142811 |
|
| 2021-06-23 |
Deleterious Effects of SARS-CoV-2 Infection on Human Pancreatic Cells (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FCIMB.2021.678482 |
34282405 |
| 2021-06-23 |
Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection? (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FENDO.2021.665134 |
34248841 |
| 2021-06-22 |
Genome‐wide association analysis of COVID‐19 mortality risk in SARS‐CoV‐2 genomes identifies mutation in the SARS‐CoV‐2 spike protein that colocalizes with P.1 of the Brazilian strain (edit) |
SARSコロナウイルス2 (edit) |
10.1002/GEPI.22421 |
|
| 2021-06-22 |
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSOMEGA.1C01785 |
34179644 |
| 2021-06-22 |
Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41594-021-00619-0 |
34158638 |
| 2021-06-22 |
The total number and mass of SARS-CoV-2 virions (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2024815118 |
34083352 |
| 2021-06-22 |
Altered amino acid profile in patients with SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1073/PNAS.2101708118 |
34088793 |
| 2021-06-22 |
Factors affecting the transmission of SARS-CoV-2 in school settings (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.18.21259156 |
34189533 |
| 2021-06-22 |
Interplay between SARS-CoV-2-derived miRNAs, immune system, vitamin D pathway and respiratory system (edit) |
SARSコロナウイルス2 (edit) |
10.1111/JCMM.16694 |
34159729 |
| 2021-06-22 |
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABI4708 |
|
| 2021-06-22 |
The SARS-CoV-2 Spike Protein Subunit 1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells (edit) |
SARSコロナウイルス2 (edit) |
10.1152/AJPLUNG.00223.2021 |
|
| 2021-06-21 |
Transmission of SARS-CoV-2 in Inpatient and Outpatient Settings in a Veterans Affairs Health Care System (edit) |
SARSコロナウイルス2 (edit) |
|
|
| 2021-06-21 |
Simultaneous enrichment and separation of neutral and sialyl glycopeptides of SARS-CoV-2 spike protein enabled by dual-functionalized Ti-IMAC material (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S00216-021-03433-1 |
|
| 2021-06-21 |
On the airborne transmission of SARS-CoV-2 and relationship with indoor conditions at a hospital (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ATMOSENV.2021.118563 |
34177342 |
| 2021-06-21 |
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JAUT.2021.102682 |
|
| 2021-06-21 |
SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24007-W |
34155207 |
| 2021-06-21 |
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24013-Y |
34155214 |
| 2021-06-21 |
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-24123-7 |
34155209 |
| 2021-06-21 |
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92206-Y |
|
| 2021-06-21 |
Quantifying SARS-CoV-2 Infection Risk Within the Google/Apple Exposure Notification Framework to Inform Quarantine Recommendations (edit) |
SARSコロナウイルス2 (edit) |
10.1111/RISA.13768 |
34155669 |
| 2021-06-21 |
Design of specific primer sets for SARS-CoV-2 variants using evolutionary algorithms (edit) |
SARSコロナウイルス2 (edit) |
10.1145/3449639.3459359 |
|
| 2021-06-21 |
Ingestion of Cyanogens from Cassava Generates Disinfectant Hypothiocyanite That May Decrease the Transmissibility of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.20935/AL1211 |
|
| 2021-06-21 |
What impacts have geographical locations on the cases and deaths from COVID-19/SARS-CoV-2 pandemic in 36 states and union territories of India:-observational analysis in India (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-640243/V1 |
|
| 2021-06-21 |
A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3' Untranslated Region (UTR) Is Evolving and Generating Increased Viral Diversity (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.665041 |
34234758 |
| 2021-06-21 |
Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern (edit) |
SARSコロナウイルス2 (edit) |
10.5802/CRBIOL.53 |
|
| 2021-06-20 |
Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JBC.2021.100902 |
34157282 |
| 2021-06-20 |
SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance (edit) |
SARSコロナウイルス2 (edit) |
10.1111/TRF.16555 |
34121205 |
| 2021-06-19 |
Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients (edit) |
SARSコロナウイルス2 (edit) |
10.1002/SMTD.202100058 |
34514088 |
| 2021-06-19 |
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ANTIVIRAL.2021.105115 |
34157321 |
| 2021-06-19 |
Construction of an autophagy interaction network based on competitive endogenous RNA reveals the key pathways and central genes of SARS-CoV-2 infection in vivo (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MICPATH.2021.105051 |
34153417 |
| 2021-06-19 |
What impacts have geographical locations on the cases and deaths from COVID-19/SARS-CoV-2 pandemic in 36 states and union territories of India:-observational analysis in India (edit) |
SARSコロナウイルス2 (edit) |
10.31219/OSF.IO/GR6VU |
|
| 2021-06-18 |
Molecular insight into the genomic variation of SARS-CoV-2 strains from current outbreak (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.COMPBIOLCHEM.2021.107533 |
|
| 2021-06-18 |
Immunohistochemistry for protein detection in PFA-fixed paraffin-embedded SARS-CoV-2-infected COPD airway epithelium (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.XPRO.2021.100663 |
34250510 |
| 2021-06-18 |
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSCENTSCI.1C00519 |
34341772 |
| 2021-06-18 |
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 (edit) |
SARSコロナウイルス2 (edit) |
10.1093/JAC/DKAB072 |
33880524 |
| 2021-06-18 |
SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada (edit) |
SARSコロナウイルス2 (edit) |
10.1101/2021.06.16.21258861 |
|
| 2021-06-18 |
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1126/SCIENCE.ABG8985 |
34006597 |
| 2021-06-18 |
A Computational-Based Drug Repurposing Method Targeting SARS-CoV-2 and its Neurological Manifestations Genes and Signaling Pathways (edit) |
SARSコロナウイルス2 (edit) |
10.1177/11779322211026728 |
34211268 |
| 2021-06-18 |
Bayes Lines Tool (BLT): a SQL-script for analyzing diagnostic test results with an application to SARS-CoV-2-testing (edit) |
SARSコロナウイルス2 (edit) |
10.12688/F1000RESEARCH.51061.2 |
|
| 2021-06-18 |
The landscape of antibody binding in SARS-CoV-2 infection (edit) |
SARSコロナウイルス2 (edit) |
10.1371/JOURNAL.PBIO.3001265 |
34143766 |
| 2021-06-18 |
Non-Uniform Aspects of SARS-CoV-2 Intraspecies Evolution Reopen Questions on Its Origin (edit) |
SARSコロナウイルス2 (edit) |
10.20944/PREPRINTS202106.0472.V1 |
|
| 2021-06-18 |
What Impact has lockdown on SARS-CoV-2/COVID-19 incidence, prevalence and mortality during second wave of pandemic in 2021: - observational analysis of Bihar (edit) |
SARSコロナウイルス2 (edit) |
10.21203/RS.3.RS-635528/V1 |
|
| 2021-06-18 |
The First Molecular Characterization of Serbian SARS-CoV-2 Isolates From a Unique Early Second Wave in Europe (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMICB.2021.691154 |
34220784 |
| 2021-06-18 |
COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FNINS.2021.674204 |
|
| 2021-06-18 |
Heparan Sulfate Proteoglycans in Viral Infection and Treatment: A Special Focus on SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJMS22126574 |
34207476 |
| 2021-06-17 |
Peptides of H. sapiens and P. falciparum that are predicted to bind strongly to HLA-A*24:02 and homologous to a SARS-CoV-2 peptide (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ACTATROPICA.2021.106013 |
34146538 |
| 2021-06-17 |
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.CHEMBIOL.2021.04.020 |
33979649 |
| 2021-06-17 |
Defining the methodological approach for wastewater-based epidemiological studies-Surveillance of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.ETI.2021.101696 |
34250217 |
| 2021-06-17 |
Computational search of hybrid human/SARS-CoV-2 dsRNA reveals unique viral sequences that diverge from those of other coronavirus strains (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.HELIYON.2021.E07284 |
34179538 |
| 2021-06-17 |
Energetic and structural basis for the differences in infectivity between the wild-type and mutant spike proteins of SARS-CoV-2 in the Mexican population (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.JMGM.2021.107970 |
34242876 |
| 2021-06-17 |
Functional landscape of SARS-CoV-2 cellular restriction (edit) |
SARSコロナウイルス2 (edit) |
10.1016/J.MOLCEL.2021.04.008 |
33930332 |
| 2021-06-17 |
Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACS.JCTC.1C00372 |
|
| 2021-06-17 |
A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41541-021-00346-Z |
|
| 2021-06-17 |
Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic wave (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-91798-9 |
34140557 |
| 2021-06-17 |
ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured cornea (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41598-021-92293-X |
34140611 |
| 2021-06-17 |
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (edit) |
SARSコロナウイルス2 (edit) |
10.1056/NEJMC2103740 |
33826819 |
| 2021-06-17 |
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication (edit) |
SARSコロナウイルス2 (edit) |
10.1128/AAC.00097-21 |
33903110 |
| 2021-06-17 |
What Impact has lockdown on SARS-CoV-2/COVID-19 incidence, prevalence and mortality during second wave of pandemic in 2021: - observational analysis of Bihar (edit) |
SARSコロナウイルス2 (edit) |
10.31219/OSF.IO/SH97Q |
|
| 2021-06-17 |
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FIMMU.2021.687869 |
34220844 |
| 2021-06-17 |
Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FPHAR.2021.666600 |
|
| 2021-06-17 |
Immunological Response to SARS-CoV-2 Is Sustained by Vitamin D: A Case Presentation of One-Year Follow-Up (edit) |
SARSコロナウイルス2 (edit) |
10.3390/REPORTS4020018 |
|
| 2021-06-16 |
Current Understanding in the Pathophysiology of SARS-CoV-2-Associated Rhino-Orbito-Cerebral Mucormycosis: A Comprehensive Review (edit) |
SARSコロナウイルス2 (edit) |
10.1007/S12663-021-01604-2 |
|
| 2021-06-16 |
Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers (edit) |
SARSコロナウイルス2 (edit) |
10.1038/S41467-021-23825-2 |
34135340 |
| 2021-06-16 |
SARS-CoV-2 NSP12 protein is not an IFN-β antagonist (edit) |
SARSコロナウイルス2 (edit) |
10.1128/JVI.00747-21 |
34133897 |
| 2021-06-16 |
Structural Basis and Function of the N Terminus of SARS-CoV-2 Nonstructural Protein 1 (edit) |
SARSコロナウイルス2 (edit) |
10.1128/SPECTRUM.00169-21 |
34132580 |
| 2021-06-16 |
Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3389/FMEDT.2021.687681 |
35047933 |
| 2021-06-16 |
Serology in COVID-19: Comparison of Two Methods (edit) |
SARSコロナウイルス2 (edit) |
10.3390/IJERPH18126497 |
34208607 |
| 2021-06-16 |
Current State of Knowledge about Role of Pets in Zoonotic Transmission of SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.3390/V13061149 |
34208484 |
| 2021-06-15 |
Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2 (edit) |
SARSコロナウイルス2 (edit) |
10.1021/ACSINFECDIS.1C00017 |
|
| 2021-06-15 |
COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials (edit) |
SARSコロナウイルス2 (edit) |
10.1080/14760584.2021.1938550 |
34078215 |